,PMID,Other_terms
1470,31427038,goitre multinodulaire
1471,31427038,hyperthyroïdie infra-clinique
1472,31427038,multinodular goiter
1473,31427038,subclinical hyperthyroidism
1474,31427038,tsh
1475,31427038,thyroid
1476,31427038,thyroïde
1477,31542786,*nodular goiter
1478,31542786,*thyroid cancer cois
1479,31477522,*substernal goiter
1480,31477522,*thyroid
1481,31477522,*thyroidectomy cois disclose.
1482,29950539,american thyroid association (ata)
1483,29950539,european thyroid association (eta)
1484,29950539,grave's disease
1485,29950539,japan thyroid association/ japan endocrine society
1486,29950539,thyroid
1487,31583517,ectopic goiter
1488,31583517,ectopic thyroid
1489,31583517,intrapericardial goiter
1490,31583517,intrathoracic goiter
1491,31129908,*art
1492,31129908,*history
1493,31129908,*thyroid swelling
1496,32233333,nodules
1497,32233333,thyroid
1498,30788771,art
1499,30788771,endemic goiter
1500,30788771,history
1501,30788771,thyroid swelling
1502,30105567,goiter
1503,30105567,iodine deficiency
1504,30105567,prevalence
1505,30105567,school children
1506,30105567,urinary iodine
1507,30224035,fetal ultrasound
1508,30224035,graves’ disease
1509,30224035,maladie de basedow
1510,30224035,multidisciplinarity
1511,30224035,multidisciplinarité
1512,30224035,neonatal monitoring
1513,30224035,surveillance néonatale
1514,30224035,trab
1515,30224035,teratogenicity
1516,30224035,tératogénicité
1517,30224035,échographie fœtale
1521,30193753,antithyroid drugs
1522,30193753,antithyroïdien
1523,30193753,chirurgie
1524,30193753,graves’ disease
1525,30193753,grossesse
1526,30193753,maladie de basedow
1527,30193753,myxœdeme prétibial
1528,30193753,orbitopathie
1529,30193753,orbitopathy
1530,30193753,pregnancy
1531,30193753,radioiode
1532,30193753,radioiodine
1533,30193753,surgery
1534,30193753,thyroid dermopathy
1538,32041923,graves’ ophthalmopathy
1539,32041923,diagnosis
1540,32041923,management
1542,30342794,epidemiology
1543,30342794,graves’ disease
1544,30342794,pathophysiology
1545,31464605,children
1546,31464605,ethiopia
1547,31464605,goiter
1548,31464605,meta-analysis cois
1551,31221571,*continuous neuromonitoring
1552,31221571,*intraoperative neuromonitoring
1553,31221571,*recurrent laryngeal nerve
1554,31221571,*staged thyroidectomy
1555,31221571,*thyroidectomy
1556,31221571,*vagus nerve stimulation
1559,30177259,chirurgie ophtalmologique
1560,30177259,corticotherapy
1561,30177259,corticothérapie
1562,30177259,eugogo
1563,30177259,graves’ orbitopathy
1564,30177259,immunosuppression treatment
1565,30177259,orbitopathie basedowienne
1566,30177259,smoking
1567,30177259,tabac
1568,30177259,traitement immunosuppresseur
1569,30880038,deep vein thrombosis
1570,30880038,goiter
1571,30880038,upper-extremity
1573,30180972,adolescent
1574,30180972,carbimazole
1575,30180972,child
1576,30180972,chirurgie
1577,30180972,enfant
1578,30180972,graves’ disease
1579,30180972,hyperthyroidism
1580,30180972,hyperthyroïdie
1581,30180972,iode radioactif
1582,30180972,long term
1583,30180972,long terme
1584,30180972,maladie de basedow
1585,30180972,prognosis
1586,30180972,pronostic
1587,30180972,radioactive iodine treatment
1588,30180972,surgery
1589,30180972,thiamazole
1590,30017236,computed tomography
1591,30017236,retrosternal goiter
1592,30017236,sternotomy
1593,30017236,thyroidectomy
1594,30778906,fine arts
1595,30778906,goiter
1596,30778906,history
1597,30778906,moretto da brescia
1598,30778906,renaissance
1600,31614658,goiter
1601,31614658,iodine deficiency
1602,31614658,iodine prophylaxis
1603,31614658,urinary iodine concentration cois
1606,30055961,neck approach
1607,30055961,sternotomy
1608,30055961,substernal goiter
1609,30055961,tertiary center
1610,30055961,thyroidectomy
1612,31552848,goiter
1613,31552848,iodine
1614,31552848,reproductive age
1615,31552848,salt iodine
1616,31552848,urinary iodine
1617,31552848,women cois
1618,31691192,iodine
1619,31691192,nodular goiter
1620,31691192,selenium
1621,31691192,thyroid gland
1622,31691192,thyroid hormones
1625,30803411,*longterm
1626,30803411,*methimazole
1627,30803411,*radioiodine
1628,30803411,*toxic multinodular goiter
1629,31074402,cervico-mediastinal goiter
1630,31074402,sternotomy
1631,31074402,thyroidectomy
1632,31074402,thyroiditis cois
1634,30900322,microwave
1635,30900322,substernal goiter
1636,30900322,thermal ablation
1637,30900322,thyroid
1638,30900322,ultrasound
1640,31447477,coronary artery
1641,31447477,ectopic goiter
1642,31447477,intrapericardial tumor
1643,31447477,thyroid tissue
1644,30694184,*endocrine disruptor
1645,30694184,*goiter
1646,30694184,*groundwater
1647,30694184,*subclinical hypothyroidism
1649,31270773,*art
1650,31270773,*goiter
1651,31270773,*history of medicine
1652,31270773,*thyroid
1654,31376092,genetic interaction analysis
1655,31376092,goiter
1656,31376092,hif-1α
1657,31376092,multifactor dimensionality reduction methodology
1658,31376092,polymorphisms
1659,31376092,vegf
1660,31376092,vegfr-2
1661,31668873,*adipocyte complement factors
1662,31668873,*adipokines
1663,31668873,*brown fat commitment
1664,31668873,*brown fat differentiation
1665,31668873,*extracellular matrix proteins
1666,31668873,*human batokines
1667,31668873,*human brown adipocytes
1668,31668873,*human brown fat
1669,31668873,*mitochondria
1670,31668873,*secretomics
1674,28840845,*sternotomy
1675,28840845,*computerized tomography
1676,28840845,*retrosternal goiter substernal.
1677,28840845,*surgery
1678,28840845,*thyroid
1679,28840845,*thyroidectomy
1681,29897006,*copy-number variation
1682,29897006,*genome-wide linkage analysis
1683,29897006,*multinodular goiter
1684,29897006,*next-generation sequencing
1685,29315620,amyloid goiter
1686,29315620,subacute thyroiditis
1687,29315620,thyroid
1688,29315620,ultrasonography
1689,30146569,*fdg-pet
1690,30146569,*hashimoto's thyroiditis
1691,30146569,*malignant lymphoma cois
1693,30306416,advances
1694,30306416,decade
1695,30306416,thyroid cois
1700,30141079,artificial pneumothorax
1701,30141079,carina
1702,30141079,mediastinal goiter
1703,30141079,prone position
1704,30141079,two-lung ventilation
1706,29310524,*art
1707,29310524,*goiter
1708,29310524,*sculptures
1709,31030636,*french-canadian
1710,31030636,*airway compromise
1711,31030636,*congenital hypothyroidism
1712,31030636,*dyshormonogenesis
1713,31811573,colloid goiter
1714,31811573,metals
1715,31811573,oxidative stress
1716,31811573,papillary thyroid carcinoma
1717,31285663,*dicer1
1718,31285663,*sertoli–leydig
1719,31285663,*genetic mutation
1720,31285663,*microrna
1721,31285663,*multinodular goiter
1722,31285663,"*sex cord–stromal tumour cois policy on disclosing conflicts of interest, and we declare that we have none."
1723,29275168,*goiter
1724,29275168,*hypothyroidism
1725,29275168,*mutation
1726,29275168,*thyroglobulin gene
1727,29275168,*truncated thyroglobulin protein
1728,28602544,*sternotomy
1729,28602544,*substernal goiter
1730,28602544,*thyroidectomy
1731,29548512,developed world
1732,29548512,developing world
1733,29548512,iodine deficiency
1734,29548512,low-resource setting
1735,29548512,thyroid cancer
1736,29548512,thyroid disease
1737,29548512,thyroid surgery
1738,29242007,*ecmo
1739,29242007,*extracorporeal membrane oxygenation
1740,29242007,*airway management
1741,29242007,*airway obstruction
1742,29242007,*mediastinal goiter
1743,29242007,*thyroid surgery
1744,30989520,*thyroid nodule
1745,30989520,*benign adenoma
1746,30989520,*multinodular goiter
1747,30989520,*thyroid cancer
1748,30037617,goiter
1749,30037617,hypothyroidism
1750,30037617,iodine deficiency
1751,30037617,native americans
1752,30037617,paleopathology
1755,31740871,thyroid papillary cancer haemogram
1756,29406821,graves' disease
1757,29406821,traditional chinese medicine
1758,29406821,goiter dispersion formula
1759,29406821,hyperthyroidism
1760,29406821,neurologic manifestations
1762,29215302,traditional chinese medicine
1763,29215302,goiter
1764,29215302,herbal regimen
1765,30055100,children
1766,30055100,iodine supply
1767,30055100,thyroid diseases
1768,30055100,thyromegaly
1769,29452573,metformin
1770,29452573,diffuse/nodular goiter
1771,29452573,insulin resistance
1772,29452573,obesity
1773,29452573,thyroid
1774,30820869,acute external compression of the trachea
1775,30820869,basedow’s goiter
1776,30820869,death
1777,30820869,intra-thyroid hemorrhage
1779,30084100,*euthyroid nodular goiter
1780,30084100,*insulin resistance
1781,30084100,*pulse wave velocity
1782,30084100,*strain index
1787,30506185,intrathoracic goitres
1788,30506185,retrosternal goitres
1789,30506185,substernal goitres
1790,30506185,thyroidectomy
1795,30220410,diagnosis
1796,30220410,diagnostic
1797,30220410,graves’ disease
1798,30220410,hyperthyroidism
1799,30220410,hyperthyroïdie
1800,30220410,maladie de basedow
1801,30843179,graves’ disease
1802,30843179,n-glycosylation
1803,30843179,tshr
1804,30843179,sialylation
1805,30843179,thyroid
1807,29360235,*avoiding sternotomy
1808,29360235,*intracapsular thyroidectomy
1809,29360235,*microdebrider
1810,29360235,*retrosternal goiter
1811,29360235,*thyroidectomy
1813,29348117,*graves' disease
1814,29348117,*carbimazole
1815,29348117,*radioiodine
1816,29348117,*thyroid
1817,29348117,*thyrotoxicosis cois
1823,30583800,completion thyroidectomy
1824,30583800,complications
1825,30583800,hemithyroidectomy
1826,30583800,hormone replacement
1827,30583800,isthmolobectomie
1828,30583800,supplémentation hormonale
1829,30583800,thyroïdectomie totale
1830,30583800,total thyroidectomy
1831,30583800,totalisation
1833,31813786,*antigen-specific immunotherapy
1834,31813786,*autoimmune thyroid disorders
1835,31813786,*corticosteroids
1836,31813786,*rituximab
1837,31813786,*teprotumumab
1838,31813786,*tocilizumab cois
1841,31281088,*asymmetrical nodular goitre
1842,31281088,*benign thyroid disease
1843,31281088,*hemithyroidectomy
1844,31281088,*thyroid surgery
1846,30634005,fetal therapy
1847,30634005,fetal thyroid
1848,30634005,thyroid disorders
1849,30158361,bone mineral density
1850,30158361,multinodular goiter
1851,30158361,thyroxine
1855,30044192,goitre
1856,30044192,theodor kocher
1857,30044192,thyroidectomy
1864,30701789,graves’ disease
1865,30701789,hyperthyroidism
1866,30701789,thyroid
1867,30701789,thyrotoxicosis
1868,30701789,toxic multinodular goiter
1869,31512191,graves’ disease
1870,31512191,graves’s orbithopathy
1871,31512191,lenin
1872,31512191,theodor kocher
1873,30417713,autoimmune thyroid disease
1874,30417713,graves’ disease
1875,30417713,hashitoxicosis
1876,30417713,fetal and neonatal hyperthyroidism
1877,30417713,methimazole treatment
1878,30417713,pediatric age
1879,30417713,radioiodine therapy
1880,30417713,thyroidectomy
1882,30456548,goiter
1883,30456548,graves’ disease
1884,30456548,iodine
1885,30456548,thyroid function tests
1886,30456548,thyroid gland
1887,31250924,*endocrinology
1888,31250924,*head and neck surgery
1889,31250924,*thyroid diseases
1890,31250924,*thyroid hormones
1898,31758881,*hashimoto’s thyroiditis
1899,31758881,*hypothyroidism
1900,31758881,*precocious puberty
1901,31758881,*stature cois
1902,31533103,acne
1903,31533103,minocycline
1904,31533103,tetracycline
1905,31533103,thyroiditis
1906,31235068,acfa
1907,31235068,atrial fibrillation
1908,31235068,complication
1909,31235068,complications
1910,31235068,heart failure
1911,31235068,hyperthyroidism
1912,31235068,hyperthyroïdie
1913,31235068,insuffisance cardiaque
1915,30637676,*goiter
1916,30637676,*hypothyroidism
1917,30637676,*iodine deficiency disorders
1919,31127592,goiter
1920,31127592,medical diagnosis
1921,31127592,painting
1922,31127592,saints
1924,31757411,*graves disease
1925,31757411,*hyperthyroidism
1926,31757411,*nodular goiter
1927,31757411,*thyroid cancer
1930,31721133,antithyroid drugs
1931,31721133,dietary supplements
1932,31721133,graves’ disease
1933,31721133,graves’ orbitopathy
1934,31721133,hyperthyroidism
1935,31721133,selenium cois assessment and supplementation.
1936,30835061,euthyroid
1937,30835061,medical diagnosis
1938,30835061,portrait
1940,28879586,amyloid
1941,28879586,amyloid goiter
1942,28879586,frozen section
1943,28879586,medullary thyroid carcinoma
1944,28879586,parathyroid cois interest to disclose. ethical approval: this article does not contain any studies with human participants or animals performed by any of the authors.
1946,29374396,adenolipoma
1947,29374396,thyroid
1948,29374396,ultrasound cois informed consent: written informed consent was obtained from the patient for the publication of this case report and accompanying images. ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards.
1950,30196262,emergency medicine
1951,30196262,haematology (incl blood transfusion)
1952,30196262,radiology (diagnostics)
1953,30196262,thyroid disease cois
1955,30989613,endocrinology
1956,30989613,frederic bazille
1957,30989613,painting cois conflict of interest.
1962,31651072,*graves' disease
1963,31651072,*hashimoto's thyroiditis
1964,31651072,*difficulty
1965,31651072,*outcomes
1966,31651072,*thyroidectomy
1968,31182347,hipocalcemia
1969,31182347,hipoparatiroidismo
1970,31182347,hormona paratiroidea
1971,31182347,hypocalcemia
1972,31182347,hypoparathyroidism
1973,31182347,parathyroid hormone
1974,31182347,thyroidectomy
1975,31182347,tiroidectomía
1976,29911397,hyperthyroidism
1977,29911397,thyroiditis
1978,29911397,thyrotoxicosis
1979,29911397,ultrasonography
1980,29911397,ultrasonography/adverse effects
1983,31007819,hyperthyroidism
1984,31007819,senegal
1985,31007819,jaundice cois
1987,28887209,*biomarkers
1988,28887209,*gas-phase fractionation (gpf)
1989,28887209,*proteomics
1990,28887209,*tandem mass tag™ (tmt)
1991,28887209,*tears
1992,28887209,*thyroid-associated orbitopathy
1993,29319139,99mtc-dtpa
1994,29319139,go
1995,29319139,hyperthyroidism
1996,31691668,balanced orbital decompression
1997,31691668,bony orbital decompression
1998,31691668,lateral orbital wall
1999,31691668,medial orbital wall
2000,31691668,optic neuropathy
2001,31691668,strabismus
2003,30918569,hyperthyroidism
2004,30918569,surgery
2005,30918569,thyroidectomy cois
2007,29395824,*airway obstruction
2008,29395824,*cardiopulmonary bypass
2009,29395824,*morbid
2010,29395824,*obese
2011,29395824,*retrosternal goiter
2012,29395824,*thyroid disease
2013,29395824,*tracheal compression
2014,30333321,*endocrinology
2015,30333321,*genetics
2016,30333321,*molecular genetics
2017,30333321,*monogenic diseases
2018,30333321,*thyroid disease cois exists
2019,30375286,* gene
2020,30375286,*congenital hypothyroidism
2021,30375286,*oligogenic mutations cois
2022,29461666,*ligament of berry
2023,29461666,*laryngeal
2024,29461666,*nerve
2025,29461666,*recurrent
2026,29461666,*thyroidectomy
2028,29729448,graves' disease
2029,29729448,graves' orbitopathy
2030,29729448,neuropsychiatric disorders
2031,29729448,quality of life
2037,31400860,ambulatoire
2038,31400860,chirurgie
2039,31400860,facteurs de risque
2040,31400860,outpatient
2041,31400860,risk factors
2042,31400860,surgery
2043,31400860,thyroid
2044,31400860,thyroïde
2045,30843109,*children
2046,30843109,*graves’ disease
2047,30843109,*proteinuria
2048,30213303,epigenetics
2049,30213303,genetics
2050,30213303,graves’disease
2051,30213303,génétique
2052,30213303,maladie de basedow
2053,30213303,prediction score
2054,30213303,score de prédiction
2055,30213303,épigénétique
2058,31562615,multinodular goiter
2059,31562615,nativity
2060,31562615,wooden little shepherds
2061,31143336,graves´ disease
2062,31143336,onycholysis
2063,31143336,hyperthyroidism
2064,31143336,hypothyroidism
2065,31143336,plummer´s nails
2066,31143336,thyroid disease cois
2068,29452583,drugs
2069,29452583,eye lids
2070,29452583,inflammation
2071,29452583,orbit
2072,29452583,vision cois publication: not applicable. competing interests: the authors state that there is no competing interests regarding the publication of this paper. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
2073,29325833,antithyroid drugs
2074,29325833,encuesta
2075,29325833,enfermedad de graves
2076,29325833,fármaco antitiroideo
2077,29325833,graves’ disease
2078,29325833,hipertiroidismo
2079,29325833,hyperthyroidism
2080,29325833,pediatric
2081,29325833,pediátrico
2082,29325833,survey
2089,29353393,autoimmunity
2090,29353393,graves’ disease
2091,29353393,hyperthyroidism
2092,29353393,iodine induced
2093,29353393,trab
2094,29353393,toxic goitre
2096,29909393,general practice / family medicine
2097,29909393,hyperthyroidism
2098,29909393,liver disease
2099,29909393,thyroid disease
2100,29909393,thyroiditis cois
2101,32461007,evaluation of results of therapeutic interventions
2102,32461007,myxedema
2103,32461007,steroids
2104,32461007,therapeutics
2105,29525760,malignant and benign haematology
2106,29525760,thyroid disease cois
2107,29721730,goitre
2108,29721730,medical diagnosis
2109,29721730,painting
2110,29721730,raphael
2112,28450378,*decompression
2113,28450378,*diplopia
2114,28450378,*graves ophthalmopathy
2115,28450378,*orbital fat
2116,28450378,*proptosis cois
2117,30949910,*biomarker
2118,30949910,*graves’ disease
2119,30949910,*microrna
2120,30949910,*plasma
2121,31424978,etiopathogenesis
2122,31424978,graves’ disease
2123,31424978,genetic factors
2124,31424978,thyroid-associated orbitopathy
2125,31424978,vitamin d receptor
2127,31132076,igf-1
2128,31132076,igf-1r
2129,31132076,thyroid cancer
2130,31637658,*differentiated thyroid carcinoma
2131,31637658,*graves’ disease
2132,31637658,*mortality
2133,31637658,*recurrence
2134,31268129,*goiter
2135,31268129,*iodine deficiency
2136,31268129,*iodine status
2137,31268129,*thyroid-stimulating hormone concentration
2138,31268129,*urinary iodine concentration
2139,30996065,respiratory medicine
2140,30996065,thyroid disease cois
2143,31292360,graves disease
2144,31292360,marine-lenhart syndrome
2145,31292360,plummer disease
2146,31144509,thyroid
2147,31144509,graves
2148,31144509,orbitopathy
2149,30504400,graves' disease
2150,30504400,ki-67
2151,30504400,metallothionein
2152,30504400,nodular goiter
2153,30504400,thyroid
2154,31496266,graves’ ophthalmopathy
2155,31496266,quantitative analysis
2156,31496266,radiation therapy
2157,31496266,thyroid eye disease
2158,31496266,volumetric analysis
2164,29027675,airway management
2165,29027675,anesthesia
2166,29027675,head and neck
2167,29027675,neck neoplasm
2168,29027675,tracheostomy
2169,29027675,ultrasound
2170,32180887,anicteric cholestasis
2171,32180887,graves’ disease
2172,32180887,hyperthyroidism cois
2173,29108474,*oncogene testing
2174,29108474,*pediatric thyroid cancer cois of the other authors have any conflicts of interest to declare.
2175,29728450,pre-tibial myxoedema
2176,29728450,thyroid acropachy
2177,29728450,thyroid associated ophthalmopathy
2178,29728450,vitiligo cois
2179,31713721,antithyroid drugs
2180,31713721,children
2181,31713721,graves’ disease
2182,31713721,hyperthyroidism
2183,31713721,“block-and-replace” method
2184,29962351,graves` associated ophthalmopathy
2185,29962351,il-6
2186,29962351,thyroid-associated ophthalmopathy
2187,29962351,extrathyroidal manifestation
2188,29962351,infiltrating cytokines
2189,29962351,tocilizumab.
2190,30935806,internal carotid artery thrombosis
2191,30935806,thromboembolic stroke
2192,30935806,thyroid goitre
2193,30257972,anaesthesia
2194,30257972,cardiovascular medicine
2195,30257972,"ear, nose and throat/otolaryngology"
2196,30257972,resuscitation
2197,30257972,thyroid disease cois
2198,32476968,graves’ disease
2199,32476968,eosinophil
2200,32476968,sarcoidosis
2201,30307028,graves’ disease
2202,30307028,depressive symptoms
2203,30307028,hyperthyroidism
2204,30307028,sexual functioning
2205,30307028,thyroid nodules
2206,29574428,emergency medicine
2207,29574428,endocrinology
2208,29574428,paediatrics
2209,29574428,thyroid disease cois
2210,29791909,fetal goiter
2211,29791909,fetal hypothyroidism
2212,29791909,intra-amniotic treatment
2213,29791909,iodine
2214,29791909,wolff-chaikoff effect
2216,30351170,fam167a-blk
2217,30351170,graves' disease (gd)
2218,30351170,hashimoto's thyroiditis (ht)
2219,30351170,autoimmune thyroid disease (aitd)
2220,30351170,polymorphism
2222,30311856,*pakistan
2223,30311856,*goiter prevalence
2224,30311856,*iodine deficiency disorder
2225,30311856,*iodized salt
2226,30311856,*pregnancy
2227,31383679,asthma
2228,31383679,"ear, nose and throat"
2229,31383679,pregnancy
2230,31383679,thyroid disease cois
2231,30509783,anestesia general
2232,30509783,general anaesthesia
2233,30509783,glucogenosis
2234,30509783,glycogenosis
2235,30509783,hipertermia maligna
2236,30509783,hipoglucemia
2237,30509783,hypoglycaemia
2238,30509783,malignant hyperthermia
2239,30509783,mcardle's syndrome
2240,30509783,mioglobinuria
2241,30509783,miopatía
2242,30509783,myoglobinuria
2243,30509783,myopathy
2244,30509783,síndrome de mcardle
2245,31450040,*graves' disease
2246,31450040,*hyperthyroidism
2247,31450040,*toxic multinodular goiter
2248,31450040,*toxic solitary nodule
2249,30455812,graves
2250,30455812,child
2251,30455812,treatment
2252,30541519,graves’ disease
2253,30541519,graves’ disease treatment.
2254,30541519,i131.
2255,30541519,radioiodine. cois metro south human research ethics committee (reference number: lnr/qms/43580). all necessary permissions to access medical records from the princess alexandra hospital were obtained. consent to participate was not a requirement. competing interests: the authors declare they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
2256,30626069,*graves’ orbitopathy
2257,30626069,*corticosteroids
2258,30626069,*hyperthyroidism
2259,30626069,*ophthalmopathy
2260,30626069,*prednisone cois
2263,31869260,* tnfsf15
2264,31869260,*graves’ disease
2265,31869260,*graves’ ophthalmopathy
2266,31869260,*tl1a
2267,31869260,*single nucleotide polymorphism
2268,31827052,aequorin
2269,31827052,graves’ ophthalmopathy
2270,31827052,thyroid-stimulating antibody
2271,31827052,thyrotropin receptor antibody
2272,31408196,*dicer1 syndrome
2273,31408196,*childhood
2274,31408196,*genetic counselling
2275,31408196,*multinodular goitre
2276,31408196,*thyroid pathologies
2282,30537006,*graves' disease
2283,30537006,*rln injury
2284,30537006,*complications
2285,30537006,*hypoparathyroidism
2286,30537006,*thyroidectomy
2287,31155292,*crispr/cas9
2288,31155292,*hearing loss
2289,31155292,*mouse model
2290,31155292,*pendred syndrome
2291,31155292,*slc26a4
2292,31155292,*vestibular dysfunction
2295,31377715,"ear, nose and throat/otolaryngology"
2296,31377715,hyperthyroidism
2297,31377715,otolaryngology/ent
2298,31377715,thyroid disease
2299,31377715,thyrotoxicosis cois
2302,31252621,ebv
2303,31252621,graves’ disease
2304,31252621,autoimmune thyroid disease
2305,31252621,hyperthyroidism
2306,31252621,viruses cois as prejudicing the impartiality of the research.
2307,31762351,receptive language outcomes
2308,31762351,non-syndromic enlarged vestibular aqueduct
2309,31762351,peabody picture vocabulary test
2310,31762351,pediatric cohort
2311,31762351,pendred syndrome
2313,30654201,depression
2314,30654201,hyperthyroidism
2315,30654201,thyroid disease
2316,30654201,women’s health
2317,31633822,*dfnb4
2318,31633822,*eva
2319,31633822,*pendred syndrome
2320,31633822,*slc26a4
2321,31633822,*genotype vs. phenotype
2322,31633822,*inner ear morphology
2323,31633822,*nonsyndromic enlarged vestibular aqueduct
2327,31749116,*antithyroid drug
2328,31749116,*graves’ disease
2329,31749116,*lymphocyte
2330,31749116,*neutrophil
2331,31749116,*relapse
2333,30955175,*fine-needle aspiration
2334,30955175,*goiter
2335,30955175,*hyperthyroidism
2336,30955175,*hypothyroidism
2337,30955175,*thyroid cancer
2338,30955175,*thyroid nodule
2339,30955175,*thyroid ultrasound
2340,29053044,graves’ ophthalmopathy
2341,29053044,graves’ orbitopathy
2342,29053044,thyroid eye disease
2343,29053044,superior ophthalmic vein thrombosis
2345,31290382,fluorescence microscopy
2346,31290382,thyroid nodule
2347,31372509,*cell biology
2348,31372509,*endocrinology
2349,31372509,*genetics
2350,31372509,*pathogenesis cois
2353,31187663,*hearing loss
2354,31187663,*iran
2355,31187663,*missense variant
2356,31187663,*next-generation sequencing
2359,27773627,bocio multinodular
2360,27773627,horner
2361,27773627,multinodular goiter
2362,27773627,oculosympathetic pathway
2363,27773627,thyroid
2364,27773627,tiroides
2365,27773627,vía oculosimpática
2366,31407208,autoimmune poliglandular syndromes
2367,31407208,graves’ disease
2368,31407208,hyperthyroidism
2369,31407208,thyroid
2370,30513035,dyshormonogenesis
2371,30513035,graves disease
2372,30513035,trab
2373,30513035,fetal goiter
2374,30513035,hyperthyroidism
2375,30513035,hypothyroidism
2376,31222404,corvis st
2377,31222404,goldmann applanation tonometry
2378,31222404,intraocular pressure
2379,31222404,ora
2380,31222404,thyroid-associated orbitopathy
2381,31222404,icare
2382,30862149,*graves’ disease
2383,30862149,*hyperthyroidism
2384,30862149,*antithyroid drugs cois
2385,31217394,adenovirus
2386,31217394,graves disease
2387,31217394,model
2389,30688164,*graves' disease
2390,30688164,*graves' ophthalmopathy
2391,30688164,*graves' orbitopathy
2392,30688164,*patient knowledge
2393,30688164,*thyroid eye disease
2394,30173328,*cognitive function
2395,30173328,*graves’ disease
2396,30173328,*graves’ ophthalmopathy
2397,30173328,*hyperthyroidism
2398,30173328,*quality of life
2399,30924917,*cancer
2400,30924917,*inflammation
2401,30924917,*neutrophil to lymphocyte ratio
2402,30924917,*thyroid nodule
2403,30263008,*dgge
2404,30263008,*gd
2405,30263008,*gut microbiota
2406,30263008,*high-throughput sequencing
2407,30263008,*hyperthyroidism
2408,30263008,*ophthalmopathy cois
2409,29281760,*complications
2410,29281760,*epidemiology biochemistry
2411,29281760,*hypoparathyroidism
2412,29281760,*mortality
2413,30955162,*graves’ disease
2414,30955162,*hyperthyroidism
2415,30955162,*leg tremor
2416,30955162,*postural tremor
2417,29923059,cholesterol
2418,29923059,graves
2419,29923059,ophthalmopathy
2420,29923059,orbitopathy
2421,29923059,statins
2422,29043478,goiter
2423,29043478,growth
2424,29043478,mri
2425,29043478,observer agreement
2426,29043478,quality of life
2427,29043478,thyroid function
2428,29043478,thyroidectomy
2429,30057393,graves orbitopathy
2430,30057393,deppression
2431,30057393,quality of life
2433,31184263,*external branch of the superior laryngeal nerve
2434,31184263,*goiter
2435,31184263,*quality of life
2436,31184263,*recurrent laryngeal nerve
2437,31184263,*thyroidectomy
2438,31184263,*voice
2439,31849168,graves' disease
2440,31849168,antithyroid drug
2441,31849168,children
2442,31849168,remission
2443,31849168,thyroid-stimulating hormone receptor antibodies
2444,30390961,benign/goiter
2445,30390961,preoperative workup
2446,30390961,thyroid
2447,30390961,thyroid surgery
2448,30390961,ultrasound/imaging
2449,30409157,gitelman syndrome
2450,30409157,graves’ disease
2451,30409157,"hypokalemia cois ethics approval and consent to participate: this study was performed according to the helsinki declaration. written informed consent to participate in the study was obtained from the patient and his mother. the patient’s son was 17 years old, and written informed consent was obtained from him and his parents as legal guardians. consent for publication: written informed consent was obtained from the patient and his mother for publication of the details of the case report. the patient’s son was 17 years old, and written informed consent was obtained from him and his parents as legal guardians. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2452,30457413,biotherapies
2453,30457413,eugogo
2454,30457413,graves’ ophthalmopathy
2455,30457413,proptosis
2456,30457413,tocilizumab
2457,30339291,*cornea
2458,30339291,*dysthyroid optic neuropathy
2459,30339291,*orbital decompression
2460,30339291,*sight-threatening graves’ orbitopathy
2462,30760283,*myotonic dystrophy
2463,30760283,*papillary thyroid carcinoma
2464,30760283,*thyroid goiter
2465,30760283,*thyroid nodule
2466,30760283,"*ultrasound scan cois person (cpp), iorg 0009553 – institutional review board for the university hospital of lille. ethical committee under number: hp 1821 (benhamou_ethics_ojrd.pdf). consent for publication: na competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2467,31655515,*lymphocyte
2468,31655515,*monocyte
2469,31655515,*neutrophil
2470,31655515,*platelet
2471,31655515,*ratio
2472,31655515,*thyrotoxicosis cois
2473,31323889,goiter
2474,31323889,hypothyroidism
2475,31323889,iodine deficiency
2476,31323889,iodine deficiency disorders
2477,31323889,iodine prophylaxis
2478,31323889,pregnancy
2479,31323889,schoolchildren cois as prejudicing the impartiality of the research reported.
2481,30880636,*graves' disease
2482,30880636,*autoimmune disease
2483,30880636,*balance
2484,30880636,*muscle strength
2485,30880636,*thyroid
2486,31715677,clinical protocols
2487,31715677,glaucoma
2488,31715677,graves ophthalmopathy
2489,31715677,ocular hypertension
2490,29306930,adolescents
2491,29306930,antithyroid drugs
2492,29306930,children
2493,29306930,hyperthyroidism
2494,29306930,management
2495,29306930,radioiodine
2496,29306930,thyrotoxicosis
2499,28569050,graves’ disease
2500,28569050,mir-146a
2501,28569050,mir-155
2502,28569050,mir-210
2503,28569050,regulatory t cells
2505,30302663,nodular recurrence
2506,30302663,thyroid lobectomy
2507,30302663,thyroid nodules
2508,32397019,disease attribute
2509,32397019,"lymphoma, non-hodgkin"
2510,32397019,prognosis
2511,32397019,thyroid neoplasms
2512,29595868,*goitre
2513,29595868,*hypocalcaemia
2514,29595868,*hypoparathyroidism
2515,29595868,*retrosternal goitre
2516,29595868,*thyroid gland
2517,29595868,*thyroidectomy
2518,29450866,diplopia
2519,29450866,graves’ orbitopathy
2520,29450866,orbital decompression
2521,29450866,proptosis
2522,29450866,quality of life
2523,29771881,endocrine ophthalmopathy
2524,29771881,multidimensional linear regression modeling
2525,29771881,prognostication
2526,29771881,risk factors
2527,29771881,toxic diffuse goiter
2529,30485487,*graves’ disease treatment
2530,30485487,*thyrotrophin receptor antibodies
2533,30540214,pulsed ivmp
2534,30540214,active ted
2535,30540214,efficacy and safety
2536,30540214,medical management
2537,30540214,steroid sparing agents
2540,31646433,*exophthalmos
2541,31646433,*graves’ disease
2542,31646433,*orbital decompression
2543,31646433,*orbital radiotherapy
2544,31646433,*orbitopathy
2545,31586293,*endogenous thyrotropin
2546,31586293,*methimazole
2547,31586293,*multinodular goitre
2548,31586293,*radioiodine cois
2549,30334140,*+49a/g polymorphism of the ctla4 gene
2550,30334140,*graves’ hyperthyroidism
2551,30334140,*graves’ orbitopathy
2552,30334140,*methimazole
2553,30334140,*predictors of remission
2555,31849350,cervical oesophageal perforation
2556,31849350,oesophageal injury
2557,31849350,oesophagogastroscopy
2558,31849350,oesophagus dilation
2559,31849350,thyroidectomy
2564,30369298,*ecological momentary assessments
2565,30369298,*patient-reported outcomes
2566,30369298,*thyroid diseases
2567,30369298,*thyroid-related quality of life
2569,30194634,graves’ ophthalmopathy
2570,30194634,tbii
2571,30194634,trab
2572,30194634,tsab
2573,31536167,afirma
2574,31536167,cytology
2575,31536167,fine-needle aspiration (fna)
2576,31536167,gene expression classifier (gec)
2577,31536167,genomic sequencing classifier (gsc)
2578,31536167,molecular
2579,31536167,thyroid
2583,29759035,*nis
2584,29759035,*slc5a5
2585,29759035,*congenital hypothyroidism
2586,29759035,*goiter
2587,29759035,*novel mutation
2588,29759035,*sodium–iodide symporter cois
2589,30135996,graves’ disease
2590,30135996,lipidomic analysis
2591,30135996,ophthalmopathy
2592,30135996,plasma
2593,30135996,urine
2594,30135996,nuplc-esi-ms/ms
2596,29332250,dysfunctional tear syndrome
2597,29332250,hyperthyroidism
2598,29332250,ocular surface inflammation
2599,29332250,tear cytokines
2600,29332250,thyroid-associated orbitopathy
2604,30696398,*acute airway obstruction
2605,30696398,*goitre
2606,30696398,*pregnancy
2607,30696398,*respiratory arrest cois publication: written informed consent for publication of the clinical details and clinical images was obtained from the patient. written informed consent for publication of the clinical details and clinical images was obtained from patient. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
2608,31727496,children
2609,31727496,iodized salt
2610,31727496,thyroid abnormalities
2611,31727496,urinary iodine
2612,31727496,water iodine
2613,31727496,water replacement
2614,28766837,dicer1
2615,28766837,cystic nephroma
2616,28766837,multinodular goiter
2617,28766837,mutation
2618,28766837,neuroblastoma
2619,28766837,syndrome
2622,30387079,benign thyroid disease
2623,30387079,meta-analysis
2624,30387079,prospective study
2625,30387079,thyroid cancer
2627,31237847,intraocular pressure
2628,31237847,thyroid-associated orbitopathy
2629,31201593,extraocular muscle
2630,31201593,graves’ ophthalmopathy
2631,31201593,magnetic resonance imaging
2632,31201593,radiation therapy
2633,31201593,steroids
2638,30217613,basedow
2639,30217613,graves
2640,30217613,quality of life
2641,30217613,qualité de vie
2642,30217613,questionnaire
2643,30217613,strabisme
2644,30217613,strabismus
2645,30217613,thyroid
2646,30217613,thyroïde
2647,30217607,chirurgie de strabisme
2648,30217607,diplopia
2649,30217607,diplopie
2650,30217607,dysthyroid orbitopathy
2651,30217607,graves’ disease
2652,30217607,maladie de basedow
2653,30217607,orbitopathie dysthyroïdienne
2654,30217607,strabismus surgery
2655,31641884,computed tomography
2656,31641884,deep lateral orbital wall decompression
2657,31641884,fat removal
2658,31641884,graves’ orbitopathy
2659,31641884,prediction
2660,31641884,the greater wing of the sphenoid
2661,30862763,graves’ disease
2662,30862763,children
2663,30862763,long-term outcome
2664,30862763,methimazole treatment
2665,30862763,remission
2666,31340806,bleeding
2667,31340806,hematoma
2668,31340806,risk factor
2669,31340806,thyroid surgery
2670,31340806,thyroidectomy cois
2671,31023276,bioassay
2672,31023276,graves’ disease
2673,31023276,trab
2674,31023276,"thyroid cois involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. the study protocol was approved by the local ethics committee (ethikkommission nordwest und zentralschweiz (eknz) project no. 2015/227). need for informed consent was waived by the local ethics committee due retrospective nature of analysis with no impact on health outcome. consent for publication: not applicable. competing interests: bm and ps received research support by thermo fisher scientific, roche diagnostics, abbott and siemens unrelated to this study. all authors confirm that they do not have a conflict of interest associated with this manuscript. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2675,30132285,autoimmune thyroiditis
2676,30132285,graves’ disease
2677,30132285,graves’ ophthalmopathy
2678,30132285,graves’ orbitopathy
2679,30132285,insulin-like growth factor-1 receptor
2680,30132285,thyroid
2681,30132285,thyroid autoimmunity
2682,30132285,thyroid eye disease
2683,30049435,*graves' disease
2684,30049435,*thyroid cancer
2685,30049435,*thyroid nodules
2686,30696370,*children
2687,30696370,*goiter
2688,30696370,*sufficient iodine intake
2689,30696370,*thyroid volume
2690,31622299,"thyroidectomy, complications, hypocalcaemia, recurrent laryngeal nerve injury,  haemorrhage. (jpma 69: 1470; 2019).doi:10.5455/jpma.301233"
2693,30767621,*graves' disease
2694,30767621,*ciliogenesis
2695,30767621,*nodular hyperplasia
2696,30767621,*primary cilia
2697,30767621,*thyrocytes
2698,29649988,lipid layer thickness
2699,29649988,meibomian gland dysfunction
2700,29649988,"thyroid eye diseases cois (irb)/ethics committee approval was obtained from the committee of medical ethics and human experiments of chang gung memorial hospital (cgmh), taiwan. informed consent was obtained from each subject in the cgmh. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2703,31309667,fukushima
2704,31309667,japanese black
2705,31309667,cattle
2706,31309667,goiter
2707,31309667,thyroid gland
2710,31094460,hormones
2711,31094460,immunological
2712,31094460,liquidators of the chernobyl accident
2713,31094460,non-hospital pneumonia
2714,30197184,*autoimmune disease
2715,30197184,*celiac disease
2716,30197184,*graves’ disease
2717,30197184,*myotonic dystrophy type 2
2718,29183262,*sds
2719,29183262,*globus symptoms
2720,29183262,*quality of life
2721,29183262,*thyroid surgery
2722,30719623,cyclosporine
2723,30719623,graves’ orbitopathy
2724,30719623,intravenous glucocorticoids
2725,30719623,methotrexate
2726,30737677,*hashimoto’s thyroiditis
2727,30737677,*iodothyronine deiodinase
2728,30737677,*thyroid gland
2729,30737677,*thyroid hormone metabolism
2730,31170960,destructive thyrotoxicosis
2731,31170960,diagnostic meta-analysis
2732,31170960,differential diagnosis
2733,31170960,graves’ disease
2734,31170960,peak systolic velocity of superior thyroid artery
2735,31170960,thyrotoxicosis cois
2736,31933295,focus harmonic scalpel
2737,31933295,hypocalcaemia
2738,31933295,hypoparathyroidism
2739,31933295,thyroidectomy
2740,31514388,diagnosis
2741,31514388,exosomes
2742,31514388,goiter
2743,31514388,heat shock proteins (hsp)
2744,31514388,molecular chaperones
2745,31514388,papillary carcinoma
2746,31514388,thyroid gland cois
2747,30110704,congenital hypothyroidism
2748,30110704,duoxa2
2749,30110704,fetal goiter
2750,30110704,mutation
2751,30110704,polyhydramnios
2752,29354016,*computed tomography
2753,29354016,*euthyroidism
2754,29354016,*graves' disease
2755,29354016,*methimazole
2756,29354016,*single-photon emission computed tomography
2757,29943563,graves disease
2758,29943563,hepatitis a virus
2759,29943563,triggering factor
2762,30092670,*go-qol
2763,30092670,*graves’ ophthalmopathy (go)
2764,30092670,*thyroid eye disease (ted)
2765,30092670,*adults
2766,30092670,*psychometrics
2767,30092670,*reliability
2768,30092670,*validity
2769,30783963,*diabetes
2770,30783963,*graves’ disease
2771,30783963,*islet autoantibodies
2772,30783963,*thyroid autoantibodies cois ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. informed consent: informed consent was obtained from all individual participants included in the study.
2773,30690623,*endemic
2774,30690623,*goitre
2775,30690623,*iodine
2776,30690623,*urinary iodine excretion
2777,27659020,goiter
2778,27659020,subtotal resection
2779,27659020,thyroidectomy
2781,29032778,*iodine-deficiency disorders
2782,29032778,*iodized salt
2783,29032778,*iran
2784,29032778,*school-aged children
2785,31411490,arhi
2786,31411490,fine-needle aspiration cytology
2787,31411490,imprinted gene
2788,31411490,thyroid nodule cois
2789,31028051,"ear, nose and throat"
2790,31028051,respiratory system
2791,31028051,venous thromboembolism cois
2793,30621642,hashimoto’s thyroiditis
2794,30621642,magnetic resonance
2795,30621642,ophthalmopathy
2796,30621642,"orbitopathy cois accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. this is a case report, retrospectively describing the course of the diagnostics and therapy, thus does not require the local bioethical committee approval. consent for publication: written informed consent was obtained from the patient for the publication of this report and any accompanying images. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2797,31347001,euthyroid
2798,31347001,in vitro fertilization
2799,31347001,intra-cytoplasmic sperm injection
2800,31347001,pregnancy outcomes
2802,31696306,*epoprostenol
2803,31696306,*hyperthyroidism
2804,31696306,*prostanoids
2805,31696306,*pulmonary hypertension
2806,31696306,*selexipag
2808,30369343,*pps method
2809,30369343,*thyroid volume
2810,30369343,*urinary iodine concentration
2811,30710486,goiter
2812,30710486,iodine deficiency disorders
2813,30710486,urinary iodine
2814,30710486,urinary thiocyanate
2818,30431723,graves’ disease
2819,30431723,graves’ ophthalmopathy
2820,30431723,optic nerve diseases
2821,30431723,optic nerve injuries
2822,30431723,"ultrasonography, doppler, color"
2823,31420436,materno-fetal medicine
2824,31420436,pregnancy
2825,31420436,thyroid disease cois
2826,30515705,bihar
2827,30515705,intelligence quotient (iq)
2828,30515705,iodized salt consumption
2829,30515705,total goitre rate
2831,30484383,*cochlear implantation
2832,30484383,*enlarged endolymphatic sacs
2833,30484383,*enlarged vestibular aqueduct
2834,30484383,*pendred syndrome
2835,30484383,*slc26a4
2836,30484383,*temporal bone
2838,31565879,*autoantibodies
2839,31565879,*graves disease
2840,31565879,*recurrence
2841,31565879,*thyroid peroxidase antibody cois
2843,30667296,*graves' disease
2844,30667296,*qol
2845,30667296,*sf-36
2846,30667296,*thypro
2847,30667296,*long-term
2848,30667296,*radioiodine
2849,30392997,hipocalcemia
2850,30392997,hipoparatiroidismo
2851,30392997,hypocalcemia
2852,30392997,hypoparathyroidism
2853,30392997,parathormone
2854,30392997,paratohormona
2855,30392997,thyroidectomy
2856,30392997,tiroidectomía
2857,31677639,*goiter
2858,31677639,*salt iodine concentration
2859,31677639,*shanghai
2860,31677639,*thyroid volume
2861,31677639,*urinary iodine concentration cois
2863,31860407,*graves'
2864,31860407,"*disease, graves'"
2865,31860407,"*orbitopathy, radioiodine, glucocorticoids, tsh receptor antibodies"
2866,30814438,graves’ disease
2867,30814438,hashimoto’s thyroiditis
2868,30814438,interleukin-17
2869,30814438,interleukin-1β
2870,30814438,interleukin-23
2873,29198022,*glaucoma
2874,29198022,*graves' disease
2875,29198022,*register study
2876,29198022,*toxic nodular goiter
2877,30890403,fna
2878,30890403,ptc
2879,30890403,mir-137
2880,30890403,mir-181b
2881,30890403,mir-214
2882,30890403,mir-222
2885,30593716,blinking
2886,30593716,dry eye
2887,30593716,meibomian gland dysfunction
2888,30593716,thyroid eye disease
2889,30577987,thyroid surgery
2890,30577987,transcutaneous laryngeal ultrasound
2891,30577987,vocal cord mobility
2892,31691654,mechanical high-speed bone removal
2893,31691654,orbital bone decompression
2894,31691654,osteodestruction
2895,31691654,scanning electron microscopy
2896,31691654,thyroid eye disease
2897,31691654,ultrasonic bone removal
2900,30701793,graves’ disease
2901,30701793,endocrine ophthalmopathy
2902,30701793,polymorphic genetic markers
2903,29446011,iodine
2904,29446011,iodine deficiency
2905,29446011,iodized salt
2906,29446011,iran
2907,29446011,uic cois ethical approval: the local ethics committee approved the study protocol. informed consent: informed consent was obtained from all individual participants included in the study.
2910,29946800,antithyroid drugs
2911,29946800,goiter
2912,29946800,graves’ disease
2913,29946800,graves’ orbitopathy
2914,29946800,hyperthyroidism
2915,29946800,predictive models
2916,29946800,recurrence
2917,29946800,tsh-receptor antibody
2918,31841476,accident at chnpp
2919,31841476,breast cancer
2920,31841476,functional parameters
2921,31841476,malignant tumors
2922,31841476,mammary gland
2923,31841476,structural parameters
2924,31841476,thyroid gland
2925,29937466,dysthyroid eye disease
2926,29937466,glucocortoid-resistant
2927,29937466,graves’ orbitopathy
2928,29937466,rituximab
2929,29940879,goiter
2930,29940879,iodine deficiency
2931,29940879,iodized salt
2932,29940879,pregnant women
2933,29940879,urinary iodine cois the institutional review board of hawassa university (irb 065-06). the local authorities were informed about the study objectives. after the study purpose was explained to the pregnant women informed written consent was obtained. confidentiality of the data obtained from participants was strictly secured and maintained. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
2934,29334119,elastography
2935,29334119,nodular goitre
2936,29334119,thyroid
2937,29334119,thyroid imaging reporting and data system
2938,29334119,ultrasound
2940,31660895,hmga2
2941,31660895,thyroid carcinoma
2942,31660895,microrna
2943,31660895,molecular markers
2944,31660895,preoperative diagnosis cois
2945,31810448,goitre
2946,31810448,iodine
2947,31810448,thyroid
2948,31810448,uic
2949,31810448,wic
2950,31810448,water cois
2951,29556769,ablation techniques
2952,29556769,high-intensity focused ultrasound ablation
2953,29556769,interventional ultrasonography
2954,29556769,nodular goitre
2955,29556769,ultrasound imaging
2957,30219088,antithyroid drugs
2958,30219088,cascore
2959,30219088,graves’ disease
2960,30219088,graves’ ophthalmopathy
2961,30219088,hyperthyroidism
2962,30219088,muscle index
2963,30219088,nospecs
2964,30219088,superonasal index
2965,30219088,"thyroidectomy cois medical university vienna gave a positive vote on the protocol and consent to participate. (protocol record 1839/2015). the trial was registered at the european clinical trials database (eudra-ct: 2015–003515-38). consent for publication: in consenting to participate in the clinical trial, all patients also consent to publication, as is stated in their consent form. competing interests: the author(s) declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2967,31171533,acute renal failure
2968,31171533,liver disease
2969,31171533,thyroid disease cois
2970,31312298,graves´ disease
2971,31312298,hashimoto´s thyroiditis
2972,31312298,south africa
2973,31312298,autoimmune thyroid disease
2974,31312298,hyperthyroidism
2975,31312298,hypothyroidism cois
2976,30885146,cyclin d1
2977,30885146,cytology
2978,30885146,diagnosis
2979,30885146,ngs
2980,30885146,"thyroid nodule cois the patients, and the ethical committee of the national cancer center hospital, tokyo, japan, approved the procedures (approval #2010–077). the informed consent will be written or verbal from participants. the research poses no more than minimal risk to patients and includes appropriate safeguards to protect the patients’ rights, safety and privacy. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2981,28656526,antioxidant
2982,28656526,fibroblast
2983,28656526,graves’
2984,28656526,melatonin
2985,28656526,n-acetyl-l-cysteine
2986,28656526,ophthalmopathy
2987,28656526,orbitopathy
2988,28656526,vitamin c
2989,29026936,*eyelid retraction
2990,29026936,*graves’ orbitopathy
2991,29026936,*lid surgery
2992,29026936,*upper eyelid retraction
2993,29983514,goitre
2994,29983514,difficult intubation
2995,29983514,modified intubation difficulty score
2996,29983514,predictive factors
2997,29983514,thyroidectomy
2998,30572375,cohort study
2999,30572375,school-aged children
3000,30572375,thyroid
3001,30572375,volume
3002,28832090,*aortic grafting
3003,28832090,*goitre
3004,28832090,*retrotracheal
3005,28832090,*thoracotomy
3006,28832090,*thyroidectomy
3007,29764405,excessive iodine intake
3008,29764405,goitre
3009,29764405,iodine deficiency
3010,29764405,pregnant women
3011,29764405,"thyroid volume cois approved by the committee on human research, publications and ethics, knust, school of medical sciences and komfo anokye teaching hospital. the ethical approval reference number is chrpe/rc/058/16. permission to undertake the study at the hospitals was also sought from the hospital management. written informed consent was obtained from all participants recruited into the study. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
3012,29319381,dwi
3013,29319381,grave’s orbitopathy
3014,29319381,mri
3015,29319381,head and neck
3016,29319381,orbit
3017,29319381,thyroid eye disease
3018,29787340,cd8+ t cells
3019,29787340,cd8+ t-regulatory cells
3020,29787340,graves’ ophthalmopathy
3021,29787340,thyroid autoimmunity
3026,29708883,graves’ disease
3027,29708883,allogenic hematopoietic stem cell transplantation
3028,29708883,hyperthyroidism; severe aplastic anemia
3030,30458118,*rthβ
3031,30458118,*thrb gene
3032,30458118,*novel mutation
3033,28992728,intrapartum treatment
3034,28992728,cesarean section
3035,28992728,congenital high airway obstruction
3036,28992728,fetal neck tumors
3037,28992728,trachea
3039,30224619,graves’ disease
3040,30224619,glucose intolerance
3041,30224619,glycosuria
3042,30224619,hyperthyroidism
3043,30224619,urine glucose screening program
3044,29409479,dysthyroid optic neuropathy
3045,29409479,orbital radiotherapy
3046,29409479,three-wall decompression
3047,29409479,thyroid eye disease cois this case report was approved by the ethics committee of shanghai ninth people’s hospital (no. [2016]-29). the report was in compliance with the tenets of the declaration of helsinki for clinical research. consent for publication: written informed consent was obtained from the patient for publication of this case report and any accompanying images. a copy of the consent is available for review by the editor of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3048,29307098,hybrid procedure
3049,29307098,lung tumor
3050,29307098,mediastinal tumor
3051,29307098,robotic surgery
3052,29307098,single incision
3053,29307098,thyroid tumor
3055,29786585,pesticides
3056,29786585,morbidity
3057,29786585,thyroid gland
3058,29786585,application rate
3062,30413358,(99m)tc-pertechnetate uptake
3063,30413358,calculated-dose
3064,30413358,captación de (99m)tc-pertecnetato
3065,30413358,clinical outcomes
3066,30413358,cálculo de dosis
3067,30413358,enfermedad de graves
3068,30413358,graves’ disease
3069,30413358,radioiodine
3070,30413358,resultados clínicos
3071,30413358,yodo radiactivo
3073,31670633,postoperativehypocalcemia
3074,31670633,recurrentlaryngealnervepalsy
3075,31670633,totalthyroidectomy
3076,31670633,tubercleofzuckekandl
3080,30610492,antithyroid antibodies
3081,30610492,antithyroid drugs
3082,30610492,graves’ disease
3083,30610492,hyperthyroidism
3084,30610492,type 2 deiodinase
3085,29096966,*calcificaciones
3086,29096966,*calcifications
3087,29096966,*carcinoma tiroideo
3088,29096966,*doppler
3089,29096966,*ecografía
3090,29096966,*elastografía
3091,29096966,*elastography
3092,29096966,*malignancy
3093,29096966,*malignidad
3094,29096966,*nódulo tiroideo
3095,29096966,*thyroid carcinoma
3096,29096966,*thyroid nodule
3097,29096966,*ultrasound
3098,30426886,*graves' disease
3099,30426886,*tsh receptor antibody
3100,30426886,*incidence
3101,30426886,*neonatal hyperthyroidism
3102,30426886,*radioiodine therapy
3103,29633307,*graves’ disease
3104,29633307,*thypro
3105,29633307,*thyrotoxicosis
3106,29633307,*treatment choice
3107,29633307,*treatment satisfaction
3108,29023978,body mass index
3109,29023978,levothyroxine
3110,29023978,radioactive iodine ablation
3111,31369161,*grave's
3112,31369161,*cancer
3113,31369161,*nodules
3114,31369161,*thyroid
3115,31124148,*immunology
3116,31124148,*immunosuppression
3117,31124148,*thyroid diseases
3118,31124148,*vasculitis
3119,31079052,*cosmesis
3120,31079052,*eye lids
3121,31079052,*orbit cois
3122,30658624,99mtc-dtpa
3123,30658624,graves’ orbitopathy
3124,30658624,mri
3125,30658624,"spect/ct cois involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964. helsinki declaration and its later amendments or comparable ethical standards. the study was approved by the bioethical commission of medical university of bialystok, poland. all participants provided written informed consent to participate. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
3126,30628510,clinical activity score
3127,30628510,color doppler imaging
3128,30628510,thyroid eye disease
3129,30616573,*diagnosis
3130,30616573,*graves’ disease
3131,30616573,*hashimoto’s thyroiditis
3132,30616573,*model
3133,29959506,computed tomography
3134,29959506,eyelid retraction
3135,29959506,graves’ orbitopathy
3136,29959506,inferior rectus muscle
3137,29959506,levator palpebrae superioris muscle
3138,29959506,margin reflex distance
3139,29959506,superior rectus muscle
3141,28738723,*thyroid eye disease
3142,28738723,*patient expectations
3143,28738723,*psychosocial adjustment
3144,28738723,*reconstructive surgery
3145,28738723,*treatment satisfaction
3148,29469200,*dicer1
3149,29469200,*cryptic exon
3150,29469200,*deep intronic mutation
3151,29469200,*lung cyst
3152,29469200,*multinodular goiter
3153,29469200,*ovarian sertoli-leydig cell tumor
3154,30761931,graves’ disease
3155,30761931,movement disorders
3156,30761931,autoimmune
3157,30761931,chorea
3158,30761931,hyperthyroidism
3159,30761931,myoclonus
3160,30761931,tremor
3161,30721670,*bone morphogenic protein 4
3162,30721670,*orbit
3163,30721670,*pathology
3164,30721670,*site-specific adipogenesis
3168,31784912,embryopathy
3169,31784912,graves’ diseases
3170,31784912,methimazole
3171,31784912,pancreatitis
3172,31784912,pregnancy
3173,31784912,propylthiouracil
3175,28568286,gpr174
3176,28568286,ptpn22
3177,28568286,rnaset2
3178,28568286,gene polymorphism
3179,28568286,liver damage
3180,29521049,graves’ disease
3181,29521049,matrix metalloproteinases
3182,29521049,orbithopathy
3183,29521049,tissue inhibitors of metalloproteinases
3184,30918165,antithyroid drug
3185,30918165,graves’ disease
3186,30918165,hyperthyroidism
3187,30918165,tsh receptor antibody
3188,30918165,thyroid
3191,30151919,*3d
3192,30151919,*thyroid-associated orbitopathy
3193,30151919,*eye-tracking
3194,30151919,*facial deformity
3195,30151919,*scanpath
3196,29739340,*brazil
3197,29739340,*hereditary deafness
3198,29739340,*pendrin gene
3199,29739340,"*slc26a4 cois written informed consent was obtained from all individuals or their legal guardians (if patients were under 18). the project was approved by the ethics committee, instituto de biociências, universidade de são paulo (protocol n(o) 109/2010). consent for publication: all subjects have approved the submission of the manuscript by written informed consent. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
3202,29096933,graves’ orbitopathy
3203,29096933,balanced decompression
3204,29096933,deep lateral decompression
3205,29096933,intact rim
3206,29096933,proptosis
3207,29096933,rim removal
3210,30167837,graves’ orbitopathy
3211,30167837,nasal airflow
3212,30167837,olfactory performance
3213,30167837,orbital decompression
3214,30167837,surgical outcome
3219,32202741,*igg4-associated disease
3220,32202741,*autoimmune thyroiditis
3221,32202741,*case report
3222,32202741,*inflammatory orbital disease
3223,32202741,*orbital involvement
3224,32202741,*thyroid eye disease
3228,30442552,graves’ orbitopathy
3229,30442552,deep lateral decompression
3230,30442552,proptosis
3231,30442552,rim-sparing
3232,32476690,"cholesterol, hdl"
3233,32476690,"igf1 protein, human"
3234,32476690,"igf2 protein, human"
3235,32476690,insulin
3236,32476690,insulin-like growth factor i
3237,32476690,insulin-like growth factor ii
3238,32476690,iodine
3239,32476690,"obesity, abdominal"
3240,32476690,thyroid nodule
3241,32476690,case-control studies
3242,32476690,insulin resistance
3243,32476690,metabolic syndrome
3244,30223781,*cd40
3245,30223781,*ctla-4
3246,30223781,*genetic polymorphism
3247,30223781,*graves’ disease cois the medical ethics committee of the affiliated hospital of guangdong medical university. the approval number was: pj2012029. all the above enrolled patients signed an informed consent document. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3248,31188037,*bézier curves
3249,31188037,*graves orbitopathy
3250,31188037,*contour analysis
3251,31188037,*lower eyelid
3252,31188037,*lower eyelid retraction
3255,29627743,chronic autoimmune thyroiditis
3256,29627743,diffuse thyroid disease
3257,29627743,swe
3258,29627743,ft3/ft4 ratio
3259,31474503,graves’ orbitopathy
3260,31474503,endocrine ophthalmopathy
3261,31474503,fat removal
3262,31474503,orbital decompression
3263,30543152,*mapk/erk pathway
3264,30543152,*pi3k/akt pathway
3265,30543152,*tbx1
3266,30543152,*epithelial–mesenchymal transition
3267,30543152,*thyroid cancer
3268,30954956,endocrine system
3269,30954956,thyroid disease cois
3270,30084099,*craniosynostosis
3271,30084099,*graves’ orbitopathy
3272,31831041,graves disease
3273,31831041,thrombotic thrombocytopenic purpura cois
3275,30142011,color doppler imaging
3276,30142011,orbital decompression
3277,30142011,thyroid eye disease
3278,29937157,extraocular muscles
3279,29937157,graves’ ophthalmopathy
3280,29937157,grosor muscular
3281,29937157,muscle thickness
3282,29937157,músculos extraoculares
3283,29937157,oftalmopatía de graves
3284,29937157,optical coherence tomography
3285,29937157,orbitopatía tiroidea
3286,29937157,thyroid orbitopathy
3287,29937157,tocilizumab
3288,29937157,tomografía de coherencia óptica
3289,31056988,extraocular muscle
3290,31056988,graves’ eye disease
3291,31056988,superior recuts
3292,31056988,thyroid eye disease
3293,30009641,*human extraocular muscle
3294,30009641,*human extraocular muscle myoblasts
3295,30009641,*myogenesis
3296,30009641,*thyroid-associated ophthalmopathy
3297,30009641,*thyroid-stimulating hormone receptor
3299,30941511,anterior blepharotomy
3300,30941511,esthetic outcome
3301,30941511,graves’ ophthalmopathy
3302,30941511,tarsal platform show
3303,30941511,upper eyelid retraction
3309,31365979,graves orbitopathy
3310,31365979,graves orbitopathy guality of life questionnaire
3311,31365979,quality of life
3312,31059842,cxcl10
3313,31059842,cxcl8
3314,31059842,fibroblasts
3315,31059842,graves' disease
3316,31059842,graves' ophthalmopathy
3317,31059842,thyrocytes
3320,29319400,graves’
3321,29319400,orbital decompression
3322,29319400,strabismus
3323,29166180,*corvis-st
3324,29166180,*dynamic scheimpflug analyzer
3325,29166180,*biomechanics
3326,29166180,*thyroid orbitopathy
3327,29166180,*whole eye movement
3328,28177666,graves’ disease
3329,28177666,graves’ ophthalmopathy
3330,28177666,cytokine
3331,28177666,gene
3332,28177666,genetic polymorphism
3333,28177666,maladie de graves
3334,28177666,ophtalmopathie de graves
3335,28177666,poly (adp-ribose) polymerase-1
3336,28177666,poly (adp-ribose) polymérase-1
3337,28177666,polymorphism
3338,28177666,polymorphisme
3339,28177666,polymorphisme génétique
3341,30535759,autoimmune thyroid diseases
3342,30535759,graves’ disease
3343,30535759,hashimoto’s thyroiditis
3344,30535759,magi2
3345,30535759,single-nucleotide polymorphisms
3346,30513237,graves’ orbitopathy
3347,30513237,orbital decompression
3348,30513237,diplopia
3349,30513237,piezosurgery
3350,30513237,proptosis reduction
3352,29190000,autoimmune
3353,29190000,dna methylation
3354,29190000,genome-wide
3355,29190000,graves’ orbitopathy
3356,30937820,hypoparathyroidism
3357,30937820,recurrent nerve injury
3358,30937820,reoperative thyroid surgery
3359,30937820,total thyroidectomy
3360,31604721,calcium and bone
3361,31604721,thyroid disease cois
3362,30801749,*calcium
3363,30801749,*hypoparathyroidism
3364,30801749,*dyspepsia
3365,30801749,*hospitalization
3366,30801749,*patient survey
3367,30801749,*vitamin d
3368,30176063,*chinese cohort
3369,30176063,*graves' disease
3370,30176063,*genome-wide association study
3371,30176063,*susceptibility loci
3372,29336220,*graves'
3373,29336220,*cholesterol
3374,29336220,*ophthalmopathy
3375,29336220,*orbitopathy
3376,29336220,*statins
3377,29273685,*igf receptor
3378,29273685,*immune system
3379,29273685,*signal transduction
3380,29273685,"*thyroid cois member at the ucla school of medicine covering the diagnostic methods for monitoring anti-igf-ir antibodies and the therapeutic targeting of igf-ir in graves’ disease and other autoimmune diseases. i have requested that my current employer, the university of michigan medical school, adjudicate any conflicts of interest."
3381,31271716,*graves’ disease
3382,31271716,*pretibial myxedema
3383,31271716,*thyroid dermopathy
3386,31884304,autoantibodies
3387,31884304,graves' disease
3388,31884304,smoking
3389,31884304,vitamin 25(oh)d3 cois
3391,30092570,childhood onset
3392,30092570,graves’ disease
3393,30092570,papillary thyroid carcinoma
3394,30092570,slc5a5
3395,30092570,tfg/ntrk1
3396,30092570,tshr
3398,31685507,*graves' disease
3399,31685507,*cognitive impairment
3400,31685507,*functional near-infrared spectroscopy
3401,31685507,*hippocampus
3402,31685507,*magnetic resonance volumetry
3403,31685507,*quality of life cois and bristol-myers squibb.
3404,31338585,dexamethasone
3405,31338585,interleukin 6
3406,31338585,interleukin 6 receptor
3407,31338585,thyroid eye disease
3408,31338585,tocilizumab
3411,31462328,aggressive carcinoma
3412,31462328,graves’ disease
3413,31462328,matched cohort
3414,31462328,outcomes
3415,31462328,papillary thyroid carcinoma cois
3416,31304517,graves’ disease
3417,31304517,mig
3418,30825882,champagne bottle neck sign
3419,30825882,graves’ disease
3420,30825882,moyamoya vasculopathy
3421,30825882,recurrence
3422,30825882,vasculitis cois publication: written informed consent was obtained from the patient for publication of this case report. a copy of the written consent is available for review by the editor of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3424,29742012,eyelid
3425,29742012,recession
3426,29742012,retraction
3427,29742012,spacer graft
3428,29742012,thyroid
3432,28822031,thyroid eye disease
3433,28822031,thyroid ophthalmopathy
3434,28822031,visa
3436,31482765,*graves' disease
3437,31482765,*antithyroid drugs
3438,31482765,*hyperthyroidism
3439,31482765,*long-term follow-up
3440,31482765,*radioiodine
3441,31482765,*recurrence
3442,31482765,*remission
3443,31482765,*thyroidectomy
3446,31057005,compressive optic neuropathy
3447,31057005,dysthyroid optic neuropathy
3448,31057005,extra-ocular muscles
3449,31057005,orbital computed tomography
3450,31057005,thyroid eye disease
3451,31057005,visual field
3453,30803176,orbital fibroblast
3454,30803176,pirfenidone
3455,30803176,thyroid
3456,30803176,transforming growth factor
3459,29439614,*131i
3460,29439614,*graves' disease
3461,29439614,*thyroglobulin autoantibodies
3462,29439614,*thyroglobulin measurement
3463,29439614,*thyroglobulin metabolic clearance
3464,29439614,*thyroid cancer
3465,28776731,*+49a/g
3466,28776731,*131i
3467,28776731,*graves' disease
3468,28776731,*cytotoxic t lymphocyte antigen 4
3469,28776731,*polymorphism
3470,28776731,*radionuclide
3471,28776731,*−318c/t
3474,28944477,*endoscopy
3475,28944477,*graves disease
3476,28944477,*orbit
3477,28944477,*paranasal sinus
3478,28944477,*quality of life
3479,28944477,*surgical decompression
3480,31152536,graves’ orbitopathy
3481,31152536,orbit decompression
3482,31152536,thyroid-associated orbitopathy
3485,31595798,*graves’ ophthalmopathy
3486,31595798,*retina
3487,31595798,*density
3488,31595798,*microvasculature
3489,31595798,*optical coherence tomography angiography
3491,29784035,american thyroid association guidelines
3492,29784035,graves’ disease
3493,29784035,hyperthyroid
3494,29784035,thyroid hormones
3495,29784035,thyroid storm
3496,29784035,thyroidectomy cois obtained through our review ethics board committee prior to the study. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3497,29648895,autoimmune thyroid disease
3498,29648895,d1
3499,29648895,d2
3500,29648895,severity
3501,29648895,single nucleotide polymorphism
3502,29421653,*fibroblast proliferation
3503,29421653,*hyaluronan
3504,29421653,*igf-1
3505,29421653,*membrane potential
3506,29421653,*molecular weight
3507,29421653,*ph20
3509,31025590,b cells
3510,31025590,graves’ disease
3511,31025590,graves’ orbitopathy
3512,31025590,rituximab
3513,31025590,thyroid eye disease
3514,31025590,anti-cd20
3515,31025590,proptosis
3517,30354697,*graves’ disease
3518,30354697,*thyroid stimulating hormone receptor antagonist
3519,30354697,*antithyroid drugs
3520,30354697,*hyperthyroidism
3521,30354697,*immunosuppressive treatment
3522,30354697,*radioiodine
3523,30354697,*thyroid receptor antagonists
3524,30354697,*thyroid stimulating hormone
3525,30354697,*thyrotoxicosis
3526,30229982,*intravenous methylprednisolone
3527,30229982,*thyroid-associated ophthalmopathy
3528,30229982,*triglycerides
3530,29448964,exophthalmos
3531,29448964,myxedema
3532,29448964,primary hyperthyroidism
3533,29448964,rituximab cois case to the institutional ethics committee. consent for publication: written informed consent was obtained from the patient for publication of this case report and any accompanying images. copies of the written consent are available for review by the editor-in-chief of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3536,30924084,*gene
3537,30924084,*graves’ disease
3538,30924084,*polymorphisms
3539,30924084,*vdr
3540,30924084,*vitamin d receptor
3541,30173330,*i-ionm
3542,30173330,*neuromonitoring
3543,30173330,*recurrent laryngeal nerve stimulation
3544,30173330,*staged thyroidectomy
3545,30173330,*thyroid
3547,31530446,*dunhill procedure
3548,31530446,*graves' disease
3549,31530446,*graves' ophthalmopathy
3550,31530446,*bilateral subtotal thyroidectomy
3551,31530446,*subtotal thyroidectomy
3552,31530446,*total thyroidectomy
3553,28388869,graves’ disease
3554,28388869,s-trabs
3555,28388869,hyperthyroidism
3556,29343299,graves’ disease
3557,29343299,hashimoto’s thyroiditis
3558,29343299,metamorphic autoimmunity
3559,29343299,natural history
3560,29343299,thyroid status cois publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3561,30912336,*antithyroid agents
3562,30912336,*cure
3563,30912336,*graves hyperthyroidism
3564,30912336,*long term outcome
3565,30912336,*radioactive iodine
3566,30912336,*remission
3567,30912336,*thyroidectomy cois
3568,31169822,arteriovenous fistula
3569,31169822,false aneurysm
3570,31169822,goiter
3571,31169822,thyroidectomy
3572,31391354,graves’ disease
3573,31391354,hyperthyroidism
3574,31391354,iodine-131 radioactive iodine uptake
3575,31391354,radioiodine therapy
3576,31379878,*graves' disease
3577,31379878,*tshr
3578,31379878,*next-generation sequencing
3579,31379878,*splicing isoforms
3580,31379878,*thymus
3581,31379878,*thyroid
3582,31379878,*tolerance
3586,30256028,autografts
3587,30256028,dermis-fat graft
3588,30256028,eyelids – surgery
3589,30256028,graves ophthalmopathy – surgery
3590,30256028,reconstructive surgical procedures – methods
3591,30256028,skin transplantation
3592,31146635,*jordan
3593,31146635,*hyperthyroidism
3594,31146635,*hypothyroidism
3595,31146635,*prevalence
3596,31146635,*thyroid dysfunction
3597,31665858,hypercholesterolemia
3598,31665858,thyroid associated ophthalmopathy
3599,31636036,ent surgery
3600,31636036,endocrine surgery
3601,31636036,gbi
3602,31636036,glasgow benefit inventory
3603,31636036,graves' disease
3604,31636036,patient recorded outcome measure
3605,31636036,patient satisfaction score
3606,31636036,thyroid
3607,31636036,total thyroidectomy cois
3609,29562915,extra-thyroidal autoimmunity
3610,29562915,graves’ disease
3611,29562915,hashimoto’s thyroiditis
3612,29562915,metamorphic autoimmunity
3613,29562915,thyroid status cois publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3615,30506346,gender
3616,30506346,graves’ disease (gd)
3617,30506346,hyperthyroidism
3618,30506346,hyperuricemia
3619,30506346,serum uric acid (sua)
3621,30170970,diplopia
3622,30170970,dysthyroid optic neuropathy
3623,30170970,exophthalmos
3624,30170970,grave's disease
3625,30170970,orbital decompression
3626,30170970,vision loss
3630,29996609,"decompression, surgical"
3631,29996609,graves ophthalmopathy
3632,29996609,optic nerve diseases
3633,29996609,orbit
3634,31021263,lower eyelid retraction
3635,31021263,orbital decompression
3636,31021263,proptosis
3637,31021263,surgical technique
3638,31021263,thyroid eye disease
3641,29367360,"ear, nose and throat/otolaryngology"
3642,29367360,head and neck surgery
3643,29367360,otolaryngology / ent
3644,29367360,thyroid disease cois
3647,31418705,*haemoglobin a2
3648,31418705,*hyperthyroidism
3649,31418705,*β-thalassemia trait
3651,30220185,choroid
3652,30220185,graves ophthalmopathy
3653,30220185,"tomography, optical coherence"
3654,29996608,"decompression, surgical"
3655,29996608,endoscopy
3656,29996608,graves ophthalmopathy
3657,29996608,orbit
3659,29890310,forkhead box p3 (foxp3)
3660,29890310,graves' disease
3661,29890310,regulatory t cells
3662,29890310,restriction fragment length polymorphism
3663,29890310,single nucleotide polymorphism
3666,29027055,deficiency disorder
3667,29027055,iodine in soil and plants
3668,29027055,people’s perception
3669,29027055,socio-economic determinants
3670,29027055,wheat crop
3673,30099999,*autoimmune disorders
3674,30099999,*crohn disease
3675,30099999,*graves disease
3676,30099999,*hashimoto thyroiditis
3677,30099999,*inflammatory bowel disease
3678,30099999,*multiple sclerosis
3679,30099999,*systemic lupus erythematosus
3680,30099999,*ulcerative colitis
3681,29406005,*fetal
3682,29406005,*graves disease
3683,29406005,*hyperthyroidism
3684,29406005,*neonatal
3685,29406005,*thyrotoxicosis
3686,31742747,*hyperthyroidism
3687,31742747,*thyroid scintigraphy
3688,31742747,*thyroid ultrasonography
3689,31742747,*thyroid-stimulating immunoglobulins (tsi)
3690,31742747,*thyrotropin receptor antibodies (trab)
3691,30244229,cardiovascular medicine
3692,30244229,thyroid disease cois
3693,30670519,*clinical trials
3694,30670519,*immunology
3695,30670519,*paediatric endocrinology
3696,30670519,*thyroid disease cois
3699,31460819,endocrine ophthalmopathy
3700,31460819,endoscopic sinus surgery
3701,31460819,orbital complication
3702,31460819,rhinosinusitis
3703,31460819,vision loss
3705,29510406,autoimmune thyroid disease (aitd)
3706,29510406,graves’ disease (gd)
3707,29510406,hashimoto’s thyroiditis (ht)
3708,29510406,ikaros family of zinc finger3 (ikzf3)
3709,29510406,single nucleotide polymorphism (snp)
3711,28598035,graves’ disease
3712,28598035,association analysis
3713,28598035,early-onset
3714,28598035,heterogeneity analysis
3715,28598035,single nucleotide polymorphisms
3717,30226207,graves’ disease
3718,30226207,membranoproliferative glomerulonephritis
3719,30226207,proteinuria
3720,29310665,*graves’ disease
3721,29310665,*hyperthyroidism
3722,29310665,*methimazole
3723,29310665,"*thyroid receptor antibodies cois analysis of de-identified data collected for another purpose. all data are retrospective and presented in an aggregated fashion. so, no irb approval was required. patient numbers used in the model validation section of the article are spreadsheet numbers from data, which can not be used to identify the patients name, family name or other specific details. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
3724,31280470,*arterial stiffness
3725,31280470,*blood pressure
3726,31280470,*graves’ disease
3727,31280470,*pulse wave analysis
3730,31899052,*igf-1
3731,31899052,*orbital fibroblasts
3732,31899052,*thyroid-associated ophthalmopathy
3733,31899052,*thyroid-stimulating hormone receptor cois conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.
3734,31827051,autoimmune thyroid diseases
3735,31827051,graves’ disease
3736,31827051,hashimoto’s thyroiditis
3737,31827051,meta-analysis
3738,31827051,regulatory t cells
3739,31617239,graves' disease
3740,31617239,autoantibody
3741,31617239,catalase
3742,31617239,hydrogen peroxide
3743,31617239,malondialdehyde
3744,31617239,oxidative stress
3746,29976201,*circulating mirnas
3747,29976201,*graves’ disease
3748,29976201,*let-7b
3749,29976201,*thyrotropin receptor antibody
3752,29549672,autoantibodies
3753,29549672,autoimmune thyroid diseases
3754,29549672,blood platelets
3755,29549672,chronic inflammation
3756,29549672,lymphocytes
3757,28343872,*balanced decompression
3758,28343872,*dysthyroid optic neuropathy
3759,28343872,*fat decompression
3760,28343872,*lateral decompression
3761,28343872,*medial decompression
3762,28343872,*orbital decompression
3763,28343872,*surgical technique
3764,28343872,*thyroid eye disease
3769,30369529,graves’ disease
3770,30369529,cerebral venous thrombosis
3771,30369529,factor viii procoagulant protein
3772,30369529,hyperthyroidism
3773,29319130,anaplastic thyroid carcinoma
3774,29319130,thyrotoxicosis
3777,31932147,*autoimmune thyroid diseases
3778,31932147,*chemokines
3779,31932147,*cytokines
3780,31932147,*dermatological autoimmune diseases
3781,31932147,*systemic autoimmune diseases cois
3782,30843111,*anti-pla2r
3783,30843111,*children
3784,30843111,*graves’ disease
3785,30843111,*membranous nephropathy
3786,30843111,*rituximab
3791,29266775,*bmpr2
3792,29266775,*epstein-barr virus
3793,29266775,*graves’ disease
3794,29266775,*tgf-β/bmp
3795,29266775,*expression assay
3796,29266775,*functional analysis
3797,29266775,*lymphoblastoid cell lines
3798,29266775,*pulmonary arterial hypertension
3800,31279175,*autoimmune thyroid disease
3801,31279175,*development
3802,31279175,*ifng
3803,31279175,*methylation
3804,31279175,*prognosis
3805,30880626,*graves'
3806,30880626,*bimatoprost
3807,30880626,*fat atrophy
3808,30880626,*orbitopathy
3809,30880626,*prostaglandin f
3810,30880626,*thyroid eye disease
3811,30565709,*graves ophthalmopathy
3812,30565709,*inactive phase
3813,30565709,*interleukin-15
3814,30565709,*interleukin-17
3815,30057255,anca
3816,30057255,antineutrophil cytoplasmic antibodies
3817,30057255,methimazole
3818,30057255,metimazol
3819,30057255,vasculite
3820,30057255,vasculitis
3821,29517388,blood vessel density
3822,29517388,graves’ orbitopathy
3823,29517388,oct angiography
3824,29517388,decompression
3825,29517388,dysthyroid optic neuropathy
3826,29325496,*graves' disease
3827,29325496,*trab
3828,29325496,*neonatal thyrotoxicosis
3829,29325496,*pregnancy
3830,29325496,*thyroid
3831,30452877,calprotectin
3832,30452877,graves’ orbitopathy
3833,30452877,inflammation
3834,30452877,orbital fibroblast
3835,30452877,thyroid eye disease
3836,29174550,decompression
3837,29174550,endocrine orbitopathy
3838,29174550,scleral show
3839,31792849,graves’ ophthalmopathy
3840,31792849,spect/ct
3841,31792849,triamcinolone
3844,30044728,*graves’ disease
3845,30044728,*autoimmune
3846,30044728,*monoclonal antibody
3847,30044728,"*signaling cois antibody-mediated inflammatory auto-immune disorders (us 6936426), the diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders (us 7998681 and us 8153121), and diagnostic methods related to graves’ disease and other autoimmune disorders (us 8178304). he was previously a paid consultant for river vision."
3848,29601105,*graves' ophthalmopathy
3849,29601105,*graves' orbitopathy
3850,29601105,*glucocorticoids
3851,29601105,*rituximab
3852,29601105,*thyroid eye disease
3856,31223030,graves' disease
3857,31223030,inflammation
3858,31223030,neutrophils platelet count.
3860,30187962,corticosteroid
3861,30187962,endocrine disorders
3862,30187962,topical
3864,30358895,*graves' disease
3865,30358895,*hcp5
3866,30358895,*autoimmunity
3867,30358895,*children
3868,30358895,*genetics
3869,30358895,*single nucleotide polymorphism
3870,30358895,*thyroid
3875,30854863,iodine radioisotopes
3876,30854863,neck dissection
3877,30854863,thyroid neoplasms
3878,30854863,thyrotoxicosis
3879,30814442,anti-thyroid drugs
3880,30814442,autotaxin
3881,30814442,graves’ disease
3882,30814442,lysophosphatidic acids
3883,30814442,thyroid hormones
3884,30488266,asymmetric enlargement
3885,30488266,lacrimal gland
3886,30488266,malignancy
3887,30488266,thyroid eye disease
3888,30463536,8-ohdg
3889,30463536,graves’ orbitopathy
3890,30463536,mda
3891,30463536,oxidative stress
3892,30463536,"tear cois all patients, and the study was conducted with approval from the institutional review board at chonnam national university hospital. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
3893,30148416,graves disease
3894,30148416,lasik
3895,30148416,salzmann’s nodular degeneration
3896,30148416,thyroid eye disease
3898,29949121,coagulation
3899,29949121,graves’ orbitopathy
3900,29949121,methylprednisolone
3901,29949121,pulmonary embolism
3902,29949121,venous thromboembolic event cois ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. informed consent: informed consent was obtained from all individual participants included in the study.
3904,29507013,adrenal disorders
3905,29507013,endocrine system
3906,29507013,thyroid disease cois
3908,30568070,graves’ disease
3909,30568070,surgical complications
3910,30568070,total thyroidectomy
3911,29482520,case report
3912,29482520,graves’ ophthalmopathy
3913,29482520,graves’ disease
3914,29482520,loss of vision
3915,29482520,orbital decompression
3916,29482520,strabismus cois publication: written informed consent was obtained from the patient for publication of this case report and any accompanying images. a copy of the written consent is available for review by the editor of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3917,30325581,99mtc-anti-tnf
3918,30325581,graves disease
3919,30325581,graves ophthalmopathy
3920,30325581,diagnosis
3921,30325581,nuclear medicine
3922,30188609,*aggregation
3923,30188609,*autoimmune thyroid diseases
3924,30188609,*blood platelets
3925,30188609,*platelet-derived microparticles
3927,31257166,*graves’ disease
3928,31257166,*hashimoto’s thyroiditis
3929,31257166,*autoimmune disease
3930,31257166,*dysbiosis
3931,31257166,*enterohepatic cycling of thyroid hormones
3932,31257166,*probiotics
3933,30302684,*hyperthyreodism
3934,30302684,*antithyroid drug
3935,30302684,*radioiodine therapy
3936,30302684,*thermoablation
3937,30302684,*thyroid surgery
3939,31240859,slco1b1
3940,31240859,grave's disease
3941,31240859,drug-induced liver injury
3942,31240859,methimazole
3943,31240859,polymorphisms
3944,31715678,acellular dermis
3945,31715678,eyelids
3946,31715678,graves ophthalmopathy
3947,31715678,reconstructive surgical procedures
3948,31715678,"transplantation, heterologous"
3950,29440561,*graves’ disease
3951,29440561,*polymorphism
3952,29440561,*tumor necrosis factor-α cois manuscript.
3956,28856610,ablation
3957,28856610,autoimmunity
3958,28856610,graves’ disease
3959,28856610,graves’ orbitopathy
3960,28856610,radioiodine
3961,28856610,thyroid
3962,31691261,graves’ disease
3963,31691261,graves’ orbitopathy
3964,31691261,idiopathic orbital inflammation
3965,31691261,orbital lymphoma
3966,31691261,pseudotumor
3967,31453725,graves’ disease
3968,31453725,thyrotropin
3969,31453725,hyperthyroidism
3970,31453725,immunoassay
3971,31453725,thyroid-stimulating antibody
3974,29571699,apparent diffusion coefficient
3975,29571699,diffusion-weighted imaging
3976,29571699,graves’ disease
3977,29571699,orbit
3978,29571699,thyroid associated ophthalmopathy
3979,29147850,*active
3980,29147850,*cytokines
3981,29147850,*eye
3982,29147850,*graves’
3983,29147850,*specificity
3984,29147850,*tears
3985,31834613,adverse events
3986,31834613,graves’ orbitopathy
3987,31834613,mycophenolate
3988,31834613,safety
3989,31782290,*thyroid hormone
3990,31782290,*thyroid volume
3991,31782290,*graves’ disease
3992,31782290,*soluble cd40 ligand (scd40l)
3993,31705858,graves' orbitopathy
3994,31705858,nrf2
3995,31705858,oxidative stress
3996,31705858,polydatin cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
3997,31612195,cxcr3
3998,31612195,graves’ophthalmoapthy
3999,31612195,mig
4000,31612195,thyroid eye disease
4002,31316787,*aih
4003,31316787,*graves' ophthalmopathy
4004,31316787,*methylprednisolone-induced liver injury
4005,31316787,*multiple sclerosis
4006,31316787,*steroid pulses
4007,30261581,graves’ disease
4008,30261581,nt-probnp
4009,30261581,ambulatory blood pressure monitoring
4010,30261581,blood pressure
4011,30261581,glucocorticoids
4012,30261581,graves’ orbitopathy
4013,30261581,hypertension
4014,30261581,methylprednisolone
4015,30261581,pulse therapy cois
4016,30222206,graves’ disease
4017,30222206,hashimoto thyroiditis
4018,30222206,alopecia areata
4019,30222206,autoimmune disease
4020,30222206,autoimmune thyroid disease
4021,29457989,"*aav, anti-neutrophil cytoplasmic antibody-associated vasculitis"
4022,29457989,"*anca, anti-neutrophil cytoplasmic antibody"
4023,29457989,"*dress, drug reaction with eosinophilia and systemic symptoms"
4024,29457989,"*ivig, intravenous ɤ-globulin"
4025,29457989,"*kd, kawasaki disease"
4026,29457989,*kawasaki disease
4027,29457989,"*mmi, methimazole"
4028,29457989,"*mpo, myeloperoxidase"
4029,29457989,"*ptu, propylthiouracil"
4030,29457989,*propylthiouracil
4031,29457989,*anti-neutrophil cytoplasmic antibody
4032,29457989,*general paediatrics
4033,29457989,*immunology
4034,29457989,*intravenous ɤ-globulin
4035,31393984,*basedow disease
4036,31393984,*dysthyroid optic neuropathy
4037,31393984,*endoscopic endonasal surgery
4038,31393984,*graves disease
4039,31393984,*optic nerve decompression
4040,31393984,*orbital apex
4041,31393984,*thyroid eye disease
4042,31296093,extraocular muscle
4043,31296093,graves’ ophthalmopathy
4044,31296093,real-time ultrasound elastography
4045,31236779,*antithyroid drug
4046,31236779,*graves’ disease
4047,31236779,*relapse
4048,31236779,*remission
4050,30179522,graves' disease
4051,30179522,autopsy
4052,30179522,high-altitude cerebral edema
4053,30179522,high-altitude pulmonary edema
4054,30179522,hyperthyroidism
4055,30179522,sudden death
4058,31255731,*autoimmune thyroid disease (aitd)
4059,31255731,*fas
4060,31255731,*hla-dr
4061,31255731,*hypothyroidism
4062,31255731,*il-1β
4063,31255731,*uterus globulin associated protein 1 (ugrp1)
4064,31176495,estrabismo
4065,31176495,fistula
4066,31176495,fístula
4067,31176495,hipertiroidismo
4068,31176495,hyperthyroidism
4069,31176495,orbit
4070,31176495,orbitopatía tiroidea
4071,31176495,strabismus
4072,31176495,thyroid orbitopathy
4073,31176495,órbita
4075,29866676,stroke
4076,29866676,thyroid disease cois
4077,29371709,"grave's disease, pcr-rflp, snps, cd 28, cd 40."
4078,31672295,cytology
4079,31672295,false-negative diagnoses
4080,31672295,false-positive diagnoses
4081,31672295,fine-needle aspiration
4082,31672295,thyroid cancer
4083,31672295,thyroid nodule cois this work did not receive any specific grant funding.
4084,31587179,adverse events
4085,31587179,graves’ disease
4086,31587179,graves’ orbitopathy
4087,31587179,oral prednisone
4088,31587179,radioiodine
4089,31587179,steroid prophylaxis
4090,31207925,graves’ disease
4091,31207925,oxidative stress
4092,31207925,thiol/disulphide homeostasis cois
4093,31091045,*graves’ disease
4094,31091045,*alpha-2-macroglobulin
4095,31091045,*cytokines
4096,31091045,*lactoferrin
4097,30618332,*graves' disease
4098,30618332,*autoimmunity
4099,30618332,*peptides
4100,30618332,*thyroid
4103,29383806,*hla
4104,29383806,*association study
4105,29383806,*autoimmunity
4106,29383806,*haplotype
4107,29383806,*type 1 diabetes
4109,30474825,acute pancreatitis
4110,30474825,drug-induced pancreatitis
4111,30474825,methimazole
4114,29566435,*graves’ disease
4115,29566435,*anaemia
4116,29566435,*haemoglobin
4117,29566435,*hyperthyroidism
4118,29566435,*thyroid function tests
4119,29566435,*thyroid hormones
4120,29566435,*thyrotoxicosis
4121,29412482,*3d reconstruction
4122,29412482,*orbital soft tissue volume
4123,29412482,*thyroid associated ophthalmopathy
4124,31301652,mutation
4125,31301652,polymorphism
4126,31301652,thyroid digenesis
4127,31301652,thyroid gland
4128,31301652,thyroid hormones
4129,31612654,decompression
4130,31612654,extraocular muscles
4131,31612654,graves ophthalmopathy
4132,31612654,optic nerve
4133,31612654,optical coherence tomogrphy cois
4134,31538314,cytokine
4135,31538314,graves’ orbitopathy
4136,31538314,human leukocyte antigen
4137,31538314,immunohistochemistry
4138,31538314,orbital tissue
4139,31538314,tsh receptor
4140,31202168,drug-induced liver injury
4141,31202168,human leukocyte antigens
4142,31202168,methimazole
4143,31202168,molecular docking
4147,30086864,*graves' disease
4148,30086864,*childhood
4149,30086864,*fetus
4150,30086864,*hyperthyroidism
4151,30086864,*neonates
4153,30414981,*biomarkers
4154,30414981,*fibrosis
4155,30414981,*graves' disease
4156,30414981,*inflammatory cytokines
4157,30414981,*orbitopathy
4158,30414981,*pai-1
4159,30414981,*plasmin cascade
4160,30414981,*serpins
4161,30414981,*tgf-β
4162,30414981,*tissue remodeling cois
4163,31446546,131i therapy
4164,31446546,hyperthyroidism
4165,31446546,hypothyroidism
4166,31446546,ku-70
4167,31446546,radiosensitivity
4168,29101123,*experimental laboratory cois
4169,31023005,*graves’ disease
4170,31023005,*methimazole
4171,31023005,*selenium
4172,31023005,*trab
4173,31023005,*tpoab
4174,31023005,*tgab cois
4176,29256262,*ago
4177,29256262,*autoimmune thyroid disease
4178,29256262,*intractability
4179,29256262,*polymorphism
4180,29256262,*severity
4182,29300515,b-cell lymphoma
4183,29300515,graves’ orbitopathy
4184,29300515,r-chop
4185,29300515,rituximab
4186,29300515,immunochemotherapy
4187,29300515,thyroid orbitopathy
4191,29308951,alexis retractor
4192,29308951,retractor
4193,29308951,lateral orbit
4194,29308951,thyroid eye disease
4196,31162982,eyelid retraction
4197,31162982,hering’s phenomenon
4198,31162982,mueller’s muscle-conjunctiva resection
4199,31162982,marginal reflex distance
4200,31162982,phenylephrine test
4201,31162982,thyroid eye disease
4202,30012381,anemarrhena bunge
4203,30012381,case report
4204,30012381,graves’ disease
4205,30012381,herbal decoction
4206,30012381,tsh binding inhibitory immunoglobulins
4207,30012381,thyroid stimulating hormone
4215,31740989,*grave’s disease
4216,31740989,*hepatotoxicity
4217,31740989,*mao-a
4218,31740989,*metabolomics
4219,31740989,*methimazole
4220,31740989,*ugt1a1*6
4223,30913888,adjustable sutures
4224,30913888,congenital fibrosis of the extraocular muscles
4225,30913888,double elevator palsy
4226,30913888,thyroid eye disease
4227,30913888,transposition procedure sec. knapp
4228,30913888,vertical strabismus
4229,30103255,*graves’ orbitopathy
4230,30103255,*methotrexate
4231,30103255,*methylprednisolone
4232,30103255,*steroid-sparing agents
4233,30103255,*thyroid eye disease
4234,29652204,corticoresistant
4235,29652204,graves’ orbitopathy
4236,29652204,low-dose
4237,29652204,rituximab
4238,29652204,treatment
4239,29491282,graves' disease
4240,29491282,central diabetes insipidus
4241,29491282,hyperthyroidism
4242,29491282,lymphocytic infundibulo-neurohypophysitis and thyroid crisis
4243,31194638,*graves' disease
4244,31194638,*autoimmune thyroid disease
4245,31194638,*desensitization
4246,31194638,*immunomodulation
4247,31194638,*peptide immunotherapy
4248,31194638,"*thyroid stimulating hormone receptor cois attending study meetings and for ad hoc advice. s.h.s.p. has received speaker fees from sanofi, quidel, and berlin-chemie. c.d. has consulted for apitope, has received speaker fees, and has consulted for sanofi-genzyme. d.c.w. serves as chief scientific officer for apitope technology (bristol) ltd. and apitope international nv on a consultative basis; is on the scientific advisory board for apitope international nv and has sat on scientific advisory boards for actelion pharma and zealand pharma; received travel funding from apitope international nv; is a senior editor for immunotherapy; holds patents for peptides, tolerization-inducing composition, fviii peptides, and their use in tolerizing hemophiliacs, composition, disease markers, tolerogenic peptides from mbp, peptide selection method, and improvements relating to influenza vaccine; has consulted for peptide therapeutics ltd., teva, gsk bio, hoffmann-la roche, novartis, dti, and the food standards agency; received research support within the past three years from apitope international nv, ucb celltech, mrc, the immune tolerance network, and the wellcome trust; holds stock and stock options with apitope international nv; and was an expert witness for geron. k.b. is employed by apitope technology (bristol) ltd. n.o. was a contractor to apitope technology (bristol) ltd., a subsidiary of apitope international nv. l.j. is an employee of apitope international nv. t.w.-s. was an employee of apitope technology (bristol) ltd., a subsidiary of apitope international nv. c.c. serves as chief medical officer for apitope technology (bristol) ltd. and apitope international nv on a consultative basis. k.f.m. was an executive director of apitope international nv and its subsidiary, apitope technology (bristol) ltd. he was an employee of apitope technology (bristol) ltd. he is currently a non-executive director of and shareholder in apitope international nv. p.p. consults for ibsa. b.v. has received speaker fees from berlin-chemie. s.r. has received speaker fees from merck plc and abbott india ltd. g.j.k. consults for apitope and quidel and has received speaker fees from merck and berlin-chemie. k.b., j.g., c.e.h., i.m., r.d.m., and f.w. report no disclosures."
4250,30562606,ampk/mtor signaling pathway
4251,30562606,orbital preadipocyte
4252,30562606,sf1
4253,30562606,thyroid-associated ophthalmopathy
4255,29037117,*graves'
4256,29037117,"*disease, relapse, predictive biomarker, siglec1, ifn signature"
4259,29397435,aldehyde dehydrogenase 2
4260,29397435,autoantigen
4261,29397435,graves’ orbitopathy
4262,29397435,orbital fat
4263,29397435,proteomic analysis
4265,31271712,*graves’ disease
4266,31271712,*acromegaly
4267,31271712,*case report
4268,31271712,*panhypopituitarism
4269,31271712,*radiosurgical treatment
4270,31271712,*secondary hypothyroidism
4271,31271712,*thyrotoxicosis
4273,30674011,16s rrna gene
4274,30674011,graves’ orbitopathy (go)
4275,30674011,gut microbiota
4276,30674011,thyrotropin receptor antibody (trab)
4278,30269213,graves’ disease
4279,30269213,hyperthyroidism
4280,30269213,robotic-assisted surgery
4281,30269213,surgical outcomes
4282,29848886,th2
4283,29848886,autoimmune thyroid disease
4284,29848886,intractability
4285,29848886,polymorphism
4286,29848886,severity
4288,30938833,cd4+p35+ebi3+t cell
4289,30938833,graves’ disease
4290,30938833,immunology
4291,30938833,interleukin 35
4297,29058517,thyroid eye disease
4298,29058517,abducens nerve
4299,29058517,orbital decompression
4300,30777066,corneal dynamic scheimpflug analyser
4301,30777066,corvis st
4302,30777066,graves ophthalmopathy
4303,30777066,orbital soft tissue
4304,30777066,whole eye movement cois the tenets of the declaration of helsinki and received institutional review board (irb) approval from seoul st. mary’s hospital for the analysis of their medical records. the need for consent was waived by irb (name of irb: cmc irb). consent for publication: not applicable. competing interests: hhs is a member of the editorial board (associate editor) of bmc ophthalmology. the other authors declare that they have no competing interests. the authors declare that they have no financial competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
4305,30297028,*dry eye disease
4306,30297028,*graves' ophthalmopathy
4307,30297028,*tear break up time
4308,30297028,*tear osmolarity
4309,30297028,*thyroid eye disease
4310,30232923,*graves' disease
4311,30232923,*x chromosome
4312,30232923,*association analysis
4313,30232923,*dosage compensation
4314,30232923,*genetic model
4315,29875930,graves´ disease
4316,29875930,hyperthyroidism
4317,29875930,nuclear medicine
4318,29875930,thyroid neoplasms
4319,29377729,*ct
4320,29377729,*thyroid eye disease
4321,29377729,*exophthalmometer
4322,29377729,*exophthalmos
4323,30470210,intraoperative relaxed muscle positioning
4324,30470210,restrictive strabismus
4325,30470210,thyroid orbitopathy cois approval from the local ethical committee (cerrahpasa ethics committee) was received. informed consent was obtained from the patients for the participation in the study. consent for publication: additional consent was obtained from the patients whose preoperative and postoperative photos were used in the manuscript. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
4326,31705696,graves disease
4327,31705696,hashimoto thyroiditis
4328,31705696,superb microvascular imaging
4329,31705696,chronic autoimmune thyroiditis
4330,31705696,color doppler
4331,31705696,vascularity index
4332,31310160,*graves' disease
4333,31310160,*long-term
4334,31310160,*methimazole
4335,31310160,*remission rates
4337,30384566,*shear wave elastography
4338,30384566,*virtual touch tissue imaging quantification
4339,30384566,*thyroid
4340,30384566,*hashimoto’s thyroiditis
4341,30384566,*graves’ disease
4342,30281845,*b-lymphocytes
4343,30281845,*b-cell activating factor
4344,30281845,*graves
4345,30281845,*autoimmune
4346,30281845,*disease
4347,30281845,*genotyping
4348,30281845,*polymorphism
4349,30281845,*thyroid
4350,29478847,breast cancer
4351,29478847,cancer du sein
4352,29478847,graves’ disease
4353,29478847,hyperthyroidism
4354,29478847,hyperthyroïdie
4355,29478847,maladie de basedow
4356,29478847,thyroxine
4357,29478847,triiodothyronine
4358,31690110,graves’ orbitopathy
4359,31690110,endoscopic orbital decompression
4360,31690110,feasibility
4361,31690110,robotic endoscope guiding system
4362,31690110,robotic surgery
4363,31209622,ablation techniques
4364,31209622,graves’ disease
4365,31209622,high-intensity focused ultrasound ablation
4366,31209622,interventional ultrasonography
4367,31209622,thyrotoxicosis
4368,31203506,cosmesis
4369,31203506,endoscopic surgery
4370,31203506,graves’ ophthalmopathy
4371,31203506,optic nerve
4372,31203506,orbital decompression
4375,28181061,amsterdam declaration
4376,28181061,graves’ disease
4377,28181061,joint thyroid eye clinic
4378,28181061,ophthalmopathy
4379,28181061,thyroid
4380,31552761,*il-6
4381,31552761,*autoimmune thyroid disease
4382,31552761,*intractability
4383,31552761,*methylation
4384,31552761,*severity
4385,31308303,abo
4386,31308303,blood groups
4387,31308303,hashimoto
4388,31308303,thyroid
4389,31184281,*graves' disease
4390,31184281,*thyroglobulin antibody
4391,31184281,*thyroid peroxidase antibody
4392,31184281,*thyroiditis
4393,31184281,*thyrotropin receptor
4394,31184281,*transgenics cois
4395,31111437,pd-1 inhibitor
4396,31111437,pdl-1 inhibitor
4397,31111437,pembrolizumab
4398,31111437,small cell carcinoma of ovary
4399,31111437,thyroid
4400,31111437,thyroiditis
4401,31111437,thyrotoxicosis
4403,29319128,graves’ disease
4404,29319128,hif-1α
4405,29319128,pdgf-bb
4406,29319128,immunology
4407,29319128,macrophages
4410,28548552,biomarker
4411,28548552,ccn1
4412,28548552,cyr61
4413,28548552,inflammation
4414,28548552,thyroid ophthalmopathy
4415,31473202,biotin
4416,31473202,biotin interference
4417,31473202,biotin supplements
4418,31473202,immunoassay
4420,31554206,b lymphocytes
4421,31554206,graves’ disease
4422,31554206,t lymphocytes
4423,31554206,toll-like receptor 2
4424,31554206,toll-like receptor 4
4425,31554206,cytokines cois
4426,31134819,*graves’ disease
4427,31134819,*treg-th17-related immunosuppressive cytokines
4428,31134819,*dihydrotestosterone
4429,31134819,*mice
4430,31134819,*oxidative stress
4432,29372654,*functional tsh receptor antibodies
4433,29372654,*autoimmune thyroid diseases
4434,29372654,*bioassays
4435,29372654,*children
4436,29372654,*drug delivery
4437,29372654,*thyroid associated orbitopathy
4438,29372654,*thyroid blocking antibodies
4439,29372654,*thyroid stimulating antibodies
4440,29199443,inferior laryngeal nerve
4441,29199443,nonrecurrent laryngeal nerve
4442,29199443,thyroid surgery
4443,29336230,*dnmt
4444,29336230,*graves' disease
4445,29336230,*autoimmune thyroid disease
4446,29336230,*global dna methylation
4447,29336230,*lymphocyte
4448,31387688,hipocalcemia
4449,31387688,hipoparatiroidismo
4450,31387688,hormona paratiroidea
4451,31387688,hypocalcemia
4452,31387688,hypoparathyroidism
4453,31387688,parathyroid hormone
4454,31387688,thyroidectomy
4455,31387688,tiroidectomía
4456,31407938,*graves’ orbitopathy
4457,31407938,*thyroid eye disease
4458,31407938,*ocular ductions
4459,31407938,*recession
4460,31407938,*resection
4461,31407938,*squint surgery
4463,30927115,autoimmune thyroid disease
4464,30927115,chronic widespread pain
4465,30927115,fibromyalgia
4466,30927115,hashimoto thyroiditis
4467,30927115,osteoarthritis
4468,30927115,spinal degenerative disc disease
4470,29960265,ct
4471,29960265,graves' orbitopathy
4472,29960265,iterative model reconstruction
4473,29420104,decompression
4474,29420104,graves’ orbitopathy
4475,29420104,dysthyroid optic neuropathy
4476,29420104,steroids
4477,29420104,tocilizumab
4479,29098964,biotin
4480,29098964,graves’ hyperthyroidism
4481,29098964,tsh receptor antibodies
4482,29098964,false laboratory results
4483,29098964,immunoassay
4484,31505972,cd58
4485,31505972,autoimmune thyroid disease
4486,31505972,severity
4487,31505972,single nucleotide polymorphism
4488,31034694,choroid
4489,31034694,optical coherence tomography
4490,31034694,thickness
4491,31034694,thyroid-associated orbitopathy
4492,30270655,diplopia
4493,30270655,graves ophthalmopathy
4494,30270655,inferior oblique muscle
4495,30270655,orbital decompression
4497,29614339,*co-expression modules
4498,29614339,*functional pathways
4499,29614339,*graves' disease
4500,29614339,*pathogenesis
4501,29614339,*weighted gene co-expression network analysis
4502,29463244,duration of eye symptoms
4503,29463244,intravenous glucocorticoid therapy
4504,29463244,pretreatment clinical activity score
4505,29463244,restoration of euthyroidism
4506,29463244,thyroid-associated ophthalmopathy cois by the ethics committee of shanghai ninth people’s hospital. the written informed consents were obtained from all participants. this study was in compliance with the tenets of the declaration of helsinki for clinical research. consent for publication: not applicable competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
4507,29360077,graves' disease
4508,29360077,hyperthyroidism
4509,29360077,struma ovarii
4513,30646996,decompression
4514,30646996,graves ophthalmopathy
4515,30646996,strabismus
4516,30646996,surgical
4517,31674156,cytology
4518,31674156,fine-needle aspiration biopsy
4519,31674156,histopathology
4520,31674156,hyperthyroidism
4521,31674156,radioactive iodine
4522,30850507,*graves’ disease
4523,30850507,*hemoglobin
4524,30850507,*multispectral optoacoustic tomography (msot)
4525,30850507,*thyroid nodule
4526,30257816,graves’ disease
4527,30257816,hashimoto thyroiditis
4528,30257816,mrc 65/93
4529,30257816,antithyroglobulin antibodies
4530,30257816,immunoassays
4531,30257816,thyroglobulin
4532,30204589,*graves’ disease
4533,30204589,*biotin
4534,30204589,*multiple sclerosis
4535,30204589,*thyroid
4537,31755324,cd80
4538,31755324,cd86
4539,31755324,intractability
4540,31755324,polymorphism
4541,31755324,severity
4542,31657648,adipogenesis
4543,31657648,graves’ orbitopathy
4544,31657648,fibroblast growth factor receptors
4545,31657648,fibroblast growth factors
4546,31657648,myofibroblast
4547,31494956,*graves' disease
4548,31494956,*hashimoto's thyroiditis
4549,31494956,*autoimmune thyroid disease
4550,31494956,*interferon regulatory factor 3
4551,31494956,*interferon regulatory factor 7
4552,31055979,graves’ disease
4553,31055979,il-21
4554,31055979,th17 cells
4555,31055979,treg cells
4556,31055979,immune
4557,31488432,*graves’ orbitopathy
4558,31488432,*orbital adipose tissue
4559,31488432,*orbital fibroblast cois
4560,29361886,*antiretroviral therapy
4561,29361886,*graves’ disease
4562,29361886,*hiv
4563,29361886,*iris
4564,29361886,*immune thrombocytopenic purpura
4565,31707189,*3d anatomical modeling
4566,31707189,*biomechanical simulation
4567,31707189,*computer-assisted surgery planning
4568,31707189,*endocrine orbitopathy
4569,31707189,*fibrosis
4570,31707189,*retrospective cohort study
4572,30560705,graves’ ophthalmopathy
4573,30560705,oxidative stress
4574,30560705,thiol-disulfide homeostasis
4575,30351237,*graves’
4576,30351237,*antagonist
4577,30351237,*disease
4578,30351237,*hyperthyroidism
4579,30351237,*orbitopathy
4580,30351237,*small molecule
4581,30351237,*thyrotropin receptor
4584,29053038,igg4-related orbital disease
4585,29053038,thyroid eye disease
4586,29053038,rituximab
4587,29023175,orbital
4588,29023175,autologous
4589,29023175,cosmetic
4590,29023175,decompression
4591,29023175,fat
4592,29023175,graft
4593,31366254,*cd4+cd8+
4594,31366254,*graves’ disease
4595,31366254,*rtes
4596,31366254,*trab
4597,31366254,*effector memory cd8
4598,31366254,*lymphocyte subpopulations
4601,31036428,cigarette
4602,31036428,cigarro
4603,31036428,dejar de fumar
4604,31036428,graves orbitopathy
4605,31036428,orbitopatía de graves
4606,31036428,orbitopatía tiroidea
4607,31036428,smoke cessation
4608,31036428,tabaco
4609,31036428,thyroid orbitopathy
4610,31036428,tobacco
4611,30182361,cd-20
4612,30182361,graves’ disease
4613,30182361,graves’ ophthalmopathy
4614,30182361,graves’ orbitopathy
4615,30182361,lymphocytes
4616,30182361,thyroid
4617,30182361,thyroid eye disease
4618,29987165,*graves’ disease
4619,29987165,*hla
4620,29987165,*mhc
4621,29987165,*amino acid position
4622,29987165,*genome-wide association studies cois
4624,29103088,diastolic function
4625,29103088,echocardiography
4626,29103088,graves’ disease
4627,29103088,left ventricular function
4628,29103088,left ventricular mass index
4629,29103088,myocardial performance index
4630,29103088,tissue doppler imaging
4631,31739945,*arteriovenous malformations
4632,31739945,*benign disease
4633,31739945,*desmoid tumor
4634,31739945,*dupuytren contracture
4635,31739945,*graves ophthalmopathy
4636,31739945,*gynecomastia
4637,31739945,*heterotopic ossification
4638,31739945,*histiocytosis
4639,31739945,*radiation therapy
4640,30814476,*antithyroid drug-induced agranulocytosis
4641,30814476,*antithyroid drug-induced neutropenia
4642,30814476,*association
4643,30814476,*flavin-containing monooxygenase 3
4644,30814476,*graves’ disease
4648,30335539,ocular pulse amplitude
4649,30335539,choroidal perfusion in thyroid eye disease
4650,30335539,choroidal thickness in thyroid eye disease
4651,30335539,dynamic contour tonometry
4652,30335539,thyroid eye disease
4655,29973096,*children
4656,29973096,*graves’ disease
4657,29973096,*hashimoto’s disease
4658,29973096,*ifih1 gene
4659,29973096,*ptpn gene
4660,29973096,*tshr gene
4661,29973096,*single nucleotide polymorphisms
4662,29058307,*graves' disease
4663,29058307,*graves' orbitopathy
4664,29058307,*autoimmunity
4665,29058307,*self-antigen mouse model
4666,29058307,*thyroid disease
4668,31266487,*dfnb4
4669,31266487,*deafness
4670,31266487,*haplotype
4671,31266487,*hearing
4672,31266487,*noncoding
4673,31266487,*pendred syndrome
4674,31266487,*slc26a4 cois
4675,31327128,graves’ disease
4676,31327128,graves’ orbitopathy
4677,31327128,outcome
4678,31327128,radioiodine
4679,31327128,tsh-receptor antibody
4680,31327128,thyroid carcinoma
4681,31327128,thyroidectomy
4682,31267667,hyperthyroidism
4683,31267667,obesity
4684,31267667,treatment
4685,31267667,weight changes
4687,31444554,macular vasculature
4688,31444554,peripapillary vasculature
4689,31444554,thyroid eye disease
4690,30372544,*graves’ disease
4691,30372544,*trab
4692,30372544,*tshr
4693,30372544,*hyperthyroidism
4694,30372544,*thyroid scintigraphy
4695,30197231,*adderall
4696,30197231,*attention deficit hyperactivity disorder
4697,30197231,*etomidate
4698,30197231,*fentanyl
4699,30197231,*graves disease
4700,30197231,*hyperthyroidism
4701,30197231,*midazalom
4702,30197231,*moderate sedation
4703,30197231,*procedural sedation
4704,30197231,*propofol
4705,30197231,*rapid sequence intubation
4706,30197231,*rocuronium
4707,30197231,*thyroid storm
4709,29329570,case report
4710,29329570,graves’ disease
4711,29329570,graves’ orbitopathy
4712,29329570,igg4-related disease
4713,29329570,igg4-related orbitopathy cois of the declaration of helsinki. approval by the institutional ethics comittee was not required as this was a single case report. consent for publication: written informed consent was obtained from the patient for publication of this case report and any accompanying images. a copy of written consent is available for review by the editor of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
4715,29288501,*graves’ disease
4716,29288501,*iodine
4717,29288501,*iodine restricted
4718,29288501,*iodine supplemented
4719,29288501,*recurrence rate
4720,31669312,autoimmune hypothyroidism
4721,31669312,cribado neonatal tiroideo
4722,31669312,enfermedad de graves
4723,31669312,graves disease
4724,31669312,hipertirotropinemia
4725,31669312,hipotiroidismo autoinmune
4726,31669312,hyperthyrotropinemia
4727,31669312,neonatal thyroid screening
4728,31669312,thyroiditis
4729,31669312,tiroiditis
4730,31108563,*agranulocytosis
4731,31108563,*antithyroid drug
4732,31108563,*human leucocyte antigen
4733,31108563,*meta-analysis cois
4734,30528501,national health insurance research database
4735,30528501,cohort study
4736,30528501,hyperthyroidism
4737,30528501,hypothyroidism
4738,30528501,psoriasis
4739,30528501,psoriatic arthritis
4740,30528501,thyroid diseases
4741,29485308,*diplopia
4742,29485308,*resection
4743,29485308,*thyroid eye disease
4744,29485308,*vertical strabismus
4745,30900216,angptl8
4746,30900216,graves’ disease cois
4747,30673921,*autoantigen
4748,30673921,*autoimmune
4749,30673921,*flow cytometry
4750,30673921,*immune
4751,30673921,*interleukin 2
4752,30673921,*lupus
4753,30673921,*metformin
4754,30673921,*multiple sclerosis
4755,30673921,*orbitopathy
4756,30673921,*pcsk9
4757,30673921,*rheumatoid arthritis
4758,30673921,*somatostatin
4759,30673921,*statin
4760,30673921,*testosterone
4761,30673921,*thyroid
4762,30291728,*graves’ disease
4763,30291728,*graves’ ophthalmopathy
4764,30291728,*hypothyroidism
4765,30291728,*iodine radioisotopes
4766,30291728,*thyroid function tests
4767,30291728,*thyrotoxicosis
4768,30291728,*treatment failure
4769,30291728,*weight gain
4771,31580214,*epstein-barr virus
4772,31580214,*graves' disease
4773,31580214,*asymptomatic infection
4774,31580214,*autoantibody
4775,31580214,*thyrotropin receptor autoantibody (trab)
4776,31580214,*viral reactivation cois
4777,30911279,biomarker
4778,30911279,diagnostics
4779,30911279,genetic signature
4780,30911279,molecular alteration
4781,30911279,papillary thyroid cancer cois
4782,31033004,cd32b
4783,31033004,fcγr
4784,31033004,fcγrii
4785,31033004,graves' disease
4786,31033004,autoimmunity
4788,31708111,*ctla4
4789,31708111,*graves’ disease
4790,31708111,*restriction fragment length polymorphism
4791,31708111,*single nucleotide polymorphism
4792,29974826,*cd4+ helper t cells
4793,29974826,*graves’ disease
4794,29974826,*t cell immunoglobulin domain and mucin domain 3
4795,29974826,*thyroid-associated ophthalmopathy
4796,29974826,*autoimmune thyroid disease
4797,29974826,*immune tolerance.
4798,31733941,*graves’ disease
4799,31733941,*ifih1 gene
4800,31733941,*lada diabetes
4801,31733941,*multiple sclerosis
4802,31733941,*polymorphism cois
4803,31557136,graves’ ophthalmopathy
4804,31557136,graves’ orbitopathy
4805,31557136,calcium
4806,31557136,methylprednisolone
4807,31557136,phosphate
4809,31272958,*graves’ ophthalmopathy
4810,31272958,*glucocorticoid
4811,31272958,*network meta-analysis cois
4812,30549306,*graves' orbitopathy
4813,30549306,*immunosuppression
4814,30549306,*methotrexate
4815,30549306,*methylprednsolone
4816,30549306,*rituximab
4819,31833078,graves' disease
4820,31833078,hyperthyroidism
4821,31833078,tissue doppler imaging
4822,31833078,two-dimensional speckle tracking echocardiography
4824,30771152,*autoimmune thyroid disease
4825,30771152,*ctla-4
4826,30771152,*foxp3
4827,30771152,*graves’ disease
4828,30771152,*hashimoto’s thyroiditis
4829,30771152,*polymorphism
4831,29589999,*graves'
4832,29589999,*adipogenesis
4833,29589999,*extracellular-regulated kinase (erk)
4834,29589999,*hyaluronan production
4835,29589999,"*orbitopathy, biguanides, amp-activated protein kinase"
4836,29526990,false-positive
4837,29526990,lithium-heparin plasma
4838,29526990,tsh receptor antibody (trab)
4839,29526990,third-generation
4841,30979639,dysthyroid optic neuropathy
4842,30979639,medial orbital wall decompression
4843,30979639,transcaruncular approach
4844,30979639,transnasal endoscopic approach
4845,30979639,vision
4847,30111225,graves' disease
4848,30111225,acute kidney injury
4849,30111225,hyperthyroidism
4850,30111225,methimazole
4851,30111225,nephrotoxicity
4852,30616690,*graves disease
4853,30616690,*hashimoto thyroiditis
4854,30616690,*macrophage-nk cells cross talk
4855,30616690,*thyroid cancer
4856,30616690,*tumor immunity cois competing interests: the authors declare that they have no conflict of interest. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
4857,30335556,graves’ disease
4858,30335556,orbital decompression
4859,30335556,infraorbital anaesthesia
4860,30335556,piezoelectric surgery
4861,30335556,thyroid eye disease
4862,29631510,*graves' ophthalmopathy immunoglobulins
4863,29631510,*igf-1 receptor
4864,29631510,*tsh receptor
4865,29631510,*pakt
4866,29631510,*perk1/2 cois
4867,30246383,*t follicular helper cells (tfh)
4868,30246383,*t helper 17 (th17)
4869,30246383,*t helper 22 (th22)
4870,30246383,*autoimmune thyroid diseases (aitds)
4871,30246383,*cytokines
4872,30246383,*immune tolerance
4873,30246383,*interleukin 17 (il-17)
4874,30246383,*interleukin 21 (il-21)
4875,29941778,autoimmune thyroid disease
4876,29941778,celiac disease
4877,29941778,glandular autoimmunity
4878,29941778,polyglandular autoimmune syndrome
4879,29941778,type 1 diabetes cois
4885,30973094,*graves' orbitopathy
4886,30973094,*toll-like receptor 2
4887,30973094,*high mobility group box 1
4888,30973094,*inflammation
4889,30973094,*receptor for advanced glycation end products
4890,30391932,*foxp3 acetylation
4891,30391932,*graves’ disease (gd)
4892,30391932,*treg function defect
4893,30391932,*mir-23a-3p
4896,30519958,bone mineral density
4897,30519958,bone turnover markers
4898,30519958,glucocorticoid
4899,29174716,autoimmune thyroid disease
4900,29174716,ctla4
4901,29174716,drb1*
4902,29174716,graves' disease
4903,29174716,hashimoto's thyroiditis
4904,29174716,human leukocyte antigen
4905,29021480,continuous glucose monitoring
4906,29021480,methylprednisolone pulse therapy
4907,29021480,mitiglinide
4908,29021480,rapid-acting insulin secretagogue
4909,29021480,repaglinide
4910,29021480,steroid-induced diabetes
4911,30515677,*continuous glucose monitoring
4912,30515677,*glycemic variation
4913,30515677,*graves’ disease
4914,30515677,*mean amplitude of glycemic excursions cois
4915,29804271,*durvalumab
4916,29804271,*graves’ orbitopathy
4917,29804271,*tremelimumab
4918,29256181,antioxidant
4919,29256181,fibroblast
4920,29256181,graves’
4921,29256181,ophthalmopathy
4922,29256181,orbitopathy
4923,29256181,retinol
4924,29256181,vitamin e
4925,29256181,β-carotene
4926,30284412,donor sclera
4927,30284412,ocular deviations
4928,30284412,strabismus
4929,30284412,surgical technique
4933,30196781,*ophthalmoplegia
4934,30196781,*carotid-cavernous sinus fistula
4935,30196781,*cranial neuropathy
4936,30196781,*diplopia
4937,30196781,*hypoglobus
4938,30196781,*proptosis
4939,29482415,inter-ethnic
4940,29482415,orbit
4941,29482415,orbital decompression
4942,29482415,trigone
4944,29549956,*graves' disease
4945,29549956,*autoantibodies
4946,29549956,*breast milk
4947,29549956,*methimazole
4948,29549956,*propylthiouracil
4949,29549956,*thyroid hormones
4950,31062662,*graves’ disease
4951,31062662,*autoantibody
4952,31062662,*decoy effect
4953,31062662,*exosome
4954,31062662,*thyrotropin receptor
4956,30222515,*epstein–barr virus
4957,30222515,*epstein–barr virus reactivation
4958,30222515,*epstein–barr virus-encoded small rna1
4959,30222515,*graves' disease
4960,30222515,*igg4-related disease cois
4961,31809586,*b10 cells
4962,31809586,*graves’ disease
4963,31809586,*ilc2s
4964,31809586,*autoantibodies
4965,29656212,autoimmune thyroid disease
4966,29656212,calgranulins
4967,29656212,mrp14
4968,29656212,mrp6
4969,29656212,mrp8
4970,29656212,oxidative stress
4971,29141453,*nodular thyroid diseases
4972,29141453,*goitre
4973,29141453,*insulin resistance
4974,29141453,*metabolic syndrome
4975,29141453,*thyroid volume
4977,30503299,*coronary artery vasospasm
4978,30503299,*graves’ disease
4979,30503299,*interleukin-6
4980,30503299,*silent myocardial infarction
4981,29557700,*decompression
4982,29557700,*graves’ orbitopathy
4983,29557700,*dose-effect
4984,29557700,*eye muscle surgery
4985,29557700,*tendon elongation of medial rectus muscle
4986,29233566,*anergy
4987,29233566,*autoimmune thyroid disease
4988,29233566,*b lymphocytes
4989,29233566,*flow cytometry
4992,30938100,*graves' disease
4993,30938100,*ptpn22 gene
4994,30938100,*gene polymorphism cois
4996,30724135,*graves' orbitopathy
4997,30724135,*pdgf-bb
4998,30724135,*adipogenesis
4999,30724135,*basic-fgf
5000,30724135,*tyrosine kinase inhibitor
5002,29780146,anca-related vasculitis
5003,29780146,mpo-anca
5004,29780146,omaav
5005,29780146,propylthiouracil
5007,30679116,autologous fat
5008,30679116,esthetic
5009,30679116,hyaluronic acid
5010,30679116,lateral orbital wall decompression
5011,30679116,temporal hollowing
5012,30679116,thyroid eye disease
5014,29800560,*graves' opthalmopathy
5015,29800560,*lfa-1/icam-1/gsk-3β pathway
5016,29800560,*logistic regression
5017,29800560,*mdr model
5018,29800560,*single nucleotide polymorphism
5019,29800560,*smoking
5020,29454070,graves’ disease
5021,29454070,interleukin-1 receptor antagonist
5022,29454070,interleukin-1-β
5023,29454070,restriction fragment length polymorphism
5024,29454070,single nucleotide polymorphism
5026,29970608,endocrine system
5027,29970608,thyroid disease cois
5028,29269558,*endocrinology
5029,29269558,*pharmacology cois
5030,31328557,*circadian rhythm
5031,31328557,*graves’ disease
5032,31328557,*hashimoto’s thyroiditis
5033,31328557,*polymorphism
5034,31264142,anti-gastric parietal cell antibodies
5035,31264142,autoimmune gastritis
5036,31264142,autoimmune thyroid disease
5037,31264142,children
5038,31264142,screening
5039,31411123,*graves' disease
5040,31411123,*levothyroxine
5041,31411123,*radioiodine treatment
5042,31411123,*thyrotropin
5043,31411123,*triiodothyronine cois
5044,31088643,abhormone
5045,31088643,colloid antigen 2
5046,31088643,graves’ disease
5047,31088643,thyroid blocking antibody
5048,31088643,thyroid stimulating antibody
5049,29666119,*experimental – laboratory
5050,29666119,*inflammation
5051,29666119,*orbit
5052,29666119,*pathology
5053,29666119,*stem cells cois
5054,29729713,autoimmune diseases
5055,29729713,meta-analysis.
5056,29729713,ptpn22
5057,31399042,*adipogenesis
5058,31399042,*go animal model
5059,31399042,*graves’ disease
5060,31399042,*graves’ ophthalmopathy
5061,31399042,*thyroid disease
5062,31399042,*hpmscs cois
5063,31034586,b cell-activating factor
5064,31034586,graves' disease
5065,31034586,hashimoto's thyroiditis
5066,31034586,autoimmune thyroid disease
5067,31034586,osteopontin
5068,30208979,* aitd autoimmune thyroid disease
5069,30208979,* dio deiodinases
5070,30208979,* gd graves’ disease
5071,30208979,* gpx glutathione peroxidases
5072,30208979,* ht hashimoto's thyroiditis
5073,30208979,* id iron deficiency
5074,30208979,* l-t4 levothyroxine
5075,30208979,* rct randomised controlled trial
5076,30208979,* t3 tri-iodothyronine; t4
5077,30208979,* tpo thyroid peroxidase
5078,30208979,* tsh thyroid-stimulating hormone
5079,30208979,* tg thyroglobulin
5080,30208979,* thyroxine
5081,30208979,*autoimmune thyroid disease
5082,30208979,*autoimmune thyroiditis
5083,30208979,*iodine
5084,30208979,*iron
5085,30208979,*nutrition
5086,30208979,*selenium
5088,28960748,hashimoto's
5089,28960748,autoimmune
5090,28960748,goiter
5091,28960748,hypothyroidism
5092,28960748,iodine
5093,28960748,vitiligo
5095,31091046,*graves’ ophthalmopathy
5096,31091046,*fibrosis
5097,31091046,*glycosaminoglycans
5098,31091046,*matrix metalloproteinases
5099,31091046,*pathogenesis
5100,31091046,*tissue inhibitor of metalloproteinases
5101,30684216,*autoantibodies
5102,30684216,*graves’ disease
5103,30684216,*hashimoto’s thyroiditis
5104,30684216,*tsh receptor
5105,30684216,*thyroid
5106,31439560,dermatology
5107,31439560,meningitis
5108,31439560,paediatrics cois
5109,31384956,fibroblast growth factor 23
5110,31384956,graves’ disease
5111,31384956,osteoporosis
5112,31384956,phosphorus
5113,30725486,*graves’ disease
5114,30725486,*hashimoto’ s thyroiditis
5115,30725486,*autoimmune thyroid disease
5116,30725486,*metabolomics
5117,30725486,*polyamine metabolites
5118,30725486,*serum
5119,30725486,*spermine
5120,29709954,carcinoembryonic antigen
5121,29709954,hypothyroidism
5122,31527321,denosumab
5123,31527321,fibroblast growth factor 23 (fgf-23)
5124,31527321,hypercalcemia
5125,31527321,hyperthyroidism
5126,31527321,zoledronic acid
5127,30506426,*bone mineral density
5128,30506426,*graves’ ophthalmopathy
5129,30506426,*graves’ orbitopathy
5130,30506426,*gucocorticoid-induced osteoporosis
5131,30506426,*methylprednisolone
5132,30506426,*trabecular bone score cois
5133,29526119,*graves’ disease
5134,29526119,*hashimoto’s disease
5135,29526119,*tnf-α
5136,29526119,*methylation
5137,29526119,*polymorphism
5138,31750736,4q21.1
5139,31750736,cxcl9
5140,31750736,hashimoto's thyroiditis
5141,31750736,naaa
5142,31750736,single nucleotide polymorphisms
5144,29864750,*autoimmunity
5145,29864750,*rheumatic diseases
5146,29864750,*thyroiditis
5148,31359380,autoimmune thyroid diseases
5149,31359380,dna methylation
5150,31359380,graves’ disease
5151,31359380,hashimoto thyroiditis
5152,31359380,icam-1
5154,30589937,b lymphocyte kinase
5155,30589937,graves' disease
5156,30589937,hashimoto’s thyroiditis
5157,30589937,autoimmune thyroid disease
5158,30589937,secreted phosphoprotein 1
5159,30133352,*ebv reactivation
5160,30133352,*graves’ disease
5161,30133352,*ig production
5162,30133352,*estradiol cois
5163,29791034,cd10
5164,29791034,adenomatous goitre
5165,29791034,anaplastic thyroid carcinoma
5166,29791034,immunohistochemistry
5167,29791034,thyroid tumour
5169,28725932,alzheimer’s disease
5170,28725932,chronological age
5171,28725932,dna methylation
5172,28725932,graves’ disease
5173,28725932,neural networks
5174,28725932,prediction accuracy
5175,31573408,*antithyroid drugs
5176,31573408,*drug-induced hepatotoxicity
5177,31573408,*drug-induced liver injury
5178,31573408,*metimazole
5179,31573408,*propylthiouracil
5181,30067105,antibody
5182,30067105,antithyroid drugs
5183,30067105,autoimmunity
5184,30067105,cutaneous reactions
5185,30067105,hepatotoxicity
5186,30417843,goitre
5187,30417843,incidence
5188,30417843,pyramidal lobe
5189,30417843,thyroidectomy cois
5191,31793246,highly differentiated follicular carcinoma of ovary
5192,31793246,imprint cytology
5193,31793246,monodermal teratoma
5194,31793246,struma ovarii
5195,30201436,*autoimmunity
5196,30201436,*immune regulation
5197,30201436,*t cells
5198,30201436,*microrna-183
5199,30201436,*microrna-96
5200,31105122,gitelman syndrome
5201,31105122,slc12a3 gene
5202,31105122,eplerenone
5203,31105122,hypokalemia
5204,31105122,thyrotoxic hypokalemic periodic paralysis
5205,31434818,graves’ disease
5206,31434818,hashimoto’s thyroiditis
5207,31434818,immune-checkpoint inhibitors
5208,31434818,immunoglobulin g4
5209,31434818,riedel’s thyroiditis
5210,30599051,*benign thyroid disease
5211,30599051,*radioiodine therapy
5212,30599051,*radioiodine uptake test
5213,30599051,*thyroid
5214,30599051,*thyroid stunning
5215,31301659,autopsy
5216,31301659,goiter
5217,31301659,malignancy
5218,31301659,metastatic disease
5219,31301659,thyroid
5220,31301659,thyroid nodule
5221,29956299,l-thyroxine in utero treatment
5222,29956299,dyshormonogenesis
5223,29956299,foetal goitre
5224,30936024,*biological therapy
5225,30936024,*disease progression
5226,30936024,*prognosis
5227,30936024,*treatment
5228,31387553,diagnostic criteria
5229,31387553,metastasis
5230,31387553,painful goiter
5231,31387553,subacute thyroiditis
5232,31387553,thyroid cancer cois
5233,29398296,*goitre
5234,29398296,*myasthenia gravis
5235,29398296,*ophthalmoplgia
5236,29398296,*thyrotoxicosis
5237,29923170,ancient greece
5238,29923170,endocrinology
5239,29923170,galen
5240,29923170,goitre
5241,29923170,hippocrates
5242,29923170,history
5243,29923170,thyroid
5244,30589040,nodular goiters
5245,30589040,ultrasound grayscale ratio (usgr)
5246,30589040,papillary carcinoma
5247,30589040,thyroid nodules cois
5248,28693960,backdoor
5249,28693960,lateral approach
5250,28693960,open throidectomy
5251,28693960,sternomastoid
5252,29396842,age-related changes
5253,29396842,chemical elements
5254,29396842,inductively coupled plasma mass spectrometry
5255,29396842,neutron activation analysis
5256,29396842,thyroid
5257,30175973,casc2
5258,30175973,long non-coding rna
5259,30175973,lymph node metastasis
5260,30175973,papillary thyroid cancer
5261,29724875,diabetes
5262,29724875,thyroid disease cois
5265,30860079,*endoscopic thyroidectomy using vestibular approach
5266,30860079,*scar.free thyroidectomy
5267,30860079,*transoral endoscopic thyroidectomy cois
5268,30939883,* thyroid nodules
5269,30939883,*fnab of thyroid gland
5270,30939883,*the bethesda 2017 revised classification of thyroid fnab
5271,30939883,*the bethesda system for reporting thyroid cytology 2010
5272,30939883,*goitre
5273,30939883,*thyroid cancer
5274,31691509,*echogenicity
5275,31691509,*nodular goiters
5276,31691509,*papillary thyroid carcinoma
5277,31691509,*ultrasonic diagnosis
5278,31691509,*ultrasound gray scale ratio cois
5281,31155540,deiodinase
5282,31155540,ft3/ft4 ratio
5283,31155540,hashimoto thyroiditis
5284,31155540,thyroid hormone
5285,31155540,thyroid volume
5286,29197093,*fndc5 gene
5287,29197093,*hyperthyroidism
5288,29197093,*hypothyroidism
5289,29197093,*irisin
5290,29996756,*thyroid diseases
5291,28627279,graves’ disease
5292,28627279,maternal autoantibodies
5293,28627279,anti-ro and anti-la antibodies
5294,28627279,athrogryposis multiplex congenital
5295,28627279,autoimmune thrombocytopenia
5296,28627279,fetal brain hemorrhage
5297,28627279,fetal heart block
5298,28627279,fetal thyroid goiter
5299,28627279,myasthenia gravis
5300,31670631,calciumsupliments
5301,31670631,calciumvalue
5302,31670631,thyroidectomy
5303,29626393,fnac
5304,29626393,children
5305,29626393,thyroid
5306,29409458,*breast cancer
5307,29409458,*goitre
5308,29409458,*lobular breast cancer
5309,29409458,*metastases to thyroid cois publication: written informed consent was obtained from the patient for the publication of this case report and any accompanying images. a copy of the written consent is available for review by the editor-in-chief of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
5310,31580203,neuromonitoring
5311,31580203,goiter
5312,31580203,recurrent laryngeal nerve palsy
5313,31580203,thyroid
5314,31580203,vocal cords
5315,31178475,congenital hypothyroidism
5316,31178475,gene mutation
5317,31178475,goiter
5318,31178475,thyroglobulin cois
5319,31292912,c cell hyperplasia
5320,31292912,c cells
5321,31292912,papillary carcinoma
5322,31292912,thyroid
5323,31292912,thyroidectomy
5324,31127647,*dnmt1
5325,31127647,*mgmt
5326,31127647,*ms-hrm
5327,31127647,*ctdna
5328,31127647,*methylation
5329,31127647,*papillary thyroid cancer
5330,31255196,autoimmune thyroiditis
5331,31255196,graves’ disease
5332,31255196,hashimoto's thyroiditis
5333,31255196,surgical management
5334,29724805,spect/ct
5335,29724805,parallax error
5336,29724805,parathyroid scintigraphy
5337,29724805,pinhole collimator
5338,29724805,thyroid scintigraphy
5339,30927996,history of thymectomy
5340,30927996,myasthenia gravis
5341,30927996,myasthenic
5342,30927996,surgical management of myasthenia gravis
5343,30927996,thymoma
5344,30927996,thymus
5345,30927996,transcervical
5346,30884127,cep78
5347,30884127,wdr62
5348,30884127,lateral lymph node metastasis
5349,30884127,thyroid cancer
5350,30739612,*deficiency
5351,30739612,*excess
5352,30739612,*iodine
5353,30739612,*sub-saharan africa
5354,29459090,cancer thyroïdien
5355,29459090,goitre ovarien
5356,29459090,ovarian teratoma
5357,29459090,struma ovarii
5358,29459090,thyroid carcinoma
5359,29459090,tératome ovarien
5360,31430255,tpo gene
5361,31430255,congenital goiter
5362,31430255,congenital hypothyroidism
5363,31430255,thyroid carcinoma
5364,31430255,thyroid dyshormonogenesis
5365,29313120,ablation techniques
5366,29313120,high-intensity focused ultrasound ablation
5367,29313120,induced hyperthermia
5368,29313120,interventional ultrasonography
5369,29313120,nodular goitre
5370,29503241,atrial fibrillation
5371,29503241,congestive heart failure
5372,29503241,graves’ disease
5373,29503241,hyperthyroidism
5374,29503241,toxic multinodular goitre
5377,29845469,*family health
5378,29845469,*health promotion
5379,29845469,*screening cois
5380,31267862,*nrf2
5381,31267862,*personalized nutrition
5382,31267862,*flavonoid
5383,31267862,*goiter
5384,31267862,*hyperthyroidism
5385,31267862,*hypothyroidism
5386,31267862,*phytochemical
5387,31267862,*thyroid.
5388,29676344,histopathology
5389,29676344,retrospective
5390,29676344,thyroid diseases cois
5391,31297898,*bipolar disorders
5392,31297898,*lithium
5393,31297898,*thyroid hormones
5394,31297898,*thyroid structure
5396,30665612,*hypocalcemia
5397,30665612,*indocyanine green
5398,30665612,*multinodular goiter
5399,30665612,*parathyroid
5400,30665612,*parathyroid hormone
5401,30665612,*thyroidectomy
5403,29354015,*benign thyroid nodule
5404,29354015,*laser
5405,29354015,*laser ablation
5406,29354015,*quality of life
5407,29354015,*thyroid
5408,29354015,*thyroid nodule
5409,29330630,ablation techniques
5410,29330630,high-intensity focused ultrasound ablation
5411,29330630,interventional ultrasonography
5412,29330630,nodular goitre
5413,29330630,pain management
5414,30009365,galen
5415,30009365,thomas wharton
5416,30009365,botium
5417,30009365,thyroid foramen
5418,30949714,autonomous thyroid function
5419,30949714,hyperthyroidism
5420,30949714,hypothyroidism
5421,30949714,iodine exposure
5422,30949714,nodular goiter
5425,30903785,children
5426,30903785,morbidity
5427,30903785,pesticides
5428,30903785,thyroid gland
5429,30717458,diet
5430,30717458,gestational diabetes mellitus
5431,30717458,microbiota
5432,30717458,"pregnancy cois design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results."
5433,31670642,crp
5434,31670642,anaplastic
5435,31670642,cancer
5436,31670642,ferritin
5437,31670642,inflammatorymarkers
5438,31670642,thyroid
5439,30732901,congenital hypothyroidism
5440,30732901,goiter
5441,30732901,idd
5442,30732901,iran
5443,30732901,salt iodisation
5445,30358496,*goiter
5446,30358496,*iodine deficiency
5447,30358496,*iodine in salt
5448,30358496,*thyroid volume
5449,30358496,*urinary iodine
5450,30378716,*foxq1
5451,30378716,*papillary thyroid carcinoma
5452,30378716,*poor prognosis
5453,30568076,infertility
5454,30568076,negative thyroid antibody
5455,30568076,nongoitrous
5456,30568076,subclinical hypothyroidism
5457,30568076,thyroid autoimmunity
5458,28952819,ebsln
5459,28952819,ionm
5460,28952819,rln
5461,28952819,goiter
5462,28952819,surgery
5463,28952819,thyroid
5464,28940588,ectopic thyroid
5465,28940588,endobronchial ultrasonography
5466,28940588,transbrochial needle aspiration
5467,29770856,benign thyroid disease
5468,29770856,mixed follicular-papillary variant
5469,29770856,multifocality
5470,29770856,papillary thyroid microcarcinoma
5471,29770856,risk factors
5472,29770856,thyroid weight
5473,29770856,tumour size
5474,31237859,vegf-a
5475,31237859,angiogenic factor
5476,31237859,histopathological factors
5477,31237859,immunohistochemistry
5478,31237859,papillary thyroid carcinoma
5479,31237859,thyroid carcinoma
5481,28224254,eastern mediterranean region (emr)
5482,28224254,goiter
5483,28224254,iodine
5484,28224254,iodine deficiency disorders (idds)
5485,28224254,who
5486,31445060,environmental chemicals
5487,31445060,pesticides
5488,31445060,thyroid diseases
5489,31445060,case–control study
5490,30521675,*goiter
5491,30521675,*health insurance
5492,30521675,*socioeconomic disparities
5493,30521675,*thyroid disease
5494,30521675,*thyroid volume
5496,30773379,*fusion imaging
5497,30773379,*hybrid imaging
5498,30773379,*single-photon emission computed tomography/ultrasound
5499,30773379,*thyroid
5500,30773379,*ultrasound
5502,31074384,follicular proliferation
5503,31074384,lobectomy
5504,31074384,malignancy
5505,31074384,surgery
5506,31074384,tir3b
5507,31074384,thyroid cancer
5508,31074384,total thyroidectomy cois
5509,30734891,dysgenesis
5510,30734891,dyshormonogenesis
5511,30734891,hashimoto thyroiditis
5512,30734891,hypothyroidism
5513,30734891,iodine deficiency
5514,30734891,levothyroxine
5515,30734891,mental retardation
5516,30734891,stunted growth
5519,32312925,benign thyroidectomy
5520,32312925,cervical thyroid remnant
5521,32312925,papillary thyroid carcinoma
5526,31142293,hashimoto’s thyroiditis
5527,31142293,papillary thyroid carcinoma cois
5528,29544745,adults
5529,29544745,influences
5530,29544745,prevalence
5531,29544745,thyroid nodules
5534,30371103,neuromonitoring
5535,30371103,nonrecurrent laryngeal nerve
5536,30371103,palsy
5537,30371103,recurrent laryngeal nerve
5538,30371103,thyroidectomy
5539,29573939,*shear wave
5540,29573939,*cancer
5541,29573939,*elastography
5542,29573939,*thyroid nodules
5543,29573939,"*ultrasound cois device or technology referenced in this paper. ag, mb, vk, bhk, jw, ddm, mr, jmk, mf, and aa have no competing financial interests in the technology described in this study. the content is solely the responsibility of the authors and does not necessarily represent the official views of the national institutes of health."
5544,30829140,*benign/goiter
5545,30829140,*endocrine
5546,30829140,*thyroid
5547,30829140,*thyroid cancer
5548,30829140,*thyroid/parathyroid
5549,30829140,*thyroidectomy
5550,30086865,*complication prevention
5551,30086865,*congenital hypothyroidism
5552,30086865,*goiter
5553,30086865,*next generation sequencing
5554,30086865,*systemic disease complications
5555,30086865,*thyroid
5556,30637454,hypocalcemia
5557,30637454,postoperative hypoparathyroidism
5558,30637454,thyroid surgery
5559,30637454,thyroidectomy
5560,30637454,vitamin d deficiency
5561,29695560,*bad
5562,29695560,*bax
5563,29695560,*bcl-2
5564,29695560,*benign thyroid nodules
5565,29695560,*apoptosis
5566,29695560,*gene expression
5567,29720101,*congenital hypothyroidism
5568,29720101,*goiter
5569,29720101,*novel mutations
5570,29720101,*tg
5571,29720101,"*thyroglobulin cois performed in miami has been approved by the human subject research office of the university of miami (irb number: 20140632). written informed consent for participating in the study has been obtained from all study participants and in the case of subjects under the age of 18 assent was obtained from the child and consent from their parents. consent for publication: written informed consent for publishing all data of the study, such as medical data, images and genetic results has been obtained from all study participants or in the case of subjects under the age of 18 assent was obtained from the child and consent from their parent. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
5572,31326901,genetics
5573,31326901,pituitary disorders
5574,31326901,thyroid disease cois
5576,30666977,iccidd
5577,30666977,iodine deficiency disorder
5578,30666977,iodized salt
5579,30666977,last mile
5580,30666977,public health nutrition
5581,30666977,success story
5582,30666977,way forward cois
5583,31169246,anaplastic thyroid carcinoma
5584,31169246,giant cells
5585,31169246,osteoclasts cois
5588,30610567,collision
5589,30610567,double tumor
5590,30610567,pit-1
5591,30610567,pituitary tumor
5592,30610567,plurihormonal
5593,30610567,sf-1
5594,30610567,stem cell
5595,29717097,*complication
5596,29717097,*elderly
5597,29717097,*morbidity
5598,29717097,*mortality
5599,29717097,*tracheostomy cois
5600,30707410,early diagnosis of rth β
5601,30707410,rth β management
5602,30707410,resistance to thyroid hormones
5603,30707410,spanish cohort
5604,30707410,thrb gene
5607,31250039,billing diagnosis
5608,31250039,coding quality
5609,31250039,prevalence of thyroid disorders
5610,31250039,primary data
5611,31250039,validation
5612,30700956,cardiovascular disease
5613,30700956,hyperthyroidism
5614,30700956,pattern
5615,30700956,presentation
5616,30700956,thyro-cardiac disease
5617,31489070,sarcoidosis
5618,31489070,endoscopy
5619,31489070,hypothalamus
5620,31489070,neurosarcoidosis
5621,31489070,pituitary gland
5622,31489070,sella turcica cois
5623,30450534,congenital hypothyroidism
5624,30450534,screening
5625,30450534,thyroid dysgenesis
5626,30450534,thyroid scintigraphy
5627,29409365,*percutaneous laser ablation
5628,29409365,*hyperthyroidism
5629,29409365,*toxic nodules
5630,31243250,igg4
5631,31243250,hypertrophic pachymeningitis
5632,31243250,non-caseating granuloma
5633,31243250,sarcoidosis
5635,30236136,conventional
5636,30236136,hypocalcemia
5637,30236136,ligasure® small jaw
5638,30236136,recurrent laryngeal nerve
5639,30236136,"thyroidectomy cois chancellor of research and development, tabriz university of medical sciences (committee reference number: 92170), and registered in iranian registry of clinical trials (www.irct.com), trial registration: irct2014010516077n1, registered: 23 may 2014). all patients provided written consent form in order to participate in the study and the procedures followed were in accordance with the ethical standards of the ethics committee of the tabriz university of medical sciences. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
5640,29039144,*endoscopic thyroidectomy
5641,29039144,*natural orifice transluminal endoscopic surgery
5642,29039144,*robotic thyroidectomy
5643,29039144,*transoral thyroidectomy
5644,30919068,ablation techniques
5645,30919068,high-intensity focused ultrasound ablation
5646,30919068,interventional ultrasonography
5647,30919068,nodular goiter
5648,30919068,pain management
5649,30778718,ablation techniques
5650,30778718,high-intensity focused ultrasound ablation
5651,30778718,interventional ultrasonography
5652,30778718,nodular goiter
5653,30778718,ultrasound imaging
5654,32202723,*cancer
5655,32202723,*cytology
5656,32202723,*nodular goiter
5657,32202723,*stratification
5658,32202723,*thyroid gland
5659,32202723,*ultrasonography
5660,30105949,*tirads
5661,30105949,*imaging
5662,30105949,*multinodular goiter
5663,30105949,*scoring system
5664,30105949,*ultrasonography
5665,30039748,*graves' disease
5666,30039748,*hashimoto's thyroiditis
5667,30039748,*quality of life
5668,30039748,*sexual dysfunction
5669,30039748,*thyroid autoimmunity
5670,31741093,adolescent
5671,31741093,child
5672,31741093,thyroid neoplasm
5673,31741093,thyroid nodule
5674,31741093,ultrasonography
5675,30833205,e-learning
5676,30833205,personalized learning environment
5677,30833205,practice-based learning and improvement
5678,30833205,professionalism
5679,30833205,systems-based practice
5680,30833205,vodcast vs. lecture
5682,30666981,anaemia
5683,30666981,diagnosis
5684,30666981,hypertension
5685,30666981,interventions
5686,30666981,recovery
5687,30666981,status fluorosis
5688,30666981,stillbirth cois
5689,29239041,familial adenomatous polyposis
5690,29239041,familial medullary thyroid carcinoma
5691,29239041,familial non-medullary thyroid carcinoma
5692,29239041,familial thyroid carcinoma
5693,29239041,multiple endocrine neoplasia
5694,29683529,*braf mutation
5695,29683529,*immunocytochemistry
5696,29683529,*molecular testing
5697,29683529,*plump cells
5698,29683529,*thyroid malignancies
5699,29683529,*thyroid nodules
5700,29529424,*goiter
5701,29529424,*iodine deficiency disorders
5702,29529424,*iodine supplementation
5703,29529424,*pregnancy
5704,29529424,*thyroid hormones
5705,31752761,bilateral cataract
5706,31752761,hypocalcemia
5707,31752761,hypoparathyroidism
5708,31752761,serum calcium and ethiopia
5709,31752761,tetany
5710,31752761,total thyroidectomy cois authors have any proprietary interests or conflicts of interest related to this submission.
5711,30595314,autopsy
5712,30595314,hypothyroidism
5713,30595314,ischemic heart disease
5714,30595314,thyroid
5715,31074392,cancer
5716,31074392,fine needle aspiration citology
5717,31074392,follicular
5718,31074392,goiter
5719,31074392,kidney transplantation
5720,31074392,papillary
5721,31074392,thyroid
5722,31074392,thyroid nodule cois
5724,31396854,ezh2
5725,31396854,h3k27me3
5726,31396854,immunohistochemistry
5727,31396854,thyroid cancer
5728,30197365,carcinoma thyroid
5729,30197365,poorly differentiated
5730,30197365,thyroglobulin cois
5731,31254103,"chronic hypocalcaemia, permanent hypoparathyroidism, operative volume"
5732,31254103,endocrine surgery
5733,31254103,surgeon volume
5734,31254103,thyroidectomy
5735,31254103,volume-outcome
5736,29637242,notes
5737,29637242,parathyroid gland
5738,29637242,toetva
5739,29637242,thyroid gland
5740,30252648,adolescent
5741,30252648,anthropometry
5742,30252648,blood pressure
5743,30252648,child
5744,30252648,glucose metabolism
5745,30252648,lipid metabolism
5746,30252648,subclinical hypothyroidism
5747,29885011,*biobanking
5748,29885011,*fine needle aspiration cytology
5749,29885011,*preanalytical procedures
5750,29885011,*thyroid
5751,28771678,sjögren syndrome
5752,28771678,annular erythema
5753,28771678,eccrine gland
5754,28771678,hidradenitis
5755,28771678,lymphocyte
5759,31565844,*intraoperative neuromonitoring
5760,31565844,*nerves at risk
5761,31565844,*phonosurgical therapy
5762,31565844,*recurrent laryngeal nerve
5763,31565844,*vocal fold paralysis
5764,31565844,*vocal function
5765,31133065,children
5766,31133065,deficiency
5767,31133065,excess
5768,31133065,nepal
5769,31133065,salt iodine
5770,31133065,thyroid
5771,31133065,urinary iodine cois
5772,31502218,acromegaly
5773,31502218,complications
5774,31502218,doppler
5775,31502218,ultrasound
5776,31502218,visceromegaly
5778,29319359,hyperthyroidism
5779,29319359,hypothyroidism
5780,29319359,pregnancy and thyroid
5781,29319359,prevention
5782,29319359,screening
5783,29319359,thyroid cancer
5784,29319359,thyroid disease
5785,31820353,iodine
5786,31820353,kombu
5787,31820353,risk assessment
5788,31820353,seaweeds
5789,31820353,toxic risk
5790,31820353,wakame
5791,31671395,choriocarcinoma
5792,31671395,germ cell tumors
5793,31671395,human chorionic gonadotropin
5794,31671395,hyperthyroidism
5796,29886838,anaplastic thyroid carcinoma
5797,29886838,aetiology
5798,29886838,new approaches
5799,29886838,prognostic factors
5800,29886838,risk factors
5801,29886838,treatment.
5802,31409088,dicer1
5803,31409088,cystic nephroma
5804,31409088,genetic testing
5805,31409088,hereditary cancer syndromes
5806,31409088,pleuropulmonary blastoma
5807,31238185,carotid body tumor
5808,31238185,ectopic thyroid
5809,31238185,in-111 pentetreotide
5810,31238185,paraganglioma
5811,29444549,body weight
5812,29444549,endocrine surgery
5813,29444549,general surgery
5814,29444549,thyroidectomy
5815,30259504,calcifediol
5816,30259504,sunlight
5817,30259504,thyroid disease
5818,30259504,ultraviolet rays
5819,30259504,vitamin d deficiency
5820,31400012,*epidemiology
5821,31400012,*hyperthyroidism
5822,31400012,*hypothyroidism
5823,31400012,*incidence
5824,31400012,*iodine
5825,31400012,*myxoedema
5826,31400012,*thyrotoxicosis
5827,29851122,*epidemiology
5828,29851122,*hyperthyroidism
5829,29851122,*incidence
5830,29851122,*iodine
5831,29851122,*thyrotoxicosis
5833,30681972,hashimoto’s thyroiditis
5834,30681972,thrβ gene mutation
5835,30681972,resistance to thyroid hormone
5836,29798143,collagen triple helix repeat containing 1
5837,29798143,epithelial-mesenchymal transition
5838,29798143,immunohistochemistry
5839,29798143,thyroid neoplasms cois relevant financial relationships with commercial interests to disclose.
5840,29333819,autoimmune thyroiditis
5841,29333819,child
5842,29333819,hashimoto's disease
5843,29333819,hypothyroidism
5844,31468286,anaplastic thyroid carcinoma
5845,31468286,ham-1
5846,31468286,in situ hybridization
5847,31468286,long non-coding rna
5848,31468286,pca3
5849,31468286,pcr array
5850,31468286,papillary thyroid carcinoma
5851,31468286,rt-pcr
5852,31468286,thyroid carcinoma
5853,30413933,aggressiveness
5854,30413933,id genes
5855,30413933,thyroid cancer
5856,30413933,bhlh
5860,31610911,children
5861,31610911,conseil génétique
5862,31610911,dicer1
5863,31610911,dépistage
5864,31610911,enfant
5865,31610911,genetic counseling
5866,31610911,ovarian sertoli-leydig tumor
5867,31610911,pleuropneumoblastoma
5868,31610911,pleuropneumoblastomes
5869,31610911,rare tumors
5870,31610911,screening
5871,31610911,surveillance
5872,31610911,tumeur ovarienne de sertoli-leydig
5873,31610911,tumeurs rares
5874,31375535,cancer
5875,31375535,cytopathology
5876,31375535,endocrine pathology
5877,31375535,thyroid cancer cois
5878,30074074,benign thyroid surgery
5879,30074074,head and neck surgery
5880,30074074,postoperative complications
5881,30074074,thyroid surgery
5882,30074074,vocal fold palsy
5884,30387163,*rct
5885,30387163,*cholecalciferol
5886,30387163,*hypocalcaemia
5887,30387163,*thyroidectomy
5888,30387163,*vitamin d
5889,30306604,adolescents
5890,30306604,autoimmune thyroiditis
5891,30306604,children
5892,30306604,l-selenomethionine
5893,30306604,organic selenium
5895,30902382,*carcinoma de células renales
5896,30902382,*neoplasia metastásica
5897,30902382,*neoplasm metástasis
5898,30902382,*renal cell carcinoma
5899,30902382,*thyroid
5900,30902382,*tiroides
5901,29466241,graves’ disease
5902,29466241,amiodarone-induced thyrotoxicosis
5903,29466241,hyperthyroidism
5905,32372175,c cell
5906,32372175,cancer
5907,32372175,diagnosis
5908,32372175,foxa1
5909,32372175,thyroid
5911,30891786,*iodine
5912,30891786,*iodine excess
5913,30891786,*iodized salt
5914,30891786,*thyroglobulin
5915,30891786,*thyroid autoimmunity
5917,29459556,autoimmune polyglandular syndrome
5918,29459556,hashimoto’s thyroiditis
5919,29459556,pulmonary hypertension
5920,29459556,type 1 diabetes
5921,31770674,iodine
5922,31770674,adolescents
5923,31770674,children
5924,31770674,deficiency
5925,31770674,dietary intake
5926,31770674,pre-schoolers
5928,31835129,copper
5929,31835129,iodine
5930,31835129,selenium
5931,31835129,thyroiditis
5932,31835129,zinc
5935,28717869,endoscopic thyroidectomy
5936,28717869,toetva
5937,28717869,thyroidectomy
5938,28717869,transoral
5939,28717869,transoral endoscopic thyroidectomy
5940,28717869,transoral neck surgery
5941,30953492,epidemiology
5942,30953492,hepatitis c infection
5943,30953492,interferon
5944,30953492,morbidity
5945,30953492,ribavirin
5946,30953492,"thyroid dysfunction cois database. according to the regulation of ministry of health and welfare, taiwan, all of the nhir datasets are only available from the information center, ministry of health and welfare, taiwan. the study was approved by the institute review board of the show chwan memorial hospital, taiwan (no. 1051201). informed consent from the subjects was not obtained because there was no personal contact between the patients and the data collectors. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
5947,30168266,inguinal hernia
5948,30168266,uroflowmetry
5949,30168266,visual analog scale
5950,30168266,voiding dysfunction
5952,31881874,acdf
5953,31881874,anterior cervical discectomy and fusion
5954,31881874,c7/t1 anterior discectomy
5955,31881874,cervicothoracic junction
5956,31881874,hemithyroidectomy cois
5957,30955264,"carcinoma, papillary"
5958,30955264,prognosis
5959,30955264,thyroid neoplasms
5960,29079441,graves’ disease
5961,29079441,ompf porin
5962,29079441,serological cross-reactivity
5963,29079441,thyroid-stimulating hormone receptor
5964,29079441,yersinia pseudotuberculosis
5965,29993215,color doppler
5966,29993215,neoplasms
5967,29993215,thyroid nodule
5968,29993215,ultrasonography
5971,30784009,acoustic respiratory rate monitoring
5972,30784009,airway obstruction
5973,30784009,postoperative hemorrhage
5974,30784009,tachypnea
5975,30784009,thyroidectomy
5976,30298217,cross-sectional studies
5977,30298217,epidemiology
5978,30298217,general practice
5979,30298217,health services research
5980,30298217,otolaryngologists
5981,30298217,thyroid gland
5982,30272298,*co-morbidities
5983,30272298,*endometriosis
5984,30272298,*whole exome sequencing
5985,30272298,*autoimmune diseases
5986,30272298,*family history
5987,29730784,*neuromonitoring
5988,29730784,*quality of life
5989,29730784,*surgery
5990,29730784,*thyroid
5991,29730784,*voice cois ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. informed consent: informed consent was obtained from all individual participants included in the study.
5992,31248397,3d printing
5993,31248397,airway pathology
5994,31248397,bronchial tree
5995,31248397,bronchoscopy
5996,31248397,multi-material
5997,31248397,simulation cois
5999,30264384,choline
6000,30264384,parathyroid adenoma
6001,30264384,positron emission tomography computed tomography
6002,30264384,primary hyperparathyroidism
6003,29380231,*diagnose
6004,29380231,*glucocorticoid treatment
6005,29380231,*igg4
6006,29380231,*inflammation
6007,29380231,*riedel cois ethical approval: for this type of retrospective study formal consent was not required.
6009,31821747,*braf mutation
6010,31821747,*fine-needle aspiration cytology
6011,31821747,*personalized medicine
6012,31821747,*programmed death-ligand 1 (pd-l1)
6013,31821747,*thyroid cancer
6014,31751626,*congenital hypothyroidism
6015,31751626,*erad
6016,31751626,*protein folding
6017,31751626,*thyroid genes
6019,30260174,gh
6020,30260174,igf-1
6021,30260174,acromegaly
6022,30260174,cancer
6023,30260174,neoplasms
6024,30260174,registry
6025,29504626,rdw
6026,29504626,heart failure
6027,29504626,hypothyroidism
6028,29504626,radioiodine therapy
6029,29317181,extramedullary hematopoiesis
6030,29317181,fine needle aspiration
6031,29317181,thyroid
6032,31914295,lymphatic metastasis
6033,31914295,melatonin
6034,31914295,melatonin receptor
6035,31914295,papillary thyroid cancer cois relevant financial relationships with commercial interests to disclose.
6038,30691690,"abordaje biaxilo-biareolar, ba-ba"
6039,30691690,abordaje extracervical
6040,30691690,baba endoscopic thyroidectomy
6041,30691690,bilateral axillo-breast approach
6042,30691690,endoscopic thyroidectomy
6043,30691690,scarless thyroidectomy
6044,30691690,tiroidectomía endoscópica
6045,30691690,tiroidectomía sin cicatriz cervical
6046,30406929,autoimmune
6047,30406929,empty sella
6048,30406929,pituitary adenoma
6049,30406929,prolactin
6050,30406929,thyroid
6051,30218312,iodine
6052,30218312,iodine deficiency disorder
6053,30218312,pregnancy
6054,30218312,thyroid
6055,29582344,hypothyroidism
6056,29582344,levothyroxine formulation
6057,29582344,liquid levothyroxine
6058,29582344,tsh
6059,29022276,central hyperthyroidism
6060,29022276,hyperthyroidism
6061,29022276,pituitary tumors
6062,29022276,tsh-secreting pituitary adenoma
6063,29022276,thyrotropinoma
6064,30740757,*18f-fdg pet/ct
6065,30740757,*eu-tirads
6066,30740757,*diagnosis
6067,30740757,*thyroid cancer
6068,30740757,*ultrasound
6069,31703968,*contrast-enhanced ultrasonography
6070,31703968,*papillary thyroid microcarcinoma
6071,31703968,*tumor size stratification
6072,31918249,braf(v600e)
6073,31918249,hbme-1
6074,31918249,lymph node metastasis
6075,31918249,papillary thyroid carcinoma
6076,31918249,ultrasound
6077,30443896,difficulty scale
6078,30443896,operative time
6079,30443896,total thyroidectomy
6080,30267376,autoimmune thyroid disease
6081,30267376,greece
6082,30267376,iodine
6083,30267376,thyroid
6084,30267376,thyroiditis
6085,30182360,incidence
6086,30182360,recurrence
6087,30182360,risk factors
6088,30182360,thyroid lobectomy
6089,30182360,thyroid nodules
6090,29774590,*anatomy handbook
6091,29774590,*pathogenesis and classification of neoplasms
6092,29774590,*prostatic hyperplasia
6093,30058426,electrophoresis
6094,30058426,mass spectrometry
6095,30058426,proteomics
6096,30058426,serum
6097,30058426,thyroid cancer
6098,29698806,14q32 deletion
6099,29698806,cancer
6100,29698806,dicer1 syndrome
6101,29536247,indocyanine green
6102,29536247,mivat
6103,29536247,near-infrared fluorescence
6104,29536247,parathyroid
6105,29536247,video-assisted thyroidectomy
6106,29164514,iodine
6107,29164514,microcarcinoma
6108,29164514,papillary thyroid cancer
6109,29164514,risk factors
6110,29164514,thyroid thyroglobulin antibody
6111,29164514,thyroid-stimulating hormone
6113,29438906,*fgf19
6114,29438906,*fgfr4
6115,29438906,*serum concentration
6116,29438906,*thyroid cancer
6117,29438906,*βklotho
6118,29273943,children
6119,29273943,pten hamartoma tumor syndrome (phts)
6120,29273943,screening
6121,29273943,thyroid cancer
6122,29273943,thyroid disease
6123,31841457,131і
6124,31841457,chornobyl disaster
6125,31841457,late endocrine and neuropsychiatric effects
6126,31841457,pathogenesis
6127,31841457,prenatal irradiation
6128,29968224,*apheresis
6129,29968224,*therapeutic plasma exchange
6130,29968224,*thyroid hormones
6131,29968224,*thyrotoxicosis
6132,29340973,age
6133,29340973,iodine status
6134,29340973,reference intervals
6135,29340973,thyroid dysfunction
6136,29340973,thyrotropin
6137,31190472,cold nodule
6138,31190472,cytology
6139,31190472,histopathology
6140,31190472,hot nodule
6141,31190472,warm nodule
6143,30639646,autoimmune thyroid diseases
6144,30639646,autoimmune thyroiditis
6145,30639646,celiac disease
6146,30639646,chronic autoimmune gastritis
6147,30639646,graves' diseases
6148,30639646,graves' ophthalmopathy
6149,30639646,multiple sclerosis
6150,30639646,polymyalgia rheumatica
6151,30639646,rheumatoid arthritis
6152,30639646,sarcoidosis
6153,30639646,sjogren disease
6154,30639646,systemic lupus erythematosus
6155,30639646,type 1 diabetes (type 1)
6156,30639646,vitiligo
6157,29949024,cytology
6158,29949024,diagnosis
6159,29949024,fine-needle aspiration
6160,29949024,niftp
6161,29949024,negative
6162,29949024,thyroid
6164,31383578,hypocalcemia
6165,31383578,hypoparathyroidism
6166,31383578,pediatric population
6167,31383578,total thyroidectomy
6168,31365889,etiology
6169,31365889,thyroid disease
6170,31365889,thyroid tissue
6171,31365889,toxic/essential trace metals
6172,30953130,*brain tumor
6173,30953130,*cns sarcoma
6174,30953130,*ciliary body medulloepithelioma
6175,30953130,*dicer1
6176,30953130,*dicer1-associated cns sarcoma
6177,30953130,*etmr
6178,30953130,*pineoblastoma
6179,30953130,*pituitary blastoma
6181,29703200,classification and regression tree method (cart)
6182,29703200,low transmission
6183,29703200,malaria exposure
6184,29703200,plasmodium falciparum
6185,29703200,plasmodium vivax
6186,29703200,reservoir of infection
6187,29703200,sero-epidemiology
6188,29703200,vietnam
6189,30410095,*diagnostic evaluation
6190,30410095,*etiology
6191,30410095,*genetic
6192,30410095,*hydrops fetalis
6193,30410095,"*nonimmune cois through the ucsf center for maternal-fetal precision medicine. m.e.n. is a consultant to invitae and has received research funding from natera, but this funding was not applied to this study. the other authors declare no conflicts of interest."
6194,31699952,congenital
6195,31699952,hypothyroidism
6196,31699952,young adult
6198,31621051,autoregulation
6199,31621051,cognition
6200,31621051,primary hyperparathyroidism
6201,31621051,vascular stiffness
6202,31621051,vasomotor reactivity cois
6203,30997493,*developing countries
6204,30997493,*effectiveness
6205,30997493,*folic acid
6206,30997493,*fortification
6207,30997493,*functional outcomes
6208,30997493,*iodine
6209,30997493,*iron
6210,30997493,*micronutrient status
6211,30997493,*systematic review
6212,30997493,*vitamin a
6214,31323353,hypocalcemia
6215,31323353,intact parathyroid hormone (pth)
6216,31323353,pediatric thyroidectomy
6217,30973063,*tbab
6218,30973063,*trab
6219,30973063,*tsab
6220,30973063,*fetal hyperthyroidism
6221,30973063,*fetal malformation
6222,30973063,*maternal hashimoto's disease
6223,30772970,tyumen region
6224,30772970,iodine deficiency
6225,30772970,iodized salt
6226,30772970,nutrition
6227,30772970,prevention cois publication of this article.
6228,30963819,*s1pr1
6229,30963819,*sphingosine 1 phosphate
6230,30963819,*sphingosine kinase 1
6231,30963819,*thyroiditis
6232,29650436,concentración urinaria de yodo
6233,29650436,epidemiological survey
6234,29650436,escolares
6235,29650436,estudio epidemiológico
6236,29650436,schoolchildren
6237,29650436,tsh en sangre capilar
6238,29650436,tsh in capillary blood
6239,29650436,urinary iodine concentration
6240,29030129,acoustic analysis
6241,29030129,análise acústica
6242,29030129,disfonia
6243,29030129,dysphonia
6244,29030129,hoarseness
6245,29030129,laryngeal paralysis
6246,29030129,paralisia laríngea
6247,29030129,rouquidão
6248,29030129,thyroidectomy
6249,29030129,tireoidectomia
6250,30891966,*classification
6251,30891966,*convolutional neural network
6252,30891966,*deep learning
6253,30891966,*head and neck cancer
6254,30891966,*hyperspectral imaging
6255,30891966,*optical biopsy
6256,30891966,*squamous cell carcinoma
6257,30472362,carbon nanoparticles
6258,30472362,parathyroid glands
6259,30472362,recurrent laryngeal nerve
6260,30472362,total thyroidectomy
6261,30443770,foxp3
6262,30443770,garp
6263,30443770,papillary thyroid carcinoma
6264,30443770,thyroid cancer
6265,29848235,*central neck
6266,29848235,*hypocalcemia
6267,29848235,*hypoparathyroidism
6268,29848235,*parathyroid hormone
6269,29848235,*paresthesia
6270,29848235,*thyroidectomy
6271,28875268,hashimoto’s thyroiditis
6272,28875268,papillary thyroid carcinoma
6273,28875268,tsh
6274,28875268,thyroid cytology
6275,28875268,thyroid nodules
6276,29170092,*adaptive redox homeostasis
6277,29170092,*antioxidant defense
6278,29170092,*argpyrimidine-modified heat-shock proteins
6279,29170092,*ccm1/krit1
6280,29170092,*cerebral cavernous malformations
6281,29170092,*cerebrovascular disease
6282,29170092,*glyoxalase 1 (glo1)
6283,29170092,*heme oxygenase-1 (ho-1)
6284,29170092,*nuclear factor erythroid 2-related factor 2 (nrf2)
6285,29170092,*oxidative dna damage and apoptosis
6286,29170092,*oxidative stress
6287,29170092,*redox signaling
6288,29170092,*c-jun
6290,31619220,calcitonin
6291,31619220,carcinoembryogenic antigen
6292,31619220,medullary thyroid carcinoma
6293,31619220,thyroid cancer cois
6294,31135104,*braf mutation
6295,31135104,*hyalinizing trabecular tumor
6296,31135104,*immunocytochemistry
6297,31135104,*molecular testing
6298,31135104,*personalized medicine
6299,31135104,*thyroid malignancy
6300,31135104,*thyroid nodule
6301,29043574,autoimmunity
6302,29043574,ctla4
6303,29043574,immune checkpoint inhibitors
6304,29043574,melanoma
6305,29043574,pd1
6306,29043574,thyroid diseases
6308,30684524,diagnostic marker
6309,30684524,ptc
6310,30684524,plasma microrna
6311,30684524,qrt-pcr
6312,30509240,braf v600e
6313,30509240,matrix metalloproteinase-9
6314,30509240,"papillary thyroid cancer cois institutional review board and ethics committee of the research institute for endocrine sciences, shahid beheshti university of medical sciences, tehran, iran (25ecries93/10/23); and was conducted in accordance with the declaration of helsinki guidelines a written informed consent was obtained from all participants. consent for publication: not applicable. competing interests: the authors do not report any relevant conflict of interest. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
6315,31784815,comparison between germany and switzerland
6316,31784815,degs1
6317,31784815,iodine
6318,31784815,iodine-containing foods
6319,31784815,iodized salt
6320,31784815,salt
6322,30909759,*statement
6323,30909759,*minimally invasive treatments
6324,30909759,*percutaneous thermal ablation
6325,30909759,*thyroid gland
6326,30909759,*thyroid nodule
6327,30909759,*ultrasonography
6328,31182340,*autoimmunity
6329,31182340,*graves' disease
6330,31182340,*ifnγ
6331,31182340,*immune checkpoints
6332,31182340,*pd-1
6333,31182340,*pd-l1
6334,31182340,*pd-l2
6335,31182340,*t-lymphocytes
6336,31182340,*tolerances
6338,35288841,anaplastic thyroid carcinoma
6339,35288841,cribriform-morular thyroid carcinoma
6340,35288841,follicular nodular disease
6341,35288841,follicular thyroid carcinoma
6342,35288841,high-grade thyroid carcinoma
6343,35288841,hyalinizing trabecular tumor
6344,35288841,medullary thyroid carcinoma
6345,35288841,papillary thyroid carcinoma
6346,35288841,poorly differentiated thyroid carcinoma
6347,35288841,thyroblastoma
6348,35288841,who classification of thyroid tumors
6350,34506000,compression syndrome
6351,34506000,goiter
6352,34506000,ischemic stroke
6353,34506000,thrombosis
6354,34417736,autoimmune
6355,34417736,fibrocyte
6356,34417736,graves’ ophthalmopathy
6357,34417736,insulin-like growth factor receptor
6358,34417736,orbit
6360,35657195,basedow
6361,35657195,hashimoto
6362,35657195,inflammation
6363,35657195,thyroiditis
6364,35657195,auto
6365,35657195,immunity
6366,34792795,autoimmune/inflammatory syndrome induced by adjuvants (asia)
6367,34792795,covid-19
6368,34792795,graves’ disease
6369,34792795,sars-cov2 vaccination
6370,34792795,thyroiditis cois
6371,34670889,hyperthyroidism
6372,34670889,multinodular goiter
6373,34670889,thyroglobulin
6374,34670889,tracheal compression
6375,34670889,tracheal deviation cois
6376,35685217,*massive goiter
6377,35685217,*multinodular goiter
6378,35685217,*retrosternal extension
6379,35685217,*sternotomy
6380,35685217,*thyroidectomy cois commercial or financial relationships that could be construed as a potential conflict of interest.
6381,34342859,covid
6382,34342859,graves’ disease
6383,34342859,sars-cov-2 rna vaccination
6384,34342859,thyroid cois employment by an organization that may gain or lose financially from publication of the article. there are also no other competing interests regarding the manuscript.
6387,35538703,giant goiter
6388,35538703,hashimoto’s thyroiditis
6389,35538703,case report
6390,35538703,en bloc excision
6391,35538703,hyperthyroidism
6392,35538703,thyroid
6393,35567330,complication
6394,35567330,large intrathoracic goiter
6395,35567330,minimally invasive surgery
6396,35567330,robot-assisted thoracoscopic surgery
6397,35567330,tracheal stenosis cois
6398,34272677,fine arts
6399,34272677,giovanni martino spanzotti
6400,34272677,goiter
6401,34272677,history
6402,34272677,renaissance
6403,34688699,*long-term
6404,34688699,*proptosis
6405,34688699,*re-treatment
6406,34688699,*teprotumumab
6407,34688699,*thyroid eye disease
6409,34915750,*adaptor protein
6410,34915750,*aging
6411,34915750,*cytoskeleton
6412,34915750,*hypothyroidism
6413,34915750,*iodide organification cois
6414,34476761,fermo stella
6415,34476761,fine arts
6416,34476761,goiter
6417,34476761,history
6418,34476761,renaissance
6419,35331216,micronodular goiter
6420,35331216,papillary thyroid microcarcinoma
6421,35331216,ultrasound grayscale ratio cois
6426,35221176,*airway stenosis
6427,35221176,*ecmo
6428,35221176,*nodular goiter cois authors were disclosed.
6430,34405392,autonomous multinodular goiter
6431,34405392,gene expression
6432,34405392,thyroid nodule cois
6433,34448414,audiometry
6434,34448414,graves ophthalmopathy
6435,34448414,hearing loss
6436,34448414,miscellaneous
6437,34448414,otolaryngology
6438,34448414,otology
6439,34448414,ototoxicity
6440,34448414,teprotumumab
6441,35186140,alt – alanine aminotransferase
6442,35186140,ap – alkaline phosphatase
6443,35186140,ast – aspartate aminotransferase
6444,35186140,arttg – antibodies to thyroid-stimulating hormone receptors
6445,35186140,cdld – chronic diffuse liver diseases
6446,35186140,dtg – diffuse toxic goiter
6447,35186140,swv – shear wave velocity
6448,35186140,t3f – free triiodothyronine
6449,35186140,t4f – thyroxine free
6450,35186140,tg – thyroid gland
6451,35186140,tsh – thyroid-stimulating hormone
6452,35186140,diffuse toxic goiter
6453,35186140,shear wave elastography
6454,35186140,ultrasound examination
6455,34980104,*iodine
6456,34980104,*nodular goiter
6457,34980104,*perchlorate
6458,34980104,*thyroid cancer
6459,34980104,*thyroid function cois
6460,35469855,bkmr analysis
6461,35469855,ng
6462,35469855,pbdes
6463,35469855,risk factor
6464,35436270,diffuse non-toxic goiter
6465,35436270,mathematical model
6466,35436270,risk
6467,35436270,type 2 diabetes mellitus
6468,35390148,benign multinodular goiter
6469,35390148,postoperative morbidity
6470,35390148,total thyroidectomy
6471,35390148,vocal cord palsy
6472,35390148,weight of specimen
6475,33218789,extra-adrenal paraganglioma
6476,33218789,paraganglioma
6477,33218789,subclavian paraganglia
6478,33218789,superior mediastinum
6482,34874796,graves’ ophthalmopathy
6483,34874796,thyroid-associated orbitopathy
6484,34874796,thyroid eye disease
6485,34874796,thyroid ophthalmopathy
6489,34928376,*graves’ disease
6490,34928376,*adolescents
6491,34928376,*children
6492,34928376,*rituximab
6493,34928376,*thionamide
6494,34928376,*thyrotoxicosis
6496,35037871,hypercalcemia
6497,35037871,lithium
6498,35037871,nephrogenic diabetes insipidus
6499,35037871,thyroid disorders
6500,34787691,environment
6501,34787691,genetic codes
6502,34787691,graves’ ophthalmopathy
6503,34787691,human organism
6504,34787691,risk factor
6505,33832185,*congenital goiter
6506,33832185,*hypothyroidism
6507,33832185,*thyroglobulin
6508,33832185,*novel mutation
6509,33832185,*case report
6513,33226264,bactericide
6514,33226264,intestinal microbiota
6515,33226264,iodine
6516,33226264,nutrition
6517,33226264,thyroid diseases
6518,33226264,thyroid hormones
6521,35264385,immunology
6522,35264385,materno-fetal medicine
6523,35264385,neonatal intensive care
6524,35264385,thyrotoxicosis cois
6525,35574000,epidemiology
6526,35574000,evaluation
6527,35574000,graves orbitopathy
6528,35574000,novel therapeutic approach
6529,35574000,pathogenesis cois commercial or financial relationships that could be construed as a potential conflict of interest.
6530,33349089,*elephantiasis
6531,33349089,*graves dermopathy
6532,33349089,*graves disease
6533,33349089,*thyroid eye disease
6534,35307540,*covid-19
6535,35307540,*graves' disease
6536,35307540,*hashimoto's thyroiditis
6537,35307540,*thyroid cois
6538,35226548,coronavirus disease 2019
6539,35226548,hyperthyroidism
6540,35226548,hypothyroidism
6541,35226548,non-thyroidal illness
6542,35226548,thyroid
6543,35226548,thyroid cancer
6544,35226548,thyroiditis cois conflict of interest.
6545,35334525,cervicotomy
6546,35334525,intrathoracic goitre
6547,35334525,morbidity
6548,35334525,sternotomy
6549,35334525,thyroid surgery cois
6550,32975863,graves ophthalmopathy
6551,32975863,thyroid eye disease
6553,35167950,*dry eye
6554,35167950,*exposure keratopathy
6555,35167950,*ocular surface disease
6556,35167950,*thyroid eye disease
6559,35226748,*graves disease
6560,35226748,*autoimmune addison disease
6561,35226748,*autoimmune hypothyroidism
6562,35226748,*autoimmune polyendocrine syndromes
6563,33525898,teprotumumab
6564,33525898,compressive optic neuropathy
6565,33525898,dysthyroid optic neuropathy
6566,33525898,graves’ ophthalmopathy
6567,33525898,thyroid eye disease
6568,34334562,emo syndrome
6569,34334562,graves' disease
6570,34334562,musculoskeletal ultrasound
6571,34334562,osteoarthropathy cois
6572,35684009,cancer
6573,35684009,iodine
6574,35684009,iodine deficiency
6575,35684009,iodine supplementation
6576,35684009,prevalence
6577,35684009,thyroid dysfunction cois
6579,35614620,"graves, orbital fibroblasts, autoimmunity."
6580,35230257,graves‘ disease
6581,35230257,iceland
6582,35230257,pediatric
6583,35230257,treatment
6584,35422184,autoimmune eye diseases
6585,35422184,graves’ orbitopathy
6586,35422184,anti-il6-receptor antibodies
6587,35422184,neuromyelitis optica spectrum disorders
6588,35422184,noninfectious uveitis
6589,35422184,optic neuropathy
6590,35422184,peripheral ulcerative keratitis
6591,35422184,tocilizumab
6593,33908335,graves disease
6594,33908335,antithyroid agents
6595,33908335,hemodynamics
6596,33908335,hyperthyroidism
6597,33908335,thyroidectomy
6598,33908335,thyrotropin
6599,35287535,*graves’ disease
6600,35287535,*graves’ orbitopathy
6601,35287535,*k1-70
6602,35287535,*antithyroid drugs
6603,35287535,*hyperthyroidism
6604,35287535,*iscalimab
6605,35287535,*methimazole
6606,35287535,*propylthiouracil
6607,35287535,*radioactive iodine
6608,35287535,*rituximab
6609,35287535,*thyroidectomy
6610,35287535,*thyrotropin receptor
6611,34487995,diplopia
6612,34487995,endoscopic
6613,34487995,eye
6614,34487995,graves'
6615,34487995,oculoplastic
6616,34487995,orbital decompression
6617,34487995,proptosis
6618,34487995,revision
6619,34487995,rhinology
6620,34487995,sinus
6621,34487995,thyroid
6622,33775197,entropion
6623,33775197,eyelid retraction
6624,33775197,orbital decompression
6625,33775197,thyroid eye disease
6626,33775197,ultrasound biomicroscopy
6627,34954838,graves' disease
6628,34954838,head and neck
6629,34954838,hyperthyroidism
6630,34954838,surgery
6632,34663089,*graves'
6633,34663089,*disease
6634,34663089,*patient-reported outcomes
6635,34663089,*quality of life
6636,34663089,*thyroidectomy cois
6637,35534869,*autoimmune thyroid disease
6638,35534869,*human leucocyte antigen
6639,35534869,*relapsing polychondritis cois
6640,35315985,graves' ophthalmopathy
6641,35315985,proptosis
6642,35315985,thiol-disulfide
6643,35658138,parathyroidectomy
6644,35658138,prevention of damage
6645,35658138,recurrent laryngeal nerve
6646,35658138,thyroidectomy
6647,34291428,*art
6648,34291428,*exophthalmos
6649,34291428,*graves’ disease
6650,34291428,*history
6651,33579690,*eye (globe)
6652,33579690,*eye lids
6653,33579690,*immunology
6654,33579690,*orbit
6655,33579690,*pathology cois medical centre has received research-associated funding from horizon therapeutics.
6656,34687316,*graves disease
6657,34687316,*adolescents
6658,34687316,*children
6659,34687316,*rituximab
6660,34687316,*thionamide
6661,34687316,*thyrotoxicosis
6662,35600602,graves’ disease
6663,35600602,central hypothyroidism
6664,35600602,maternal trab
6665,35600602,neonatal hyperthyroidism
6666,35600602,neonates cois commercial or financial relationships that could be construed as a potential conflict of interest.
6667,35379490,hypoparathyroidism
6668,35379490,paediatrics
6669,35379490,postoperative complications
6670,35379490,thyroidectomy
6671,35379490,"vocal cord palsy cois hy chung, and kenneth ky wong have no conflicts of interest or financial ties to disclose."
6675,35015288,adjuvants
6676,35015288,autoimmune syndrome
6677,35015288,graves’ disease
6678,35015288,sars-cov-2 vaccination
6679,35015288,subacute painful thyroiditis
6680,35015288,thyrotoxicosis cois
6681,35381100,graves’ disease
6682,35381100,antithyroid agents
6683,35381100,pericarditis
6684,35381100,pleurisy
6686,35504153,multinodular goiter
6687,35504153,neck hematoma
6688,35504153,recurrent laryngeal nerve injury
6689,35504153,substernal thyroid goiter
6690,35504153,thyroidectomy
6691,35303084,graves’ orbitopathy
6692,35303084,cystine deprivation
6693,35303084,ferroptosis
6694,35303084,glycolysis
6695,35303084,orbital fibroblast
6696,35100622,*covid-19
6697,35100622,*graves’ disease
6698,35100622,*sars-cov-2
6699,35100622,*revaccination
6700,35100622,*subacute thyroiditis
6701,35100622,*vaccine
6702,34996091,*addison disease
6703,34996091,*autoantibodies
6704,34996091,*graves
6705,34996091,*hashimoto thyroiditis
6706,34996091,*disease
6707,34996091,*insulin-dependent diabetes mellitus
6709,35580958,gynecological cancer
6710,35580958,obstetrics and gynaecology cois
6711,32912014,myositis
6712,32912014,whipple’s disease
6713,32912014,orbitopathy
6714,32912014,tropheryma whipplei
6716,35662442,antithyroid drugs
6717,35662442,graves disease
6718,35662442,hyperthyroidism
6719,35662442,radioiodine therapy
6720,35662442,thyroid eye disease
6721,35662442,thyroidectomy cois
6722,35069441,*dna methylation
6723,35069441,*graves’ ophthalmopathy
6724,35069441,*epigenetics
6725,35069441,*gut microbiome
6726,35069441,*histone modification
6727,35069441,*noncoding rnas cois commercial or financial relationships that could be construed as a potential conflict of interest.
6730,35734334,compressive goitre
6731,35734334,case report
6732,35734334,dyspnea
6733,35734334,thyroidectomy cois
6734,35039921,central neck tumour
6735,35039921,hypercalcaemia
6736,35039921,hyperparathyroidism
6737,35039921,parathyroid adenoma
6738,35039921,parathyroid cancer
6739,35039921,parathyroid neoplasms
6740,34515780,graves’ disease
6741,34515780,juvenile dermatomyositis
6742,34515780,anti-melanoma differentiation antigen 5
6743,34515780,soluble interleukin-2 receptor
6744,34250837,choroidal vascularity
6745,34250837,graves’ disease
6746,34250837,binarization
6747,34250837,choroidal thickness
6748,34250837,thyroid
6749,33884704,graves' disease
6750,33884704,tsh receptor antibody
6751,33884704,antithyroid drug
6752,33884704,remission
6753,34642808,dysthyroid optic neuropathy
6754,34642808,graves orbitopathy
6755,34642808,magnetic resonance imaging
6756,34642808,muscle index
6757,34642808,optic neuropathy
6758,35413468,covid-19
6759,35413468,graves' disease
6760,35413468,graves' ophthalmopathy
6761,35413468,sars-cov-2
6762,35413468,vaccine cois personal relationships that could have appeared to influence the work reported in this paper.
6763,35418378,contraindications and precautions
6764,35418378,"ear, nose and throat/otolaryngology"
6765,35418378,eye
6766,35418378,ophthalmology
6767,35418378,thyroid disease cois
6770,35562686,multinodular goitre
6771,35562686,rln trifurcations
6772,35562686,recurrent laryngeal nerve variations
6773,35562686,thyroidectomy cois
6775,35504602,*graves disease
6776,35504602,*hashimoto disease
6777,35504602,*immunoglobulin g4
6778,35504602,*riedel thyroiditis
6779,35504602,*thyroid diseases cois was reported.
6781,35168232,benign intracranial hypertension
6782,35168232,child
6783,35168232,graves’ disease
6784,35168232,idiopathic intracranial hypertension
6785,35168232,pseudotumor cerebri
6786,34365588,asthenia
6787,34365588,parathyroidectomy
6788,34365588,quality of life
6789,34365588,thyroidectomy
6792,34895729,*graves hyperthyroidism
6793,34895729,*endocrine ophthalmopathy
6794,34895729,*orbital irradiation
6795,34895729,*radiotherapy
6796,34895729,*thyroid eye disease
6797,34895729,*thyroid-associated orbitopathy
6798,35119087,18f-fch pet/ct
6799,35119087,fluorocholine
6800,35119087,hyperparathyroidism
6801,35119087,parathyroid imaging
6802,35651979,*graves’ disease (gd)
6803,35651979,*autoimmune disease (aid)
6804,35651979,*autoimmune thyroid disease (aitd)
6805,35651979,*inactivated sars-cov-2 vaccine
6806,35651979,*thyrotropin receptor antibody (trab) cois commercial or financial relationships that could be construed as a potential conflict of interest.
6807,35627231,graves’ disease
6808,35627231,x chromosome
6809,35627231,covariates
6810,35627231,logistic regression
6811,35627231,robust cois
6812,35403994,*amyloid encephalopathy
6813,35403994,*graves’ orbitopathy
6814,35403994,*hearing loss
6815,35403994,*inflammatory bowel disease
6816,35403994,*teprotumumab
6817,35403994,*thyroid-eye disease
6819,35734176,*graves’ disease
6820,35734176,*auto-immune thyroiditis
6821,35734176,*kidney biopsy
6822,35734176,*membranous nephropathy
6823,35734176,*renal pathology cois commercial or financial relationships that could be construed as a potential conflict of interest.
6824,35320248,"graves, thyroid associated orbitopathy, immunomodulation"
6825,35614367,*compressive optic neuropathy (con)
6826,35614367,*diplopia
6827,35614367,*dysthyroid optic neuropathy (don)
6828,35614367,*graves ophthalmopathy (go)
6829,35614367,*teprotumumab
6830,35614367,*thyroid eye disease (ted)
6831,35112273,*atrial fibrillation
6832,35112273,*hypothyroidism
6833,35112273,*subclinical thyroid disease
6834,35112273,*thyroid disease
6835,35548945,graves disease
6836,35548945,hyperthyroidism
6837,35548945,newborn
6838,35548945,pregnancy
6839,35548945,thyroid-stimulating hormone receptor antibodies
6840,35615845,clinical activity score; intraocular pressure; orbitopathy; thyroid dysfunction.
6841,35707463,graves orbitopathy
6842,35707463,adipogenesis
6843,35707463,fibroblasts
6844,35707463,fibrosis
6845,35707463,inflammation
6846,35707463,periostin cois commercial or financial relationships that could be construed as a potential conflict of interest.
6847,35331947,decompression
6848,35331947,endonasal
6849,35331947,endoscopic
6850,35331947,nonthyroid
6851,35331947,orbital
6856,34752624,*graves disease
6857,34752624,*amygdala
6858,34752624,*cognition
6859,34752624,*depression
6860,34752624,*hippocampus
6861,34752624,*longitudinal
6862,35022743,*graves disease
6863,35022743,*pittsburgh sleep quality index
6864,35022743,*hyperthyroidism
6865,35022743,*subjective sleep disorders
6866,35022743,*sympathetic tone
6867,35606042,endocrine cancer
6868,35606042,hyperthyroidism
6869,35606042,thyroid disease
6870,35606042,thyrotoxicosis cois
6871,32017356,*iodine deficiency
6872,32017356,*nepal
6873,32017356,*micronutrients
6874,32017356,"*salt iodization cois unicef, support the government of nepal's effort toward universal salt iodization but have no conflict of interest in developing this summary. the opinions and statements in this article are those of the authors and may not reflect official unicef policies. kedar parajuli, in his capacity working for government of nepal to prevent and control iodine deficiency in nepal, has no conflict of interest in developing this summary. robin houston, chandra pandav, macha raja maharjan, and jonathan gorstein have all both undertaken consultancies with various agencies working in nepal on nutrition issues, including in support of the usi program, but have no conflict of interest related to this paper."
6876,33865565,graves’ disease
6877,33865565,iodine therapy
6878,33865565,meta-analysis
6879,33865565,radioactive iodine
6880,33865565,thyroid diseases
6881,35182078,c-reactive protein
6882,35182078,graves' disease
6883,35182078,hashimoto's thyroiditis
6884,35182078,interleukin-39
6885,35182078,white blood cell cois
6886,34347269,*antiquity
6887,34347269,*endocrinology
6888,34347269,*etruscan
6889,34347269,*goitre
6890,34347269,*palaeopathology
6891,34347269,*thyroid
6892,33910662,*copper deficiency
6893,33910662,*hematological disease
6894,33910662,*mri
6895,33910662,*myeloneuropathy
6896,34487739,*graves’ orbitopathy
6897,34487739,*thyroid eye disease
6898,34487739,*fibroblast
6899,34487739,*insulin-like growth factor 1 receptor
6900,34487739,*microrna
6901,34487739,*orbital fibroblast
6902,34487739,*teprotumumab
6903,34487739,"*therapeutics, targeted therapy cois"
6904,33059514,epiblepharon
6905,33059514,singapore
6906,33059514,graves’ ophthalmopathy
6907,33059514,pediatric
6908,33059514,thyroid eye disease
6909,35432203,*22q11.2 deletion syndrome
6910,35432203,*digeorge syndrome
6911,35432203,*growth disorders
6912,35432203,*hypoparathyroidism
6913,35432203,*thyroid disorders cois commercial or financial relationships that could be construed as a potential conflict of interest.
6915,35628410,smad
6916,35628410,tgfβ
6917,35628410,adipogenesis
6918,35628410,hpmscs
6919,35628410,thyroid disease
6920,35628410,thyroid-associated ophthalmopathy cois
6921,35528009,hashimoto thyroiditis
6922,35528009,anti-parietal cell antibodies
6923,35528009,gastric malignancies
6924,35528009,organ-specific autoimmunity
6925,35528009,systemic autoimmunity cois commercial or financial relationships that could be construed as a potential conflict of interest.
6927,33172865,*anatomy
6928,33172865,*orbit
6929,33172865,"*treatment medical cois ak—employer, horizon therapeutics."
6930,34970859,*graves' disease
6931,34970859,*metabolomics
6932,34970859,*myopathy
6933,34970859,*senescence
6934,34970859,*t cells cois
6935,34920294,cyclind1
6936,34920294,d2–40
6937,34920294,follicular neoplasm
6938,34920294,multinodular goiter with dominant nodules
6939,34920294,oncocytic cell tumors
6940,34920294,poorly differentiated thyroid carcinoma
6942,35489725,gapdh
6943,35489725,papillary thyroid carcinoma
6944,35489725,cfdna integrity index
6945,35489725,circulating cell-free dna
6946,35489725,β-actin
6948,35675824,graves’ disease
6949,35675824,hashimoto’s thyroiditis
6950,35675824,autoimmune thyroid disease
6951,35675824,gut microbiota
6952,34374618,graves’ hyperthyroidism
6953,34374618,anti-ttg
6954,34374618,celiac disease
6955,34374618,false-positivity
6958,32965148,graves’s orbitopathy
6959,32965148,tocilizumab
6960,32965148,outcome
6961,32965148,rituximab
6963,35429598,*autoimmune thyroid diseases
6964,35429598,*high-throughput sequencing
6965,35429598,*immune repertoires
6966,35429598,*t cells receptor
6967,34782167,*nodular goiter
6968,34782167,*operated recurrent goiter
6969,34782167,*shear-wave velocity
6970,34782167,*thyroid sonoelastography cois
6972,35108585,"*botox-a (btx-a, botulinum toxin type a)"
6973,35108585,*orbital fibroblast
6974,35108585,*tgf-β/smad signaling
6975,35108585,*thyroid-associated ophthalmopathy (tao)
6976,35672057,"ear, nose and throat/otolaryngology"
6977,35672057,oncology
6978,35672057,thyroid disease cois
6979,35459655,cardiothoracic surgery
6980,35459655,surgical oncology
6981,35459655,thyroid disease cois
6982,34193409,experimental and laboratory
6983,34193409,orbit cois
6984,35338690,*childhood cancer survivors
6985,35338690,*head and neck radiation
6986,35338690,*hypoparathyroidism
6987,35338690,*pediatric thyroidectomy
6988,35338690,*recurrent laryngeal nerve paralysis
6989,34799942,c-reactive protein
6990,34799942,graves’ disease
6991,34799942,hashimoto's thyroiditis
6992,34799942,autoimmune thyroid disease
6993,34799942,interleukin-38 cois
6994,34933777,b cell subsets
6995,34933777,cd32b
6996,34933777,graves’ disease
6997,34933777,inhibitory receptors cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
6998,34291345,diplopia
6999,34291345,exophthalmos
7000,34291345,graves’ orbitopathy
7001,34291345,orbital decompression
7002,34291345,surgical outcome cois paper and did not receive any financial support toward the completion of this work.
7003,35018816,*italy
7004,35018816,*age-standardized rates
7005,35018816,*thyroid surgery
7006,35018816,*thyroidectomies
7007,35018816,*time trends
7008,35522861,autoimmune thyroiditis
7009,35522861,ctla
7010,35522861,graves’ disease
7011,35522861,hashimoto’s thyroiditis (ht)
7012,35522861,il-17
7013,35522861,il-23
7015,35235663,*graves’ disease
7016,35235663,*sars-cov-2 vaccine
7017,35235663,*hyperthyroidism
7018,35145479,*b lymphocytes
7019,35145479,*graves’ disease
7020,35145479,*graves’ orbitopathy
7021,35145479,*rituximab
7022,35145479,*tsh-receptor antibodies cois commercial or financial relationships that could be construed as a potential conflict of interest.
7023,35135806,general surgery
7024,35135806,head and neck surgery
7025,35135806,otolaryngology / ent
7026,35135806,thyroid disease
7027,35135806,thyrotoxicosis cois
7028,35024887,computed tomography
7029,35024887,correlations
7030,35024887,itmig classification
7031,35024887,lymphadenopathy
7032,35024887,thoracic radiography
7033,35285929,graves disease
7034,35285929,endocrinology
7035,35285929,hyperthyroidism
7036,35285929,thyroid function
7037,35285929,thyroid-stimulating antibody
7038,35285929,thyrotropin receptor antibody
7039,35381687,*antithyroid agents
7040,35381687,*epidemiology
7041,35381687,*graves disease
7042,35381687,"*kidney failure, chronic cois was reported."
7044,32878536,ct imaging
7045,32878536,extraocular muscle
7046,32878536,fatty infiltration
7047,32878536,thyroid eye disease
7048,35624535,graves’ disease
7049,35624535,hyperthyroidism
7050,35624535,hypercalcemia
7051,35624535,liver damage
7052,35624535,palpitation
7053,35624535,vomiting cois non-financial interests to disclose.
7054,35273577,*il-11
7055,35273577,*clinical activity score
7056,35273577,*fibrosis
7057,35273577,*orbital fibroblast
7058,35273577,*thyroid-associated ophthalmopathy cois commercial or financial relationships that could be construed as a potential conflict of interest.
7059,34788857,*m22 (a monoclonal tsab)
7060,34788857,*tsh receptor (tshr)
7061,34788857,*tshr stimulating antibody (tsab)
7062,34788857,*crosstalk
7063,34788857,*insulin-like growth factor receptor 1 (igf1r)
7064,34788857,*teprotumumab
7065,34788857,*thyroid eye disease (ted)
7067,34324163,autoimmune thyroid diseases
7068,34324163,bioassay
7069,34324163,disease
7070,34324163,functional thyrotropin receptor antibodies
7071,34324163,graves
7072,34324163,orbitopathy
7073,34324163,stimulatory antibodies
7074,35663306,erk
7075,35663306,graves’ ophthalmopathy
7076,35663306,stat3
7077,35663306,dihydroartemisinin
7078,35663306,fibrosis
7079,35663306,inflammation
7080,35663306,orbital fibroblast cois commercial or financial relationships that could be construed as a potential conflict of interest.
7081,35018442,*individual participant data
7082,35018442,*meta-analysis
7083,35018442,*muscle strength
7084,35018442,*quality of life
7085,35018442,*vitamin d
7086,35728893,oculoplastics
7087,35728893,orbital and lacrimal disorders
7088,35728893,thyroid disease cois
7089,35119800,drug reaction with eosinophilia and systemic symptoms (dress)
7090,35119800,severe cutaneous adverse drug reactions (scars)
7091,35119800,thyroid dysfunction
7092,35119800,thyroiditis
7093,35244288,99mtechnetium uptake
7094,35244288,grave's disease
7095,35244288,trab
7096,35244288,nonuniform uptake
7097,35610583,bayesian method
7098,35610583,graves’ disease data
7099,35610583,minnesota center for twin and family research data
7100,35610583,penalized fieller’s method
7101,35610583,skewed x chromosome inactivation cois
7102,35184917,*decompression surgery
7103,35184917,*endocrine orbitopathy
7104,35184917,*fully digital analysis
7105,35184917,*navigated surgery
7106,35066781,*blood markers
7107,35066781,*clinical biomarkers
7108,35066781,*graves’ ophthalmopathy
7109,35066781,*orbital imaging
7110,35066781,*tear cytokines
7111,35220164,*autoimmune thyroid diseases
7112,35220164,*graves' disease
7113,35220164,*hyperthyroidism
7114,35220164,*inactivated covid-19 vaccine
7115,35220164,*sars-cov-2
7116,35220164,*mrna vaccine cois
7117,35563653,graves’ orbitopathy
7118,35563653,disulfiram
7119,35563653,fibrosis
7120,35563653,myofibroblasts
7121,35563653,perimysial orbital fibroblasts cois
7122,35307774,dicer1
7123,35307774,multinodular goiter
7124,35307774,pediatric poorly differentiated thyroid carcinoma
7125,35307774,thyroblastoma cois
7126,35088381,antithyroid drug
7127,35088381,graves’ disease
7128,35088381,long-term
7129,35088381,methimazole
7130,35088381,remission
7131,35088381,thionamides
7132,35295987,*cancer diagnosis
7133,35295987,*cancer risk
7134,35295987,*familial non-medullary thyroid carcinoma
7135,35295987,*familial thyroid cancer
7136,35295987,*papillary thyroid carcinoma
7137,35295987,*susceptibility genes cois commercial or financial relationships that could be construed as a potential conflict of interest.
7138,35398834,dysthyroid optic neuropathy
7139,35398834,fat decompression
7140,35398834,grave’s disease
7141,35398834,orbital decompression
7142,35398834,thyroid eye disease
7143,34861792,*graves' disease
7144,34861792,*mica
7145,34861792,*mendelian randomization
7146,34861792,*nkg2d
7147,34861792,*community-based cohort
7148,34861792,*phenome-wide association
7149,35189399,*cd4(+) t cells
7150,35189399,*graves’ disease (gd)
7151,35189399,*immune
7152,35189399,*regulatory t cells
7153,35189399,*t helper cells 17
7154,35241008,*adpkd
7155,35241008,*polycystic kidney disease
7156,35241008,*thyroid nodules
7157,35241008,*ultrasonography cois commercial or financial relationships that could be construed as a potential conflict of interest.
7158,35615718,graves’ disease
7159,35615718,graves’ orbitopathy
7160,35615718,antithymocyte globulin
7161,35615718,proptosis
7162,35615718,thyroid eye disease cois commercial or financial relationships that could be construed as a potential conflict of interest.
7163,35300630,intraocular pressure
7164,35300630,strabismus
7165,35300630,surgery
7166,35300630,thyroid eye disease cois
7168,34549377,extra-cellular volume fraction
7169,34549377,extraocular muscle
7170,34549377,fibrosis
7171,34549377,t1 mapping
7172,34549377,thyroid-associated ophthalmopathy
7173,34532987,graves’ eye disease
7174,34532987,graves’ ophthalmopathy
7175,34532987,graves’ orbitopathy
7176,34532987,diplopia
7177,34532987,outcomes
7178,34532987,strabismus surgery
7179,34532987,thyroid eye disease
7180,34532987,topical anaesthesia
7181,35565939,graves’ disease
7182,35565939,antithyroid drugs
7183,35565939,neonate
7184,35565939,thyroid volume
7185,35565939,ultrasound cois
7186,33103521,graves’ disease
7187,33103521,hashimoto’s thyroiditis
7188,33103521,autoimmune thyroid diseases
7189,33103521,polymorphism
7190,33103521,protein tyrosine phosphatase nonreceptor 22
7191,35508893,graves' disease
7192,35508893,dosimetry
7193,35508893,hyperthyroidism
7194,35508893,multinodular goitre
7195,35508893,radioiodine
7196,35508893,theranostics
7197,35508893,toxic adenoma
7198,34988642,benign goitre
7199,34988642,quality of life
7200,34988642,thypro 39 questionnaire
7201,34988642,thyroidectomy
7203,34850456,autoimmune thyroid disease
7204,34850456,interference
7205,34850456,nonthyroid autoimmune diseases
7206,34850456,thyroid hormone autoantibody
7207,34347224,blepharoptosis
7208,34347224,graves' disease
7209,34347224,myasthenic ptosis
7210,34347224,myogenic ptosis
7211,34347224,thyroid eye disease
7212,33390059,exophthalmos
7213,33390059,eyelid retraction
7214,33390059,orbital decompression
7215,33390059,thyroid-associated orbitopathy
7216,33390059,vertical diplopia
7217,34871593,*autoimmune thyroid disease
7218,34871593,*homogeneous camp biosensor
7219,34871593,*thyroid blocking immunoglobulins or antibodies
7220,34871593,*thyroid stimulating immunoglobulins or antibodies
7221,34871593,*thyroid-stimulating hormone receptor
7222,35386700,*cd11c+ b cells
7223,35386700,*cxcr3-cxcl10
7224,35386700,*graves’ disease
7225,35386700,*trab
7226,35386700,*cytokines cois commercial or financial relationships that could be construed as a potential conflict of interest.
7228,34605662,*graves'
7229,34605662,*adipogenesis
7230,34605662,*antifibrotic
7231,34605662,*disulfiram
7232,34605662,*orbital fibroblast
7233,34605662,*orbitopathy
7235,34773561,clinical features
7236,34773561,cytokines
7237,34773561,graves’ disease
7238,34773561,igg4-related diseases
7239,34773561,serum igg4
7241,34928110,pediatric age.
7242,34928110,thyroid cancer
7243,34928110,grave's disease
7244,34877883,*go-qol
7245,34877883,*graves' orbitopathy
7246,34877883,*decompression
7247,34877883,*lid
7248,34877883,*quality of life
7249,34877883,*strabismus surgery
7250,34877883,*systematic review
7251,35458147,sarawak
7252,35458147,usi
7253,35458147,goitre
7254,35458147,school children
7255,35458147,urinary iodine concentration cois
7259,35405683,inflammatory myofibroblastic tumor
7260,35405683,surgery
7261,35405683,thyroid cancer
7262,35405683,ultrasonic examination
7263,35459658,endocrine system
7264,35459658,hyperthyroidism
7265,35459658,thyroid disease cois
7268,35402292,*16 rrna gene sequencing
7269,35402292,*graves’ disease
7270,35402292,*th17 & treg axis
7271,35402292,*intestinal flora
7272,35402292,*short chain fatty acids cois commercial or financial relationships that could be construed as a potential conflict of interest.
7274,35713042,"multinodular goitre, complications of total thyroidectomy, surgeons' experience  in thyroid surgery."
7276,35220890,graves’ disease
7277,35220890,nrcam
7278,35220890,th1 cells
7279,35220890,lncrna runx1-it1 cois
7280,35187713,elisa
7281,35187713,graves’ disease
7282,35187713,tsh-receptor antibody
7283,35187713,diagnostic performance
7284,35187713,dot blot assay cois
7285,34778997,*hirata disease
7286,34778997,*human leukocyte antigen
7287,34778997,*hyperinsulinaemic hypoglycaemia
7288,34778997,*insulin autoantibody
7289,34778997,*insulin autoimmune syndrome
7290,34778997,*sulfhydryl group
7291,34489313,*cardiomyopathies
7292,34489313,*diastolic
7293,34489313,*heart failure
7294,34489313,*systolic cois
7295,34060342,graves’ disease
7296,34060342,hematoma
7297,34060342,hypocalcemia
7298,34060342,recurrent laryngeal nerve injury
7299,34060342,"thyroidectomy cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
7300,35064543,bone mineral density
7301,35064543,graves’ disease
7302,35064543,muscle mass
7303,35064543,thyroid hormone
7304,33637620,experimental – laboratory
7305,33637620,inflammation
7306,33637620,"orbit cois coinvestigator on a study funded by genentech to evaluate the use of rituximab for orbital inflammatory diseases. jtr, rad, bsk, dok, and gjh are consultants to horizon pharmaceuticals which manufactures teprotumumab. jtr receives research support from horizon pharmaceuticals."
7307,35569928,graves' disease
7308,35569928,coronavirus disease 2019
7309,35569928,type 1 diabetes
7310,35569928,vaccination cois
7312,35568525,*puberty
7313,35568525,*fetal programming
7314,35568525,*goiter
7315,35568525,*hyperthyroidism
7316,35568525,*hypothyroidism
7319,34545512,collagen1
7320,34545512,fibrocytes
7321,34545512,graves orbitopathy
7322,34545512,tshr
7323,34545512,peripheral blood mononuclear cells
7324,34671950,b cells
7325,34671950,graves' ophthalmopathy
7326,34671950,graves' orbitopathy
7327,34671950,lymphocytes
7328,34671950,plasmacells
7329,34671950,t-cells
7330,34671950,thyroid eye disease
7331,35439657,dysthyroid optic neuropathy
7332,35439657,graves' disease
7333,35439657,orbital decompression surgery
7334,35439657,orbital surgery
7335,35439657,visual acuity
7336,34613563,graves’ orbitopathy
7337,34613563,immunoassay
7338,34613563,thyroid stimulating immunoglobulin
7339,34613563,thyroid-associated orbitopathy
7342,34714163,*graves' disease
7343,34714163,*trab assay
7344,34714163,*thyroid autoimmunity-clinical
7345,34714163,*thyroid eye disease
7346,34714163,*thyroid stimulating immunoglobulins
7347,34927457,*graves' orbitopathy
7348,34927457,*igf-1r
7349,34927457,*tshr antibody
7350,34927457,*teprotumumab cois
7351,35320246,"sub acute thyroiditis, nuclear scan, pyrexia of unknown origin, thyroid  antibodies."
7354,34544941,graves’ disease
7355,34544941,graves’ ophthalmopathy
7356,34544941,hyperthyroidism
7357,34544941,internal ophthalmoplegia
7358,34544941,tonic pupil
7360,34781042,graves ophthalmopathy
7361,34781042,diabetes
7362,34781042,extraocular muscles
7363,34781042,optic neuropathy
7364,34781042,severity
7365,34781042,thyroid eye disease
7366,35555881,fat-suppression
7367,35555881,intravenous glucocorticoid therapy
7368,35555881,magnetic resonance imaging
7369,35555881,t2 mapping
7370,35555881,thyroid-associated ophthalmopathy
7371,35555881,treatment response cois
7372,35278055,abuja
7373,35278055,goitres
7374,35278055,management outcome
7375,35278055,pattern cois
7376,34241830,autoimmunity
7377,34241830,goiter
7378,34241830,lupus
7379,34241830,malar
7380,34241830,pregnancy
7381,34241830,rash
7382,34241830,sle
7383,34241830,thyroid cois
7384,35734310,bahirdar
7385,35734310,ethiopia
7386,35734310,salt iodization
7387,35734310,households
7388,35734310,iodine deficiency cois
7390,35698219,case report
7391,35698219,graves' disease
7392,35698219,guillain-barré syndrome
7393,35698219,hashimoto's disease
7394,35698219,transition cois
7396,35082799,*graves’ disease
7397,35082799,*berberine
7398,35082799,*methimazole
7399,35082799,*microbiome
7400,35082799,*prebiotics cois commercial or financial relationships that could be construed as a potential conflict of interest.
7401,35396078,ethanol
7402,35396078,radiofrequency
7403,35396078,thermal ablation
7404,35396078,thyroid cancer
7405,35396078,thyroid nodule
7409,34714162,*graves' disease
7410,34714162,*graves' orbitopathy
7411,34714162,*orbital cell stimulation
7412,34714162,*thyroid stimulation
7413,34714162,"*thyrotropin receptor stimulatory autoantibodies cois germany, has received research-associated funding from the jgu medical faculty, advancecor (germany), apitope (united kingdom), berlin-chemie (germany), byondis (the netherlands), horizon therapeutics (usa), immunovant (usa), isar (germany), mediomics (usa), merck (germany), novartis (usa), quidel (usa), river vision (usa), and roche (switzerland). g.j.k. consults for glycoera (switzerland), immunovant, mediomics, merck, novartis, roivant (usa), quidel, and vasaragen (usa)."
7414,34743487,*eyelids
7415,34743487,*inflammation
7416,34743487,*orbit
7417,34743487,*selenium cois was reported.
7418,35592782,*diffusion tensor imaging
7419,35592782,*dysthyroid optic neuropathy
7420,35592782,*magnetic resonance imaging
7421,35592782,*optic nerve
7422,35592782,*thyroid-associated ophthalmopathy cois commercial or financial relationships that could be construed as a potential conflict of interest.
7423,35413779,*blood flow velocity
7424,35413779,*graves disease
7425,35413779,"*receptors, thyrotropin"
7426,35413779,*thyroiditis
7427,35413779,*thyrotoxicosis
7428,35413779,"*ultrasonography, doppler, color cois samsung medison co., ltd. (seoul, korea). the sponsor had no role in the writing of the manuscript or in the decision to submit the manuscript for publication."
7429,35144579,extraocular muscles
7430,35144579,graves’ disease
7431,35144579,lacrimal gland
7432,35144579,magnetic resonance imaging
7433,35144579,prolapse
7434,35144579,proptosis
7435,35144579,thyroid-associated ophthalmopathy cois
7436,34330200,dry eye
7437,34330200,graves’ ophthalmopathy
7438,34330200,meibography
7439,34330200,meibomian glands
7440,34330200,ocular surface
7441,34774300,*drinking water
7442,34774300,*goiter
7443,34774300,*nitrate
7444,34774300,*perchlorate
7445,34774300,*sodium iodide symporter
7446,34774300,*thiocyanate
7447,35405579,clinical activity score prediction
7448,35405579,disease activity differentiation
7449,35405579,magnetic resonance imaging
7450,35405579,magnetization transfer
7451,35405579,thyroid-associated ophthalmopathy
7452,35235144,angptl3
7453,35235144,graves’ disease
7454,35235144,hdl subfractions
7455,35235144,hyperthyroidsim
7456,35235144,hypothyroidism
7457,35235144,pre-β1 hdl
7458,34637060,dysthyroid optic neuropathy
7459,34637060,octa
7460,34637060,peripapillary vessel density
7461,34637060,retinal nerve fiber layer thickness
7462,34637060,thyroid-associated ophthalmopathy cois
7463,34979862,central choroidal thickness
7464,34979862,choroidal vascularity index
7465,34979862,clinical activity score
7466,34979862,non-inflammatory active ted
7467,34979862,thyroid eye disease
7468,35370997,*graves’ disease (gd)
7469,35370997,*hashimoto’s thyroiditis (ht)
7470,35370997,*n-glycosylation
7471,35370997,*immunoglobulin g (igg)
7472,35370997,*immunosuppressive therapy
7473,35370997,*ultraperformance liquid chromatography  cois commercial or financial relationships that could be construed as a potential conflict of interest.
7477,34325607,autoimmune thyroid disease
7478,34325607,graves’ disease
7479,34325607,hashimoto’s thyroiditis
7480,34325607,psors1c1
7481,34325607,single nucleotide polymorphism
7482,34645767,autoimmune polyglandular syndrome
7483,34645767,superior mesenteric artery syndrome
7484,34645767,type 1 diabetes cois
7486,35094312,*antithyroid drugs
7487,35094312,*efficacy
7488,35094312,*graves
7489,35094312,*hyperthyroidism
7490,35094312,*therapeutic plasma exchange
7492,34536118,medial orbital wall decompression
7493,34536118,medial rectus muscle expansion
7494,34536118,medial rectus muscle misalignment
7495,34536118,periosteal flap
7496,34536118,thyroid eye disease
7498,34822305,atf4
7499,34822305,pct
7500,34822305,ret mutation
7501,34822305,cancer médullaire de la thyroïde
7502,34822305,medullary thyroid carcinoma
7503,34822305,mutation de ret
7504,34822305,recurrence
7505,34822305,récidive
7506,34822305,survie
7507,34822305,survival
7509,35069439,*graves’ disease
7510,35069439,*autoimmune thyroid disease
7511,35069439,*hyperthyroidism
7512,35069439,*pulmonary hypertension
7513,35069439,*thyroid hormone cois commercial or financial relationships that could be construed as a potential conflict of interest.
7514,35061094,mibi
7515,35061094,parathyroidectomy
7516,35061094,primary hyperparathyroidism
7517,35061094,surgery
7518,35061094,thyroid nodule cois
7519,35429846,graves' disease
7520,35429846,incidentally discovered
7521,35429846,medullary thyroid carcinoma
7522,35429846,thyroid
7523,35619700,*cd40
7524,35619700,*pd-l1
7525,35619700,*t cell
7526,35619700,*orbital fibroblast
7527,35619700,*thyroid associated ophthalmopathy cois commercial or financial relationships that could be construed as a potential conflict of interest.
7528,34779257,*graves'
7529,34779257,*autoimmunity
7530,34779257,*disease
7531,34779257,*orbitopathy
7532,34779257,*preclinical mouse model
7533,35265076,*akt/nfκb signaling pathway
7534,35265076,*graves ophthalmopathy
7535,35265076,*glucocorticoid sensitivity
7536,35265076,*mir-885-3p
7537,35265076,*plasma exosomes cois commercial or financial relationships that could be construed as a potential conflict of interest.
7538,35321340,*graves’ disease (gd)
7539,35321340,*electronic medical record (emr)
7540,35321340,*genome-wide association study (gwas)
7541,35321340,*human leukocyte antigen (hla)
7542,35321340,*phenome-wide association studies (phewas) cois commercial or financial relationships that could be construed as a potential conflict of interest.
7545,35667695,"*ear, nose and throat"
7546,35667695,*genetics
7547,35667695,*thyroid disease cois
7550,33198545,octa
7551,33198545,ted
7552,33198545,thyroid eye disease
7553,33198545,optical coherence tomography angiography
7554,33198545,retinal vascularity
7555,34859391,anti-tg
7556,34859391,anti-tpo
7557,34859391,ctla-4
7558,34859391,graves´ disease
7559,34859391,radioiodine
7560,34859391,trab cois
7561,35489145,biomedical informatics
7562,35489145,computer-aided diagnosis (cad)
7563,35489145,convolutional neural network (cnn)
7564,35489145,deep learning
7565,35489145,multi-class classification
7566,35489145,thyroid disease diagnosis
7568,34477926,computed tomography
7569,34477926,extraocular muscles
7570,34477926,graves’ orbitopathy
7571,34477926,quantitative analysis
7572,34477926,thyroid eye disease
7576,34544076,16s ribosomal rna
7577,34544076,25(oh)d
7578,34544076,graves’ disease
7579,34544076,il-17
7580,34544076,intestinal flora
7581,35637045,multiple autoimmunity
7582,35637045,pediatrics
7583,35637045,type 1 diabetes cois potential conflicts of interest to disclose.
7584,34851466,bell’s phenomenon
7585,34851466,graves
7586,34851466,ophthalmopathy
7587,34851466,orbital wall decompression
7588,34851466,thyroid-associated ophthalmopathy
7589,35720300,graves’ disease
7590,35720300,hashimoto’s thyroiditis
7591,35720300,cell communication
7592,35720300,immune dysregulation
7593,35720300,thyroid tissue cois commercial or financial relationships that could be construed as a potential conflict of interest.
7595,35784325,graves’ disease
7596,35784325,graves’ orbitopathy
7597,35784325,ted
7598,35784325,estrogen
7599,35784325,estrogen receptor
7600,35784325,sex steroids
7601,35784325,steroid homeostasis
7602,35784325,thyroid eye disease cois commercial or financial relationships that could be construed as a potential conflict of interest.
7603,35721705,*graves’ disease
7604,35721705,*biomedical modeling
7605,35721705,*computer-aided treatment
7606,35721705,*hyperthyroidism
7607,35721705,*mathematical thyroid model cois commercial or financial relationships that could be construed as a potential conflict of interest.
7608,35698208,biomechanical simulation
7609,35698208,computer tomography data
7610,35698208,decompression surgery
7611,35698208,endocrine orbitopathy cois
7613,35413827,antithyroid drug
7614,35413827,maternal subtotal thyroidectomy
7615,35413827,neonatal hyperthyroidism
7616,35413827,thyroid function
7617,35413827,thyroid-stimulating hormone receptor antibody cois
7618,35088429,graves' disease
7619,35088429,graves' ophthalmopathy
7620,35088429,autoimmune diseases
7621,35088429,hyperthyroidism
7622,35088429,thyroid diseases
7624,35229626,*graves' disease
7625,35229626,*autoimmune thyroid disease
7626,35229626,*primary thyroid lymphoma
7627,34468829,octa
7628,34468829,pulse therapy
7629,34468829,thyroid-associated orbitopathy cois
7632,35566351,graves orbitopathy (go)
7633,35566351,alternative tobacco products
7634,35566351,cigarette smoke extract
7635,35566351,real time cell electronic sensing (rt ces)
7636,35566351,retrobulbar fibroblast cois
7637,33913798,graves’ disease
7638,33913798,medullary thyroid carcinoma
7639,33913798,carcinogenesis
7640,33913798,endothelin
7641,34580763,dicer1
7642,34580763,papillary thyroid carcinoma
7643,34580763,poorly differentiated thyroid carcinoma
7644,34580763,thyroid carcinoma
7646,35370990,*graves’ disease
7647,35370990,*iodine radioisotopes
7648,35370990,*radiopharmaceuticals
7649,35370990,*subclinical thyrotoxicosis
7650,35370990,*toxic multinodular goitre
7651,35370990,*toxic nodule
7652,35370990,*treatment outcome cois commercial or financial relationships that could be construed as a potential conflict of interest.
7654,35145480,*lymph node metastasis
7655,35145480,*papillary thyroid carcinoma
7656,35145480,*postoperative radioactive iodine
7657,35145480,*treatment strategy
7658,35145480,*tumor location cois commercial or financial relationships that could be construed as a potential conflict of interest.
7659,35465762,*goiter
7660,35465762,*thyroid
7661,35465762,*thyroid nodule
7662,35465762,*thyroiditis
7663,35465762,"*ultrasound cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
7665,35538553,intraocular pressure
7666,35538553,lateral gaze
7667,35538553,primary gaze
7668,35538553,teprotumumab
7669,35538553,thyroid eye disease
7670,35538553,upgaze cois
7671,35144533,case report
7672,35144533,glucocorticoids
7673,35144533,graves’ disease
7674,35144533,hepatitis b virus
7675,35144533,methimazole cois
7676,33443352,*activating variant of tshr gene
7677,33443352,*non-autoimmune hyperthyroidism
7678,33443352,*neonatal hyperthyroidism
7679,35441746,benign thyroid nodule
7680,35441746,papillary thyroid carcinoma
7681,35441746,platelet count
7682,35441746,platelet distribution width
7683,35441746,thyroglobulin cois
7684,34854944,*fibrous dysplasia
7685,34854944,*gnas
7686,34854944,*intramuscular myxoma
7687,34854944,*mazabraud’s syndrome
7688,34854944,*mccune-albright syndrome
7689,35579208,aneurysmal bone cyst
7690,35579208,graves’ disease
7691,35579208,moyamoya disease
7692,35579208,case report
7693,35579208,ischemic cerebral infarction
7694,35579208,proximal femur cois conflict of interest.
7695,35443720,case report
7696,35443720,germ cell tumor
7697,35443720,human chorionic gonadotropin
7698,35443720,hyperthyroidism
7699,35443720,paraneoplastic syndrome cois
7700,35091101,graves' disease
7701,35091101,trab
7702,35091101,bioassay
7703,35091101,diagnosis
7704,35091101,thyroid-stimulating immunoglobulin
7705,35091101,thyrotoxicosis
7706,35090420,acute transient thyroid swelling
7707,35090420,adenomatous goiter
7708,35090420,airway obstruction
7709,35090420,aortic regurgitation
7710,35090420,fine-needle aspiration
7711,35090420,nodular goiter
7712,35090420,thyroid gland
7713,35090420,tracheal intubation cois
7716,35562642,machine learning
7717,35562642,mass spectrometry imaging
7718,35562642,papillary thyroid carcinoma
7719,35562642,probe electrospray ionization mass
7720,35562642,rapid diagnosis
7721,35659565,acute inflammation
7722,35659565,fucoidan
7723,35659565,neutrophil adhesion
7724,35659565,p-selectin
7725,35659565,sargassum fusiforme
7726,34751793,laser therapy
7727,34751793,nodular goiter
7728,34751793,radiofrequency ablation
7729,34751793,thyroid nodule
7730,35039349,immunological products and vaccines
7731,35039349,lung cancer (oncology)
7732,35039349,safety
7733,35039349,therapeutic indications
7734,35039349,thyroid disease cois
7735,35784564,graves’ disease
7736,35784564,hyperthyroidism treatment
7737,35784564,quality of life
7738,35784564,selenium
7739,35784564,vitamin d cois commercial or financial relationships that could be construed as a potential conflict of interest.
7741,34050454,dental fluorosis
7742,34050454,ptpn22
7743,34050454,polymorphisms
7744,34050454,tshr
7745,34050454,thyroid
7746,34780050,congenital hypothyroidism
7747,34780050,goiter
7748,34780050,next-generation sequencing
7749,34780050,tpo
7750,34780050,thyroid dyshormonogenesis
7751,34755283,autoimmune thyroiditis
7752,34755283,hypothyroidism
7753,34755283,survey
7754,34755283,thyroid
7755,34755283,thyroid hormones
7756,34861221,euthyroidism
7757,34861221,euthyroïdie
7758,34861221,french endocrine society
7759,34861221,hypothyroidism
7760,34861221,hypothyroïdie
7761,34861221,levothyroxine
7762,34861221,liothyronine
7763,34861221,lévothyroxine
7764,34861221,société française d’endocrinologie
7765,34861221,survey
7766,34861221,sondage
7767,35593680,l-thyroxine
7768,35593680,active follow-up
7769,35593680,active surveillance
7770,35593680,fine-needle aspiration biopsy
7771,35593680,indications for hemithyroidectomy
7772,35593680,nodular goiter
7773,35593680,papillary thyroid microcarcinoma
7774,35593680,radioiodine treatment
7775,35593680, thyroid cancer
7777,34416585,france
7778,34416585,goiter cause
7779,34416585,hair analysis
7780,34416585,historical samples
7781,34416585,lead contamination
7782,34416585,savoy
7783,35382047,graves’ disease
7784,35382047,case report
7785,35382047,type 1 diabetes mellitus
7790,28668317,goiter
7791,28668317,retrograde dissection of the inferior laryngeal nerve
7792,28668317,sternotomy
7793,27701774,graves’ ophthalmopathy
7794,27701774,graves’ orbitopathy
7795,27701774,thyroid eye disease
7797,28648509,*pendred syndrome
7798,28648509,*congenital hypothyroidism
7799,28648509,*goiter
7800,28648509,*iodide
7801,28648509,*sensorineural deafness
7802,28648509,*thyroid hormone
7803,27221572,*substernal goiter
7804,27221572,*thyroid disease
7805,27221572,*thyroid neoplasm
7806,27221572,*thyroid nodule
7807,27221572,*thyroidectomy
7808,28572231,grave’s disease
7809,28572231,radioiodine
7810,28572231,thionamides
7811,28572231,thyroidectomy
7812,28572231,thyrotoxicosis
7817,26392367,clinical evaluation
7818,26392367,multinodular goiter
7819,26392367,physiopathology
7820,26392367,treatment
7821,27480576,*goiter
7822,27480576,*rhtsh
7823,26708850,benign multinodular goiter
7824,26708850,dunhill procedure
7825,26708850,goiter recurrence
7826,26708850,post-operative complications
7827,26708850,subtotal thyroidectomy
7828,26708850,total thyroidectomy
7829,26433162,arrhythmias
7830,26433162,carlos chagas
7831,26433162,goiter
7832,26433162,history
7833,26433162,myxedema
7834,26433162,thyroid
7835,28516755,dietary iodine intake
7836,28516755,goiter
7837,28516755,iodine
7838,28516755,japanese
7839,28516755,kombu
7840,28516755,seaweed
7841,28516755,thyroid function
7845,26520480,ct
7846,26520480,fiberoptic endoscopy
7847,26520480,goiter
7848,26520480,substernal
7849,26520480,surgery
7850,27687679,anatomy
7851,27687679,intrathoracic goiter
7852,27687679,multinodular goiter
7853,27687679,thoracic inlet
7854,27687679,thyroid gland
7855,27687679,thyroidectomy
7856,28749783,children
7857,28749783,goiter
7858,28749783,l thyroxine
7859,28749783,nodular
7860,28749783,recurrence
7861,28749783,thyroidectomy
7864,29172409,ethiopia
7865,29172409,goiter
7866,29172409,prevalence
7867,29172409,risk factors cois
7868,27173499,*clinical images
7869,27173499,*endocrinology
7870,27173499,*surgery cois
7875,28271464,goiter
7876,28271464,medical diagnosis
7877,28271464,painting
7878,28271464,rubens
7880,27059986,graves’ disease
7881,27059986,graves’ orbitopathy
7882,27059986,immunmodulatory therapy
7883,27059986,reconstructive surgical procedures
7884,27059986,thyroid-stimulating hormone receptor
7885,28551882,acid sulfate soils
7886,28551882,iodide
7887,28551882,laterite
7888,28551882,salt iodization
7889,28551882,selenium
7890,28551882,soil organic matter
7892,28395497,"goiter, substernal"
7893,28395497,harmonic scalpel
7894,28395497,"surgical procedures, operative"
7895,26995097,cervical approach
7896,26995097,ectopic goiter
7897,26995097,ectopic thyroid
7898,26995097,intrathoracic goiter
7899,26995097,substernal goiter
7900,26995097,thyroidectomy
7902,26472934,asthma
7903,26472934,goiter
7904,26472934,mediastinum
7905,26472934,sternotomy
7906,26472934,thyroidectomy
7907,26472934,substernal
7909,28331628,*china
7910,28331628,*iodine deficiency disorders (idd)
7911,28331628,*iodized salt
7912,28258641,amyloid goiter
7913,28258641,familial mediterranean fever
7914,28258641,head and neck ultrasound
7915,28258641,thyroid
7921,26742784,*creutzfeldt-jacob disease
7922,26742784,*heidenhain variant
7923,26742784,*compressive optic neuropathy
7924,26742784,*higher visual processing
7925,26742784,*proptosis
7926,26742784,*spongiform encephalopathy
7927,26742784,*thyroid eye disease
7928,26742784,*visual fields
7934,28612896,*complications
7935,28612896,*recurrent goiter
7936,28612896,*surgery
7937,28612896,*thyroidectomy
7944,28648505,*digeorge syndrome
7945,28648505,*hypoparathyroidism
7946,28648505,*parathyroid
7947,28648505,*pseudohypoparathyroidism
7948,28648505,*thyroid
7951,27005286,*areola approach
7952,27005286,*laparoscope
7953,27005286,*silk thread
7954,27005286,*strategies
7955,27005286,*substernal goiter
7956,27005286,*thyroidectomy
7957,26403613,body surface area
7958,26403613,drinking water
7959,26403613,goiter
7960,26403613,iodized salt
7961,26403613,prevalence
7962,28606271,"antigens, cd40"
7963,28606271,bone marrow cells
7964,28606271,fibroblasts
7965,28606271,graves ophthalmopathy
7966,28606271,insulin-like growth factor ⅰ
7967,28606271,"receptors, thyrotropin"
7969,28535654,clinicopathological characteristics
7970,28535654,nuclear factor erythroid 2-related factor 2
7971,28535654,thyroid neoplasms
7972,26708863,cervical approach
7973,26708863,mediastinal goiter
7974,26708863,sternotomy
7975,26708863,thoracotomy
7976,26708863,thyroidectomy
7977,26721191,cervico-mediastinal goiter
7978,26721191,cervicosternotomy
7979,26721191,cervicotomy
7980,26721191,goiter
7981,26721191,intrathoracic thyroid mass
7982,26721191,total thyroidectomy
7985,28471268,*graves' disease
7986,28471268,*cardiovascular risk
7987,28471268,*hyperthyroidism
7988,28471268,*morbidity
7989,28471268,*mortality
7990,28471268,*toxic nodular goiter
7991,28190186,iodine
7992,28190186,nis
7993,28190186,nodular goiter
7994,28190186,tshr
7996,28292346,*endemic goiter
7997,28292346,*high iodine
7998,28292346,*iodine deficiency
8001,27779276,adolescents
8002,27779276,children
8003,27779276,overt hypothyroidism
8004,27779276,pregnancy
8005,27779276,subclinical hypothyroidism
8007,28805773,diffuse toxic goiter
8008,28805773,long-term results
8009,28805773,subtotal resection of the thyroid gland
8010,28805773,surgical treatment
8011,28805773,thyroidectomy
8012,29265071,angiogenesis
8013,29265071,apoptosis
8014,29265071,diffuse toxic goiter
8015,29265071,thyroid cell proliferation
8017,28835334,fine needle aspiration and biopsy
8018,28835334,nodules
8019,28835334,thyroid
8020,28835334,ultrasound
8021,26900630,*autoimmune thyroiditis
8022,26900630,*cxcl10
8023,26900630,*cxcr3
8024,26900630,*graves ophthalmopathy
8025,26900630,*graves disease
8026,26900630,*chemokines
8027,26900630,*corticosteroids
8028,26900630,*rituximab
8029,26900630,*teprotumumab
8030,26900630,*tocilizumab
8031,28215480,goiter prevalence
8032,28215480,iodine deficiency disorder
8033,28215480,iodine nutritional status
8034,28215480,pakistan
8035,28215480,salt iodization
8038,27106540,boron
8039,27106540,goiter
8040,27106540,iodine
8041,27106540,schoolchildren
8042,27106540,silicon
8043,27106540,thyroid
8044,28841887,intravascular lymphoma
8045,28841887,large b-cell
8046,28841887,nodular goiter
8047,28841887,"thyroid cois waived by the institutional ethics committee of the central hospital of wuhan, china. consent for publication: written informed consent for the publication of clinical details and clinical images of the patient was obtained from a relative of the patient. a copy of the consent form is available for review by the editor of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
8051,28061776,*ethiopia
8052,28061776,*goiter
8053,28061776,*salt iodine content
8054,28061776,*school children
8056,28011236,dicer
8057,28011236,iodine metabolism-related genes
8058,28011236,microrna
8059,28011236,thyroid
8060,28011236,thyroid cell differentiation
8061,28011236,thyroid tumor
8063,28127991,*autoimmunity
8064,28127991,*graves’ disease
8065,28127991,*ophthalmopathy
8066,28127991,*tyrosine kinase
8067,26966785,*graves’ disease
8068,26966785,*graves’ ophthalmopathy
8069,26966785,*graves’ orbitopathy
8070,26966785,*antithyroid drugs
8071,26966785,*glucocorticoids
8072,26966785,*hyperthyroidism
8073,26966785,*radiotherapy
8074,26966785,*rituximab
8075,26966785,*selenium
8076,28872214,*thyroid-related quality-of-life patient-reported outcome (thypro)
8077,28872214,*goiter
8078,28872214,*quality of life
8079,28872214,*surgery
8080,28872214,*thyroid
8081,28580573,*ex-utero intrapartum treatment
8082,28580573,*airways obstruction
8083,28580573,*fetus
8084,28580573,*neck tumors
8085,28580573,*ultrasound
8088,27460951,congenital goiter
8089,27460951,endemic goiter
8090,27460951,fifteenth century
8091,27460951,fine arts
8092,27460951,hyperthyroidism
8093,28703113,intraoperative neuromonitoring
8094,28703113,recurrent goiter
8095,28703113,recurrent laryngeal nerve
8096,26750728,benign thyroid diseases
8097,26750728,changes of radioiodine therapy
8098,26750728,jóindulatú pajzsmirigybetegségek
8099,26750728,pajzsmirigyrák
8100,26750728,radiojódterápia változásai
8101,26750728,thyroid cancer
8104,27927635,*children
8105,27927635,*thyroid volume
8106,27927635,*total goiter rate
8107,27927635,*urine iodine concentration
8108,27927635,*urine iodine excretion
8109,26884295,doppler
8110,26884295,elasticity imaging techniques
8111,26884295,goiter
8112,26884295,nodular
8113,26884295,thyroid
8114,26884295,ultrasonography
8115,27153850,*hepatotoxicity
8116,27153850,*hyperthyroidism
8117,27153850,*methimazole
8118,27153850,*propylthiouracil
8119,27153850,*radioactive iodine
8120,27153850,*thyroid
8121,27153850,*thyroidectomy
8124,26298554,autoimmune thyroiditis
8125,26298554,child
8126,26298554,doppler
8127,26298554,goiter
8128,26298554,thyroid gland
8129,26298554,ultrasound
8130,28891673,lead
8131,28891673,nodular goiter
8132,28891673,papillary thyroid carcinoma
8133,28891673,thyroid adenoma
8134,28891673,thyroid hormones
8139,27673426,*goiter
8140,27673426,*hypothyroidism
8141,27673426,*respiratory function
8142,27673426,*sleep apnea syndrome
8143,27673426,*thyroid disease
8144,27673426,*upper airway obstruction
8149,27552913,bmn
8150,27552913,egipcios
8151,27552913,egyptian
8152,27552913,mng
8153,27552913,tsh
8154,27552913,vitamin d
8155,27552913,vitamina d
8157,28025831,*goiter
8158,28025831,*headache attributed to hypothyroidism
8159,28025831,*hyperthyroidism
8160,28025831,*migraine
8161,28025831,*new daily persistent headache
8163,28178662,han chinese
8164,28178662,snps
8165,28178662,vegfa
8166,28178662,nodular goiter
8167,28178662,papillary thyroid carcinoma cois
8171,27862717,*congenital hypothyroidism
8172,27862717,*fetal therapy
8173,27862717,*goiter
8174,28506088,leukocytes
8175,28506088,papillary thyroid carcinoma
8176,28506088,platelets
8177,28506088,thyroid cancer
8178,28506088,white blood cells
8179,28728986,benign multi-nodular goitre
8180,28728986,thyroidectomy
8181,26841373,i-131
8182,26841373,large goiter
8183,26841373,multinodular goiter
8184,26841373,radioiodine therapy
8185,26841373,radioiodine uptake
8186,26841373,rhtsh
8187,27931874,follicular thyroid cancer
8188,27931874,goiter
8189,27931874,papillary thyroid cancer
8190,27931874,raman spectroscopy
8191,27931874,thyroid
8195,29183897,paediatrics
8196,29183897,thyroid disease cois
8198,27828690,*graves disease
8199,27828690,*hashimoto’s thyroiditis
8200,27828690,*igg4 related disease
8201,27828690,*riedel’s thyroiditis
8202,27828690,*immunoglobulin
8207,26260217,antonello da messina
8208,26260217,goiter in holy images
8209,26260217,italian renaissance
8211,27029843,graves’ disease
8212,27029843,hyperthyroidism
8213,27029843,mediastinal mass
8214,27029843,thyroid remnant
8215,27029843,total thyroidectomy
8216,28578595,*graves’ disease
8217,28578595,*autoimmune
8218,28578595,*hyperplasia
8219,28578595,*thymic
8220,28578595,*thymic lymphoid hyperplasia
8221,28578595,*true thymic hyperplasia
8222,26850414,*goiter
8223,26850414,*medical diagnosis
8224,26850414,*painting
8225,26850414,*titian
8226,27385363,disparity
8227,27385363,graves’ ophthalmopathy
8228,27385363,orbitopathy
8229,27385363,socioeconomic status
8232,28533884,graves’ disease
8233,28533884,thyroid gland
8234,28533884,tuberculosis
8236,28606272,autoimmunity
8237,28606272,genetic predisposition to disease
8238,28606272,graves ophthalmopathy
8239,28606272,oxidative stress
8240,28606272,smoking
8247,27565137,*cretinism
8248,27565137,*goiter
8249,27565137,*iodine
8250,27565137,*thyroid
8252,28899873,endocrine system
8253,28899873,paediatrics (drugs and medicines)
8254,28899873,thyroid disease cois
8258,29075974,adjuvant treatment
8259,29075974,escape
8260,29075974,hyperthyroidism
8261,29075974,iodide
8262,29075974,thyroidectomy cois ethical approval: this article does not contain any studies with human participants or animals performed by any of the authors.
8263,28942732,*etiology
8264,28942732,*graves’ disease
8265,28942732,*pathophysiology
8266,28942732,*primary immunodeficiency
8267,28942732,*review cois publication: not applicable competing interests: all authors declare they have no competing interest.
8268,28770897,"thyroid associated orbitopathy, graves ophthalmopathy, hypothyroidism."
8285,27169853,dietary
8286,27169853,goitrogens
8287,27169853,nitrate
8288,27169853,perchlorate
8289,27169853,risk assessment
8290,27169853,thiocyanate
8293,27795799,*toxic goiter
8294,27795799,*thyroid abscess
8295,27795799,*thyroiditis cois
8297,27819113,ata
8298,27819113,graves’ disease
8299,27819113,igg4
8300,27819113,ophthalmopathy
8301,27819113,tpoab
8303,28493593,*recurrent laryngeal nerve
8304,28493593,*superior parathyroid
8305,28493593,*thyroid
8306,28493593,*thyroidectomy
8310,27481173,*thyroidectomy
8311,27481173,*graves
8312,27481173,*hematoma
8313,27481173,*malignancy
8314,27481173,*toxic nodular goitre
8316,27470116,drainage
8317,27470116,hematoma
8318,27470116,surgical outcomes
8319,27470116,thyroid surgery
8322,29138656,hyperthyroidism
8323,29138656,senegal
8324,29138656,child
8325,29138656,profile
8327,26994869,*graves' ophthalmopathy
8328,26994869,*chronic lymphocytic leukemia (cll)
8329,26994869,*lymphoproliferative disorder
8330,26994869,*orbital inflammation
8331,26994869,*orbital lymphoma
8332,26994869,*proptosis
8333,26994869,*small lymphocytic lymphoma (sll)
8334,26994869,*thyroid eye disease
8336,28450994,graves-basedow's disease
8337,28450994,child
8338,28450994,student abuse cois
8340,27933384,autoimmune thyroid disease
8341,27933384,papillary thyroid cancer
8342,27933384,thyroglobulin antibodies
8343,27933384,thyroid peroxidase antibodies
8345,29422752,goiter
8346,29422752,graves' disease
8347,29422752,ophthalmopathy
8348,29422752,thyroid
8349,29422752,thyroid-associated orbitopathy cois
8351,26477042,goiter
8352,26477042,iodine deficiency disorders
8353,26477042,salt iodization
8354,26477042,urinary iodine concentration
8356,28533836,thyroid
8357,28533836,pathology
8358,28533836,sarcoma
8359,28533836,treatment cois
8361,28363119,ct
8362,28363119,grave's disease
8363,28363119,pulmonary hypertension
8364,29890100,*thyroidectomy
8365,29890100,*thyroid nodule
8366,29890100,*recurrent laryngeal nerve palsy
8367,29890100,*hypoparathyroidism
8368,29890100,*postoperative pain
8369,28755510,graves' disease
8370,28755510,graves' hyperthyroidism
8371,28755510,graves' orbitopathy
8372,28755510,thyroid eye disease
8373,28606263,"decompression, surgical"
8374,28606263,graves ophthalmopathy
8375,28606263,"imaging, three-dimensional"
8376,28606263,orbit
8377,28278511,graves ophthalmopathy
8378,28278511,il-6
8379,28278511,microrna-146a
8380,28278511,notch2
8381,28278511,orbital fibroblast reporter gene
8382,28278511,qrt-pcr
8383,27609530,diplopia
8384,27609530,intraocular pressure
8385,27609530,orbital decompression
8386,27609530,proptosis
8387,27609530,visual acuity
8388,27609530,visual field
8393,28635216,"carcinoma, papillary"
8394,28635216,multifocal tumor
8395,28635216,ret/ ptcrearrangement
8396,28635216,thyroid neoplasms
8398,26927707,*graves' disease
8399,26927707,*thyroid surgery
8400,26927707,*hyperthyroidism
8401,26927707,*thyroid storm
8402,26927707,*thyroidectomy
8403,26927707,*thyrotoxicosis
8404,27375108,antithyroïdien de synthèse
8405,27375108,graves’ disease
8406,27375108,grossesse
8407,27375108,hyperthyroidism
8408,27375108,hyperthyroïdie
8409,27375108,maladie de basedow
8410,27375108,pregnancy
8411,27375108,synthetic antithyroid drug
8414,26466836,*graves’ disease
8415,26466836,*ophthalmopathy
8416,26466836,*radiotherapy
8418,27494076,*biomarkers
8419,27494076,*graves’ disease
8420,27494076,*hashimoto thyroiditis
8421,27494076,*vegf
8422,27494076,*splicing isoforms
8424,27555041,calcium oxalate
8425,27555041,colloid
8426,27555041,crystals
8427,27555041,cytology
8428,27555041,thyroid
8430,27402179,bocio endémico
8431,27402179,cirugía general
8432,27402179,cooperación sanitaria
8433,27402179,endemic goiter
8434,27402179,equipamiento quirúrgico
8435,27402179,general surgery
8436,27402179,nódulo tiroideo
8437,27402179,surgical aid program
8438,27402179,surgical equipment
8439,27402179,thyroid gland
8440,27402179,thyroid nodule
8441,27402179,thyroidectomy
8442,27402179,tiroidectomía
8443,27402179,tiroides
8444,28456099,goiter
8445,28456099,hashimoto thyroiditis
8446,28456099,hyperthyroidism
8447,28456099,hypothyroidisms
8448,28456099,mammographic density
8449,28456099,thyroid
8452,29871201,e-cadherin
8453,29871201,papillary thyroid carcinoma
8454,29871201,serum cois relevant financial relationships with commercial interests to disclose.
8462,26932403,hashimoto thyroiditis
8463,26932403,igg4-related disease
8464,26932403,immunoglobulin g cois
8468,26813846,disparity
8469,26813846,substernal goiter
8470,26813846,thyroidectomy
8471,27083552,art
8472,27083552,goitre
8473,27083552,renaissance
8476,28329777,graves’ disease
8477,28329777,children
8478,28329777,thyreostatics
8479,28606260,clinical protocols
8480,28606260,graves ophthalmopathy
8481,28606260,practice guidelines as topic
8482,27619197,*airflow
8483,27619197,*cfd
8484,27619197,*energy loss
8485,27619197,*goiters
8486,27619197,*trachea
8490,28420409,adolescent students
8491,28420409,ethiopia
8492,28420409,iodine deficiency
8493,28420409,wolaita and dawuro zone
8501,27222685,nodular goiter
8502,27222685,malignancy
8503,27222685,ultrasound
8506,29798067,hornor's symptoms
8507,29798067,lymph node dissection
8508,29798067,thyroid gland operation cois relevant financial relationships with commercial interests to disclose.
8509,26315305,goitrous children
8510,26315305,iodine
8511,26315305,selenium
8512,26315305,trace elements
8513,26315305,zinc
8516,25261415,*life cycle
8517,25261415,*minerals/trace elements
8518,25261415,*nutrition
8519,25261415,*parenteral nutrition
8520,25261415,*pediatrics
8523,28606261,clinical protocols
8524,28606261,glucocorticoids
8525,28606261,graves ophthalmopathy
8526,28606261,radiotherapy
8529,27383156,e-cadherin
8530,27383156,thyroid cancer
8531,27383156,β-catenin
8532,26669779,autoimmune thyroiditis
8533,26669779,fibrosing variant of hashimoto’s thyroiditis
8534,26669779,igg4-related disease
8535,26669779,riedel’s thyroiditis
8536,29541314,intubation
8537,29541314,cervical spine surgery
8538,29541314,thyroidectomy
8544,27809623,*hyperthyroidism
8545,27809623,*hypothyroidism
8546,27809623,*pregnancy
8548,28537560,tsh
8549,28537560,calcium
8550,28537560,hypocalcemia
8551,28537560,multinodular goiter
8552,28537560,thyroidectomy
8553,27687458,difficult airway
8554,27687458,difficult ventilation
8555,27687458,fiberoptic intubation
8556,27687458,general anesthesia
8559,28457178,*complications
8560,28457178,*hematoma
8561,28457178,*hypocalcemia
8562,28457178,*outcomes
8563,28457178,*safety
8564,28457178,*thyroidectomy
8565,28389809,computer-assisted
8566,28389809,diagnosis
8567,28389809,thyroid neoplasms
8568,28389809,ultrasonography
8569,28389359,aitd
8570,28389359,ps
8571,28389359,slc26a4
8572,28389359,splicing minigene assay
8574,27426718,cáncer de tiroides
8575,27426718,cáncer tiroideo incidental
8576,27426718,incidental thyroid cancer
8577,27426718,prognosis
8578,27426718,pronóstico
8579,27426718,thyroid cancer
8584,28699427,*t3
8585,28699427,*t4
8586,28699427,*hyperthyroidism
8587,28699427,*metabolomics
8589,27601286,methimazole
8590,27601286,mild graves' disease
8591,27601286,thyroid function
8592,27601286,thyroid volume
8593,29084476,*graves' disease
8594,29084476,*graves' orbitopathy
8595,29084476,*mortality
8596,29084476,*suicide
8597,29084476,*unnatural death
8604,26438397,autophagy
8605,26438397,graves’ orbitopathy
8606,26438397,statins
8608,28806880,*goiter
8609,28806880,*neck ultrasound
8610,28806880,*nodular goiter
8611,28806880,*thyroid gland
8612,28806880,*volume
8617,27882431,cervico-mediastinal goiters
8618,27882431,chest x-rays
8619,27882431,intrathoracic goiters
8620,27882431,mediastinal nodules
8621,27882431,thyroid surgery
8622,28255974,*acromegaly
8623,28255974,*meta-analysis
8624,28255974,*pituitary
8625,28255974,*thyroid
8626,28255974,*thyroid cancer
8628,26925783,*are
8629,26925783,*auf1
8630,26925783,*ftc.
8631,26925783,*hur
8632,26925783,*follicular adenoma
8633,26925783,*thyroid carcinoma
8635,28974848,i131 therapy
8636,28974848,hyperthyreoidism treatment
8637,28974848,"incidence of hypotihyeoidism cois sabrina licina participate in study design and acquisition, analysis and interpretation of data. authors equally participate in drafting the article and give final approval for the version which is submitted."
8638,27716078,*asystole
8639,27716078,*hyperextension
8640,27716078,*position
8641,27716078,*thyroidectomy
8643,29120123,*graves ophthalmopathy – diagnostic imaging
8644,29120123,*orbit – diagnostic imaging
8645,29120123,*multidetector computed tomography
8646,29120123,*exophthalmos – diagnosis
8647,29120123,*cross-sectional studies
8649,26337375,multinodular goiter
8650,26337375,thyroid autotransplantation
8651,26337375,thyroidectomy
8655,27438852,slovenia
8656,27438852,food supply
8657,27438852,iodine
8658,27438852,sales
8659,27438852,salt
8660,27438852,sodium
8663,26270564,gpx
8664,26270564,gsh
8665,26270564,hashimoto’s thyroiditis
8666,26270564,lpo
8667,26270564,oxidative stress
8668,26270564,catalase
8669,26270564,thyroid cancer
8670,26270564,thyroid goitre
8672,28619420,(131)i treatment
8673,28619420,bocio nodular
8674,28619420,fracaso de tratamiento
8675,28619420,hipertiroidismo
8676,28619420,hipotiroidismo
8677,28619420,hyperthyroidism
8678,28619420,hypothyroidism
8679,28619420,nodular goitre
8680,28619420,tratamiento (131)i
8681,28619420,treatment failure
8682,26969710,*imaging
8683,26969710,*muscles
8684,26969710,*orbit
8685,26969710,*treatment surgery
8686,29197845,materno-fetal medicine
8687,29197845,neonatal and paediatric intensive care
8688,29197845,neonatal health cois
8692,27693824,harmonic scalpel
8693,27693824,ligasure vessel sealing system
8694,27693824,substernal goitre
8695,27693824,thyroid surgery
8696,27693824,total thyroidectomy
8701,28025026,graves
8702,28025026,pulmonary hypertension
8703,28025026,right heart function
8704,28025026,strain
8705,28025026,tapse
8706,28025026,thyroid
8707,26936928,*dyshormonogenesis
8708,26936928,*goiter
8709,26936928,*hypothyroidism
8710,26936928,*pendred syndrome
8715,28771438,fetal goiter
8716,28771438,intra-amniotic levothyroxine administration
8717,28771438,maternal graves’ disease
8724,26272351,taiwan
8725,26272351,iodine
8726,26272351,iodized salt
8727,26272351,nutrition survey
8728,26272351,thyroid gland
8734,28737965,m22
8735,28737965,trab
8736,28737965,diagnosis
8737,28737965,hyperthyroidism
8741,26603660,graves' disease
8742,26603660,radioiodine therapy
8743,26603660,thyroid
8744,26603660,ultrasound
8745,26886211,autoimmune thyroid disease
8746,26886211,breast neoplasms
8747,26886211,trastuzumab cois
8748,28576912,endocrine cancer
8749,28576912,head and neck cancer
8750,28576912,head and neck surgery
8751,28576912,pathology
8752,28576912,thyroid disease cois
8754,28781316,graves' disease
8755,28781316,autoimmune hepatitis
8756,28781316,interface hepatitis
8757,28781316,liver histology
8758,28781316,pediatric case
8760,27586672,robotics
8761,27586672,thymectomy
8762,27586672,thymus
8763,27586672,thyroid
8764,27586672,transaxillary thyroidectomy
8769,26708845,fine needle cytology
8770,26708845,hurthle cells
8771,26708845,rapid on-site evaluation
8772,26708845,ultrasound
8775,26321232,case-control study
8776,26321232,disease
8777,26321232,fcrl3
8778,26321232,graves’
8779,26321232,single nucleotide polymorphisms
8780,26062519,graves’ orbitopathy
8781,26062519,hepatocyte growth factor
8782,26062519,interleukin-8
8783,26062519,methylprednisolone treatment
8784,26796368,recurrent laryngeal nerve injury
8785,26796368,substernal goitres
8786,26796368,surgical management
8787,28444621,criminal offense
8788,28444621,goiter
8789,28444621,major part
8790,28444621,metabolic disease
8791,28444621,public health
8792,28427469,*eugogo
8793,28427469,*epidemiology
8794,28427469,*graves’ orbitopathy
8795,28427469,*incidence
8796,28427469,*ophthalmopathy
8797,28427469,*prevalence
8798,28427469,*rare disease
8800,27206523,antiviral
8801,27206523,extrahepatic manifestation
8802,27206523,graves’ hyperthyroidism
8803,27206523,hbv infection
8805,27465670,*antithyroid drugs
8806,27465670,*goiter
8807,27465670,*graves’ disease
8808,27465670,*graves’ orbitopathy
8809,27465670,*hyperthyroidism
8810,27465670,*thyrotropin receptor antibody
8812,27422154,bocio multinodular
8813,27422154,bocio multinodular tóxico
8814,27422154,hipertiroidismo
8815,27422154,hyperthyroidism
8816,27422154,multinodular goitre
8817,27422154,radioiodine
8818,27422154,radioyodo
8819,27422154,toxic multinodular goitre
8820,27422154,rhtsh
8821,28215490,ectopic goitre
8822,28215490,horner's syndrome
8823,28215490,parapharyngeal space
8827,26626435,coagulación
8828,26626435,coagulation
8829,26626435,thyroid
8830,26626435,tiroides
8833,28389487,*surgery
8834,28389487,*cancer
8835,28389487,*overdiagnosis cois
8836,27531964,surgery
8837,28124062,papillon initiative
8838,28124062,diffuse goitre
8839,28124062,geriatric medicine
8840,28124062,nodular goitre
8841,28124062,thyroid dysfunction
8842,27358549,*coronary artery bypass grafting
8843,27358549,*subtotal thyroidectomy
8844,27358549,*surgery
8846,27241825,cochlear implantation
8847,27241825,pendred syndrome
8848,27241825,enlarged vestibular aqueduct
8849,27241825,gusher
8850,27241825,malformations
8851,27241825,surgical complications
8858,28458607,*computed tomography
8859,28458607,*euthyroidism
8860,28458607,*graves' disease
8861,28458607,*methimazole
8862,28458607,*single-photon emission computed tomography
8865,26066526,children
8866,26066526,endemic goitre
8867,26066526,iodine-deficiency goitre
8868,26066526,salt iodine
8870,28812921,dacryoadenitis
8871,28812921,idiopathic orbital inflammatory syndrome
8872,28812921,silent sinus syndrome
8873,28812921,thyroid eye disease
8874,26975391,autoimmunity
8875,26975391,hormone secretion
8876,26975391,nodular goiter
8877,26975391,thyroid
8878,27553050,graves’ disease
8879,27553050,marinelli’s formula
8880,27553050,thyroid iodine uptake
8881,27553050,thyroid technetium uptake cois
8883,28874217,hypocalcemia
8884,28874217,hypoparathyroidism
8885,28874217,parathyroid hormone
8886,28874217,thyroidectomy
8887,28874217,vitamin d
8890,27927064,*graves’ disease
8891,27927064,*cytokines
8892,27927064,*traditional chinese medicine
8893,27051255,computed tomography
8894,27051255,exophthalmos reduction
8895,27051255,graves ophthalmopathy
8896,27051255,orbital decompression cois was reported.
8897,26897110,iodine deficiency
8898,26897110,iodine prophylaxis
8899,26897110,iodized salt
8900,26897110,thyroid volume
8901,26897110,urinary iodine concentration
8905,28540810,*thyroid nodules
8906,28540810,*combined therapy
8907,28540810,*radiofrequency ablation (rfa)
8908,28540810,*radioiodine therapy (rit)
8911,26726836,hashimoto’s thyroiditis
8912,26726836,nodular goiter
8913,26726836,hepatocyte growth factor
8914,26726836,hypothyroidism
8916,28154699,*autoimmunity
8917,28154699,*dakar
8918,28154699,*hyperthyroidism cois
8919,27214836,berkeley drosophila genome project (bdgp)
8920,27214836,computerised tomography (ct)
8921,27214836,enlarged vestibular aqueduct (eva)
8922,27214836,hearing loss (hl)
8923,27214836,magnetic resonance imaging (mri)
8924,27214836,pendred syndrome (ps)
8925,27214836,videonystagmography (vng)
8926,27465319,*graves’ disease
8927,27465319,*graves’ ophthalmopathy
8928,27465319,*genetic polymorphism
8929,27465319,*meta-analysis
8932,28052261,*pendred syndrome
8933,28052261,*disease-specific ips cells
8934,28052261,*inner ear
8935,28052261,*outer sulcus cells
8941,27510038,*developmental delay
8942,27510038,*failure to thrive
8943,27510038,*spontaneous transient graves’ thyrotoxicosis
8953,28458304,basedow's disease
8954,28458304,igg4
8955,28458304,igg4 thyroiditis
8956,28458304,igg4-related disease
8957,27941044,*diagnostic tests/investigation
8958,27941044,*eye (globe)
8959,27941044,*imaging
8960,27941044,*orbit cois
8964,27906671,bethesda category iii
8965,27906671,acoustic radiation force impulse elastography
8966,27906671,fine-needle aspiration cytology
8967,27906671,thyroid nodules
8968,27906671,ultrasound cois
8970,26567024,immunology
8971,26567024,inflammation
8972,26567024,orbit
8973,26567024,treatment medical
8978,27157450,*hashimoto thyroiditis
8979,27157450,*autoimmune disease
8980,27157450,*autoimmune thyroid disease
8981,27157450,*hyperthyroidism
8982,27157450,*hypothyroidism
8983,27157450,*type 1 diabetes
8986,28688760,hypothyroidism
8987,28688760,hypothyroïdie
8988,28688760,l-thyroxine
8989,28688760,non adherence
8990,28688760,non-observance
8993,26801325,depression
8994,26801325,exophthalmos
8995,26801325,graves’ disease
8996,26801325,psychotherapy
8997,26801325,stress
8998,28074218,graves disease
8999,28074218,hashimoto disease
9000,28074218,hyperthyroidism
9001,28074218,hypothyroidism
9002,28074218,levothyroxine
9003,28050807,alternative first-line therapy
9004,28050807,graves ophthalmopathy
9005,28050807,orbital radiotherapy
9006,28050807,thyroid eye disease
9007,28001456,*graves’ ophthalmopathy
9008,28001456,*rasch analysis
9009,28001456,*quality of life
9010,28001456,*questionnaires
9011,28001456,*reliability
9012,28001456,*validation study
9013,28001456,*validity
9015,27106887,down's syndrome
9016,27106887,graves’ disease
9017,27106887,adolescent
9018,27106887,hemodialysis
9019,27106887,renal transplantation
9022,27350133,carcinoma
9023,27350133,diagnostic discrepancies
9024,27350133,histology
9025,27350133,sources of error
9026,27350133,thyroid cytology
9030,28861686,bell’s phenomenon
9031,28861686,inferior rectus muscle recession
9032,28861686,nasal transposition of the inferior rectus muscle
9033,28861686,thyroid-associated inferior rectus myopathy
9035,28296512,amsterdam declaration
9036,28296512,thyroid eye disease
9037,28296512,radioiodine
9038,28296512,smoking
9039,28296512,thyroid function
9040,26996584,thymus hyperplasia
9041,26996584,graves disease
9042,26996584,"immunoglobulins, thyroid-stimulating"
9043,26996584,receptors thyrotropin cois
9045,27651496,graves
9046,27651496,hyperthyroidism
9047,27651496,radioiodine
9048,27651496,thyroidectomy
9051,28755140,biomarker
9052,28755140,enzyme-linked immunosorbent assay
9053,28755140,klln protein
9054,28755140,pten protein
9055,28755140,papillary thyroid carcinoma
9060,28870952,*metallothioneins
9061,28870952,*papillary thyroid carcinoma
9062,28870952,*thyroid gland
9064,28882932,muscle disease
9065,28882932,thyroid disease cois
9066,28805160,*graves' disease
9067,28805160,*graves' ophthalmopathy
9068,28805160,*clinical activity score
9069,28805160,*immunoglobulin g4
9070,28805160,*thyroid autoantibody
9071,28675712,graves’ disease
9072,28675712,hashimoto’s disease
9073,28675712,thyroglobulin
9074,28675712,polymorphism
9075,28675712,severity
9076,28162094,graves’ disease
9077,28162094,human leukocyte antigen
9078,28162094,hyperthyroidism
9079,28162094,thiamazole
9080,28162094,thyroid scintigraphy
9081,28162094,thyroid-stimulating hormone-binding inhibitory immunoglobulin
9082,27664101,graves’ disease
9083,27664101,graves’ orbitopathy
9084,27664101,natural course
9086,26100786,cd69
9087,26100786,graves’ disease
9088,26100786,hashimoto thyroiditis
9089,26100786,il-10
9090,26100786,nkg2d
9091,26100786,treg cells
9094,28319410,*mean platelet volume
9095,28319410,*papillary thyroid cancer
9096,28319410,*platelet distribution width plateletcrit.
9098,28478488,anti-thyroid drugs
9099,28478488,graves’ disease
9100,28478488,hyperthyroidism
9101,28478488,radio-iodine
9102,28478488,surgery
9103,28478488,"thyroid cois currently in uk for observational studies. conflict of interest: the authors declare that they have no competing interests. ethical approval: no specific approval was obtained from an ethics committee. as this is an observational study of a current clinical pathway and no intervention was involved, permission was only obtained from the audit and service evaluation office of the sheffield teaching hospitals nhs foundation trust. as the data was anonymised and individual patients cannot be identified from the report, individual patient consent was not deemed to be necessary and was not obtained."
9107,28379055,diffusion
9108,28379055,graves
9109,28379055,magnetic resonance imaging
9110,28379055,orbit
9112,27804243,*graves’ disease
9113,27804243,*hyperthyroidism
9114,27804243,*pulmonary hypertension
9115,27804243,*pulmonary hypertensive crisis
9116,27804243,*thyroid storm
9117,27486810,dysthyroid optic neuropathy
9118,27486810,graves’ orbitopathy
9119,27486810,thyroid eye disease
9124,28500433,dysthyroid optic neuropathy
9125,28500433,orbital radiation therapy
9126,28500433,thyroid-associated orbitopathy
9127,28130596,angle kappa
9128,28130596,interpupillary distance
9129,28130596,orbital decompression
9130,28130596,thyroid-associated orbitopathy
9134,27638651,*graves’ disease
9135,27638651,*hyperthyroidism
9136,27638651,*mathematical modeling
9137,27638651,*relapse
9144,27319009,agranulocytosis
9145,27319009,alemtuzumab
9146,27319009,childhood
9147,27319009,graves’ disease
9148,27319009,graves’ orbitopathy
9149,27319009,hyperthyroidism
9150,27319009,methimazole
9151,27319009,pregnancy
9152,27319009,propylthiouracil
9153,27319009,radioiodine
9154,27319009,thionamides
9155,27319009,thyroidectomy
9158,26951052,autoimmunity
9159,26951052,graves’ disease
9160,26951052,hla
9161,26951052,stress
9162,27838267,*graves’ disease
9163,27838267,*coronary vasospasm
9164,27838267,*hyperthyroidism
9165,27838267,*methimazole
9166,27838267,*nitroglycerin
9167,27838267,*thyroid peroxidase antibody
9168,27838267,*thyroid-stimulating immunoglobulin
9169,28835054,graves′ disease
9170,28835054,hashimoto disease
9171,28835054,thyroid neoplasms
9172,28811719,cirrhosis
9173,28811719,cognitive impairment
9174,28811719,hepatic encephalopathy
9175,28811719,hypothyroidism
9176,28811719,magnetic resonance spectroscopy
9177,28811719,portosystemic shunt cois regarding funding or conflict of interest with respect to this manuscript.
9180,27560939,thyroid eye disease
9181,27560939,ptosis
9182,27560939,upper eyelid retraction
9185,26787873,cell engineering
9186,26787873,designer cells
9187,26787873,gene switch
9188,26787873,prosthetic networks
9189,26787873,synthetic biology cois
9190,28070771,*graves disease
9191,28070771,*clinical reasoning
9192,28070771,*dual process theory
9193,28070771,*framing cois interest. funding: none.
9194,27169807,compressive optic neuropathy
9195,27169807,dysthyroid optic neuropathy
9196,27169807,dysthyroid orbitopathy
9197,27169807,graves’ orbitopathy
9198,27169807,optical coherence tomography
9199,27169807,peripapillary retinal nerve fiber layer thickness
9202,27599688,graves ophthalmopathy
9203,27599688,quality of life
9204,27599688,thyroid eye disease
9205,27159575,graves’ ophthalmopathy
9206,27159575,long-term follow-up
9207,27159575,orbital decompression
9208,27159575,quality of life
9209,27159575,thyroid associated ophthalmopathy
9213,28222800,*autosomal recessive inheritance
9214,28222800,*childhood deafness
9215,28222800,*exome sequencing
9216,28222800,*pendred syndrome
9217,28222800,*syndromic hearing loss
9218,28347567,*art
9219,28347567,*exophthalmos
9220,28347567,*graves disease
9221,27086918,benign nodule
9222,27086918,programmed death-ligand 1
9223,27086918,protein biomarkers
9224,27086918,subcellular localization
9225,27086918,"thyroid cancer cois (sc, jv, fj, op, aa and cm) have nothing to disclose."
9226,27914141,children
9227,27914141,hashimoto disease
9228,27914141,hypothyroidism
9229,27914141,thyroid disease cois
9232,27220843,*antithyroid drugs
9233,27220843,*graves’ disease
9234,27220843,*graves’ ophthalmopathy
9235,27220843,*radioactive iodine
9236,27220843,*thyroidectomy
9240,28273705,congenital hypothyroidism
9241,28273705,gene
9242,28273705,mutation
9243,29270757,graves’ ophthalmopathy
9244,29270757,magnetic resonance
9245,29270757,methylprednisolone
9249,28715111,* hla-b*40:238
9250,28715111,*new allele
9251,28715111,*sequencing-based typing
9252,27715404,african descent
9253,27715404,graves orbitopathy
9254,27715404,pediatric
9255,27715404,optic neuropathy
9256,27709471,age
9257,27709471,glucocorticoids
9258,27709471,graves’ disease
9259,27709471,graves’ orbitopathy
9260,27709471,natural history
9261,27709471,radiotherapy
9262,27680576,echocardiography
9263,27680576,graves’ disease
9264,27680576,tissue doppler
9265,27170049,*graves’ ophthalmopathy
9266,27170049,*histamine
9267,27170049,*histamine receptor type-1
9268,27170049,*loratadine
9269,27170049,*mast cell
9270,27170049,*nf-κb controlled cytokine
9271,27170049,*nf-κb inhibitor
9272,27170049,*orbital fibroblast
9279,28941661,*anion transporters
9280,28941661,*homology modeling
9281,28941661,*membrane proteins
9282,28941661,*pathogenic mutations
9283,28941661,*slc26
9284,28941661,*solute carriers
9285,28941661,*trafficking
9286,28941661,*transport
9287,28063079,autoimmunity
9288,28063079,graves’ disease
9289,28063079,graves’ orbitopathy
9290,28063079,microbiota and dysbiosis
9291,26864507,*graves disease
9292,26864507,*hypothyroidism
9293,26864507,*radioiodine therapy
9294,26864507,*thyroid hormones
9295,26864507,*treatment outcome
9297,26686233,lateral rim repositioning
9298,26686233,orbital decompression
9299,26686233,proptosis
9300,26686233,thyroid eye disease
9301,26686233,thyroid related orbitopathy
9307,27762730,*tshr
9308,27762730,*autoimmune thyroid disease
9309,27762730,*intractability
9310,27762730,*polymorphism
9311,27762730,*severity
9312,27245701,col13a1
9313,27245701,thyroid-associated ophthalmopathy
9314,27245701,collagen xiii
9315,27245701,extraocular fat
9316,27245701,thyroid eye disease
9322,26799350,breastfeeding
9323,26799350,endocrinology
9324,26799350,pharmacology
9325,26799350,pregnancy
9326,26799350,thyroid
9327,26799350,women's health
9328,28463526,*overcorrection
9329,28463526,*strabismus surgery
9330,28463526,*thyroid eye disease
9331,28463526,*vertical strabismus
9333,27376649,ectopic (parasitic) goiter
9334,27376649,hashimoto’s autoimmune thyroiditis
9335,27376649,high plasma cell content
9336,27376649,hürthle cell
9337,27376649,lymph node metastasis
9338,29262478,genetic testing
9339,29262478,"receptors, thyroid hormone"
9340,29262478,thyroid hormone resistance syndrome
9341,28684549,*bisphenol a
9342,28684549,*endocrine disrupting chemical
9343,28684549,*iodine excess intake
9344,28684549,*nodular goiter
9345,28684549,*papillary thyroid carcinoma cois manuscript.
9353,27371612,histopathology
9354,27371612,molecular pathology
9355,27371612,thyroid cancer
9356,26876240,*graves’ orbitopathy
9357,26876240,*orbital radiation
9358,26876240,*systemic steroids
9359,26876240,*thyroid-associated orbitopathy
9362,29085976,grave’s orbitopathy
9363,29085976,increase of intraorbital pressure
9364,29085976,orbital diseases
9365,29085976,postoperative complications
9366,29085976,postoperative intraorbital hemorrhage
9368,26540014,intraoperative neuromonitoring (ionm)
9369,26540014,recurrent laryngeal nerve (rln)
9370,26540014,robotic thyroid surgery
9371,26540014,transaxillary robotic surgery
9372,26540014,vagal automatic periodic stimulation (aps)
9375,28392335,(131)i
9376,28392335,agranulocitosis
9377,28392335,agranulocytosis
9378,28392335,anti-thyroid drugs
9379,28392335,enfermedad de graves
9380,28392335,fármacos antitiroideos
9381,28392335,graves’ disease
9385,27848228,dna polymerase
9386,27848228,graves’ disease
9387,27848228,iodide peroxidase and mrnas
9388,29047240,exophthalmos
9389,29047240,korea
9390,29047240,sialyltransferases
9391,29047240,single nucleotide polymorphism
9392,29047240,thyroid-associated ophthalmopathy cois
9393,27792295,*graves' disease
9394,27792295,*hashimoto's thyroiditis
9395,27792295,*lymphocytic thyroiditis
9396,27792295,*papillary carcinoma
9397,27792295,*thyroid cancer
9399,27729751,*age group
9400,27729751,*computed tomography
9401,27729751,*computer communication network
9402,27729751,*lacrimal gland
9403,27729751,*thyroid-associated ophthalmopathy cois
9405,28195542,autoimmune thyroid diseases
9406,28195542,intractability
9407,28195542,intraindividual variation
9408,28195542,microrna
9409,28195542,severity
9411,27844093,diffusion tensor imaging
9412,27844093,extraocular muscle
9413,27844093,mri
9414,27844093,thyroid associated orbitopathy
9417,26860528,botulinum toxin
9418,26860528,restrictive strabismus
9419,26860528,strabismus surgery
9420,26860528,thyroid eye disease
9421,27449491,alternating diplopia
9422,27449491,alternating orthotropia
9423,27449491,cyclic vertical deviation
9424,27449491,dysthyroid ophthalmopathy
9426,27272160,*graves’ disease
9427,27272160,*adverse drug reactions
9428,27272160,*cutaneous figurate erythema
9429,27272160,"*methimazole cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
9430,29030215,cost-effectiveness
9431,29030215,ionm
9432,29030215,nerve injury
9433,29030215,neural monitoring
9434,29030215,thyroid surgery
9437,27919794,*graves disease
9438,27919794,*ischemic stroke
9439,27919794,*magnetic resonance imaging
9440,27919794,*vasculitis
9441,27919794,*vessel wall imaging
9443,28845025,anti-thyroid peroxidase antibody
9444,28845025,graves’ disease
9445,28845025,hashimoto’s disease
9446,28845025,polymorphism
9447,28845025,severity
9454,27734978,complications
9455,27734978,different approaches
9456,27734978,graves’ orbitopathy
9457,27734978,orbital decompression
9459,29152991,esophageal carcinoma
9460,29152991,gastrointestinal stromal tumors
9461,29152991,non-small cell lung cancer
9462,29152991,thyroid papillary carcinoma
9463,29152991,multi-organ primary carcinoma
9464,28284988,*cd279
9465,28284988,*graves' disease
9466,28284988,*hyperthyroidism
9467,28284988,*lymphocytes
9468,28284988,*pd-1
9470,25835075,dythyroid optic neuropathy
9471,25835075,endoscopic transethomoid medial orbital wall decompression
9472,25835075,endoscopic transethomoid orbital fat decompression
9473,25835075,proptosis reduction
9474,25835051,dysthyroid optic neuropathy
9475,25835051,mean deviation
9476,25835051,pattern standard deviation
9477,25835051,three-wall orbital decompression
9478,25835051,two-wall orbital decompression
9480,26699948,brow fat hypertrophy
9481,26699948,premalar fat hypertrophy
9482,26699948,thyroid eye disease
9484,28606259,"decompression, surgical"
9485,28606259,graves ophthalmopathy
9486,28606259,orbit
9490,28547036,atrial fibrillation
9491,28547036,graves’ disease
9492,28547036,microrna
9493,28547036,thyroid hormone
9494,28768936,hashimoto’s thyroiditis
9495,28768936,thyroglobulin antibodies
9496,28768936,thyroid peroxidase antibodies
9498,27245255,*graves’ disease
9499,27245255,*hashimoto’s disease
9500,27245255,*sirt1
9501,27245255,*snp
9502,27245255,*intractability
9503,27245255,*severity
9504,27808570,*dicer
9505,27808570,*drosha
9506,27808570,*autoimmune thyroid disease
9507,27808570,*severity
9508,27808570,*single nucleotide polymorphism
9509,27387241,graves’ orbitiopathy
9510,27387241,anti-cel
9511,27387241,anti-cml
9512,27387241,methylprednisolone treatment
9513,28669056,autoimmune thyroiditis
9514,28669056,graves’ disease
9515,28669056,hashimoto’s thyroiditis
9516,28669056,th17 cells
9517,28669056,th22 cells
9518,25567342,laryngopharyngeal reflux
9519,25567342,local neck symptoms
9520,25567342,nodular goiter
9521,25567342,thyroidectomy
9525,26567020,*cosmesis
9526,26567020,*orbit
9527,26567020,*treatment surgery
9528,27422248,*gas inflation
9529,27422248,*single-incision endoscopic thyroidectomy
9530,27422248,*trans-axillary endoscopic thyroidectomy
9536,28742402,graves’ disease
9537,28742402,hashimoto’s disease
9538,28742402,il-10
9539,28742402,mirna
9540,28742402,polymorphism
9542,26666958,*cancer
9543,26666958,*coupling
9544,26666958,*metabolism
9545,26666958,*papillary
9546,26666958,*thyroid
9547,28243072,graves ophthalmopathy
9548,28243072,age-related
9549,28243072,autoimmune thyroidopathy
9550,28243072,elderly
9551,28243072,subconjunctival orbital fat prolapse
9552,28243072,thyroid associated orbitopathy cois
9554,26744121,pendred syndrome
9555,26744121,tp53
9556,26744121,thyroid carcinoma
9557,26683653,capsular dissection
9558,26683653,guidelines
9559,26683653,intraoperative
9560,26683653,neurophysiological monitoring
9561,26683653,nodular goiter
9562,27877085,*autophagy
9563,27877085,*age-related macular degeneration
9564,27877085,*cataracts
9565,27877085,*diabetic retinopathy
9566,27877085,*ocular tumours.
9567,27877085,*thyroid-associated ophthalmopathy cois
9569,28413173,autoimmune thyroid diseases
9570,28413173,graves’ disease
9571,28413173,hashimoto’s thyroiditis
9572,28413173,serum 25-hydroxyvitamin d
9573,28413173,vitamin d deficiency
9577,28219358,*graves’ disease
9578,28219358,*innate immunity
9579,28219358,*tlrs
9580,28883260,graves’ disease
9581,28883260,metastasis
9582,28883260,thyroid carcinoma
9583,28473357,arrhythmias
9584,28473357,paediatrics (drugs and medicines)
9585,28473357,thyroid disease cois
9588,28078992,*tobacco smoking
9589,28078992,*adults
9590,28078992,*children
9591,28078992,*ocular inflammation
9592,28078992,*optic neuropathy
9593,28078992,*orbitopathy
9594,28078992,*retinopathy
9599,27769543,*grave's disease
9600,27769543,*potassium iodide
9601,27769543,*thyroidectomy
9605,26884288,graves’ disease
9606,26884288,graves’ orbitopathy
9607,26884288,dysthyroid optic neuropathy
9608,26884288,endoscopic intranasal orbital decompression
9609,26884288,methylprednisolone
9610,26884288,orbital decompression
9618,28851197,graves ophthalmopathy
9619,28851197,psychometrics
9620,28851197,quality of life
9621,28851197,root cause analysis
9622,28741406,thyroid eye disease
9623,28741406,compressive optic neuropathy
9624,28741406,decompression
9625,28741406,diplopia
9626,28741406,orbit
9627,28741406,proptosis
9628,28699478,*graves' disease
9629,28699478,*antithyroid drugs
9630,28699478,*continuous therapy
9631,28699478,*long-term therapy
9632,28699478,*meta-analysis
9633,28699478,*methimazole
9634,28699478,*propylthiouracil
9636,27692684,*endocrine orbitopathy
9637,27692684,*navigated surgery
9638,27692684,*piezosurgery
9644,28341401,*hearing loss
9645,28341401,*localization
9646,28341401,*misfolding
9647,28341401,*molecular chaperone
9648,28341401,*morphological analysis
9649,28341401,*p123s mutant
9650,28341401,*pendrin
9652,26979769,*graves’ orbitopathy
9653,26979769,*pai-1
9654,26979769,*tgf-β
9655,26979769,*cell density
9656,26979769,*hyaluronan
9657,26979769,*orbital fibroblasts
9660,26701678,antithyroid drugs
9661,26701678,graves’ disease
9662,26701678,natural killer t cells
9663,26701678,radioactive iodine
9664,26701678,regulatory t cells
9666,28859864,decision making
9667,28859864,game of dice task
9668,28859864,graves’ disease
9669,28859864,hyperthyroidism
9670,28859864,thyroid hormones
9671,28235670,*comparative study
9672,28235670,*conventional open
9673,28235670,*endoscopy
9674,28235670,*graves' disease
9675,28235670,*meta-analysis
9676,28235670,*thyroidectomy
9677,27615550,*graves’ disease
9678,27615550,*hyperthyroidism
9679,27615550,*antithyroid drugs
9680,27615550,*carbimazole
9681,27615550,*methimazole
9682,27615550,*propylthiouracil
9683,28259878,cytopathology
9684,28259878,fine needle aspiration
9685,28259878,graves disease
9686,28259878,thyroid
9690,27771369,homology modeling
9691,27771369,mutation mapping
9692,27771369,non-syndromic hearing loss with enlarged vestibular aqueduct (ns-eva)
9693,27771369,pendred syndrome
9694,27771369,pendrin
9695,27771369,slc26a4
9696,27771369,transmembrane protein
9700,28515387,aitd
9701,28515387,il-12
9702,28515387,il-18
9703,28515387,polymorphism
9704,28515387,socs1
9712,27612658,*graves' disease
9713,27612658,*autoimmunity
9714,27612658,*fibrocyte
9715,27612658,*interleukin-12
9716,27612658,*thyroid-associated ophthalmopathy cois interest in any material discussed in this article.
9718,27543288,*biochemistry
9719,27543288,*experimental &#8211 laboratory
9720,27543288,*inflammation
9721,27543288,*orbit
9726,27160433,*diabetes mellitus
9727,27160433,*endocrine tumor
9728,27160433,*granulomatous insulitis
9729,27160433,*pancreas
9730,27580012,col13a1
9731,27580012,collagen xiii
9732,27580012,thyroid eye disease
9733,27580012,thyroid-associated ophthalmopathy
9735,28500376,graves’ disease
9736,28500376,ptpn22
9737,28500376,rheumatoid arthritis
9738,28500376,systemic lupus erythematosus
9739,27369733,convergence spasm
9740,27369733,cranial nerve palsy
9741,27369733,double vision
9742,27369733,graves’ disease
9743,27369733,strabismus
9748,26675405,adipocyte
9749,26675405,cytokine
9750,26675405,fibrocyte
9751,26675405,fibrosis
9752,26675405,graves' ophthalmopathy
9753,26675405,growth factor
9754,26675405,hyaluronan
9755,26675405,inflammation
9756,26675405,orbital fibroblast
9759,27987077,epstein–barr virus
9760,27987077,graves’ disease
9761,27987077,graves’ orbitopathy
9762,27987077,idiopathic inflammatory pseudotumor
9763,27987077,thyroid
9764,27637079,graves’ disease
9765,27637079,t3
9766,27637079,neutrophils
9767,27637079,resistin
9768,29093229,ctla-4 gene exon 1
9769,29093229,ctla-4 gene with promotor-318
9770,29093229,regulatory t cells
9771,29093229,tshr gene rs2268458 intron 1
9772,29093229,thyroid receptor antibody (trab)
9773,29093229,graves’ disease
9774,29093229,relapse
9777,27113266,pediatric graves' disease
9778,27113266,pediatric hyperthyroidism
9779,27113266,shared decision making
9780,27113266,thyroidectomy
9781,27793633,(177)lu-dotatate
9782,27793633,cáncer de tiroides
9783,27793633,peptide receptor radionuclide therapy
9784,27793633,radioactive iodine refractory
9785,27793633,refractario al yodo radiactivo
9786,27793633,thyroid neoplasms
9787,27793633,tratamiento con análogos de la somatostatina radiomarcados
9792,27130144,ck5/6
9793,27130144,cytokeratin
9794,27130144,lymphoepithelial complex
9795,27130144,p63
9796,27130144,squamous cell metaplasia
9797,27130144,thyroid
9798,27130144,thyroiditis
9801,28201927,graves’ disease
9802,28201927,cytological alteration
9803,28201927,histologic changes
9804,28201927,radioactive iodine treatment
9805,28201927,thyroid
9808,27700191,parathyroid autotransplantation
9809,27700191,hypocalcemia
9810,27700191,inadvertent parathyroidectomy
9811,27700191,parathormone
9812,27700191,thyroidectomy
9813,28336282,botulinum toxin type a
9814,28336282,dysthyroid orbitopathy
9815,28336282,grave's disease
9816,28336282,maladie de basedow
9817,28336282,ophtalmopathie dysthyroïdienne
9818,28336282,orbital inflammatory disease
9819,28336282,orbitopathie inflammatoire
9820,28336282,rétraction palpébrale supérieure
9821,28336282,toxine botulique a
9822,28336282,upper eyelid retraction
9823,27638540,cd28/ctla-4/icos
9824,27638540,gene polymorphism
9825,27638540,graves’ disease
9826,27638540,graves’ orbitopathy
9827,27638540,haplotype cois
9832,28825582,*immunosuppressive agents
9833,28825582,*multiple organ failure
9834,28825582,*plasmapheresis
9835,28825582,*thyroid crisis
9836,28825582,*thyroidectomy
9839,28895066,131i therapy
9840,28895066,graves’ hyperthyroidism
9841,28895066,lithium carbonate
9842,28895066,thyroid
9844,28185649,*anti-cd20
9845,28185649,*graves ophthalmopathy
9846,28185649,*neuropathie optique
9847,28185649,*optic neuropathy
9848,28185649,*orbitopathie basedowienne
9849,28185649,*rituximab
9852,28001121,*graves' disease
9853,28001121,*antithyroid agents
9854,28001121,*long-term prognosis
9855,27734319,autoimmunity
9856,27734319,graves’ disease
9857,27734319,hyperthyroidism
9858,27734319,selenium
9859,27734319,thyroid
9861,28705701,graves disease
9862,28705701,orbital decompression surgery
9863,28705701,piezosurgery
9864,28705701,thyroid-associated orbitopathy
9866,28176220,clinical activity score
9867,28176220,cyclosporine
9868,28176220,graves’ orbitopathy or ophthalmopathy
9869,28176220,intravenous glucocorticoids
9870,28176220,orbital radiotherapy
9871,28176220,shared decision-making
9872,26626367,graves' disease
9873,26626367,hyperthyroidism
9874,26626367,surgery
9875,26626367,thyroid carcinoma
9876,26626367,thyroid nodules
9879,27266815,aire
9880,27266815,apeced
9881,27266815,autoimmunity
9882,27266815,graves’ disease
9883,27266815,mutation
9884,27266815,polymorphism
9885,25855160,autoimmune thyroid disease
9886,25855160,instrumentation
9887,25855160,thyroid
9888,25855160,tissue characterization
9889,25855160,ultrasound
9892,29307154,graves
9893,29307154,interleukin-6
9894,29307154,meta-analysis
9895,29307154,polymorphism
9896,28223014,decompression
9897,28223014,endocrine orbitopathy
9898,28223014,navigated surgery
9901,27863461,*genome-wide association study
9902,27863461,*graves’ disease
9903,27863461,*pooled blood
9905,27618833,graves’ disease
9906,27618833,iodine radioisotopes
9907,27618833,pregnancy outcome
9908,27566407,calreticulin(calr)
9909,27566407,endoplasmic reticulum (er) stress
9910,27566407,graves' disease(gd)
9911,27566407,heat shock 70kda protein 5(hspa5)
9912,27566407,proteomics
9913,27419847,*choroidal thickness
9914,27419847,*graves’ disease
9915,27419847,*graves’ ophthalmopathy
9916,27419847,*clinical activity score
9917,27419847,*optical coherence tomography
9918,27163552,graves disease
9919,27163552,moyamoya
9920,27163552,stroke
9921,27163552,vasculopathy
9922,26932949,*graves’ disease
9923,26932949,*balanced decompression
9924,26932949,*endoscopic orbital decompression
9925,26932949,*orbital decompression
9926,26932949,*orbital sling
9927,26932949,*orbital strut
9930,28042648,*graves’ orbitopathy
9931,28042648,*intravenous steroids
9932,28042648,*orbital irradiation
9933,28042648,*radioiodine therapy
9935,26886940,graves’ orbitopathy
9936,26886940,ich guideline
9937,26886940,medical dictionary for regulatory activities (meddra)
9938,26886940,mycophenolate
9939,26886940,safety
9940,27206624,*graves’ disease
9941,27206624,*hashimoto’s thyroiditis
9942,27206624,*th17
9943,27206624,*tregs
9944,27206624,*anti-thyroid antibodies
9946,28506419,99m tc-mibi scintigraphy
9947,28506419,mibi uptake
9948,28506419,radioguided surgery
9949,28506419,thyroid cancer
9950,28506419,thyroid follicular neoplasm
9951,28506419,thyroidectomy
9956,27762178,endoscopic surgical procedure
9957,27762178,mri
9958,27762178,skull base
9960,27107937,*coexpression
9961,27107937,*graves' disease
9962,27107937,*ox40/ox40l
9963,27107937,*t cell activation
9964,29246597,*autoantibody
9965,29246597,*encephalitis
9966,29246597,*hashimoto's encephalopathy
9967,29246597,*intravenous immunoglobulin
9973,27143020,intraoperative neuromonitoring
9974,27143020,prognostic value
9975,27143020,recurrent laryngeal nerve
9976,27143020,staged thyroidectomy
9977,27143020,thyroid surgery cois interest: author małgorzata stopa declares that she has no conflict of interest. author marcin barczyński declares that he has no conflict of interest. ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. informed consent: informed consent was obtained from all individual participants included in the study.
9983,28119492,*antibody
9984,28119492,*gene polymorphism
9985,28119492,*hla-dq
9986,28119492,*ocular myasthenia gravis
9987,28119492,*tnf-α
9988,28119492,*thyroid associated ophthalmopathy cois manuscript.
9993,28236218,agranulocytosis
9994,28236218,antithyroid drug
9995,28236218,graves’ disease
9996,28236218,hyperthyroidism
9997,26850223,autoimmune thyroid diseases
9998,26850223,cytokines
9999,26850223,graves' disease
10000,26850223,hashimoto's disease
10001,26850223,single nucleotide polymorphisms
10002,26850223,thyroid-associated ophthalmopathy
10006,26735162,*in vivo confocal microscopy
10007,26735162,*langerhans cells
10008,26735162,*inflammation
10009,26735162,*ocular surface
10010,26735162,*thyroid-associated ophthalmopathy
10011,26559967,strabismus
10012,26559967,surgical outcomes
10013,26559967,thyroid eye disease
10014,28606262,"decompression, surgical"
10015,28606262,graves ophthalmopathy
10016,28606262,optic nerve diseases
10017,28606262,orbit
10018,28606262,treatment outcome
10020,28453366,thyroid eye disease
10021,28453366,compressive optic neuropathy
10022,28453366,visual field
10025,26775634,adjustable sutures
10026,26775634,endocrine orbitopathy
10027,26775634,orbital decompression
10028,26775634,restrictive strabismus
10029,26775634,strabismus surgery
10030,26775634,thyroid associated ophthalmopathy
10031,26635355,slc26
10032,26635355,stas domain
10033,26635355,anion transporters
10034,26635355,inherited diseases
10035,26635355,membrane protein folding
10036,28061802,endoscopy
10037,28061802,graves’ disease
10038,28061802,neurosurgery
10039,28061802,pituitary neoplasms
10040,28061802,tsh-producing tumor
10041,28061802,tshoma
10042,28061802,thyrotropin
10043,28502931,22q11.2 deletion syndrome
10044,28502931,graves' disease
10045,28502931,hla
10046,28502931,regulatory t-cell
10050,27824294,*graves'
10051,27824294,*fibroblast
10052,27824294,*ophthalmopathy
10053,27824294,*orbitopathy
10054,27824294,*selenium
10056,26795296,arylesterase
10057,26795296,autoimmune thyroid disease
10058,26795296,oxidative status
10059,26795296,paraoxonase cois that could be perceived as prejudicing the impartiality of the research reported.
10062,27838736,activity
10063,27838736,computed tomography
10064,27838736,hounsfield unit
10065,27838736,orbital volume
10066,27838736,thyroid-associated orbitopathy
10068,28070798,*addison’s disease
10069,28070798,*autoimmune polyendocrine syndromes
10070,28070798,*autoimmunity
10071,28070798,*environment
10072,28070798,*graves’ disease
10073,28070798,*hashimoto’s thyroiditis
10074,28070798,*lifestyle
10075,28070798,*type 1 diabetes mellitus
10076,28070798,*vitamin d
10077,29187926,basedow-graves ophthalmopathy
10078,29187926,corticosteroids
10079,29187926,exophthalmos decompression
10080,29187926,neuropathy
10082,28742400,autoimmune thyroid diseases
10083,28742400,cd40
10084,28742400,single nucleotide polymorphism
10089,27465669,*glucocorticoid
10090,27465669,*graves’ ophthalmopathy
10091,27465669,*hepatitis
10092,27465669,*statins
10095,26935935,autoimmunity
10096,26935935,graves’ disease
10097,26935935,primary biliary cirrhosis
10098,26864865,autoimmune thyroid diseases
10099,26864865,graves’ disease
10100,26864865,hashimoto thyroiditis
10101,26864865,cytokine
10102,26864865,interleukin-1β
10103,28209438,graves’ disease
10104,28209438,hypocretin
10105,28209438,myasthenia gravis
10106,28209438,myotonic dystrophy
10107,28630226,disturbances
10108,28630226,endocrinology
10109,28630226,fluid electrolyte and acid-base
10110,28630226,muscle
10111,28630226,thyroid disease cois
10112,27810496,alopecia areata
10113,27810496,graves’ disease
10114,27810496,non-hla genes
10115,27810496,trab
10116,27810496,type 1 diabetes
10117,26876268,graves’ orbitopathy
10118,26876268,igg4-asszociált betegség
10119,26876268,igg4-related disease
10120,26876268,endokrin orbitopathia
10121,26876268,idiopathic inflammatory orbitopathy
10122,26876268,idiopathiás inflammatorikus orbitopathia
10123,26876268,myasthenia gravis
10124,26876268,occularis lymphoma
10125,26876268,ocular lymphoma
10126,28081504,hashimoto's thyroiditis
10127,28081504,igg
10128,28081504,neonatal fc receptor
10129,28081504,tgab
10130,28081504,th1/th2 cytokines
10131,29196352,deaf awareness
10132,29196352,hearing impaired
10133,29196352,young people
10134,28238453,graves disease
10135,28238453,hashimoto thyroiditis
10136,28238453,autoimmune thyroiditis
10137,28238453,hyperthyroidism
10138,28238453,hypothyroidism
10139,28238453,thyroid cancer
10140,28238453,vitiligo
10143,26965896,endoscopic thyroidectomy
10144,26965896,graves’ disease
10145,26965896,hypocalcemia
10146,26965896,parathyroid preservation
10147,26204988,berke incision approach
10148,26204988,chemosis
10149,26204988,deep lateral orbital wall decompression
10150,26204988,swinging eyelid approach
10153,27116895,igg4-related disease
10154,27116895,lymphocyte/plasma cell infiltrations
10155,27116895,malt lymphomas
10156,27116895,orbital pseudotumors
10158,27273008,oscillopsia
10159,27273008,proptosis
10160,27273008,temporal hollowing
10161,27273008,thyroid eye disease
10162,27273008,visual acuity
10163,27259978,clpp
10164,27259978,slc26a4
10165,27259978,tbc1d24
10166,27259978,pendred syndrome
10167,27259978,perrault syndrome
10168,27259978,enlarged vestibular aqueduct
10169,27259978,hereditary deafness cois
10170,28665696,14q32.2
10171,28665696,ciqtnf6
10172,28665696,graves' disease
10173,28665696,rac2
10174,28665696,snp
10175,28665696,association
10176,28660988,graves' orbitopathy
10177,28660988,clinical activity score
10178,28660988,dysthyroid optic neuropathy
10179,28660988,rituximab
10180,28660988,thyroid gland
10182,28364200,graves’ orbitopathy
10183,28364200,inflammation
10184,28364200,orbital fibroblasts
10185,28364200,s1p receptor antagonist
10186,28364200,sphingosine-1-phosphate
10187,26955881,*genetics
10188,26955881,*graves’ disease
10189,26955881,*hashimoto thyroiditis
10190,26955881,*vegf
10191,26955881,*polymorphisms
10192,28689782,*bacteria
10193,28689782,*graves' disease
10194,28689782,*hashimotos's thyroiditis
10195,29180171,*graves' disease
10196,29180171,*hyperthyroidism
10197,29180171,*recurrence
10198,29180171,*subtotal thyroidectomy
10199,29088997,*graves' disease
10200,29088997,*antineutrophil cytoplasmic antibody
10201,29088997,*propylthiouracil
10202,29088997,*vasculitis
10203,29050489,*graves' ophthalmopathy
10204,29050489,*inflammation biomarker.
10205,29050489,*neutrophil-to-lymphocyte ratio
10206,29050489,*thyroid ophthalmopathy
10209,28260364,"decompression, surgical"
10210,28260364,graves ophthalmopathy
10211,28260364,orbit
10212,28260364,"surgical procedures, minimally invasive"
10213,28260364,treatment outcome
10214,26865797,diplopia
10215,26865797,exophthalmos
10216,26865797,eyelid retraction
10217,26865797,graves ophthalmopathy
10218,26865797,orbital decompression cois was reported.
10220,27247969,*grave’s disease
10221,27247969,*ted
10222,27247969,*ted treatment options
10223,27247969,*thyroid eye disease
10224,28606264,graves ophthalmopathy
10225,28606264,magnetic resonance imaging
10226,28606264,oculomotor muscles
10227,28388348,decompression
10228,28388348,graves’ disease
10229,28388348,geriatric
10230,28388348,strabismus
10231,28388348,thyroid eye disease cois alone are responsible for the content and writing of the paper.
10233,28439882,*graves' disease
10234,28439882,*hashimoto's thyroiditis
10235,28439882,*tsh-receptor blocking antibodies
10236,28439882,*tsh-receptor stimulating antibodies
10237,28439882,*bioassay
10239,28743746,*graves' disease
10240,28743746,*iodination
10241,28743746,*post-translational modification (ptm)
10242,28743746,*protein processing
10243,28743746,*protein secretion
10244,28743746,*thyroglobulin
10245,28743746,*thyroid
10246,28743746,*thyroid hormone cois this article
10248,27888002,*autoimmune thyroid diseases (aitd)
10249,27888002,*graves' disease (gd)
10250,27888002,*hashimoto's thyroiditis (ht)
10251,27888002,*micrornas
10252,27888002,*single nucleotide polymorphism (snp)
10255,26767650,graves’ disease
10256,26767650,graves’ ophthalmopathy
10257,26767650,graves’ orbitopathy
10258,26767650,nicotinamide phosphoribosyltransferase
10259,26767650,pre-b cell colony-enhancing factor
10260,26767650,visfatin
10262,29110673,clinical outcomes
10263,29110673,graves’ ophthalmopathy
10264,29110673,"imrt cois ethics committee of west china hospital, sichuan university. informed consent was obtained from all individual participants included in the study. consent for publication: the consent to publish the study and accompanying images was obtained. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
10269,28895880,graves’ disease
10270,28895880,hashimoto’s thyroiditis
10271,28895880,autoimmune thyroid disease
10272,28895880,thyroid cancer
10273,28895880,vitamin d cois
10274,28833367,graves’ hyperthyroidism
10275,28833367,ferritin
10276,28833367,hepcidin
10277,28833367,iron metabolism
10278,28133945,graves' orbitopathy
10279,28133945,field of binocular single vision
10280,28133945,quality of life
10281,28133945,strabismus surgery
10283,28521825,"*graves’ disease, susceptibility, single nucleotide polymorphisms, 4p14, 6q27"
10285,29130665,hyaluronic acid
10286,29130665,insulin-like growth factor-1 receptor
10287,29130665,signal pathway
10288,29130665,thyroid associated ophthalmopathy
10289,28781323,sitsh
10290,28781323,familial dysalbuminemic hyperthyroxinemia (fdh)
10291,28781323,thiamazole
10293,27003434,acute liver damage
10294,27003434,graves’ ophthalmopathy
10295,27003434,hepatotoxicity
10296,27003434,intravenous glucocorticoid therapy
10297,27003434,methylprednisolone
10300,27160786,enlarged
10301,27160786,fluctuation
10302,27160786,hearing loss
10303,27160786,large
10304,27160786,risk factor
10305,27160786,vertigo
10306,27160786,vestibular aqueduct
10307,28756232,*akt/nf-κb
10308,28756232,*galectin-9
10309,28756232,*inflammation
10310,28756232,*thyroid-associated ophthalmopathy
10311,28756232,*tim3
10312,27718482,graves’ disease
10313,27718482,analytical interference
10314,27718482,biotin
10315,27718482,hyperestrogenism
10316,27718482,immunoassay
10317,27558389,*auto-immune thyroid dysfunction
10318,27558389,*chordoma
10319,27558389,*tyrosine kinase inhibitors
10322,27234136,células t reguladoras (tregs)
10323,27234136,enfermedad de graves
10324,27234136,graves’ disease
10325,27234136,hashimoto's thyroiditis
10326,27234136,t helper
10327,27234136,t regulatory cells (treg)
10328,27234136,th17
10329,27234136,thyroid autoimmunity
10330,27234136,tiroideas autoinmunitarias
10331,27234136,tiroiditis de hashimoto
10333,26459776,dna methylation
10334,26459776,epigenetics
10335,26459776,graves' disease
10336,26459776,t cell signaling
10337,26459776,tshr
10339,28450690,*basedow’s disease
10340,28450690,*sjogren’s syndrome
10341,28450690,*autoimmune diseases
10342,28450690,*chronic myopathic type
10343,28450690,*sarcoid myopathy
10345,27267669,*fibroblast growth factor
10346,27267669,*graves’ ophthalmopathy
10347,27267669,*hyaluronan
10348,27267669,*orbital fibroblast
10349,27267669,*platelet-derived growth factor-bb
10350,27267669,*vascular endothelial growth factor
10351,28333576,*epstein–barr virus
10352,28333576,*graves' disease
10353,28333576,*activation-induced cytidine deaminase
10354,28333576,*autoreactive b cells
10355,28333576,*polyclonal b cell activation
10356,28333576,*reactivation cois
10359,26854256,autoimmune diseases
10360,26854256,coeliac disease
10361,26854256,comorbidity
10362,28636775,autoimmune thyroid disease
10363,28636775,cd163
10364,28636775,fn14
10365,28636775,tweak
10367,27986127,*graves' disease
10368,27986127,*hyperthyroidism
10369,27986127,*irisin
10370,27986127,*myostatin
10372,28049375,*graves' disease
10373,28049375,*antithyroid drugs (atds)
10374,28049375,*comparative effectiveness
10375,28049375,*hyperthyroidism
10376,28049375,*radioactive iodine (rai)
10377,28049375,*thyroidectomy cois
10379,27458112,apoptosis
10380,27458112,autoimmune thyroid disease
10381,27458112,intractability
10382,27458112,polymorphism
10383,27458112,severity
10386,29235358,glioblastoma multiforme
10387,29235358,learning curve brain neoplasm
10388,29235358,multi-disciplinary team
10389,28187375,8-ohdg
10390,28187375,graves's disease
10391,28187375,hashimoto thyroiditis
10392,28187375,papillary thyroid carcinoma
10393,29102101,graves disease
10394,29102101,cardiogenic shock
10395,29102101,iodinated contrast
10396,29102101,thyroid storm
10398,26791860,acute graft-versus-host disease
10399,26791860,dna typing
10400,26791860,epistatic interaction
10401,26791860,genome diversity
10402,26791860,graft-versus-leukemia effect
10403,26791860,graves’ disease
10404,26791860,hla allele
10405,26791860,hla class i and class ii gene and molecule
10406,26791860,hla haplotype
10407,26791860,hashimoto thyroiditis
10408,26791860,linkage disequilibrium
10409,26791860,next-generation sequencing
10410,26791860,polymorphism
10411,26791860,regulatory t cell
10412,26791860,thyroglobulin antibody and serum level
10413,26791860,thyroid peroxidase antibody and serum level
10414,26791860,thyroid stimulating hormone receptor antibody and serum level
10415,26791860,unrelated hematopoietic stem cell transplantation
10416,26997461,goitre ovarien
10417,26997461,kyste ovaire
10418,26997461,ovarian cyst
10419,26997461,struma ovarii
10420,26997461,thyroid
10421,26997461,thyroïde
10422,28087387,*a proliferation-inducing ligand (april)
10423,28087387,*b-cell activating factor (baff)
10424,28087387,*graves' orbitopathy
10425,28087387,*orbital fibroblasts
10427,27729026,*goitre in pregnancy
10428,27729026,*iodine status in pregnancy
10429,27729026,*thyroid stimulating hormone
10430,27729026,*thyroid volume
10431,27729026,*urinary iodine
10433,28099999,*graves' disease
10434,28099999,*tshr autoantibodies
10435,28099999,*autoimmunity
10436,28099999,*intrathymic transcription
10437,28099999,*thyroid autoantigens
10438,28099999,*tolerance
10440,27345036,graves’ disease
10441,27345036,tgfbeta1
10442,27345036,nodular goiter
10443,27345036,papillary cancer
10444,27345036,thyroid
10445,27345036,transforming growth factor beta 1
10446,26518171,alopecia areata
10447,26518171,associations
10448,26518171,autoimmune disease
10449,26518171,comorbidities
10450,26518171,prevalence
10451,26518171,thyroid disease
10452,26518171,vitiligo
10453,28604944,graves’ orbitopathy
10454,28604944,adrenal insufficiency
10455,28604944,cortisol
10456,28604944,glucocorticoids
10457,28604944,methylprednisolone
10459,27245471,*autoimmune thyroid disease
10460,27245471,*chemokine
10461,27245471,*intractability
10462,27245471,*severity
10463,27245471,*single nucleotide polymorphism
10464,28595789,goitre prevalence
10465,28595789,iodine intake
10466,28595789,saharawi refugee camps
10467,28595789,urinary iodine concentration
10468,28595789,water iodine concentration
10469,27888493,goitre
10470,27888493,medical diagnosis
10471,27888493,painting
10472,27888493,de ribera
10475,28420934,"goitre, hyperthyroidism, hypothyroidism, thyroid nodules."
10476,29169383,multinodular goitre
10477,29169383,saudi arabia
10478,29169383,solitary nodule
10479,29169383,thyroid fine needle aspiration cytology
10480,26996162,airway obstruction
10481,26996162,goitre
10482,26996162,intratracheal
10483,26996162,intubation
10484,28521312,children
10485,28521312,goitre
10486,28521312,iodine prophylaxis
10487,28521312,thyroid volume
10488,28521312,ultrasound examination
10489,25880137,*iodine
10490,25880137,*cognition
10491,25880137,*development
10492,25880137,*goitre
10493,25880137,*thyroid hormones
10495,27364542,*esrd
10496,27364542,*tsh
10497,27364542,*nodular goiter
10498,27364542,*thyroid gland
10499,27364542,*urinary iodine excretion
10500,28474274,*endoscopic thyroidectomy
10501,28474274,*goiter
10502,28474274,*mediastinal emphysema
10503,28474274,*robotic thyroidectomy
10504,28474274,*subcutaneous emphysema
10505,26612322,advanced spectral imaging
10506,26612322,duel-energy computed tomography
10507,26612322,intranodular hemorrhage
10508,26612322,material decomposition
10509,26612322,thyroid nodule
10510,28098046,* ht-us hypoechoic pattern at thyroid ultrasound
10511,28098046,* iqr interquartile range
10512,28098046,* tpoab thyroperoxidase antibodies
10513,28098046,* tsh thyroid-stimulating hormone
10514,28098046,* tgab thyroglobulin
10515,28098046,* uie urinary i excretion
10516,28098046,*goitre
10517,28098046,*iodine intake
10518,28098046,*thyroid antibodies
10519,28098046,*thyroid diseases
10520,28858843,methimazole
10521,28858843,plasma exchange
10522,28858843,thrombotic thrombocytopenic purpura
10523,28858843,thyrotoxicosis
10524,28858843,toxic multinodular goiter
10528,27421794,epidemiology
10529,27421794,iodine
10530,27421794,iodine deficiency disorders
10531,27421794,iodine fortification
10532,27421794,prophylaxis
10533,27421794,risk of iodine fortification
10536,25994301,all-trans retinoic acid
10537,25994301,autoantibodies
10538,25994301,hashimoto’s thyroiditis
10539,25994301,γδ t cells
10541,27852654,*cardiomyopathies
10542,27852654,*cobalt
10543,27852654,*heart failure
10544,27852654,*hip prosthesis
10545,27852654,*polycythemia
10547,28613043,congenital hypothyroidism with defective dehalogenation of iodotyrosines
10548,28613043,cretinism
10549,28613043,endemic goiter
10550,28613043,iodine deficiency
10551,28613043,thyroid hormones and mental development
10552,27119700,thyroid nodule
10553,27119700,benign adenoma
10554,27119700,multinodular goiter
10555,27119700,thyroid cancer
10556,26527084,fish bone
10557,26527084,foreign body
10558,26527084,neck radiograph
10559,26527084,retropharyngeal abscess
10560,26527084,retropharyngeal goiter
10561,26527084,tonsillitis
10562,28585680,radioactive iodine
10563,28585680,thyroid cancer
10564,28585680,toxic multinodular goitre
10565,29589552,antithyroid medication
10566,29589552,graves' disease
10567,29589552,hashitoxicosis
10568,29589552,hyperthyroidism
10569,29589552,radioactive iodine
10570,29589552,subacute granulomatous thyroiditis
10571,29589552,thyroidectomy
10572,29589552,toxic adenoma
10573,29589552,toxic multinodular goiter.
10575,29871272,langerhans cell histiocytosis
10576,29871272,thyroid cois relevant financial relationships with commercial interests to disclose.
10578,28297755,interleukin-17
10579,28297755,micrornas
10580,28297755,thyroid neoplasms
10581,28690737,struma ovarii
10582,28690737,malignant ovarian goiter
10583,28690737,thyroid cois
10584,28262255,cowden syndrome
10585,28262255,hamartomatous tumour
10586,28262255,multinodular goiter
10587,28262255,pten
10588,28262255,pten hamartoma tumour syndrome
10589,28712235,total thyroidectomy
10590,28712235,recurrent laryngeal nerve injury
10591,28712235,subtotal thyroidectomy
10594,29415534,*pegylated interferon alpha
10595,29415534,*chronic hepatitis c
10596,29415534,*thyroid dysfunction
10599,29798345,cn0
10600,29798345,lymph node metastasis
10601,29798345,papillary thyroid carcinoma
10602,29798345,risk factors cois relevant financial relationships with commercial interests to disclose.
10603,27263038,calcifications
10604,27263038,doppler
10605,27263038,malignancy
10606,27263038,thyroid carcinoma
10607,27263038,thyroid nodule
10608,27263038,ultrasound
10610,26526666,dicer1 syndrome
10611,26526666,hodgkin lymphoma
10612,26526666,t cell type
10613,28569114,children
10614,28569114,goiter
10615,28569114,iodine deficiency disorders
10616,28569114,thyroid volume
10617,28569114,urinary iodine
10619,28476227,*congenital hypothyroidism
10620,28476227,*deiodinase
10621,28476227,*dysgenesis
10622,28476227,*dyshormonogenesis
10623,28476227,*goiter
10624,28476227,*resistance to thyroid hormone
10625,28476227,*thyroid hormone receptors
10628,27922153,*graves’ disease
10629,27922153,*guideline
10630,27922153,*hyperthyroidism
10631,27922153,*radioiodine therapy
10632,27922153,*thyrotoxicosis
10633,27922153,*toxic goiter
10638,26686396,*airflow
10639,26686396,*cfd
10640,26686396,*energy
10641,26686396,*power
10642,26686396,*trachea
10643,26686396,*work of breathing
10647,27913858,fnac
10648,27913858,frozen section
10649,27913858,multinodular goiter
10650,27913858,papillary carcinoma
10651,27913858,thyroid cancer
10652,27913858,thyroid nodule
10655,26876062,*goiter
10656,26876062,*medullary
10657,26876062,*multiple endocrine neoplasia (men)
10658,26876062,*parathyroid
10659,26876062,*thyroidectomy
10662,26511970,cyclooxygenase-2
10663,26511970,ep4 receptor
10664,26511970,microsomal prostaglandin e synthase-1
10665,26511970,papillary thyroid carcinoma
10666,26511970,prostaglandin e2
10669,28042647,*core-needle aspiration biopsy
10670,28042647,*cytokeratin 17
10671,28042647,*fine-needle aspiration biopsy
10672,28042647,*nodular goiter
10673,28042647,*thyroid
10675,28103777,iodine
10676,28103777,iodine deficiency.
10677,28103777,iodine prophylaxis
10678,28103777,metabolic pathway
10679,28103777,synthesis
10680,28103777,thyroid hormones
10681,28085013,il-23
10682,28085013,papillary thyroid carcinoma
10683,28085013,mir-15a
10684,28085013,mir-16
10685,28085013,mir-940
10688,28756521,anticholinesterase pesticide
10689,28756521,hypothyroidism
10690,28756521,poisoning
10691,28954336,"goiter, nodular"
10692,28954336,thyroid neoplasms
10693,28954336,"tomography, x-ray computed"
10694,27259353,diffuse goiter
10695,27259353,iodine intake
10696,27259353,subclinical hypothyroidism
10697,27259353,thyroid nodule
10698,27259353,universal salt iodization (usi)
10699,27259353,urinary iodine concentration (uic)
10700,28405949,endoscopic thyroidectomy
10701,28405949,minimally invasive thyroidectomy
10702,28405949,thyroid surgery
10707,26537235,atrial fibrillation
10708,26537235,elderly
10709,26537235,hyperthyroidism
10710,26537235,iodine
10711,26537235,thyreostatic therapy
10714,27152602,thyroid diseases
10715,27152602,autoimmunity
10716,27152602,iodization
10717,27152602,study
10725,28867693,congenital hypothyroidism
10726,28867693,genetics
10727,28867693,mutation
10728,28867693,newborn screening
10729,28867693,thyroid peroxidase (tpo)
10730,27510155,benign goiter
10731,27510155,complications
10732,27510155,routine data
10733,27510155,thyroid surgery
10734,27510155,volume outcome
10741,26708844,chylous fistula
10742,26708844,thoracic duct
10743,26708844,thyroid-surgery
10745,27405595,*thyroid
10746,27405595,*laser
10747,27405595,*nodule
10748,27405595,*thermal ablation
10749,27405595,*ultrasound
10751,27344303,classification
10752,27344303,juan rosai
10753,27344303,poorly differentiated carcinoma
10754,27344303,thyroid
10759,26708858,inferior thyroid artery
10760,26708858,multinodular goiter
10761,26708858,thyroidectomy
10762,28845837,*mazabraud syndrome
10763,28845837,*mccune-albright syndrome
10764,28845837,"*fibrous dysplasia, malignant transformation."
10765,28845837,*myxoma
10768,26443708,general surgery
10769,26443708,minimally invasive surgery
10770,26443708,robotics
10771,28276222,*ataxia telengiectasia
10772,28276222,*papillary thyroid carcinoma
10774,26886166,dicer1
10775,26886166,laser capture microdissection
10776,26886166,mutation
10777,26886166,well-differentiated fetal adenocarcinoma
10778,26886166,β-catenin
10779,26884118,*68ga
10780,26884118,*cck2 receptor
10781,26884118,*pet/ct
10782,26884118,*medullary thyroid carcinoma
10783,26884118,*somatostatin receptor
10784,27094775,hashimotos
10785,27094775,hypothyroidism
10786,27094775,thyroiditis
10788,29050166,lymphoma
10789,29050166,pathology
10790,29050166,thyroid
10791,29050166,ultrasonography
10793,27784321,*case report
10794,27784321,*cervical sympathetic chain damage
10795,27784321,*horner’s syndrome
10796,27784321,*thyroidectomy
10798,27025990,*children
10799,27025990,*congenital hypothyroidism
10800,27025990,*cáncer de tiroides
10801,27025990,*hipotiroidismo congénito
10802,27025990,*ionising radiation
10803,27025990,*niños
10804,27025990,*radiación ionizante
10805,27025990,*thyroid cancer
10806,29038858,parathyroidectomy
10807,29038858,radiology
10808,29038858,synchronous thyroid pathology
10809,27530498,intra-operative
10810,27530498,pth
10811,27530498,post operative hypocalcemia
10812,27530498,thyroidectomy
10813,27121690,hyperthyroidism
10814,27121690,lithium
10815,27121690,radioactive iodine ablation
10816,27121690,thyroxine
10817,26884115,biopsy
10818,26884115,fine-needle biopsy
10819,26884115,thyroid cancer
10820,26884115,thyroid nodule
10821,26884115,thyroiditis
10827,26577641,basal cell carcinoma
10828,26577641,basal cell nevus syndrome
10829,26577641,dicer1 syndrome
10830,26577641,familial adenomatous polyposis
10831,26577641,pilomatrixoma
10832,26577641,pleuropulmonary blastoma
10834,28694722,acute illness
10835,28694722,guidelines
10836,28694722,thyroid tests cois
10837,28387096,diagnosis
10838,28387096,fnmtc
10839,28387096,genetic
10840,28387096,hereditary
10841,28387096,familial thyroid cancer
10844,28648507,*pax8
10845,28648507,*tshr
10846,28648507,*congenital hypothyroidism
10847,28648507,*hormone resistance
10848,28648507,*mutations
10849,28648507,*subclinical hypothyroidism
10850,28490006,adenoid cystic carcinoma
10851,28490006,cytopathology
10852,28490006,fine needle aspiration
10853,28490006,larynx
10854,28490006,thyroid
10855,27756965,*chlorpheniramine
10856,27756965,*drug-induced torsades de pointes
10857,27756965,*propranolol
10859,28276223,*kocher-debre-semelaigne syndrome
10860,28276223,*atrophic autoimmune thyroiditis
10861,28276223,*pituitary expansion
10862,28276223,*rickets
10863,27387245,*hypocalcemia
10864,27387245,*postoperative hypoparathyroidism
10865,27387245,*teriparatide
10867,29275552,hyperthyroidism
10868,29275552,blood chemical analysis
10869,29275552,case analysis
10870,29275552,"death, sudden, cardiac"
10871,29275552,forensic pathology cois relevant financial relationships with commercial interests to disclose.
10874,28479907,diagnostic accuracy
10875,28479907,cytology
10876,28479907,fine needle aspiration
10877,28479907,tertiary hospital
10878,28479907,thyroidectomy
10879,27162199,fnab
10880,27162199,immunohistochemistry
10881,27162199,neuroendocrine tumors
10882,27162199,thyroid paraganglioma
10885,27041628,fluorescence
10886,27041628,fluorescence-guided surgery
10887,27041628,indocyanine green
10888,27041628,near-infrared imaging
10889,27041628,parathyroid
10890,27041628,thyroidectomy
10892,28291538,anca anti-protéinase 3 (pr3-anca)
10893,28291538,anti-neutrophil cytoplasmic antibody (anca)
10894,28291538,anticorps anti-cytoplasme des neutrophiles (anca)
10895,28291538,propylthiouracil
10896,28291538,propylthiouracile
10897,28291538,proteinase3-anca (pr3-anca)
10898,28291538,pyoderma gangrenosum
10899,27520400,*c-reactive protein
10900,27520400,*resveratrol
10901,27520400,*resveratrol (pubchem cid: 445154)
10902,27520400,*type 2 diabetes mellitus
10903,27091372,laryngeal nerves
10904,27091372,prospective study
10905,27091372,recurrent laryngeal nerve
10906,27091372,recurrent laryngeal nerve injuries
10907,27091372,thyroidectomy
10910,28952196,c-cell
10911,28952196,ret mutation
10912,28952196,minute medullary thyroid carcinoma
10913,28952196,solid cell nests
10914,28025468,t1-weighted imaging
10915,28025468,fetus
10916,28025468,magnetic resonance imaging
10917,28025468,thyroid cois interest.
10918,27233786,diabetes mellitus
10919,27233786,hormone replacement therapy
10920,27233786,hypercalcemia
10921,27233786,hypertension
10922,27233786,osteoporosis
10923,29798949,carcinoma
10924,29798949,papillary
10925,29798949,thyroid cois
10926,28389458,drug interaction
10927,28389458,levothyroxine
10928,28389458,ritonavir
10930,28756810,high iodine
10931,28756810,iodine deficiency
10932,28756810,thyroglobulin
10933,28294052,cognition
10934,28294052,iodine deficiency
10935,28294052,iodine excess
10936,28294052,neurodevelopment
10937,28294052,pregnancy
10938,28294052,prophylaxis.
10940,29871097,"carcinoma, papillary"
10941,29871097,lymph node metastasis
10942,29871097,thyroid neoplasms cois relevant financial relationships with commercial interests to disclose.
10947,28688118,dicer1
10948,28688118,acute transient hepatitis
10949,28688118,monozygotic twins
10950,28688118,pleuropulmonary blastoma
10951,27105534,gene expression profile
10952,27105534,hypoxia
10953,27105534,microenvironment
10954,27105534,oncogenes
10955,27105534,thyroid cancer cois
10956,26193980,fnab
10957,26193980,nodule depth
10958,26193980,pain
10959,26193980,thyroid nodule
10960,26193980,vas score
10961,28196954,*metformin
10962,28196954,*thyroid cancer
10963,28196954,*thyroid disease
10964,28196954,*thyroid nodule
10965,28196954,*thyrotropin
10966,28188700,afirma
10967,28188700,fna
10968,28188700,cytology
10969,28188700,thyroid nodules
10971,28317625,*autoimmunity
10972,28317625,*hyperthyroidism
10973,28317625,*hypothyroidism
10974,28317625,*pulmonary hypertension
10975,28317625,*trab
10976,28229359,calcitonin
10977,28229359,pregnancy
10978,28229359,thyroid volume
10980,27461263,hyperthyroidism
10981,27461263,papillary thyroid cancer
10982,27461263,thyroid cancer
10983,27245300,*biokinetics
10984,27245300,*hyperthyroidism
10985,27245300,*internal dosimetry
10986,27245300,*radioiodine therapy
10987,27013327,ablation
10988,27013327,nodule
10989,27013327,radiofrequency
10990,27013327,thyroid
10991,26931517,patient safety
10992,26931517,resident involvement
10993,26931517,resident participation
10994,26931517,surgical education
10995,26931517,thyroid
10996,26744989,drinking water
10997,26744989,ion chromatography
10998,26744989,method development
10999,26744989,nis inhibitors
11000,29102947,*cancer
11001,29102947,*cardiovascular disease
11002,29102947,*end-stage renal disease
11003,29102947,*hypothyroidism
11004,29102947,*thyroid abnormalities
11005,29102947,*thyroid nodules
11006,29102947,*waiting list for renal transplant
11007,28432675,mini-invasive thyroidectomy
11008,28432675,thyroid
11009,28432675,thyroidectomy
11010,28432675,transoral thyroidectomy
11013,28684081,adherence to diet
11014,28684081,attitude towards diet
11015,28684081,body mass index
11016,28684081,meal plan
11017,28684081,type 2 diabetes mellitus
11018,28034775,*intra-operative neuro-monitoring
11019,28034775,*re-operation
11020,28034775,*recurrent laryngeal nerve palsy
11021,28034775,*thyroid cancer
11022,28034775,*thyroidectomy
11023,28238190,*pentraxin 3
11024,28238190,*resveratrol
11025,28238190,*total antioxidant status
11026,28238190,*type 2 diabetes mellitus
11027,27071746,all-cause mortality
11028,27071746,cardiovascular mortality
11029,27071746,cardiovascular risk
11030,27071746,mediterranean diet
11031,28982849,*thyroid
11032,28982849,*immunohistochemistry
11033,28982849,*lymph node metastasis
11034,28982849,*papillary thyroid carcinoma
11035,28982849,*sphingosine kinase 1
11036,28791817,binder syndrome
11037,28791817,bone graft
11038,28791817,cartilage graft
11039,28791817,maxillary underdevelopment
11040,28791817,resorption
11041,26932954,*4d ct
11042,26932954,*parathyroid adenoma
11043,26932954,*parathyroid hyperplasia
11044,26932954,*sestamibi scintigraphy
11045,26246426,hypothyroidism
11046,26246426,end-stage renal disease
11047,26246426,hemodialysis
11048,26246426,thyroid nodule
11049,28626131,congenital hypothyroidism
11050,28626131,duoxa2
11051,28626131,genetics
11052,28626131,mutation
11053,28626131,newborn screening
11054,28387647,thyroid nodule
11055,28387647,frozen section fine-needle aspiration biopsy.
11056,28387647,papillary carcinoma
11057,28387647,thyroidectomy
11058,28250870,*congenital hypothyroidism
11059,28250870,*growth retardation
11060,28250870,*mental retardation cois
11061,27488391,breast and endometrial cancer
11062,27488391,cowden syndrome
11063,27488391,multiple meningiomas
11064,27488391,pten hamartoma
11065,27488391,radiology
11066,26786663,tc99m sestamibi scintigraphy
11067,26786663,primary hyperparathyroidism
11068,26786663,thyroid disorder
11069,26786663,thyroid pathology
11070,26786663,ultrasonography
11072,28703115,completion lymphadenectomy
11073,28703115,tall-cell variant
11074,28703115,thyroid carcinoma
11075,26780986,hypocalcemia
11076,26780986,hypoparathyroidism
11077,26780986,parathyroid hormone
11078,26780986,thyroidectomy
11079,26780986,vitamin d
11080,26711165,assays
11081,26711165,biomarker
11082,26711165,differentiated thyroid cancers
11083,26711165,thyroglobulin
11088,29059259,*bone metabolism markers
11089,29059259,*hyperthyroidism
11090,29059259,*sclerostin
11092,28109483,global health
11093,28109483,haiti
11094,28109483,head and neck surgery
11095,28109483,otolaryngology
11096,27744598,99mtc-mibi
11097,27744598,autonomously functioning thyroid nodules
11098,27744598,parathyroid carcinoma
11099,27744598,parathyroid scintigraphy
11103,28604619,cancer
11104,28604619,flavonoid
11105,28604619,invasiveness
11106,28604619,iodide uptake
11107,28604619,phytochemical
11108,28604619,proliferation
11109,28604619,radioiodine therapy
11110,28604619,sodium iodide symporter (nis)
11111,28604619,thyroid cois
11112,26983701,dicer-1
11113,26983701,pleuropulmonary blastoma
11114,26983701,sertoli-leydig cell tumor
11115,26983701,thyroid carcinoma
11116,26983701,familial neoplasia
11118,28506409,bethesda classification
11119,28506409,guidelines
11120,28506409,lobectomy
11121,28506409,thyroid
11122,28506409,thyroid carcinoma
11123,28506409,thyroidectomy
11124,27639841,abtpo
11125,27639841,autoimmune thyroid diseases
11126,27639841,autoimmune thyroiditis
11127,27639841,hypothyroidism
11128,27639841,organ specific autoimmune diseases
11129,27639841,systemic rheumatological disorders
11131,28189449,hyperthyroidism
11132,28189449,lymphadenectomy
11133,28189449,pediatric thyroidectomy
11134,28189449,total thyroidectomy
11135,28189449,transient hypocalcemia
11136,27208531,computer-aided diagnosis
11137,27208531,medical imaging
11138,27208531,morphometry
11142,27809694,*us elastography
11143,27809694,*fibronectin-1
11144,27809694,*fibrosis
11145,27809694,*galectin-3
11146,27809694,*indeterminate cytology
11147,27809694,*thyroid nodules
11148,27833458,*epidemiology
11149,27833458,*monitoring
11150,27833458,*prevalence trend
11151,27833458,*thyroid disorders
11152,27288566,elderly
11153,27288566,harmonic
11154,27288566,ligasure
11155,27288566,thyroidectomy
11156,27288566,vessel sealing
11159,26838584,growth hormone deficiency
11160,26838584,hypothyroidism
11161,26838584,pituitary hyperplasia
11163,28025932,*global health
11164,28025932,*humanitarian
11165,28025932,*quality of life
11166,28025932,*resource limited
11167,28025932,*thyroid
11168,28025932,*thyroidectomy
11170,28039060,*calcium prophylaxis
11171,28039060,*hypocalcemia
11172,28039060,*oral calcium
11173,28039060,*parathyroid hormone
11174,28039060,*thyroidectomy
11179,28870235,barley young leaf
11180,28870235,chronic lymphocytic thyroiditis
11181,28870235,hypothyroidism
11182,28870235,isoflavones
11183,28870235,soybean
11184,28870235,thin-layer chromatography
11185,28870235,kale cois from the patient for publication of this case report and any accompanying images. a copy of the written consent is available for review by the editor-in-chief of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
11186,28222777,*dicer1 mutations
11187,28222777,*dicer1 syndrome
11188,26970173,*27 kd heat-shock protein
11189,26970173,*antioxidants
11190,26970173,*oxidants
11191,26970173,*thyroid tumors
11192,26370671,diagnostic
11193,26370671,foxe1
11194,26370671,follicular thyroid lesion
11195,26370671,pax8
11196,26370671,ttf-1
11197,26370671,thyroid nodules
11199,26796150,24-h urine
11200,26796150,adults
11201,26796150,benin
11202,26796150,icp-ms
11203,26796150,iodine
11204,26289771,dicer1
11205,26289771,mirna
11206,26289771,ovarian cancer
11207,26289771,sarcoma
11208,26289771,sertoli-leydig cell tumor cois interest to disclose.
11210,28964290,hearing loss
11211,28964290,slc26a4
11212,28964290,whole exome sequencing cois to report.
11217,26795600,cerebral cavernous malformation (ccm)
11218,26795600,cerebrovascular disease
11219,26795600,cytochrome p450 (cyp)
11220,26795600,disease severity
11221,26795600,familial cerebral cavernous malformation type 1
11222,26795600,free radicals
11223,26795600,genetic markers set association study
11224,26795600,inter-individual variability in disease susceptibility and outcome
11225,26795600,intracerebral hemorrhage
11226,26795600,krit1/ccm1
11227,26795600,matrix metalloproteinase (mmp)
11228,26795600,oxidative stress
11229,26795600,reactive oxygen species (ros)
11230,26795600,vascular brain lesions
12845,20463839,complications
12846,20463839,retrosternal goitre
12847,20463839,sternotomy
12848,20463839,surgical treatment
12849,20463839,thyroid
12970,19270831,graves' disease
12971,19270831,hantaan virus
12972,19270831,hemorrhagic fever with renal syndrome
13246,19759882,biometry
13247,19759882,eye abnormalities
13248,19759882,graves’
13249,19759882,graves’ disease
13250,19759882,ophthalmopathy
13251,19759882,photography
13330,19568361,drug-induced hypersensitivity
13331,19568361,graves' disease
13332,19568361,hyperthyroidism
13333,19568361,iodine therapy
13334,19568361,vogt-koyanagi-harada disease
13416,19547630,graves’ disease
13417,19547630,endocrine orbitopathy
13418,19547630,impaired earning capacity
13419,19547630,occupational disability
13420,19547630,quality of life
13882,20463832,stem cells
13883,20463832,thyroid
13884,20463832,thyroid cancer
13885,20463832,tissue repair
14076,19606248,calcitonin
14077,19606248,false-positive test
14078,19606248,ret mutation
14079,19606248,total thyroidectomy
14090,32548696,compression symptoms
14091,32548696,fine needle aspiration cytology
14092,32548696,operative indications
14093,32548696,thyroid gland
14094,32548696,thyroid imaging reporting and data system
14095,32780357,goiter
14096,32780357,goiters
14097,32780357,intrathoracic goiter
14098,32780357,intrathoracic
14099,32780357,substernal
14101,33445947,retrosternal goiter – sternotomy – thoracotomy − thyroid gland disease − vocal  cord paresis
14102,34941205,retrosternal goiter
14103,34941205,simultaneous surgery
14104,34941205,sternotomy
14105,32929476,*graves disease
14106,32929476,*tsh receptor antibodies
14107,32929476,*antithyroid drugs
14108,32929476,*diagnosis
14109,32929476,*management
14110,32929476,*radioactive iodine
14111,32929476,*thyroidectomy
14112,32929476,*treatment
14114,34151940,american medicine
14115,34151940,benjamin smith barton
14116,34151940,goiter
14117,34151940,medical geography
14118,33069387,*enfermedad de graves-basedow
14119,33069387,*glucocorticoides
14120,33069387,*glucocorticoids
14121,33069387,*graves-basedow disease
14122,33069387,*graves’ ophthalmopathy
14123,33069387,*inflamación orbitaria
14124,33069387,*orbitopathy
14125,33069387,*orbitopatía
14126,33069387,*rituximab
14127,33069387,*teprotumumab
14128,33069387,*tocilizumab
14129,33835415,art and medicine
14130,33835415,epifania benintendi
14131,33835415,florence
14132,33835415,nodal goitre
14134,34288592,aspiration cytology
14135,34288592,dyshormonogenetic goiter
14136,34288592,thyroid
14137,33895978,dante alighieri
14138,33895978,goiter
14139,33895978,history
14140,33895978,middle ages
14146,32059832,*cxcl10
14147,32059832,*cxcr3
14148,32059832,*graves' disease
14149,32059832,*graves' ophthalmopathy
14150,32059832,*th1 immune response
14151,32059832,*teprotumumab cois
14153,33878810,*congenital hypothyroidism
14154,33878810,*literacy
14155,33878810,*cognitive dysfunction
14156,33878810,*indigenous population
14157,33878810,*prenatal care
14158,33878810,*chronic malnutrition
14159,33878810,*social vulnerability cois
14160,32472406,art
14161,32472406,drawing
14162,32472406,endemic
14163,32472406,endocrinology
14164,32472406,goiter
14165,33995810,goiter
14166,33995810,follicular carcinoma
14167,33995810,lymphoma
14168,33995810,malignancy
14169,33995810,papillary carcinoma cois
14170,32970371,rose
14171,32970371,us-fna
14172,32970371,amyloid
14173,32970371,amyloid goiter
14174,32970371,interventional pathologist
14175,34149612,*graves’ disease
14176,34149612,*autoimmune
14177,34149612,*goiter
14178,34149612,*growth factor
14179,34149612,*hormone
14180,34149612,*ophthalmopathy
14181,34149612,*thyroid cois autoimmune disease and consultancy for horizon therapeutics consultant immunovant.
14184,33507686,diet
14185,33507686,goiter
14186,33507686,helicobacter pylori
14187,33507686,gastric carcinoma
14188,33507686,stature
14189,33396042,endemic goiter
14190,33396042,hypo-and hyperthyroidism
14191,33396042,iodine nutrition
14192,33396042,thiocyanate
14193,33396042,thyroid echogenicity/cytomorphology
14196,33607721,cardiovascular diseases
14197,33607721,methylarginines
14198,33607721,multinodular goiter
14199,33607721,thyroid
14200,32500695,hypoparathyroidism
14201,32500695,laryngeal paresis
14202,32500695,polidocanol
14203,32500695,recurrent nodular goiter
14204,32500695,sclerotherapy
14206,32107168,*graves’ disease
14207,32107168,*th1 chemokines
14208,32107168,*epidemiology
14209,32107168,*hepatitis c virus
14210,32107168,*risk factors
14211,32107168,*viruses cois
14212,32893229,cardiopulmonary arrest
14213,32893229,intrathoracic goiter
14214,32893229,phrenic nerve paralysis cois
14215,33409915,multinodular goiter
14216,33409915,thyroid adenoma
14217,33409915,thyroid cancer
14218,33409915,trace elements
14219,34245984,goiter
14220,34245984,risk factors
14221,34245984,trace elements
14222,34707013,maximum density of ct
14223,34707013,nodular goiter
14224,34707013,parathyroid lesions
14225,34707013,single-photon emission computed tomography/computed tomography
14227,33574798,*graves’ hyperthyroidism
14228,33574798,*graves’ orbitopathy
14229,33574798,*oxidative stress
14230,33574798,*reactive oxygen species
14231,33574798,*selenium
14232,33574798,*selenocysteine
14233,33574798,*selenoproteins cois commercial or financial relationships that could be construed as a potential conflict of interest.
14234,32493403,antithyroid drug
14235,32493403,block-replace therapy
14236,32493403,case report
14237,32493403,fetal goiter
14238,32493403,perinatal management
14239,32493403,triiodothyronine-predominant graves’ disease cois
14241,33804853,goiter
14242,33804853,sternotomy
14243,33804853,thyroidectomy cois
14245,33396135,association
14246,33396135,case-control study
14247,33396135,mineral elements
14248,33396135,thyroid function
14249,33396135,thyroid tumor and goiter
14250,34628753,acupoint indications
14251,34628753,acupoints at the upper arms
14252,34628753,goiter
14253,34628753,scrofula
14254,34628753,specific effect
14257,32078117,*congenital hypothyroidism
14258,32078117,*gene mutation
14259,32078117,*tpo deficiency
14260,32078117,*thyroid dyshormonogenesis
14261,31907822,endemic
14262,31907822,goiter
14263,31907822,iconography
14264,31907822,surgery
14265,32474859,b-cell lymphoma
14266,32474859,hashimoto’s thyroiditis
14267,32474859,core needle biopsy
14268,32474859,fine needle aspiration cytology
14269,32474859,primary thyroid lymphoma
14271,32824922,*nf-e2-related factor 2
14272,32824922,*goiter
14273,32824922,*micrornas
14274,32824922,*thyroid neoplasms
14275,32824922,*vascular endothelial growth factor a cois commercial or financial relationships that could be construed as a potential conflict of interest.
14276,34244226,endocrine
14277,34244226,instrumentation
14278,34244226,radioactive iodine therapy
14279,34244226,radioactive iodine uptake
14280,34244226,radionuclide therapy
14281,34244226,substernal goiter
14284,33468112,*excessive iodine
14285,33468112,*goiter
14286,33468112,*iodization
14287,33468112,*school children
14288,33468112,*southern ethiopia cois
14289,31994506,aortic window
14290,31994506,ectopia
14291,31994506,hyperparathyroidism
14292,31994506,parathyroid adenoma
14293,31994506,thoracoscopy
14294,34167409,*intrathoracic goiter
14295,34167409,*ablation technique
14296,34167409,*ultrasound
14297,33579801,*diffuse and nodular goiter
14298,33579801,*lab tests for benign thyroid disorders
14299,33579801,*primary autoimmune hypothyroidism
14300,33579801,*radionuclide imaging
14301,33579801,"*subacute, destructive thyroiditis"
14302,33579801,*ultrasound imaging
14307,32341696,children
14308,32341696,dental pathology
14309,32341696,diffuse nontoxic goiter
14310,32341696,local protective mechanisms
14313,33837650,*anatomy
14314,33837650,*development
14315,33837650,*embryology
14316,33837650,*retrosternal goiter
14317,33837650,*thyroidectomy
14324,33310200,nodular goiter
14325,33310200,papillary thyroid carcinoma
14326,33310200,polycyclic aromatic hydrocarbon
14327,33310200,risk assessment cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
14328,32320467,*15 mci
14329,32320467,*fixed activity
14330,32320467,*hyperthyroidism
14331,32320467,*radioiodine
14332,32320467,*toxic multinodular goiter
14333,32320467,*volume reduction
14335,33980774,graves disease
14336,33980774,hyperthyroidism
14337,33980774,large goiter
14338,33980774,radioiodine therapy
14342,34220711,*congenital hypothyroidism
14343,34220711,*fetal goiter
14344,34220711,*growth
14345,34220711,*mutations
14346,34220711,*neuropsychological evaluation
14347,34220711,*thyroid peroxidase cois commercial or financial relationships that could be construed as a potential conflict of interest.
14348,33878943,retrosternal goiter
14349,33878943,acromegaly
14350,33878943,airway management
14351,33878943,anesthesia
14352,33878943,case report
14353,33878943,multidisciplinary strategy
14354,33878943,tracheal compression cois conflict of interest.
14356,33391188,*graves’ disease
14357,33391188,*asymmetry
14358,33391188,*exophthalmos
14359,33391188,*hyperthyroidism
14360,33391188,*unilateral cois commercial or financial relationships that could be construed as a potential conflict of interest.
14362,32812038,*15 mci
14363,32812038,*fixed activity
14364,32812038,*hyperthyroidism
14365,32812038,*radioiodine
14366,32812038,*toxic multinodular goiter
14367,32812038,*volume reduction
14369,33252592,*grave’s disease
14370,33252592,*trab
14371,33252592,*ft3:ft4 ratio
14373,31984866,*graves' disease
14374,31984866,*dementia
14375,31984866,*epidemiology
14376,31984866,*hyperthyroidism
14377,31984866,*toxic nodular goiter
14380,32633627,*anaplastic thyroid cancer
14381,32633627,*gene mutation
14382,32633627,*thyroglobulin
14383,32633627,*thyroid dyshormonogenesis
14385,31950881,*graves' disease
14386,31950881,*chronic lymphocytic thyroiditis
14387,31950881,*incidental thyroid microcarcinomas
14388,31950881,*multinodular goiter
14389,31950881,*papillary thyroid cancer
14390,31950881,*papillary thyroid microcarcinomas
14391,32495658,thyroid surgery
14392,32495658,anesthesia
14393,32495658,gastrointestinal intubation
14394,32495658,goiter
14395,32495658,intratracheal intubation
14396,32495658,nasogastric tube
14400,34195868,hypocalcemia
14401,34195868,hypoparathyroidism
14402,34195868,indocyanine green (icg)
14403,34195868,near-infrared autofluorescence (nir-af)
14404,34195868,near-infrared fluorescence imaging (nifi)
14405,34195868,parathyroid glands (pgs)
14406,34195868,thyroid surgery
14407,34195868,total thyroidectomy
14412,33619720,graves’ disease
14413,33619720,coronary artery spasm
14414,33619720,myocardial infarction
14415,33619720,thyrotoxicosis
14416,33735381,*graves orbitopathy
14417,33735381,*cholesterol
14418,33735381,*statins
14419,33655885,graves' orbitopathy
14420,33655885,graves’ disease
14421,33655885,graves’ ophthalmopathy
14422,33655885,thyroid diseases
14423,32749654,graves’ orbitopathy
14424,32749654,pathogenesis
14425,32749654,thyrotropin receptor
14426,32749654,thyrotropin receptor antibodies cois
14427,32729049,compressive optic neuropathy
14428,32729049,dysthyroid optic neuropathy
14429,32729049,graves orbitopathy
14430,32729049,orbital decompression
14431,32729049,stretch optic neuropathy
14432,32729049,thyroid eye disease
14434,32826306,*oesophageal varices cois
14435,34112358,biomarkers
14436,34112358,dietary reference values
14437,34112358,estimated average requirement cut-point method
14438,34112358,goiter
14439,34112358,goitrogens
14440,34112358,iodine
14441,34112358,iodine deficiency disorders
14442,34112358,"thyroid hormones, salt iodization"
14443,34112358,urinary iodine concentration
14445,34867996,*graves’ disease
14446,34867996,*hashimoto’s thyroiditis
14447,34867996,*autoimmune thyroid diseases (aitd)
14448,34867996,*exosomes
14449,34867996,*immune regulation cois commercial or financial relationships that could be construed as a potential conflict of interest.
14450,33484076,orbital disease
14451,33484076,thyroid eye disease
14452,33484076,thyroid ophthalmopathy
14453,32326785,chorioretinal folds
14454,32326785,grave’s ophthalmopathy
14455,32326785,choroidal folds
14456,32326785,thyroid eye disease
14457,32326785,thyroid orbitopathy
14458,32663624,autoimmunity
14459,32663624,hashimoto's thyroiditis
14460,32663624,helicobacter pylori
14461,32663624,hepatitis c
14462,32663624,mimicry
14463,32663624,thyroid cois declare. the authors did not recieve any funding from any institution for this article.
14464,33387353,art
14465,33387353,graves' disease
14466,33387353,thyroid swelling
14469,34680964,*pendred syndrome
14470,34680964,*whole-exome sequencing
14471,34680964,*genotype-phenotype correlation cois
14473,34362755,covid-19
14474,34362755,thyroid disease cois
14478,33011882,*chemiluminescence
14479,33011882,*cytochrome p450 reductase
14480,33011882,*cytochrome b5-reductase
14481,33011882,*nontoxic nodular goiter
14482,33011882,*papillary thyroid cancer
14483,33011882,*toxic goiter
14487,32880074,anterior
14488,32880074,computed tomography
14489,32880074,magnetic resonance imaging
14490,32880074,mediastinum
14497,34029917,cochlear implant
14498,34029917,deafness
14499,34029917,enlarged vestibular aqueduct
14500,34029917,hearing aid
14501,34029917,hearing loss
14502,34029917,incomplete partition
14503,34029917,pendred syndrome
14504,33619715,graves’ orbitopathy
14505,33619715,exophthalmos
14506,33619715,meningioma
14511,34410066,graves’ disease
14512,34410066,graves’ ophthalmopathy
14513,34410066,ted
14514,34410066,monoclonal antibodies
14515,34410066,thyroid eye disease
14517,32571507,benign
14518,32571507,goiter
14519,32571507,graves’ disease
14520,32571507,pediatric
14521,32571507,thyroid
14523,34033289,*implications
14524,34033289,*iodine deficiency
14525,34033289,*pregnancy
14527,35004341,*graves’ disease
14528,35004341,*graves’ orbitopathy (go)
14529,35004341,*lactobacillus
14530,35004341,*prevotella
14531,35004341,*tshr (thyroid-stimulating hormone receptor)
14532,35004341,*th17 and treg cells
14533,35004341,*veillonella
14534,35004341,*gut microbiota cois commercial or financial relationships that could be construed as a potential conflict of interest.
14535,33449383,*graves' disease
14536,33449383,*hashimoto's thyroiditis
14537,33449383,*interferon lambda 1
14538,33449383,*interleukin-29
14539,33449383,*subacute thyroiditis
14540,34026662,*16s rrna
14541,34026662,*graves’ disease
14542,34026662,*clinical parameters
14543,34026662,*gut microbiota
14544,34026662,*next-generation sequencing cois commercial or financial relationships that could be construed as a potential conflict of interest.
14545,34182968,dilated cardiomyopathy
14546,34182968,ethiopia
14547,34182968,methimazole
14548,34182968,propylthiouracil
14549,34182968,thyrotoxicosis
14550,34182968,β-blocker cois
14551,34855196,graves’ disease (gd)
14552,34855196,antithyroid drugs (atds)
14553,34855196,radioactive iodine (rai)
14554,34855196,total thyroidectomy (tt)
14555,30927742,*graves’ disease
14556,30927742,*factitious disorders
14557,30927742,*thyroxine
14558,33445994,graves’ disease
14559,33445994,intelligent diagnosis
14560,33445994,deep learning
14561,33445994,diagnostic performance
14562,33445994,nuclear medicine residents
14563,33445994,subacute thyroiditis
14564,33445994,thyroid disease
14565,33445994,thyroid scintigraphy cois conflict of interest.
14567,33515213,graves’ disease
14568,33515213,graves’ ophthalmopathy
14569,33515213,graves’ orbitopathy
14570,33515213,thyroglobulin cois as prejudicing the impartiality of the research reported.
14571,31919775,corticosteroids
14572,31919775,graves’ disease
14573,31919775,tshr
14574,31919775,thyroid eye disease
14575,32893226,cushing's syndrome
14576,32893226,graves' disease
14577,32893226,central hypothyroidism
14578,32893226,syndrome of inappropriate secretion of thyroid-stimulating hormone cois
14581,33487459,adipose tissue
14582,33487459,glande thyroïde
14583,33487459,thyroid gland
14584,33487459,thyrolipoma
14585,33487459,thyrolipomatose
14586,33487459,thyrolipomatosis
14587,33487459,thyrolipome
14588,33487459,tissu adipeux
14589,34965078,*graves’ disease
14590,34965078,*radioiodine therapy
14591,34965078,*thyroid eye disease
14592,34965078,*thyroidectomy
14597,34969797,ear
14598,34969797,nose and throat/otolaryngology
14599,34969797,vascular surgery cois
14600,34118212,cancer de la thyroïde
14601,34118212,goitre multinodulaire
14602,34118212,multinodular goiter
14603,34118212,mutation du gène pds
14604,34118212,pds gene mutation
14605,34118212,pendred syndrome
14606,34118212,syndrome de pendred
14607,34118212,thyroid cancer
14608,33112798,*graves’ orbitopathy
14609,33112798,*binding immunoglobulin protein
14610,33112798,*endoplasmic reticulum stress
14611,33112798,*thyroid eye disease
14612,33112798,*unfolded protein response
14614,32638234,graves’ disease
14615,32638234,pancytopenia
14616,32638234,review
14619,33462034,calcium and bone
14620,33462034,hyperthyroidism cois
14621,33685911,pericardial disease
14622,33685911,thyroid disease cois
14630,32765422,*graves' disease
14631,32765422,*autoimmunity
14632,32765422,*hyperthyroidism
14633,32765422,*inflammation
14634,32765422,*natural killer cells
14635,33557156,*22q11.2 deletion syndrome
14636,33557156,*down syndrome
14637,33557156,*graves’ disease
14638,33557156,*hashimoto’s thyroiditis
14639,33557156,*klinefelter syndrome
14640,33557156,*prader–willi syndrome
14641,33557156,*rasopathies
14642,33557156,*turner syndrome
14643,33557156,*williams syndrome
14644,33557156,*genetic syndromes cois
14645,33661574,antithyroid drugs
14646,33661574,hepatitis
14647,33661574,hyperthyroidism
14648,33661574,plasma exchange
14649,33661574,plasmapheresis
14652,34303550,basedow
14653,34303550,dysthyroidism
14654,34303550,dysthyroïdie
14655,34303550,glaucoma
14656,34303550,glaucome
14657,34303550,graves’ disease
14658,34303550,hypertonie intra-oculaire
14659,34303550,ocular hypertension
14660,34753719,hepatitis other
14661,34753719,thyrotoxicosis cois
14663,34725062,cardiothoracic surgery
14664,34725062,otolaryngology / ent
14665,34725062,thyroid disease cois
14666,32441005,antithyroid drugs
14667,32441005,covid-19
14668,32441005,glucocorticoids
14669,32441005,graves’ disease
14670,32441005,graves’ orbitopathy cois
14672,33789121,alkaloid
14673,33789121,cyanogenic glucoside
14674,33789121,flavonoid
14675,33789121,phytochemical
14676,33789121,polyphenol
14677,33789121,thyroid
14678,32157663,art
14679,32157663,history
14680,32157663,thyroid swelling
14684,31948703,*epidemiology
14685,31948703,*goiter
14686,31948703,*national inpatient sample
14687,31948703,*predictive factors
14688,31948703,*thyroid disease
14689,31948703,*thyroidectomy cois conflicts of interest to disclose.
14690,33420947,*lingual thyroid
14691,33420947,*oropharynx
14692,33420947,*robotic thyroidectomy
14693,33420947,*thyroidectomy
14698,32910410,art
14699,32910410,graves’ disease
14700,32910410,history
14702,33569041,*graves’ disease
14703,33569041,*hyperthyroidism
14704,33569041,*review
14705,33569041,*thyroxine
14706,33569041,*treatment cois commercial or financial relationships that could be construed as a potential conflict of interest.
14707,32173798,*benign thyroid disease
14708,32173798,*chris
14709,32173798,*radioiodine therapy
14710,32173798,*stunning
14711,32173798,*thyroid
14712,33367675,*graves’ disease
14713,33367675,*slit2
14714,33367675,*thyroid-associated ophthalmopathy
14716,34227705,*graves' disease
14717,34227705,*goiter
14718,34227705,*hyperthyroidism
14719,34227705,*pediatric
14720,34227705,*scintigraphy
14721,34969799,covid-19
14722,34969799,thyroid disease
14723,34969799,thyrotoxicosis
14724,34969799,unwanted effects/adverse reactions cois
14728,32477269,*graves' disease
14729,32477269,*anti-thyroid drug
14730,32477269,*carbimazole
14731,32477269,*dose
14732,32477269,*hyperthyroidism
14733,32797478,amyloidosis
14734,32797478,goitre
14735,32797478,hypothyroidism
14736,33431523,neonatal and paediatric intensive care
14737,33431523,pregnancy
14738,33431523,thyroid disease
14739,33431523,thyrotoxicosis cois
14740,33988300,*lepr
14741,33988300,*graves' disease
14742,33988300,*immune-related genes
14743,33988300,*leptin receptor
14744,33988300,*thyroid-associated ophthalmopathy
14745,33988300,*weighted gene co-expression network analysis cois
14746,32199035,*hyperthyroidism
14747,32199035,*postoperative complications
14748,32199035,*surgery
14749,32199035,*thyroid diseases
14750,32199035,*thyroidectomy
14753,33597052,*goiter prevalence
14754,33597052,*iodine nutrition
14755,33597052,*thyroid cancer
14756,33597052,*urine iodine
14757,33934566,*graves’ disease
14758,33934566,*myh11
14759,33934566,*itraq technique
14760,33934566,*inflammatory response
14761,33934566,*proteomics
14762,33934566,*thyroid-associated obitopathy cois
14763,33367747,*graves’ disease
14764,33367747,*igf-1r
14765,33367747,*thsr
14766,33367747,*autoimmunity
14767,33367747,*exosomes
14768,33914707,*endocrinology
14769,33914707,*thyroid disease cois exists.
14771,34192497,complications
14772,34192497,goitre
14773,34192497,thyroidectomy
14774,34192497,tracheomalacia
14777,33509724,excisional biopsy
14778,33509724,foot
14779,33509724,radiation therapy
14780,33509724,thyroid dermopathy
14781,33579884,*dfnb4
14782,33579884,*menière
14783,33579884,*hydrops
14784,33579884,*mouse
14785,33579884,*pendred
14787,33283314,*graves' disease
14788,33283314,*rai
14789,33283314,*long-term atd
14790,33283314,*surgery
14791,33283314,*treatment
14792,32847459,dry eye disease
14793,32847459,grave’s disease
14794,32847459,grave’s eye disease
14795,32847459,ocular inflammation
14796,32847459,ocular surface
14797,32847459,thyroid eye disease
14798,34560868,*amhara region
14799,34560868,*dessie
14800,34560868,*ethiopia
14801,34560868,*iodine deficiency
14802,34560868,*urinary iodine concentration cois
14804,33863564,acuité visuelle
14805,33863564,antioxidant therapy
14806,33863564,cas score
14807,33863564,exophthalmos
14808,33863564,légère orbitopathie thyroïdienne
14809,33863564,mild graves’ orbitopathy
14810,33863564,ouverture palpébrale
14811,33863564,oxidative stress
14812,33863564,palpebral fissure
14813,33863564,placebo
14814,33863564,proptose
14815,33863564,selenium
14816,33863564,stress oxydatif
14817,33863564,sélenium
14818,33863564,traitement anti-oxydatif
14819,33863564,visual acuity
14820,33994519,graves' disease
14821,33994519,antithyroid drug
14822,33994519,fetal goiter
14823,33994519,fetal hyperthyroidism
14824,33994519,tachycardia
14826,32553518,*graves’ disease
14827,32553518,*nsqip
14828,32553518,*racial disparities
14829,32553518,*thyroidectomy cois conflicts of interest to disclose.
14830,32968816,*graves disease
14831,32968816,*cytokine
14832,32968816,*fibroblasts
14833,32968816,*hyaluronan
14834,32968816,*ophthalmopathy
14835,32968816,*orbit
14836,33530368,*graves’ disease
14837,33530368,*autoimmunity
14838,33530368,*dendritic cells
14839,33530368,*methimazole cois
14840,33532627,*graves' disease
14841,33532627,*trab
14842,33532627,*multivariable analysis
14843,33532627,*thyroid surgery cois
14844,34806437,*iodine deficiency
14845,34806437,*iodine excess
14846,34806437,*iodized salt
14847,32709792,*dysthyroid optic neuropathy
14848,32709792,*indian
14849,32709792,*thyroid eye disease cois
14850,32130689,graves’ disease
14851,32130689,multiple sclerosis
14852,32130689,personalized medicine
14853,32130689,thyroidectomy
14854,32130689,thyroiditis
14855,33380646,immunohistochemistry
14856,33380646,molecular genetics
14857,33380646,thyroid paraganglioma
14858,33380646,thyroid tumor
14859,33380646,total thyroidectomy cois
14861,32691849,*graves’ disease
14862,32691849,*graves’ ophthalmopathy
14863,32691849,*eye diseases
14864,32691849,*geographical locations
14865,32691849,*meta-analysis
14866,32691849,*prevalence
14867,32691849,*thyroid diseases
14868,33617351,dna methylation
14869,33617351,graves' disease
14870,33617351,bioinformatic analysis
14871,33617351,genome-wide
14872,33146848,application test
14873,33146848,artificial intelligence
14874,33146848,clinical trials
14875,33146848,thyroid-associated ophthalmopathy
14876,34774035,extraocular muscle
14877,34774035,magnetic resonance imaging
14878,34774035,short-tau inversion recovery
14879,34774035,thyroid-associated ophthalmopathy cois
14880,33658136,graves’ ophthalmopathy
14881,33658136,diffusion magnetic resonance imaging
14882,33658136,extraocular muscles
14883,33658136,magnetic resonance imaging
14884,33593429,*graves’ disease
14885,33593429,*graves’ orbitopathy
14886,33593429,*gut microbiota
14887,33593429,*human fecal microbiota transplant
14888,33593429,*microbiome modulation
14889,33593429,*murine model
14890,33593429,*probiotics
14891,33593429,*vancomycin cois other collaborative projects with cultech ltd. the other authors declare that they have no competing interests.
14892,33675208,graves’ disease
14893,33675208,antithyroid treatment
14894,33675208,pediatric thyroidology
14895,33675208,thyroidectomy
14896,33675208,thyrotoxicosis
14898,32034469,endocrine orbitopathy
14899,32034469,epidemiology
14900,32034469,graves’ disease
14901,32034469,healthcare research
14902,32034469,interdisciplinary orbit center
14903,34497059,endocrine system
14904,34497059,respiratory system
14905,34497059,thyroid disease cois
14906,32924380,graves’ disease
14907,32924380,graves’ orbitopathy
14908,32924380,children
14909,32924380,hepatic dysfunction
14910,32924380,lymphocyte subsets
14911,34647611,complications
14912,34647611,hypoparathyroidism
14913,34647611,nodular goitre
14914,34647611,surgical treatment
14915,34647611,thyroid cancer
14916,34518175,genetics
14917,34518175,hyperthyroidism
14918,34518175,thyroid disease cois
14920,34725068,general practice / family medicine
14921,34725068,otolaryngology / ent
14922,34725068,thyroid disease
14923,34725068,thyrotoxicosis cois
14925,34448404,airway obstruction
14926,34448404,asthma
14927,34448404,goitre
14928,34448404,pre-eclampsia
14929,34448404,pregnancy
14930,33779950,hypocalcemia
14931,33779950,intrathoracic goiter
14932,33779950,morbidity
14933,33779950,nerve paralysis
14934,33779950,sternotomy
14935,33779950,surgery
14936,33779950,thyroid cois
14937,32727336,graves’ disease
14938,32727336,thyrotoxicosis
14939,32727336,anti-thyroid therapy
14940,32727336,arrhythmia
14941,32727336,electrocardiogram
14942,32727336,hyperthyroidism
14943,32705333,alopecia areata
14944,32705333,cohort study
14945,32705333,epidemiology
14946,32705333,taiwan’s national health insurance research database
14947,32705333,thyroid disease
14949,33481211,graves’ disease
14950,33481211,gut microbiota
14951,33481211,lactobacillus
14952,33481211,ruminococcus
14953,33481211,trab
14955,33169897,goiter
14956,33169897,imaging mass spectrometry
14957,33169897,obesity
14958,33169897,thyroglobulin
14959,33169897,thyroid disease
14960,33169897,thyroid tissue
14961,33926416,baff
14962,33926416,br3
14963,33926416,graves’ disease
14964,33926416,hashimoto’s thyroiditis
14965,33926416,taci cois
14967,32203974,*antibodies
14968,32203974,*autoimmune diseases
14969,32203974,*drug therapy
14970,32203974,*hyperthyroidism
14971,32203974,*hypothyroidism
14972,32203974,*placenta
14973,32203974,*research laboratories
14974,32203974,*therapeutic drug monitoring
14975,32203974,*thyroid
14976,32203974,*thyroid-stimulating hormone
14978,33563685,anxiety disorders (including ocd and ptsd)
14979,33563685,endocrinology
14980,33563685,psychiatry
14981,33563685,psychotic disorders (incl schizophrenia)
14982,33563685,thyroid disease cois
14983,33966669,*endemic goitre
14984,33966669,*iodine deficiency disorders
14985,33966669,*salt iodine content
14986,33966669,*total goitre rate
14987,33966669,*ultrasonography
14988,33966669,*universal salt iodisation
14989,33966669,*urinary iodine concentration
14990,32875953,thyroid stimulating hormone
14991,32875953,hyperthyroidism
14992,32875953,thyroid uptake and scan
14995,32705522,glucocorticoids
14996,32705522,graves’ orbithopathy
14997,32705522,radiotherapy
15000,33106982,extracellular matrix
15001,33106982,fbln1 gene
15002,33106982,fibulin-1
15003,33106982,multinodular goiter
15004,33106982,papillary thyroid cancer
15006,34418335,graves’ disease
15007,34418335,hypothyroidism
15008,34418335,radioiodine therapy
15009,34418335,thyroid peroxidase antibody (tpoab)
15010,34418335,thyrotropin receptor antibody (trab)
15011,34194397,*graves’ disease
15012,34194397,*antithyroid drugs
15013,34194397,*children
15014,34194397,*hyperthyroidism
15015,34194397,*remission cois commercial or financial relationships that could be construed as a potential conflict of interest.
15016,34689799,fine-needle aspiration
15017,34689799,midkine
15018,34689799,multinodular goiter
15019,34689799,thyroid cancer
15020,34689799,thyroid nodule cois
15021,34521015,epid dosimetry
15022,34521015,machine learning
15023,34521015,multifactorial error sources
15024,34521015,positioning error detection
15025,34521015,radiomics analysis
15026,34448415,fine-needle cytology
15027,34448415,goitre
15028,34448415,thyroid cancer
15029,34448415,thyroid nodules
15030,34448415,thyroidectomy
15031,34893568,*endocrine
15032,34893568,*exophthalmos
15033,34893568,*goiter
15034,34893568,*selfie
15035,34893568,*thyroid
15036,34893568,*thyroidectomy cois
15037,33128357,*c cell hyperplasia
15038,33128357,*medullary thyroid cancer
15039,33128357,*calcitonin
15040,33128357,*pentagastrin
15041,33128357,*cut-off cois
15042,34019179,cd73
15043,34019179,immunohistochemistry
15044,34019179,papillary thyroid carcinoma
15045,34019179,thyroid adenoma
15046,34019179,thyroid carcinoma cois
15048,34782518,goitre
15049,34782518,intrathoracic
15050,34782518,retrosternal
15051,34782518,sternotomy cois
15053,33193994,grave’s disease
15054,33193994,hyperthyroidism
15055,33193994,radioactive iodine disease cois
15056,33619717,genetic
15057,33619717,mutation
15058,33619717,thyroid disease
15059,34560890,graves’ disease
15060,34560890,r282s
15061,34560890,resistance to thyroid hormone
15062,34560890,syndrome of inappropriate secretion of tsh
15063,34560890,thyroid hormone receptor β cois
15065,33474918,bony orbital decompression
15066,33474918,dysthyroid optic neuropathy
15067,33474918,endoscopic orbital decompression
15068,33474918,surgical treatment
15069,33474918,thyroid eye disease
15072,33345558,body composition
15073,33345558,hypocalcemia
15074,33345558,hypoparathyroidism
15075,33345558,thyroid
15076,33345558,total thyroidectomy
15077,34331946,diagnostic efficacy
15078,34331946,graves’ disease
15079,34331946,methimazole
15080,34331946,responsiveness
15081,34331946,thyroid-stimulating immunoglobulin
15082,32449092,16s rrna gene
15083,32449092,graves’ disease
15084,32449092,graves’ orbitopathy
15085,32449092,gut microbiota
15086,32449092,metabolic functions
15088,32057544,goiter size
15089,32057544,graves' disease
15090,32057544,outcome
15091,32057544,radioiodine therapy cois declare.
15092,34552563,*dicer1 mutation
15093,34552563,*dicer1 syndrome
15094,34552563,*goiter
15095,34552563,*goitre
15096,34552563,*hereditary cancer
15097,34552563,*thyroidectomy cois commercial or financial relationships that could be construed as a potential conflict of interest. the reviewer kt declared a past collaboration with one of the authors kw to the handling editor.
15098,33528651,european group on graves’ orbitopathy
15099,33528651,graves’ orbitopathy
15100,33528651,quality of life
15101,33528651,thyroid eye disease
15103,32847889,ophthalmology
15104,32847889,pathology cois
15105,33346898,autoimmunity
15106,33346898,goiter
15107,33346898,graves’ disease
15108,33346898,graves’ orbitopathy
15109,33346898,hyperthyroidism cois
15110,31980413,*adolescents
15111,31980413,*antithyroid drugs
15112,31980413,*children
15113,31980413,*graves disease cois
15116,34630829,ectopic thyroid tissue
15117,34630829,case report
15118,34630829,submandibular mass
15119,34630829,thyroid goiter cois
15120,33026541,hyperthyroidism
15121,33026541,hypothyroidism
15122,33026541,iodine
15123,33026541,spa
15124,33026541,thyroid gland
15126,31982255,auto-immunité
15127,31982255,autoimmunity
15128,31982255,chest pain
15129,31982255,douleur thoracique
15130,31982255,graves’ disease
15131,31982255,maladie de basedow
15132,31982255,myocardite
15133,31982255,myocarditis
15136,34256242,graves' disease
15137,34256242,graves' orbitopathy
15138,34256242,interleukin 17
15139,34256242,interleukin 23
15140,34256242,thyrotropin receptor cois
15141,34823306,*aggression
15142,34823306,*graves disease
15143,34823306,*prevalence
15144,34823306,*prognosis
15145,34823306,*thyroid neoplasms cois was reported.
15146,34164724,deep lateral orbital wall decompression
15147,34164724,extraocular muscle expansion
15148,34164724,greater wing of sphenoid bone
15149,34164724,orbital fat removal
15150,33728674,graves' disease
15151,33728674,catalytic activity
15152,33728674,thyroid proteomics
15153,33728674,thyrotoxicosis
15154,33728674,toxic multinodular goitre
15155,34090378,non-specific orbital inflammation
15156,34090378,comorbidity
15157,34090378,orbital mass
15158,34090378,prednisolone
15159,34090378,thyroid eye disease cois
15160,32527309,case report
15161,32527309,lipoma
15162,32527309,minor salivary gland
15163,32527309,parotid gland
15164,32527309,sialolipoma cois
15165,33317492,case report
15166,33317492,graves’ disease
15167,33317492,orbitopathy
15168,33317492,pregnancy
15169,33317492,smoking
15170,33317492,tao cois
15171,34300095,*saudi arabia
15172,34300095,*iodine deficiency disorders
15173,34300095,*stunting cois
15174,34938274,*swedish endocrine society
15175,34938274,*desiccated thyroid extract (dte)
15176,34938274,*euthyroidism
15177,34938274,*hypothyroidism
15178,34938274,*levothyroxine
15179,34938274,*liothyronine
15180,34938274,"*survey cois authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. ibsa had no role in the design of the survey, data analysis, data presentation, data interpretation or writing the manuscript; the authors did not receive remuneration by ibsa."
15183,32279181,gender differences
15184,32279181,graves’ disease
15185,32279181,lymphocytic infiltration
15186,32279181,papillary thyroid cancer
15187,32279181,thyroidectomy
15188,32279181,thyroiditis and cancer
15189,34033290,*graves' disease
15190,34033290,*graves' orbitopathy
15191,34033290,*hyperthyroidism
15192,33544540,body surface area
15193,33544540,middle school students
15194,33544540,thyroid volume
15195,34252869,intravenous glucocorticoid
15196,34252869,t2 ideal
15197,34252869,t2 mapping
15198,34252869,therapeutic efficacy
15199,34252869,thyroid-associated ophthalmopathy
15200,32306294,*exophthalmos
15201,32306294,*graves’ disease
15202,32306294,*graves’ orbitopathy
15203,32306294,*igf-1 receptor
15204,32306294,*teprotumumab
15205,32306294,*thyroid eye disease
15206,32798996,*graves disease
15207,32798996,*outcomes
15208,32798996,*radioactive iodine ablation
15209,32798996,*thyroidectomy
15210,32166667,diabetes
15211,32166667,euthyroid hormones
15212,32166667,free thyroxine
15213,32166667,free triiodothyronine
15214,32166667,islet beta-cell function
15216,33860431,*antithyroid agents
15217,33860431,*grave’s disease
15218,33860431,*hyperthyroidism
15219,33860431,*recurrence
15220,33860431,*treatment outcome
15221,32734611,*graves' disease
15222,32734611,*trabs
15223,32734611,*age
15224,32734611,*radioiodine
15225,32734611,*thyroid hormones cois
15226,34381549,cameroon
15227,34381549,nodular goitre
15228,34381549,cancer
15229,34381549,thyroid cois
15230,34120661,complications
15231,34120661,recurrent laryngeal nerve
15232,34120661,surgery
15233,34120661,thyroid
15234,34120661,vagus nerve
15235,34120661,vocal fold palsy
15236,33993334,cerebrospinal fluid in the optic nerve sheath
15237,33993334,dysthyroid optic neuropathy
15238,33993334,magnetic resonance imaging
15239,33993334,optic nerve
15240,33993334,quantitative water-fat sequence
15241,32524368,antithyroid drugs
15242,32524368,graves’ disease treatment
15243,32524368,graves’ orbitopathy
15244,32524368,hyperthyroidism
15245,32461446,*diabetes mellitus
15246,32461446,*thyroid eye disease
15247,32461446,*thyroid-related orbitopathy
15248,32461446,*type-2 dm cois
15249,33439464,*effective half-life
15250,33439464,*graves’ disease
15251,33439464,*radioiodine therapy
15252,33439464,*radioiodine uptake test
15253,33439464,*thyroid cois
15254,31910731,graves’
15255,31910731,timp-1
15256,31910731,strain
15257,31910731,thyroid
15258,34659126,*n1b metastasis
15259,34659126,*nomogram
15260,34659126,*papillary thyroid cancer
15261,34659126,*predicting
15262,34659126,*skip metastasis cois commercial or financial relationships that could be construed as a potential conflict of interest.
15263,31927747,differentiated thyroid cancer
15264,31927747,pediatrics
15265,31927747,thyroid
15266,31927747,thyroid nodules
15267,32595602,*graves' hyperthyroidism
15268,32595602,*graves' ophthalmopathy
15269,32595602,*anti-thyroid drugs
15270,32595602,*corticosteroid pulse therapy
15271,32595602,*relapse of graves' hyperthyroidism
15272,34266819,head and neck surgery
15273,34266819,paediatric oncology
15274,34266819,radiotherapy
15275,34266819,thyroid disease cois
15278,32527127,prolonged endotracheal intubation
15279,32527127,retrosternal goitre (rsg)
15280,32527127,tracheomalacia
15281,33023116,endemic congenital hypothyroidism
15282,33023116,endemic goitre
15283,33023116,familial aggregation
15284,33023116,iodine deficiency
15285,33023116,thyroid metabolism cois
15286,32709788,*india
15287,32709788,*orbital decompression
15288,32709788,*survey
15289,32709788,*thyroid eye disease cois
15290,32218623,point of care
15291,32218623,thyroid ultrasound cois
15292,33947272,*graves'disease
15293,33947272,*radioactive iodine therapy
15294,33947272,*thyrotropin receptor antibody
15295,33947272,*thyrotropin-binding inhibitory immunoglobulins
15296,33947272,*total thyroidectomy cois
15297,32358735,choroidal thickness
15298,32358735,ganglion cell layer thickness
15299,32358735,graves’ disease
15300,32358735,graves’ orbitopathy
15301,32358735,optic nerve head
15302,32358735,optical coherence tomography
15303,32358735,retinal thickness
15304,32975031,*thypro
15305,32975031,*benign
15306,32975031,*quality of life
15307,32975031,*thyroid
15308,32975031,*thyroidectomy
15309,32173759,*graves disease
15310,32173759,*graves orbitopathy
15311,32173759,*th17.1 cell
15312,32173759,*effector t cell
15314,32602151,autofluorescence
15315,32602151,hypocalcemia
15316,32602151,parathyroid gland
15317,32602151,thyroidectomy
15318,34278816,*graves' disease
15319,34278816,*iodothyronine deiodinase
15320,34278816,*poorly differentiated thyroid carcinoma
15321,33080613,dicer1 syndrome
15322,33080613,multinodular goitre
15323,33080613,poorly differentiated thyroid cancer
15324,33080613,thyroid carcinoma
15325,33080613,thyroid nodule
15326,32944926,graves’ disease
15327,32944926,trab
15328,32944926,trab-negative
15329,32944926,hyperthyroidism
15330,32944926,smoking
15331,34028325,radioactive iodine
15332,34028325,graves’ disease
15333,34028325,hyperthyroidism
15334,34028325,lithium
15335,34028325,toxic nodule’ toxic multinodular goiter
15336,32037571,*dysthyroid optic neuropathy
15337,32037571,*optic nerve compression
15338,32037571,*thyroid eye disease
15340,32188795,graves’ disease
15341,32188795,graves’ hyperthyroidism
15342,32188795,potassium iodide
15343,32188795,wolff-chaikoff effect
15345,32451608,compressive optic neuropathy
15346,32451608,medial wall
15347,32451608,orbital floor
15348,32451608,spontaneous decompression
15349,32451608,thyroid eye disease
15350,32316214,goitre
15351,32316214,iodine pregnant women
15352,32316214,iodine schoolchildren
15353,32316214,iodised salt
15354,32316214,urine iodine
15355,32316214,water iodine cois the views of the institutions with which they are affiliated. the authors declare that there is no conflict of interest.
15360,32487052,131i−
15361,32487052,euthyreosis
15362,32487052,factors
15363,32487052,graves’ disease
15364,32487052,hyperthyroidism
15365,32487052,predictors
15366,32487052,radioiodine
15367,32487052,toxic multinodular goiter cois
15369,32532690,hepatitis
15370,32532690,methimazole
15371,32532690,plasmapheresis
15372,32532690,thyrotoxicosis
15374,32245343,*generalized additive model
15375,32245343,*salt iodine concentration
15376,32245343,*thyroid volume
15377,32245343,*urinary iodine concentration
15378,32504380,*magnetic resonance imaging
15379,32504380,*quantitative evaluation
15380,32504380,*thyroid-associated ophthalmopathy
15381,32504380,*treatment response
15382,32020533,iodine deficiency
15383,32020533,north macedonia
15384,32020533,schoolchildren
15385,32020533,thyroid gland ultrasonography
15386,32020533,thyroid volume
15387,31948188,*prevalence
15388,31948188,*school-age children
15389,31948188,*turkey
15390,31948188,*iodine deficiency
15391,32333320,energy vessel sealant device
15392,32333320,neck hematoma
15393,32333320,surgical complications
15394,32333320,thyroidectomy
15395,32139177,*graves' disease
15396,32139177,*antithyroid drugs
15397,32139177,*relapse
15398,32139177,*risk factors
15399,32253727,cognition
15400,32253727,diffusion tensor imaging
15401,32253727,thyroid-associated ophthalmopathy
15402,32253727,vision
15403,32253727,voxel-based morphometry
15404,31973681,*antithyroid medications
15405,31973681,*effectiveness of therapy
15406,31973681,*hyperthyroidism
15407,31973681,*radioactive iodine
15408,31973681,*thyroidectomy
15409,32758269,autoimmune antibody
15410,32758269,basedow’s disease
15411,32758269,hashimoto’s thyroiditis
15412,32758269,histopathological features cois
15413,32640447,*autoimmune diseases
15414,32640447,*costimulatory molecules
15415,32640447,*degranulation
15416,32640447,*mast cells
15417,32640447,*thyroid hormones
15419,32077044,anti-tsh receptor autoantibodies
15420,32077044,autoimmunity
15421,32077044,fine-needle aspiration biopsy
15422,32077044,graves’ disease
15423,32077044,graves’ orbitopathy
15424,32077044,hyperthyroidism
15425,32077044,thyroid
15426,32077044,thyroid nodules
15427,32474767,asymmetric
15428,32474767,graves’
15429,32474767,orbitopathy
15430,32474767,thyroid
15431,32474767,unilateral cois
15432,32658864,graves’ disease
15433,32658864,hashitoxicosis
15434,32658864,sudan
15435,32658864,adolescents
15436,32658864,childhood
15438,32174327,*generative adversarial network
15439,32174327,*orbital decompression
15440,32174327,*postoperative appearance
15441,32174327,*thyroid-associated ophthalmopathy cois declare.
15442,32593739,(131)i
15443,32593739,calculated dose
15444,32593739,dosimetry
15445,32593739,dosimetría
15446,32593739,dosis calculada
15447,32593739,dosis fija
15448,32593739,fixed dose
15449,32593739,hipertiroidismo
15450,32593739,hyperthyroidism
15451,32593739,radionuclide therapy
15452,32593739,radioterapia metabólica
15453,32847555,99mtc-pertechnetate scintigraphy
15454,32847555,graves’ disease
15455,32847555,immune checkpoint inhibitor
15456,32847555,nivolumab
15457,32847555,thyroid-stimulating hormone receptor antibody
15458,32847555,thyrotoxicosis cois
15459,32666542,pds
15460,32666542,slc26a4
15461,32666542,upd7
15462,32666542,growth retardation
15463,32709791,*graves orbitopathy
15464,32709791,*hindi
15465,32709791,*quality of life
15466,32709791,*questionnaire
15467,32709791,*validation cois
15468,31465286,131i
15469,31465286,goiter
15470,31465286,carbimazol
15471,31465286,chloride
15472,31465286,creatinine
15473,31465286,thyroid function tests
15474,31465286,thyrotoxicosis.
15475,33346473,21-oh-antibodies
15476,33346473,addison’s disease
15477,33346473,graves’ disease
15478,33346473,autoimmune polyglandular syndromes
15479,33346473,diabetes mellitus type 1
15480,33038927,autoimmune polyglandular syndrome
15481,33038927,chronic urticaria
15482,33038927,graves’ disease
15483,33038927,premature ovarian failure cois
15487,32154572,graves’ disease
15488,32154572,antithyroid drugs
15489,32154572,gender
15490,32154572,hyperthyroidism
15491,33256801,autoimmune disease
15492,33256801,basedow-graves’s disease
15493,33256801,nutritional assessment
15494,33256801,pediatric disability
15495,33256801,stickler syndrome cois
15496,32499464,*clinical impression
15497,32499464,*euthyroid
15498,32499464,*goiter
15499,32499464,*thyroid disorder
15500,32499464,*thyroid function test cois
15502,32295532,*case report
15503,32295532,*congenital chloride diarrhea
15504,32295532,*deafness
15505,32295532,*neonatal diarrhea
15506,32295532,*pendred syndrome cois
15507,34916318,*clinical trials
15508,34916318,*ophthalmology
15509,34916318,*thyroid disease cois
15512,34726857,bony orbital decompression
15513,34726857,corneal ulcer
15514,34726857,exophthalmos
15515,34726857,keratopathy
15516,34726857,lagophthalmos
15517,34726857,neurotrophic keratitis
15518,34726857,tarsorrhaphy
15519,34726857,thyroid eye disease
15520,33860819,exophthalmos
15521,33860819,graves’ ophthalmopathy
15522,33860819,low dose radiation therapy
15523,33860819,radiotherapy
15524,33860819,"thyroid eye disease cois o. ott, m. hecht, r. fietkau, b. frey, and f. putz declare that they have no competing interests."
15525,33517799,*lid flare
15526,33517799,*beziér lines
15527,33517799,*graves orbitopathy
15528,33517799,*lid contour
15529,33517799,*lid retraction
15530,33109498,autoimmune thyroid disease
15531,33109498,chinese herbal medicine
15532,33109498,graves’ disease
15536,33797646,*131i
15537,33797646,*effective half-life
15538,33797646,*graves’ disease
15539,33797646,*mird
15540,33797646,*tld measurements
15541,33049131,dio2 gene
15542,33049131,graves’ disease
15543,33049131,polymorphisms
15544,32844239,epidemiology
15545,32844239,graves’ ophthalmopathy
15546,32844239,proptosis
15547,32844239,thyroid eye disease
15549,31237218,cd40
15550,31237218,cd40 ligand
15551,31237218,graves’ ophthalmopathy
15552,31237218,cytokine
15553,31237218,protein microarray
15554,31237218,tear.
15555,34531272,*graves’ disease
15556,34531272,*hyperthyroidism
15557,34531272,*thyrotoxic periodic paralysis
15558,34531272,*weakness
15562,33247453,*graves disease
15563,33247453,*edrophonium testing
15564,33247453,*myasthenia gravis
15565,33247453,*ocular myasthenia gravis
15566,33247453,*repetitive nerve stimulation
15567,33247453,*thyroid eye disease
15568,34681884,inflammation
15569,34681884,orbital fibroblasts
15570,34681884,proopiomelanocortin (pomc)
15571,34681884,thyroid eye disease
15572,34681884,α-melanocyte stimulating hormone (α-msh) cois
15573,32057773,*extraocular muscle
15574,32057773,*gene microarray
15575,32057773,*proteomic profiling
15576,32057773,*thyroid-associated ophthalmopathy cois
15579,33676921,corticosteroid therapy
15580,33676921,corticothérapie
15581,33676921,graves’ orbitopathy
15582,33676921,mycophenolate mofetil
15583,33676921,mycophénolate mofetil
15584,33676921,orbitopathie basedowienne
15585,33676921,rituximab
15586,33676921,teprotumumab
15587,33676921,tocilizumab
15588,33367784,*graves disease
15589,33367784,*hla class i
15590,33367784,*stat1
15591,33367784,*autoimmune thyroid disease
15592,33367784,*enterovirus
15593,33367784,*viral infections
15594,32506060,*free triiodothyronine
15595,32506060,*free triiodothyronine to free thyroxine ratio
15596,32506060,*subcutaneous fat area
15597,32506060,*visceral fat area cois
15599,34185860,*basedow's disease
15600,34185860,*childhood onset
15601,34185860,*general anesthesia
15602,34185860,*graves' disease
15603,34185860,*hyperthyroidism
15604,34185860,*thyroid storm
15605,34185860,*thyrotoxicosis
15606,34033291,*graves' disease
15607,34033291,*il-27
15608,34033291,*il-35
15609,34033291,*anti-tpo
15610,34033291,*anti-tg
15611,35008579,graves’ disease
15612,35008579,graves’ orbitopathy
15613,35008579,vegf-a
15614,35008579,microrna-199a
15615,35008579,oxidative stress cois competing financial interests exist.
15619,34484118,*graves’ disease (gd)
15620,34484118,*mendelian randomization
15621,34484118,*autoimmune disease (ad)
15622,34484118,*causal relationship
15623,34484118,*rheumatoid arthritis cois commercial or financial relationships that could be construed as a potential conflict of interest.
15624,34078122,*thyroid-associated ophthalmopathy
15625,34078122,*adipogenesis
15626,34078122,*adipose/connective tissue
15627,34078122,*alternative splicing
15628,34078122,"*rmats cois of interest with respect to the research, authorship, and/or publication of this article."
15629,32529279,intraocular pressure
15630,32529279,neuropathy
15631,32529279,orbitopathy
15632,32529279,thyroid
15633,32529279,visual field defect
15634,33845801,fat decompression
15635,33845801,radiological
15636,33845801,"thyroid-associated ophthalmopathy cois presentation, financial support and proprietary interest statement."
15638,32854466,*graves’ ophthalmopathy
15639,32854466,*choroidal thickness
15640,32854466,*optical coherence tomography
15641,32854466,*proptosis cois
15642,32709794,*activity
15643,32709794,*eugogo
15644,32709794,*thyroid eye disease
15645,32709794,*visa
15646,32709794,*hyperthyroidism
15647,32709794,*severity cois
15648,31804961,hyperthyroidism
15649,31804961,radioactive iodine therapy
15650,31804961,sinusitis
15651,34647609,cd4+ t cell
15652,34647609,th lymphocytes
15653,34647609,treg lymphocytes
15654,34647609,autoimmune thyroid disease
15655,33400175,*anti-thyroid drugs
15656,33400175,*hyperthyroidism
15657,33400175,*outcome
15658,33400175,*radioactive iodine therapy
15659,32737644,laryngopharyngeal reflux
15660,32737644,local neck symptoms
15661,32737644,nodular goiter
15662,32737644,thyroidectomy cois
15663,34144327,*cyclic peptide
15664,34144327,*graves' orbitopathy
15665,34144327,*long-term graves' disease mouse model
15666,34144327,*orbital collagen
15667,34144327,*thyroid dysfunction
15668,34144327,*thyrotropin receptor antibodies
15669,32088116,*autoimmune
15670,32088116,*biological agents
15671,32088116,*graves' disease
15672,32088116,*insulin-like growth factor-i receptor
15673,32088116,*monoclonal antibodies
15674,32088116,*teprotumumab
15675,33086191,*pdk2
15676,33086191,*glycolysis
15677,33086191,*orbital fibroblasts
15678,33086191,*proliferation
15679,33086191,*thyroid-associated ophthalmopathy
15680,31345156,graves’ ophthalmopathy
15681,31345156,angiotensinconverting enzyme inhibitors
15682,31345156,enalapril
15683,31345156,hyperthyroidism
15684,31345156,mild ophthalmopathy
15685,31345156,palpebral fissure.
15686,34855199,csvt
15687,34855199,graves’ disease
15688,34855199,cerebral sinus venous thrombosis
15689,34855199,child
15690,34855199,hyperthyroidism
15691,32474766,gene polymorphisms
15692,32474766,graves' disease
15693,32474766,interleukin-1 (il-1)
15694,32474766,interleukin-6 (il-6)
15695,32474766,tumor necrosis factor-α (tnf-α)
15696,34147078,graves’ orbitopathy
15697,34147078,in vivo confocal microscopy
15698,34147078,meibomian glands
15699,34147078,microstructure cois
15701,33268601,graves’ ophthalmopathy
15702,33268601,anti-thyroid-stimulating hormone receptor antibodies
15703,33268601,clinical activity score
15704,33268601,pregnancy
15705,33268601,thyroid stimulating antibody
15707,32588167,decompression
15708,32588167,diplopia
15709,32588167,exophthalmos
15710,32588167,graves’ ophthalmopathy
15711,32588167,orbit
15712,32588167,proptosis cois
15714,31953667,graves ophthalmopathy
15715,31953667,lacrimal apparatus
15716,31953667,magnetic resonance imaging
15717,31953667,orbital diseases
15720,34156783,bony regrowth
15721,34156783,deep lateral orbital decompression
15722,34156783,thyroid eye disease
15723,34156783,ultrasonic osteodestruction
15724,33431733,graves' disease
15725,33431733,painless thyroiditis
15726,33431733,potassium iodide cois
15727,32727578,circular rna
15728,32727578,exosomes
15729,32727578,graves’ disease
15730,32727578,immune activation
15731,32727578,hsa_circrna_000102 cois
15732,34273482,benign thyroid disorders
15733,34273482,biologically effective dose
15734,34273482,dose-rate effects
15735,34273482,outcome probability
15736,34273482,proportional odds model
15737,34273482,radioiodine therapy
15738,33943012,*t helper 17 cells
15739,33943012,*autoimmune thyroid disease
15740,33943012,*selenium cois
15741,32810095,"postpartum thyroiditis, graves' disease, colour doppler ultrasound."
15743,34867823,*graves’ disease (gd)
15744,34867823,*hashimoto thyroiditis (ht)
15745,34867823,*autoimmune thyroid disease
15746,34867823,*gut microbiota
15747,34867823,*meta-analysis cois commercial or financial relationships that could be construed as a potential conflict of interest.
15748,33329408,*graves’ disease
15749,33329408,*graves’ orbitopathy
15750,33329408,*tsh receptor antibodies
15751,33329408,*hyperthyroidism
15752,33329408,*hypothyroidism
15753,33329408,*radioiodine (131i) treatment
15754,33329408,*smoking cois commercial or financial relationships that could be construed as a potential conflict of interest.
15755,34628889,hyperthyroidism
15756,34628889,hypercalcemia
15757,34628889,morbidity
15758,34628889,thyroid related antibodies
15759,34628889,vitamin d3
15760,32122631,computer-assisted surgery
15761,32122631,exophthalmos
15762,32122631,neuronavigation
15763,32122631,orbital decompression
15764,32122631,proptosis
15765,32122631,thyroid-associated ophthalmopathy
15767,33941360,complications
15768,33941360,graves’ disease
15769,33941360,lugol
15770,33941360,potassium iodide
15771,33941360,thyroidectomy
15772,33832456,autoimmune disease
15773,33832456,biomarker
15774,33832456,graves’ disease
15775,33832456,thyroid eye disease cois manuscript.
15777,35285441,graves disease
15778,35285441,tsi
15779,35285441,cancer
15780,35285441,papillary
15781,35285441,thyroid
15782,34844465,*covid-19
15783,34844465,*graves’ disease
15784,34844465,*sars-cov-2
15785,34844465,*thyroid storm
15786,34844465,"*thyrotoxicosis cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
15787,31805011,*genetic diseases
15788,31805011,*genetics
15789,31805011,*oncology
15790,31805011,*rna processing
15791,31805011,*thyroid disease cois exists.
15795,32498091,*graves’ disease
15796,32498091,*hashimoto’s thyroiditis
15797,32498091,*irak1 polymorphism
15798,32498091,*x chromosome genetic analysis
15799,32498091,*autoimmune thyroid disease
15800,32498091,*thyroid-associated ophthalmopathy
15801,33568133,*graves’ disease
15802,33568133,*susceptibility genes
15803,33568133,*three generations
15804,33568133,*whole exome sequencing cois
15806,32845332,*graves’ disease
15807,32845332,*hyperthyroidism
15808,32845332,*immunomodulation
15809,32845332,*immunotherapy
15810,32845332,*thyroid hormone
15811,32845332,*thyroid-stimulating hormone receptor
15812,33858208,*graves'
15813,33858208,*sars-cov-2 vaccines
15814,33858208,*adverse vaccine reactions
15815,33858208,*autoimmune/inflammatory syndrome induced by adjuvants
15816,33858208,*disease
15817,33673340,*b cells
15818,33673340,*graves’ disease
15819,33673340,*igf-ir
15820,33673340,*igf-ir inhibitors
15821,33673340,*t cells
15822,33673340,*tshr
15823,33673340,*autoimmunity
15824,33673340,*proptosis
15825,33673340,*thyroid-associated ophthalmopathy cois inventions concerning the use of igf-ir inhibitors as therapy in graves’ disease. these patents are held by ucla school of medicine and los anglees biomedical research institute. he is a consultant for horizon therapeutics.
15826,32126013,graves
15827,32126013,hashimoto
15828,32126013,autoimmune thyroid
15831,32515628,corneal biomechanical properties
15832,32515628,corneal hysteresis
15833,32515628,ocular response analyzer
15834,32515628,thyroid associated ophthalmopathy
15837,33855963,thyroid eye disease
15838,33855963,tocilizumab
15839,33613458,*graves’ disease
15840,33613458,*hashimoto autoimmune thyroiditis
15841,33613458,*adolescents
15842,33613458,*autoimmune thyroid diseases
15843,33613458,*children cois commercial or financial relationships that could be construed as a potential conflict of interest.
15845,32930505,müllerectomy
15846,32930505,graves' orbitopathy
15847,32930505,levator disinsertion
15848,32930505,upper eyelid retraction
15849,32930505,upper eyelid surgery
15850,34020391,aitd
15851,34020391,il-10
15852,34020391,regulatory b cells
15854,34243868,graves disease
15855,34243868,hyperthyroidism
15856,34243868,thyroid
15857,34243868,thyroid cancer
15858,34243868,toxic nodule
15859,32785898,*cardiac output
15860,32785898,*echocardiography
15861,32785898,*n-terminal-pro-b-type natriuretic peptide
15862,32785898,*neonatal hyperthyroidism
15863,32785898,*thyroid-stimulating hormone receptor antibody
15864,34684053,creatine kinase
15865,34684053,graves’ disease
15866,34684053,methimazole
15867,34684053,myopathy cois
15869,32741892,graves' disease
15870,32741892,hyperthyroidism
15871,32741892,resting energy expenditure
15872,32741892,resting metabolic rate cois
15875,34742692,*eye proteins/*analysis
15876,34742692,*eye diseases/diagnosis/*metabolism
15877,34742692,*graves' ophthalmopathy
15878,34742692,*mesh
15879,34742692,*molecular diagnostic techniques/methods
15880,34742692,*orbital inflammatory diseases/diagnosis/*metabolism
15881,34742692,*proteome/*metabolism
15882,34742692,*proteomics/methods
15883,34742692,*tear biomarkers/*metabolism
15884,34742692,*tear proteomics
15885,34742692,"*tears/*metabolism cois eyevensys, santen, affibody, kyverna and covrus."
15886,33371640,cytochrome p450 system
15887,33371640,endocrine ophthalmopathy
15888,33371640,glucocorticoid receptor gene polymorphism
15889,33371640,glucocorticoid therapy
15890,33371640,resistance
15891,32507991,dynamic scheimpflug analyzer
15892,32507991,glucocorticoids
15893,32507991,graves’ orbitopathy
15894,32507991,ocular biomechanics
15895,32636230,drugs: endocrine system
15896,32636230,paediatrics (drugs and medicines)
15897,32636230,thyrotoxicosis cois
15900,32472423,*autoantibodies
15901,32472423,*graves’ disease
15902,32472423,*graves’ orbithopathy
15903,32472423,*tsh receptor
15904,32472423,*thyroid
15905,32472423,"*thyroid cancer cois a developer of medical diagnostics including kits for measuring tsh receptor antibodies. j.f., j.s. and b.r.s. are directors of av7 limited. av7 limited has no other competing interests to declare. k1-70 is currently in use as part of a phase i, single ascending intramuscular or single intravenous dose, safety, tolerability, pharmacokinetic and pharmacodynamic study in subjects with graves’ disease (iras id 199697, eudract number 2014-003815-12)."
15907,34130982,diabetes
15908,34130982,endocrinology
15909,34130982,thyroid disease
15910,34130982,thyrotoxicosis cois
15913,34037961,*antiphospholipid antibodies
15914,34037961,*apolipoproteins
15915,34037961,*autoimmune thyroid diseases
15916,34037961,*graves’ orbitopathy
15917,34037961,*interleukine 6
15920,34202024,graves’ ophthalmopathy
15921,34202024,curcumin
15922,34202024,orbital fibrosis
15923,34202024,thyroid eye disease cois
15924,33844165,ablation
15925,33844165,autoimmunity
15926,33844165,graves’ disease
15927,33844165,graves’ orbitopathy
15928,33844165,radioiodine
15929,33844165,thyroid cois
15930,33484567,*graves’ orbitopathy
15931,33484567,*genetics
15932,33484567,*thyroid eye disease
15933,33246456,case report
15934,33246456,hashimoto’s disease
15935,33246456,hashimoto’s thyroiditis
15936,33246456,ophtalmopathy
15937,33246456,orbitopathy cois
15938,32112702,graves’ disease
15939,32112702,adrenal crisis
15940,32112702,autoimmune polyglandular syndrome type ii
15943,33514849,*cd4+ cytotoxic t lymphocytes
15944,33514849,*graves’ orbitopathy
15945,33514849,*single-cell rna sequencing cois
15946,32991886,*fibroblasts
15947,32991886,*orbit
15948,32991886,*polysaccharides
15949,32991886,*prunella vulgaris
15950,32991886,*thyroid-associated ophthalmopathy
15951,32340849,cas
15952,32340849,graves orbitopathy
15953,32340849,graves’ disease
15954,32340849,maladie de basedow
15955,32340849,orbitopathie basedowienne
15956,32340849,anticorps aux récepteurs d’hormone thyréostimulante
15957,32340849,hyperthyroidism
15958,32340849,hyperthyroïdie
15959,32340849,thyroid-stimulating hormone receptor antibodies
15960,32340849,tocilizumab
15961,32293702,graves’ disease
15962,32293702,graves’ orbitopathy
15963,32293702,tsh-receptor antibodies
15964,32293702,radioiodine
15965,32293702,thyroidectomy
15966,32564766,graves' disease
15967,32564766,yersinia enterocolitica
15968,32564766,autoimmune thyroid diseases
15969,32564766,hashimoto's thyroiditis
15970,32564766,meta-analysis
15971,32564766,thyroid dysfunction
15973,34248849,*graves’ disease
15974,34248849,*children
15975,34248849,*environmental substances
15976,34248849,*metabolomics
15977,34248849,*single-nucleotide polymorphisms cois commercial or financial relationships that could be construed as a potential conflict of interest.
15978,32405700,anti-cd20 antibody
15979,32405700,basedow’s disease
15980,32405700,clinical activity score (cas)
15981,32405700,graves’ orbitopathy
15982,32405700,rituximab
15984,34616359,*graves’ disease (gd)
15985,34616359,*rna methyltransferase
15986,34616359,*rna modification
15987,34616359,*methyltransferase like 3 (mettl3)
15988,34616359,*suppressor of cytokine signaling (socs) cois commercial or financial relationships that could be construed as a potential conflict of interest.
15989,34130234,graves’ ophthalmopathy
15990,34130234,lacrimal gland
15991,34130234,magnetic resonance imaging
15992,34130234,t1 mapping
15993,34130234,t2 mapping
15996,34328251,*graves disease
15997,34328251,*hiv
15998,34328251,*immune reconstitution inflammatory syndrome
15999,34328251,*radioactive iodine treatment
16000,33746907,*clinical activity score
16001,33746907,*disease severity
16002,33746907,*ethnically diverse
16003,33746907,*immunosuppression
16004,33746907,*polyautoimmunity
16005,33746907,*psoriasis
16006,33746907,*rheumatoid arthritis
16007,33746907,*thyroid eye disease cois commercial or financial relationships that could be construed as a potential conflict of interest.
16008,33658982,*dna methylation
16009,33658982,*epigenetics
16010,33658982,*graves’ ophthalmopathy
16011,33658982,*orbital fibroblast
16012,33658982,*proteomics cois commercial or financial relationships that could be construed as a potential conflict of interest.
16013,33560351,*3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors
16014,33560351,*graves disease
16015,33560351,*graves orbitopathy
16016,33560351,*statins
16017,31927748,cytokines
16018,31927748,ocular surface
16019,31927748,tear
16020,31927748,thyroid eye disease
16021,34358537,*drug intervention
16022,34358537,*graves’ disease
16023,34358537,*hashimoto’s thyroiditis
16024,34358537,*mathematical model
16025,34358537,*thyroid hormone regulation cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
16026,33786753,exophthalmos
16027,33786753,figuration and abstraction
16028,33786753,graves’orbitopathy
16029,33786753,natalie frank
16030,33786753,post-modern american art
16032,32767605,graves disease
16033,32767605,free region of interest
16034,32767605,shear wave elastography
16035,32767605,ultrasound
16036,32107993,*graves disease
16037,32107993,*technetium (99mtc) pertechnetate thyroid scintigraphy
16038,32107993,*autoimmune disorder
16039,32107993,*color doppler ultrasonography
16040,32107993,*thyroid hormones
16041,32107993,*thyrotropin
16042,34281356,*autoimmune
16043,34281356,*comorbidities
16044,34281356,*thyroid
16045,33663404,*amiodarone
16046,33663404,*dilated thyrotoxic cardiomyopathy
16047,33663404,*heart failure
16048,33663404,*multifocal atrial tachycardia
16049,33663404,*thyroid storm cois
16053,34025584,*graves disease
16054,34025584,*graves ophthalmopathy
16055,34025584,*graves orbitopathy
16056,34025584,*optic neuropathy
16057,34025584,*thyroid eye disease
16058,34025584,*thyroid-associated ophthalmopathy cois thyroid eye disease amsterdam declaration implementation group). the remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
16059,32507887,*graves disease
16060,32507887,*epidemiology
16061,32507887,*hyperthyroidism
16062,32507887,*ulcerative colitis
16063,32315207,*graves’ disease
16064,32315207,*hyperthyroidism
16065,32315207,*antithyroid drugs
16066,32315207,*cardiovascular disease
16067,32315207,*mortality
16068,32315207,*pregnancy
16069,32315207,*radioactive iodine
16070,32315207,*thyroidectomy
16071,33941979,"carbimazole, graves's disease, hyperthyroidism, methimazole, prophylthiouracil,  thiomazole, thyrotoxicosis."
16074,33187482,child health
16075,33187482,iodine
16076,33187482,iodine deficiency
16077,33187482,iodine supplementation
16078,33187482,maternal health
16079,33187482,nutrition
16080,33187482,pregnancy
16081,33187482,psychomotor development
16082,33187482,public health intervention cois
16083,32949299,bovine pericardium
16084,32949299,strabismus surgery
16085,32949299,tendon elongation
16086,32949299,tutopatch® cois
16087,32771076,dexamethasone administration
16088,32771076,hypokalemia
16089,32771076,steroid-induced
16090,32771076,thyrotoxic periodic paralysis
16091,33711978,ocular duction
16092,33711978,orbital decompression
16093,33711978,strabismus
16094,33711978,thyroid eye disease cois
16096,32060570,chronic sinusitis
16097,32060570,eosinophilic angiocentric fibrosis
16098,32060570,igg4-related disease
16099,32060570,immunoglobulin g
16100,32060570,orbit
16101,34465342,biomarker
16102,34465342,hashimoto’s thyroiditis
16103,34465342,lymph node metastasis
16104,34465342,nodular goiter
16105,34465342,pd-1
16106,34465342,papillary thyroid carcinoma cois manuscript is approved by all authors for publication.
16108,33716970,*t2 relaxation time
16109,33716970,*extraocular muscle
16110,33716970,*intravenous methylprednisolone pulse
16111,33716970,*thyroid associated ophthalmopathy
16112,33716970,*treatment response cois commercial or financial relationships that could be construed as a potential conflict of interest.
16114,34144042,autoimmunity
16115,34144042,graves’ disease
16116,34144042,trab
16117,34144042,tsi
16118,34144042,thyroid stimulating hormone receptor autoantibodies
16119,34144042,thyroid stimulating immunoglobulin
16121,32146747,blood flow velocity
16122,32146747,graves disease
16123,32146747,"thyroiditis, autoimmune"
16124,32146747,thyrotoxicosis
16126,34232313,*akt1
16127,34232313,*egfr/pi3k/akt signaling
16128,34232313,*lncrna lpal2
16129,34232313,*mir-1287-5p
16130,34232313,*orbital fibroblast activation
16131,34232313,*thyroid eye disease
16132,33511522,*full-field electroretinography
16133,33511522,*isolated-check visual evoked potential
16134,33511522,*pattern visual evoked potential
16135,33511522,*thyroid-associated ophthalmopathy
16139,33198476,"anaesthesia, thyroid eye disease, thyroid-associated orbitopathy, graves'  ophthalmopathy"
16140,32744317,*cluster of differentiation 74
16141,32744317,*graves disease
16142,32744317,*graves ophthalmopathy
16143,32744317,*immunology & inflammation
16144,32744317,*molecular bases of health & disease
16145,32744317,*subject areas: endocrinology
16146,32744317,*single nucleotide polymorphisms cois manuscript.
16148,33613444,*graves’ ophthalmopathy
16149,33613444,*hub gene
16150,33613444,*lacrimal gland
16151,33613444,*microarray data
16152,33613444,*protein processing in endoplasmic reticulum cois remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
16153,33576183,graves’ orbitopathy
16154,33576183,deviation correction
16155,33576183,dose-effect
16156,33576183,success rates
16157,33576183,superior rectus recession
16158,33343507,*hashimoto autoimmune thyroiditis
16159,33343507,*autoimmunity
16160,33343507,*cancer
16161,33343507,*gut microbiota
16162,33343507,*thyroid cois commercial or financial relationships that could be construed as a potential conflict of interest.
16163,33130479,down syndrome
16164,33130479,graves' disease
16165,33130479,moyamoya disease
16166,33130479,quasi-moyamoya
16167,33130479,thyrotoxicosis
16168,33130479,trisomy 21 cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
16169,33000387,block and replace treatment
16170,33000387,hyperthyroidism
16171,33000387,titration regimen
16172,34102155,*graves ophthalmopathy
16173,34102155,*coefficient variation of cell area
16174,34102155,*corneal endothelium
16175,34102155,*diagnostic capacity
16176,34102155,*disease activity
16178,32684074,go treatment
16179,32684074,graves ophthalmopathy treatment
16180,32684074,ted treatment
16181,32684074,thyroid eye disease treatment
16182,32684074,teprotumumab
16183,32133893,*antithyroid
16184,32133893,*graves’ disease
16185,32133893,*carbimazole
16186,32133893,*methimazole
16187,32133893,*pediatric
16188,32133893,*propylthiouracil
16189,34243871,extraocular muscles
16190,34243871,graves disease
16191,34243871,graves eye disease (ged)
16192,34243871,lacrimal gland
16195,34235979,*graves' ophthalmopathy
16196,34235979,*extracellular matrix
16197,34235979,*histone deacetylases
16198,34235979,*orbital fibroblasts
16199,34235979,*platelet-derived growth factor-bb
16200,32739299,*cardiac arrest
16201,32739299,*coronary artery spasm
16202,32739299,*iodine contrast
16203,32739299,*thyrotoxicosis
16205,33468490,*optic nerve
16206,33468490,*orbit cois
16207,32562184,*graves’ disease
16208,32562184,*thyroid-stimulating immunoglobulin
16209,32562184,*thyroid-stimulating hormone receptor autoantibody
16210,32300961,count ivan viii drašković
16211,32300961,graves’ disease
16212,32300961,iodine
16213,32300961,orbitopathy
16214,32300961,spontaneous remission
16215,32300961,tobacco
16217,32858059,autoimmunity
16218,32858059,brahms
16219,32858059,biotin
16220,32858059,graves’ disease
16221,32858059,roche cobas
16222,32858059,trace
16223,32858059,trab
16224,32858059,tsh-receptor antibody
16225,32858059,thermo scientific kryptor
16226,32858059,thyroid stimulating antibody
16227,32134013,*channelopathies
16228,32134013,*tpp
16229,32134013,*hypokalaemia
16230,32134013,*paralysis
16231,32134013,*periodic palsy
16232,32134013,*thyroid hormones
16233,32134013,*thyrotoxicosis cois
16234,34855075,mir-155
16235,34855075,microrna
16236,34855075,rennin—angiotensin—aldosterone system
16237,34855075,thyrotoxic heart disease
16239,32666762,thyroid autoimmunity
16240,32666762,vitamin d
16241,32666762,vitamin d supplementation
16242,33349844,*maternal thyroid function
16243,33349844,*pregnancy
16244,33349844,*thyroid in pregnancy
16245,32249902,*graves’ orbitopathy
16246,32249902,*adipogenesis
16247,32249902,*autophagy
16248,32249902,*chloroquine
16249,32249902,*hydroxychloroquine
16250,32249902,*orbital fibroblasts
16252,31865369,*graves hyperthyroidism
16253,31865369,*tsh-r blocking antibodies
16254,31865369,*tsh-r stimulating antibodies
16255,31865369,*dilution analysis
16256,31865369,*prospective trial
16257,32693696,thyroid-associated ophthalmopathy
16258,32693696,dose response
16259,32693696,strabismus surgery
16260,32693696,torsion
16261,31756165,graves’ disease (gd)
16262,31756165,autoimmune polyglandular syndrome type 3 variant (aps3v)
16263,31756165,autoimmune thyroid disease (aitd)
16264,31756165,rheumatoid arthritis (ra)
16265,31756165,type 1 diabetes mellitus (t1d)
16266,31756165,type 2 diabetes mellitus (t2d)
16267,32804020,chronic sinus
16268,32804020,neck abscess
16269,32804020,polyglactin 910
16270,32804020,post thyroidectomy
16271,32804020,retained suture
16272,33880967,*adpla
16273,33880967,*rna interference
16274,33880967,*tao
16275,33880967,*adipocytes
16276,33880967,"*microneedles cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
16278,32176314,*cd34
16279,32176314,*cd68
16280,32176314,*fgf-b
16281,32176314,*foxp-3
16282,32176314,*graves’ orbitopathy
16283,32176314,*igf-1r
16284,32176314,*ihc
16285,32176314,*ppar-g
16286,32176314,*tgf-b
16287,32176314,*autoimmunity
16288,32176314,*tissue remodeling
16290,31952487,dysthyroid optic neuropathy
16291,31952487,graves’ orbitopathy
16292,31952487,japanese
16293,31952487,orbital decompression
16294,31952487,visual outcome cois
16295,33972303,endocrinology
16296,33972303,neurology (drugs and medicines)
16297,33972303,ophthalmology
16298,33972303,thyroid disease cois
16301,32638278,elastography
16302,32638278,graves
16303,32638278,medial rectus muscle
16304,32638278,optic nerve
16305,32638278,shear wave
16307,31997590,*blood vessels
16308,31997590,*children
16309,31997590,*microvascular imaging
16310,31997590,*ultrasonography
16311,31997590,"*ultrasonography, doppler, color cois"
16312,33050937,graves’ disease
16313,33050937,papillary thyroid carcinoma
16314,33050937,prognosis
16315,33050937,recurrence cois
16317,32874077,cascade testing
16318,32874077,thyroid dysfunction
16319,32874077,thyroid stimulating hormone
16320,32321476,extraocular muscles
16321,32321476,histopathology
16322,32321476,ocular myasthenia gravis
16323,32321476,thyroid-associated ophthalmopathy cois
16327,33381085,*enalapril
16328,33381085,*graves’ orbitopathy (go)
16329,33381085,*n-acetyl-l-cysteine
16330,33381085,*quercetin
16331,33381085,*vitamin c
16332,33381085,*melatonin
16333,33381085,*oxidative stress
16334,33381085,*β-carotene cois commercial or financial relationships that could be construed as a potential conflict of interest.
16338,32447327,*drugs
16339,32447327,*orbit
16340,32447327,*treatment medical cois
16344,32297812,*graves’ disease (gd)
16345,32297812,*hyperlipidemia
16346,32297812,*polycystic ovary syndrome (pcos)
16347,32090526,*diffusion tensor imaging
16348,32090526,*extraocular muscle
16349,32090526,*optic nerve
16350,32090526,*readout-segmented echo-planar imaging
16351,32090526,*thyroid-associated orbitopathy cois
16352,34939881,*covid-19 vaccines
16353,34939881,*graves disease
16354,34939881,*sars-cov-2
16355,34939881,*case report
16356,34939881,*endocrinology
16357,34939881,*immunology
16358,34939881,"*pharmacovigilance cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
16359,33158379,thyroid eye disease
16360,33158379,eyelid disease: eyelid malpositions/trichiasis/ptosis
16361,33158379,neuro ophthalmology
16362,33158379,optic neuropathy
16363,33158379,orbital disease
16364,33158379,strabismus
16365,32969067,131i
16366,32969067,dosimetry
16367,32969067,hyperthyroidism
16373,31915884,chronic sinusitis
16374,31915884,eosinophilic angiocentric fibrosis
16375,31915884,igg4-related disease
16376,31915884,immunoglobulin g
16377,31915884,orbit
16378,32712880,dicer1
16379,32712880,follicular thyroid carcinoma
16380,32712880,met
16381,32712880,macrofollicular variant
16382,32712880,mutation cois
16383,34704876,*graves’ ophthalmopathy
16384,34704876,*glucocorticoids
16385,34704876,*immunotherapy
16386,34704876,*therapy
16387,34704876,*tocilizumab
16388,34635084,bell’s phenomeon
16389,34635084,fibrosis
16390,34635084,inferior rectus muscle
16391,34635084,thryoid eye disease cois
16392,33543610,*tidm4 gene
16393,33543610,*functional mechanism
16394,33543610,*orbital adipose tissue
16395,33543610,*thyroid-associated ophthalmopathy
16399,34212219,histological confirmation
16400,34212219,idiopathic orbital inflammation
16401,34212219,lymphoid hyperplasia
16402,34212219,orbital lymphoma
16403,34212219,specific orbital inflammation
16404,33128233,*graves’ disease
16405,33128233,*hyperthyroidism
16406,33128233,*paediatric
16407,33128233,*quality of life
16408,33128233,*thyroid
16411,33121425,autoimmune hyperthyroidism
16412,33121425,gitelman syndrome
16413,33121425,endocrine
16414,33121425,gene mutation
16415,33121425,hypokalemia
16416,33121425,metabolic alkalosis.
16417,32643429,*b lymphocytes
16418,32643429,*cxcr5
16419,32643429,*cxcl13
16420,32643429,*graves’ orbitopathy
16421,32643429,*chemokine receptor
16422,32457697,*graves' disease
16423,32457697,*eosinophils
16424,32457697,*subacute thyroiditis
16425,32457697,*thyroxine
16426,32457697,*triiodothyronine
16427,34473251,*atp production
16428,34473251,*graves orbitopathy
16429,34473251,*adipogenesis
16430,34473251,*fatty acid uptake
16431,34473251,*mitochondria oxphos
16432,34473251,*orbital adipose tissue
16435,31928169,*escape
16436,31928169,*methimazole
16437,31928169,*potassium iodide
16438,31928169,*pregnancy
16439,31928169,*thyrotoxicosis
16441,33930408,*graves' disease
16442,33930408,*graves' orbitopathy
16443,33930408,*teprotumumab
16444,33930408,*translational science
16445,33930408,*biologics
16446,33930408,*clinical activity score
16447,33930408,*randomized clinical trial
16448,33930408,*review
16449,33930408,*thyroid eye disease
16450,33783712,graves’ ophthalmopathy
16451,33783712,meta-analysis
16452,33783712,rituximab
16453,33783712,treatment
16454,32908802,*graves’ ophthalmopathy
16455,32908802,*lincs
16456,32908802,*adipogenesis
16457,32908802,*orbital adipose stem cells
16458,32908802,*thyroid eye disease
16459,32908802,"*thyroid-associated orbitopathy cois d.t. tse, none; d. pelaez, none; s.t. wester, horizon therapeutics (c)"
16460,32738825,*graves´ disease
16461,32738825,*hashimoto thyroiditis
16462,32738825,*autoimmune thyroid disease
16463,32738825,*cluster analysis
16464,32738825,*polyautoimmunity
16466,34867951,*graves’ disease
16467,34867951,*hashimoto’s thyroiditis (ht)
16468,34867951,*autoimmune thyroid diseases (aitds)
16469,34867951,*exosome
16470,34867951,*proteomics cois commercial or financial relationships that could be construed as a potential conflict of interest.
16471,34412613,graves’ disease
16472,34412613,growth hormone
16473,34412613,insulin-like growth factor-i
16474,34412613,thyroid-related ophthalmopathy cois
16476,32785703,* bacteroides fragilis
16477,32785703,*graves’ disease
16478,32785703,*treg/th17
16479,32785703,*intestinal flora
16480,32785703,*propionic acid
16482,33603715,*graves’ orbitopathy
16483,33603715,*biomarker
16484,33603715,*functional thyrotropin receptor antibodies
16485,33603715,*stimulatory tsh receptor antibodies
16486,33603715,"*thyroid eye disease cois authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. the jgu medical center has received research-associated funding unrelated to this study from the jgu medical faculty, advancecor, germany, apitope, united kingdom; immunovant, usa, isar, germany, horizon, usa, mediomics, usa, merck, germany, novartis, usa, quidel, usa, river vision, usa, and roche, switzerland. this article was not specifically funded by a company. the funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication."
16487,33964007,autoimmunity
16488,33964007,covid-19
16489,33964007,graves’ disease
16490,33964007,graves’ orbitopathy
16491,33964007,sars-cov-2
16492,33964007,thyroid cois
16494,34602013,*graves’ orbitopathy
16495,34602013,*adipokines
16496,34602013,*methylprednisolone
16497,34051850,*go animal model
16498,34051850,*graves’ disease
16499,34051850,*graves’ ophthalmopathy
16500,34051850,*thyroid disease
16501,34051850,*adipogenesis
16502,34051850,*hpmscs cois paper.
16504,32567442,graves ophthalmopathy
16505,32567442,graves orbitopathy
16506,32567442,mri ted
16507,32567442,tendon sparing
16508,32567442,thyroid eye disease
16510,34117002,cardiovascular medicine
16511,34117002,emergency medicine
16512,34117002,endocrine system cois
16513,32968297,hyperthyroidism; pregnancy; pprom; thyrotoxicosis. cois
16514,32648002,clinical activity score
16515,32648002,graves’ disease
16516,32648002,graves’ ophthalmopathy
16517,32648002,graves’ orbitopathy
16518,32648002,tsh receptor autoantibodies
16519,32648002,thyroid eye disease
16520,32583374,autoimmune thyroiditis
16521,32583374,graves’ disease
16522,32583374,graves’ ophthalmopathy
16523,32583374,graves’ orbitopathy
16524,32583374,insulin-like growth factor-1 receptor
16525,32583374,thyroid
16526,32583374,thyroid autoimmunity
16527,32583374,thyroid eye disease
16528,32567373,*thyroid-associated ophthalmopathy
16529,32567373,*decompression surgery & interventional medicine
16530,32567373,*gene network analysis
16531,32567373,*graves’ ophthalmopathy
16532,32567373,*therapeutics
16533,34116129,*adipogenesis
16534,34116129,*graves' orbitopathy
16535,34116129,*orbital fibroblasts
16536,34116129,*stat3
16537,34116129,*signal transducer and activator of transcription 3
16538,34116129,*thyroid eye disease
16541,34406498,go
16542,34406498,imaging
16543,34406498,mri
16544,34406498,pet
16545,34406498,ted
16546,34406498,thyroid eye disease cois
16547,34344134,graves ophthalmopathy
16548,34344134,retinal diseases
16549,34344134,smoking cois was reported.
16550,32842335,eye injections
16551,32842335,eyelid diseases
16552,32842335,graves ophthalmopathy
16553,32842335,triamcinolone acetonide
16556,34077777,graves’ disease
16557,34077777,graves’ ophthalmopathy
16558,34077777,single nucleotide polymorphism
16559,34077777,vitamin d receptor
16560,33261249,*hyperthyroidism
16561,33261249,*agranulocytosis
16562,33261249,*methimazole
16563,33261249,*neutropenia
16564,33261249,*thionamides
16565,33866536,foxp3
16566,33866536,glucocorticosteroids
16567,33866536,orbitopathy
16568,33866536,rorγt
16569,33866536,th17
16570,33866536,treg
16571,34594339,*gnrh stimulation test
16572,34594339,*graves’ disease
16573,34594339,*autoimmune polyglandular syndrome type 3
16574,34594339,*isolated gonadotropin-releasing hormone deficiency
16575,34594339,*secondary amenorrhea
16576,34594339,*type 1 diabetes mellitus cois commercial or financial relationships that could be construed as a potential conflict of interest.
16577,34114495,*graves' ophthalmopathy
16578,34114495,*tsh receptor
16579,34114495,*antibody drugs
16580,34114495,*autoantibodies
16581,34114495,*thyroid cancer
16582,33148577,endocrine system
16583,33148577,endocrinology
16584,33148577,thyroid disease
16585,33148577,thyroiditis
16586,33148577,thyrotoxicosis cois
16588,33844898,covid-19
16589,33844898,thyroid disorders
16590,33844898,hyperthyroidism
16591,33844898,hypothyroidism
16592,33844898,subacute thyroiditis
16594,32339726,*adult
16595,32339726,*case report
16596,32339726,*magnetic resonance imaging
16597,32339726,*pathology
16598,32339726,*pituitary blastoma
16600,33882721,*graves'
16601,33882721,*age
16602,33882721,*disease
16603,33882721,*disease prognosis
16604,33882721,*hyperthyroidism
16605,33882721,*sex
16606,33505575,africa
16607,33505575,paralysis
16608,33505575,hyperthyroidism
16609,33505575,hypokalemia cois
16610,32669187,graves disease
16611,32669187,"infant, newborn"
16612,32669187,mothers
16613,32669187,pregnancy complications
16614,32669187,prenatal exposure delayed effects
16619,33409786,artifacts
16620,33409786,eye diseases
16621,33409786,magnetic resonance imaging
16622,33409786,thyroid diseases
16623,33081749,choroidal thickness
16624,33081749,optical coherence tomography angiography
16625,33081749,retinal nerve fiber layer
16626,33081749,thyroid-associated ophthalmopathy cois publication of this paper.
16627,32855872,*graves' disease
16628,32855872,*murine model
16629,32855872,*orbital inflammation
16630,32855872,"*thyroid eye disease cois none; l. ramos, none; s.k. freitag, none; d.r. bielenberg, none; l.a. kim, none; n.g. lee, none"
16631,32779176,ct
16632,32779176,mri
16633,32779176,ultrasonography
16634,32779176,ectopic thyroid
16635,32779176,multimodality
16636,32779176,thyroid scintigraphy
16638,32546346,*bone mineral density
16639,32546346,*graves’ disease
16640,32546346,*dual energy x-ray absorptiometry
16641,34526052,3d photography
16642,34526052,blepharoplasty surgery
16643,34526052,digital facial-analysis tool
16644,34526052,endocrine orbitopathy
16645,34526052,lid refinement
16646,34526052,lid repositioning
16647,34526052,ocular surface area cois
16649,32799342,*graves’ disease
16650,32799342,*hyperthyroidism
16651,32799342,*neutropenia
16652,32799342,*white blood cells
16653,33391187,*graves’ disease
16654,33391187,*autoimmune
16655,33391187,*connective tissue
16656,33391187,*insulin-like growth factor i receptor
16657,33391187,*monoclonal antibody
16658,33391187,*thyroid-associated ophthalmopathy cois inhibitors as therapy in graves’ disease. these patents are held by ucla school of medicine and los angeles biomedical research institute.
16659,33311000,grave’s disease
16660,33311000,hashimoto’s thyroiditis
16661,33311000,igg4 thyroiditis
16662,33311000,igg4-related thyroid disease
16663,33311000,riedel’s thyroiditis
16665,32919017,*long non-coding rna
16666,32919017,*orbital adipose/connective tissue
16667,32919017,*rna sequencing
16668,32919017,*thyroid-associated ophthalmopathy
16671,34106438,*ace2
16672,34106438,*autoimmune
16673,34106438,*covid-19
16674,34106438,*graves’ disease
16675,34106438,*hyperthyroidism
16676,34106438,*raas
16677,34106438,*sars-cov-2
16678,34106438,*thyroid cois
16679,34060524,compressive optic neuropathy
16680,34060524,nasal endoscopy
16681,34060524,orbital decompression
16682,34060524,thyroid eye disease cois
16683,33817897,*fractional amplitude of low-frequency fluctuation
16684,33817897,"*regional homogeneity, degree centrality"
16685,33817897,*resting-state fmri
16686,33817897,*thyroid-associated ophthalmopathy
16687,33599843,diplopia
16688,33599843,exophthalmos
16689,33599843,graves’ orbitopathy
16690,33599843,orbital decompression
16691,33446163,machine learning
16692,33446163,magnetic resonance imaging
16693,33446163,thyroid-associated ophthalmopathy cois
16697,34180765,cystic teratoma
16698,34180765,graves’ disease
16699,34180765,primary papillary thyroid carcinoma
16700,32940167,*graves'
16701,32940167,*clinical trials
16702,32940167,*diplopia
16703,32940167,*ocular ductions
16704,32940167,*orbitopathy
16705,32940167,*rehabilitation
16706,32940167,*squint surgery
16707,33849364,*graves’ orbitopathy
16708,33849364,*clinical activity score
16709,33849364,*glucocorticoids
16710,33849364,*interleukin-6
16711,33849364,*interleukin-8
16712,33849364,*interleukin–10
16714,32849306,*graves' disease
16715,32849306,*tsh secreting pituitary adenoma
16716,32849306,*tshoma
16717,32849306,*concomitant
16718,32849306,*thyrotropin
16719,32238669,agranulocytosis
16720,32238669,antithyroid drug
16721,32238669,hyperthyroidism
16722,32238669,malignancy
16723,32238669,potassium iodide
16724,31603857,graves’ disease
16725,31603857,children
16726,31603857,hyperthyroidism
16727,31603857,radioiodine ablation
16729,34431214,*graves' disease (gd)
16730,34431214,*stat4
16731,34431214,*autoimmune disease
16732,34431214,*mir-363-5p
16733,34431214,*regulatory t cells (tregs) cois
16734,32429706,graves’ disease
16735,32429706,igf-ir
16736,32429706,r1507
16737,32429706,rv001
16738,32429706,tepezza
16739,32429706,teprotumumab
16740,32429706,thyroid eye disease
16741,32429706,thyroid-associated ophthalmopathy
16742,32192806,cancer héréditaire
16743,32192806,carcinome thyroïdien familial
16744,32192806,cowden syndrome
16745,32192806,dicer1 syndrome
16746,32192806,familial adenomatous polyposis
16747,32192806,familial thyroid carcinoma
16748,32192806,hereditary cancer
16749,32192806,polypose adénomateuse familial
16750,32192806,syndrome dicer1
16751,32192806,syndrome de cowden
16753,34867796,*graves’ disease
16754,34867796,*children
16755,34867796,*metabolic pathway
16756,34867796,*serum metabolomics
16757,34867796,*untargeted metabolomics cois commercial or financial relationships that could be construed as a potential conflict of interest.
16758,33443817,*graves’ orbitopathy
16759,33443817,*neferine
16760,33443817,*adipocyte differentiation
16761,33443817,*autophagy
16762,33443817,*inflammation
16763,33443817,*oxidative stress cois topic of the manuscript.
16766,33481154,graves disease
16767,33481154,igf-1r
16768,33481154,r1507
16769,33481154,rv001
16770,33481154,tepezza
16771,33481154,teprotumumab
16772,33481154,thyroid eye disease
16773,33481154,thyroid-associated ophthalmopathy
16776,34889904,graves’ orbitopathy
16777,34889904,binding protein
16778,34889904,thyrostimulin
16779,34889904,thyrotropin receptor
16780,34889904,variant cois
16781,32823277,*nk cells
16782,32823277,*programmed cell death protein-1
16783,32823277,*autoimmune thyroid disease
16786,34122333,*graves’ disease
16787,34122333,*cross-sectional study
16788,34122333,*hyperthyroidism
16789,34122333,*iodine intake
16790,34122333,*thyroid autoimmune antibodies cois commercial or financial relationships that could be construed as a potential conflict of interest.
16791,32501499,*graves disease
16792,32501499,*autoimmune
16793,32501499,*genotyping
16794,32501499,*meta-analysis
16795,32501499,*polymorphism
16796,32501499,*thyroid
16797,34284740,diffusion tensor imaging
16798,34284740,lacrimal gland
16799,34284740,readout-segmented echo-planar imaging
16800,34284740,thyroid-associated ophthalmopathy cois
16801,33678636,graves’ disease
16802,33678636,graves’ disease associated cholestasis
16803,33678636,cholestasis
16804,33678636,clinical manifestation
16805,33678636,diagnosis
16806,33678636,treatment
16810,33906763,globe prominence
16811,33906763,proptosis
16812,33906763,thyroid eye disease cois therapeutics and osmotica pharmaceuticals.
16813,33858251,foxp3
16814,33858251,graves’ disease
16815,33858251,ethnicity
16816,33858251,meta-analysis
16817,33858251,polymorphism
16818,33858251,susceptibility cois conflict of interest.
16819,32090348,*mri t1 mapping
16820,32090348,*diplopia
16821,32090348,*extraocular muscles
16822,32090348,*fibrosis
16823,32090348,*graves ophthalmopathy
16824,32090348,*intravenous glucocorticoids
16825,32090348,*magnetic resonance imaging
16828,33551434,active surveillance
16829,33551434,graves’ disease
16830,33551434,papillary thyroid microcarcinoma
16831,33551434,radioactive iodine therapy
16832,33551434,tumor volume-doubling rate
16833,33193097,*dysthyroid optic neuropathy
16834,33193097,*grave’s disease
16835,33193097,*grave’s ophthalmopathy
16836,33193097,*orbital decompression
16837,33193097,*rituximab
16838,32495527,*chemokine
16839,32495527,*cytokine
16840,32495527,*graves' orbitopathy
16841,32495527,*interleukin-1β
16842,32495527,*tumor necrosis factor-α cois
16843,34488259,decompression
16844,34488259,eyelids
16845,34488259,graves ophthalmopathy cois
16847,33938028,*graves’ disease
16848,33938028,*graves’ ophthalmopathy
16849,33938028,*igg4
16850,33938028,*glucocorticoid therapy
16851,33682498,dexamethasone
16852,33682498,graves’ disease
16853,33682498,drug resistance
16854,33682498,hyperthyroidism
16855,33682498,inorganic iodine
16856,33682498,lithium carbonate
16857,33682498,methimazole cois conflict of interest.
16858,33517506,deep lateral decompression
16859,33517506,graves disease
16860,33517506,graves orbitopathy
16861,33517506,orbital decompression
16862,33517506,orbital surgery
16865,32814653,graves’ orbitopathy
16866,32814653,computed tomography
16867,32814653,computer-assisted image processing
16868,32814653,magnetic resonance imaging
16869,32814653,orbit
16871,33199029,dfnb4
16872,33199029,missense mutations
16873,33199029,next-generation sequencing
16874,33199029,pendred syndrome
16875,33199029,slc26a4 gene
16877,32074519,intractability
16878,32074519,polymorphism
16879,32074519,severity
16880,32074519,vegf receptor (vegfr)
16881,32074519,vascular endothelial growth factor (vegf)
16882,32374820,*mendelian randomization
16883,32374820,*tsh
16884,32374820,*coronary artery disease
16885,32374820,*mediation
16886,32374820,*stroke
16887,32374820,*thyroid function
16888,32893239,basedow disease
16889,32893239,amyotrophic lateral sclerosis
16890,32893239,soluble il-2 receptor
16891,32893239,thyrotoxic myopathy
16892,32893239,tongue atrophy
16894,34479513,cholestatic liver injury
16895,34479513,graves' disease
16896,34479513,methimazole
16897,34479513,rash
16898,34479513,turner syndrome cois
16902,33132244,graves’ disease
16903,33132244,pd-1
16904,33132244,t lymphocytes
16905,33132244,thyroid follicular cells
16907,34238277,cd160
16908,34238277,graves’ disease
16909,34238277,hashimoto’s thyroiditis
16910,34238277,polymorphism cois
16911,33423386,graves’ orbitopathy
16912,33423386,glucocorticoids
16913,33423386,long-circulating pegylated liposomal prednisolone
16914,33423386,methylprednisolone
16915,33423386,orbit
16916,32651061,*graves' disease
16917,32651061,*breastfeeding
16918,32651061,*hypothyroidism
16919,32651061,*postpartum thyroid dysfunction
16920,32651061,*postpartum thyroiditis
16921,32651061,*thyrotoxicosis
16923,33922887,antithyroid drug
16924,33922887,change
16925,33922887,ocular parameters cois
16928,34258936,dysthyroid optic neuropathy
16929,34258936,hospital anxiety and depression
16930,34258936,regional homogeneity
16931,34258936,resting-state fmri
16932,34258936,thyroid-associated ophthalmopathy cois
16933,33693700,*igf-1
16934,33693700,*il-38
16935,33693700,*m22
16936,33693700,*tgf-β1
16937,33693700,*orbital fibroblasts
16938,33693700,*thyroid-associated ophthalmopathy
16939,33386169,amino acid variants
16940,33386169,graves’ disease
16941,33386169,hla class ii
16942,33386169,hashimoto’s thyroiditis cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
16943,32825964,graves' disease
16944,32825964,hashimoto's thyroiditis
16945,32825964,prognosis
16946,32825964,thyroid cancer
16948,32025782,angio-oct
16949,32025782,choroid
16950,32025782,oct
16951,32025782,orbitopathy
16952,32025782,thyroid
16953,31900640,4-methylumbelliferone
16954,31900640,adipogenesis
16955,31900640,graves’ orbitopathy
16956,31900640,hyaluronic acid
16957,33488527,*graves’ disease
16958,33488527,*autoimmune thyroiditis
16959,33488527,*differential diagnosis
16960,33488527,*thyroid function test
16961,33488527,*thyrotoxicosis cois commercial or financial relationships that could be construed as a potential conflict of interest.
16962,33380308,graves’ disease
16963,33380308,thyroid
16964,33380308,cancer
16965,33380308,nodules
16966,33380308,surgery
16967,33380308,thyroidectomy.
16968,34018373,clinical analysis
16969,34018373,extraocular muscles
16970,34018373,magnetic resonance imaging
16971,34018373,thyroid associated ophthalmoathy
16973,33658150,graves ophthalmopathy
16974,33658150,cosmetic reconstructive surgery
16975,33658150,exophthalmos
16976,33658150,ophthalmologic surgical procedure
16977,33658150,orbital decompression
16978,33658150,proptosis
16979,33658150,surgical decompression
16980,33658150,surgical technique
16981,33658150,thyroid eye disease
16982,33658150,thyroid-associated ophthalmopathies
16983,33658150,transantral
16984,34315743,endocrinology
16985,34315743,thyroid disease cois
16986,33630733,t2 mapping
16987,33630733,magnetic resonance imaging
16988,33630733,optic nerve
16989,33630733,thyroid-associated ophthalmopathy
16990,31887836,cytokines
16991,31887836,dihydrotestosterone
16992,31887836,graves disease
16993,31887836,mice
16995,33382429,*genetics
16996,33382429,*hyperthyroidism
16997,33382429,*hypothyroidism
16998,33382429,*twin studies
16999,33009740,graves’ disease
17000,33009740,exophthalmos
17001,33009740,neurosurgery
17002,33009740,ophthalmopathy
17003,33009740,thyroid diseases.
17004,32485674,*graves’ disease
17005,32485674,*nf-κb
17006,32485674,*sirt1
17007,32485674,*thyroid
17008,32545570,agranulocytosis
17009,32545570,hyperthyroidism
17010,32545570,plasmapheresis
17011,32545570,thyroidectomy
17012,32545570,thyrotoxicosis cois
17015,32324288,*graves
17016,32324288,*bone
17017,32324288,*disease
17018,32324288,*fractures
17019,32324288,*immunoglobulins
17020,32324288,*menopause
17021,32324288,*osteoporosis
17022,32324288,*thyroid-stimulating
17024,34334593,acromegaly
17025,34334593,adenomatous goiter
17026,34334593,neurofibromatosis type 1
17027,34334593,primary hyperparathyroidism cois
17029,32500462,alemtuzumab
17030,32500462,graves’ ophthalmopathy
17031,32500462,immune-reconstitution inflammatory syndrome
17032,32500462,marine-lenhart syndrome
17033,34598656,*graves'
17034,34598656,"*disease, meta-analysis, radiation absorbed dose, radioiodine, systematic review cois research and training program 2014–2018 and national institute for health research (nihr) and funding from national health service to the nihr biomedical research centre at the royal marsden and the institute of cancer research and nihr royal marsden clinical research facility outside the work of the study. j.i.g. reports personal fees and honoraria from the eanm outside the work of the study."
17036,32612577,*foxp3
17037,32612577,*graves' disease
17038,32612577,*autoimmune thyroid disease
17039,32612577,*meta-analysis
17040,32612577,*polymorphism
17041,33853289,autoimmune thyroid disease.
17042,33853289,children and adolescents
17043,33853289,type 1 diabetes
17044,33853289,metabolic disorders
17046,32689994,molecular docking
17047,32689994,network pharmacology
17048,32689994,spica prunellae
17049,32689994,tao
17050,32689994,thyroid-associated ophthalmopathy cois
17051,32363975,orbital decompression
17052,32363975,thyroid eye disease
17053,32363975,transantral orbital decompression
17055,32983115,*addison's disease
17056,32983115,*cdcp1
17057,32983115,*graves' disease
17058,32983115,*hashimoto's thyroiditis
17059,32983115,*slamf1
17060,32983115,*plasma
17061,32983115,*proximity extension assay
17062,32983115,*type 1 diabetes
17063,34915605,*antithyroid agents
17064,34915605,*diabetes mellitus
17065,34915605,*graves disease
17066,34915605,*hyperthyroidism
17067,34915605,*radioiodine ablation cois was reported.
17069,34101720,*actemra
17070,34101720,*cellcept
17071,34101720,*rituxan
17072,34101720,*tepezza
17073,34101720,*adverse effects
17074,34101720,*corticosteroids
17075,34101720,*dosage
17076,34101720,*efficacy
17077,34101720,*eye
17078,34101720,*lactation
17079,34101720,*methylprednisone
17080,34101720,*mycophenolate mofetil
17081,34101720,*prednisone
17082,34101720,*pregnancy
17083,34101720,*rituximab
17084,34101720,*safety
17085,34101720,*teprotumumab
17086,34101720,*tocilizumab
17088,34863412,cord blood
17089,34863412,embarazo
17090,34863412,enfermedad de graves
17091,34863412,graves’ disease
17092,34863412,hipertiroidismo
17093,34863412,hyperthyroidism
17094,34863412,newborn
17095,34863412,pregnancy
17096,34863412,recién nacido
17097,34863412,sangre del cordón umbilical
17098,34863412,trab
17099,32227795,*graves’
17100,32227795,*disease
17101,32227795,*radiation thyroiditis
17102,32227795,*radioactive iodine
17104,33383445,anti-inflammation
17105,33383445,il-23/il-17 axis
17106,33383445,il-23r
17107,33383445,il-38
17108,33383445,pge(2)
17109,33383445,thyroid-associated ophthalmopathy
17112,32933065,graves’ disease
17113,32933065,hashimoto thyroiditis
17114,32933065,autoimmune thyroid disease
17115,32933065,vitamin d
17116,32933065,vitamin d receptor cois
17117,32537950,clinical activity score
17118,32537950,glucocorticoids
17119,32537950,graves' ophthalmopathy
17120,32537950,response rate cois
17125,34987480,*graves’ disease
17126,34987480,*adhesion molecules
17127,34987480,*carotid intima media thickness
17128,34987480,*hyperthyroidism
17129,34987480,*methimazole
17130,34987480,*propylthiouracil
17131,34987480,*pulse wave velocity
17132,34987480,*vascular atherosclerosis cois commercial or financial relationships that could be construed as a potential conflict of interest.
17134,33643223,*graves’ orbitopathy
17135,33643223,*t cells
17136,33643223,*immune
17137,33643223,*mucosa
17138,33643223,*paranasal sinus cois commercial or financial relationships that could be construed as a potential conflict of interest.
17139,33504525,clinical diagnostic tests
17140,33504525,hip prosthesis implantation
17141,33504525,neurology (drugs and medicines)
17142,33504525,psychiatry (drugs and medicines)
17143,33504525,rehabilitation medicine cois
17144,32893386,*graves' orbitopathy
17145,32893386,*extra-ocular muscles
17146,32893386,*eye diseases
17147,32893386,*eye muscles
17148,32893386,*muscle mri
17149,32893386,*myasthenia gravis
17150,32893386,*quantitative mri
17152,32522908,graves’ disease
17153,32522908,neonatal thyroid dysfunction
17154,32522908,tsh receptor antibody
17155,34287665,*foxo1
17156,34287665,*genetic susceptibility
17157,34287665,*graves’ disease
17158,34287665,*il2ra
17159,34287665,*mir182
17160,34287665,*mir27a
17162,33234032,*cas
17163,33234032,*cd20
17164,33234032,*graves' disease
17165,33234032,*graves' orbitopathy
17166,33234032,*cytokine release syndrome
17167,33234032,*dysthyroid optic neuropathy
17168,33234032,*rituximab
17169,33221730,*genetics
17170,33221730,*immunology
17171,33221730,*orbit cois
17173,34963497,antineutrophil cytoplasmic antibody-associated vasculitis
17174,34963497,drug-induced anca-associated vasculitis
17175,34963497,graves’ disease
17176,34963497,hypertrophic pachymeningitis
17177,34963497,myeloperoxidase-antineutrophil cytoplasmic antibody cois
17179,34523298,graves´ disease
17180,34523298,immune reconstitution therapy
17181,34523298,multiple sclerosis
17182,34523298,ocrelizumab
17183,33669123,fnah
17184,33669123,tshr
17185,33669123,central hypothyroidism
17186,33669123,familial non-autoimmune autosomal dominant hyperthyroidism
17187,33669123,radioiodine ablation therapy cois
17190,34124812,*graves' disease
17191,34124812,*hypercalcemia
17192,34124812,*hyperparathyroidism
17193,34124812,*parathyroid surgery
17194,34124812,*radioactive iodine
17195,33152840,graves ophthalmopathy
17196,33152840,macula lutea
17197,33152840,optic disk
17198,33152840,optic nerve diseases
17199,33152840,regional blood flow
17200,33152840,"tomography, optical coherence"
17202,31972501,*active graves’ orbitopathy
17203,31972501,*newly diagnosed graves’ disease
17204,31972501,*potential markers
17205,31972501,*pro-inflammatory cytokines
17206,31972501,*selenium cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
17207,34218976,exophthalmos
17208,34218976,graves hyperthyroidism
17209,34218976,graves ophthalmopathy
17210,34218976,orbital decompression
17211,34218976,quality of life
17213,33295879,*graves’ disease
17214,33295879,*autoimmune hyperthyroidism
17215,33295879,*autoimmune thyroid disease
17216,33295879,*genetic and epigenetic factors
17217,32729365,iodine
17218,32729365,endemic
17219,32729365,goiter
17220,32729365,nodule
17221,32729365,thyroid
17222,32729365,ultrasound
17223,34681587,aitd
17224,34681587,graves’ disease
17225,34681587,autoimmunity
17226,34681587,methimazole
17227,34681587,regulatory b cells
17228,34681587,thyroid cois
17230,33870911,*graves’ orbitopathy
17231,33870911,*perk
17232,33870911,*endoplasmic reticulum stress
17233,33870911,*protein kinase rna-like endoplasmic reticulum kinase
17234,33870911,*thyroid eye disease
17235,34888290,*covid-19
17236,34888290,*covid-19 vaccines
17237,34888290,*graves' disease
17238,34888290,*sars-cov-2
17239,34888290,*autoimmunity
17240,34888290,*thyroiditis cois commercial or financial relationships that could be construed as a potential conflict of interest.
17241,33451885,intraoperative neuromonitoring
17242,33451885,recurrent laryngeal nerve injury
17243,33451885,thyroid surgery
17244,31902232,2a típusú multiplex endokrin neoplasia szindróma
17245,31902232,genetic testing
17246,31902232,genetikai vizsgálat
17247,31902232,medullaris pajzsmirigydaganat
17248,31902232,medullary thyroid cancer
17249,31902232,multiple endocrine neoplasia type 2a
17250,31902232,phaeochromocytoma
17251,31902232,primary hyperparathyroidism
17252,31902232,primer hyperparathyreosis
17253,34047397,*trab
17254,34047397,*fibroblast
17255,34047397,*inducible skin-associated lymphoid tissue (isalt)
17256,34047397,*pretibial myxedema (ptm) cois
17257,32053002,t2 mapping
17258,32053002,thyroid-associated ophthalmopathy
17259,32053002,magnetic resonance imaging
17260,32053002,region of interest
17261,32053002,staging
17262,34690936,*graves’ disease
17263,34690936,*anti-thyroid drug
17264,34690936,*heart failure
17265,34690936,*hyperthyroidism
17266,34690936,*radioiodine ablation cois authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
17267,34647604,cas
17268,34647604,eugogo classification
17269,34647604,nospecs classification
17270,34647604,orbital decompression
17271,34647604,thyroid eye disease
17275,34130446,*antithyroid agents
17276,34130446,*congenital abnormalities
17277,34130446,*graves disease
17278,34130446,*iodine
17279,34130446,*pregnancy
17280,34130446,*recurrence cois was reported.
17282,32880139,bony orbital decompression
17283,32880139,computerized perimetry
17284,32880139,dysthyroid optic neuropathy
17285,32880139,endonasal orbital decompression
17286,32880139,exophthalmos
17287,32880139,thyroid eye disease
17288,32681301,deep lateral wall resection
17289,32681301,exophthalmos
17290,32681301,graves’ disease
17291,32681301,orbit
17292,32681301,pterional decompression
17295,32096552,graves’ orbitopathy
17296,32096552,anti-thymocyte globulin
17297,32096552,dysthyroid optic neuropathy
17300,31996918,*graves’ disease
17301,31996918,*hashimoto’s thyroiditis
17302,31996918,*igm
17303,31996918,*subacute thyroiditis
17304,31996918,*thyroglobulin
17305,31996918,*thyroglobulin autoantibodies
17306,33980771,22q11.2 deletion syndrome
17307,33980771,graves’ disease
17308,33980771,hypocalcemia
17309,33980771,hypoparathyroidism
17314,32227311,addison’s disease
17315,32227311,autoimmune thyroid disease
17316,32227311,diabetes mellitus
17317,32227311,meta-analysis
17318,32227311,polyglandular autoimmune syndrome cois
17319,32252386,*autoimmune thyroid disease (aitd)
17320,32252386,*grave disease (gd)
17321,32252386,*hashimoto thyroiditis (ht)
17322,32252386,*polycystic ovary syndrome (pcos) cois
17323,34149627,*cd40
17324,34149627,*graves’ disease
17325,34149627,*gene
17326,34149627,*precision medicine
17327,34149627,"*variant cois application no: 63/120,514) entitled: “method for predicting patient response to cd40-targeted therapies” which is related to the current manuscript. yt declares that he also submitted two additional patent disclosures that are not related to the content of this manuscript. yt was previously (january 2015 to june 2017) the pi on a basic research project jointly funded by the juvenile diabetes research foundation and pfizer. the current manuscript is not related to that research project. gk consults for immunovant, usa, mediomics, usa, merck, germany, novartis, switzerland, and quidel, usa. the remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
17328,33414766,*graves’ disease
17329,33414766,*graves’ ophthalmopathy
17330,33414766,*cholesterol
17331,33414766,*low-density lipoprotein cholesterol
17332,33414766,*parenteral corticosteroids cois commercial or financial relationships that could be construed as a potential conflict of interest.
17334,31842710,*graves disease
17335,31842710,*hashimoto's thyroiditis
17336,31842710,*active surveillance
17337,31842710,*cost-effectiveness
17338,31842710,*molecular markers
17339,31842710,*thyroid cancer
17340,31840740,*graves’ disease
17341,31840740,*radioactive iodine
17342,31840740,*radioiodine therapy
17343,31840740,"*thyroid radioactive iodine uptake cois association declaration of helsinki, and that all subjects provided written informed consent. the present study was approved by the irb of the second affiliated hospital, harbin medical university. the authors declare that there are no competing interests associated with the manuscript."
17344,32627588,deep lateral decompression
17345,32627588,lateral orbital wall distance
17346,32627588,removable surface area
17347,32627588,removable surface length
17348,32627588,sphenoid door jamb thickness
17349,32362875,*adolescents
17350,32362875,*autoimmune thyroid disease
17351,32362875,*children
17352,32362875,*gender difference
17353,32362875,*thyroiditis
17356,33297974,case report
17357,33297974,exophthalmos
17358,33297974,graves’ ophthalmopathy
17359,33297974,malformation
17360,33297974,ocular myasthenia gravis
17361,33297974,poland syndrome
17362,33297974,ptosis cois interest.
17363,33099562,*cystatin c
17364,33099562,*exophthalmos
17365,33099562,*serum
17366,33099562,*thyroxine
17367,33099562,*triiodothyronine cois
17368,33025559,*autoimmune thyroid disease (aitd)
17369,33025559,*graves’ disease (gd)
17370,33025559,*hashimoto’s thyroiditis (ht)
17371,33025559,*mettl3
17372,33025559,*polymorphism
17373,32592913,choroidal thickness
17374,32592913,inactive graves’ orbitopathy
17375,32592913,optical coherence tomography angiography
17376,32592913,retinal vessel density
17377,32592913,spectral domain-optical coherence tomography
17379,34142359,activating tshr pathogenic variant
17380,34142359,case report
17381,34142359,familial non-autoimmune hyperthyroidism
17382,34142359,functional study
17383,34142359,radioiodine ablative treatment
17384,34142359,repeated thyroid surgery
17387,34277969,*graves’ disease
17388,34277969,*antithyroid drugs
17389,34277969,*hyperthyroidism
17390,34277969,*index patient
17391,34277969,*international surveys
17392,34277969,*long‐term follow‐up
17393,34277969,*radioactive iodine
17394,34277969,*thyroidectomy
17395,34277969,"*treatment options cois calissendorff, mikael lantz, bengt hallengren, helena filipsson nyström, tereza planck, göran wallin: none of the authors have competing financial interests."
17396,32999132,anti-neutrophil cytoplasmic antibody
17397,32999132,hearing loss
17398,32999132,otitis media
17399,32999132,propylthiouracil
17400,32999132,vasculitis
17401,32699051,*colour vision
17402,32699051,*field of vision
17403,32699051,*orbit cois
17404,34179589,carotid cavernous fistula
17405,34179589,graves-basedow disease
17406,34179589,graves’ ophthalmopathy
17407,34179589,orbit
17408,34179589,orbital inflammation
17409,34049504,"extraocular paralysis, case report"
17410,34049504,gq1b antibody
17411,34049504,graves’ disease
17412,34049504,limb weakness cois interest.
17414,32958019,graves’ orbitopathy
17415,32958019,predictive factors
17416,32958019,radiotherapy
17417,32958019,timing cois
17418,32656666,bradycardia
17419,32656666,calcitonin
17420,32656666,calcium test
17421,32656666,cut-off
17422,32656666,medullary thyroid cancer cois perceived as prejudicing the impartiality of the research reported.
17423,33488522,*graves’ orbitopathy
17424,33488522,*pcsk9
17425,33488522,*adipogenesis
17426,33488522,*inflammation
17427,33488522,*oxidative stress
17428,33488522,*proprotein convertase subtilisin/kexin type 9
17429,33488522,*thyroid eye disease cois commercial or financial relationships that could be construed as a potential conflict of interest.
17430,32729394,*graves'
17431,32729394,*dietary iodine
17432,32729394,*disease
17433,32729394,*inorganic iodine
17434,32729394,*radioiodine
17435,32729394,*therapeutic effects
17436,31900992,il-13
17437,31900992,il-4
17438,31900992,il-5
17439,31900992,il-6
17440,31900992,autoimmune thyroid diseases
17441,31900992,polymorphism
17442,32911689,graves’ orbital fibroblasts
17443,32911689,graves’ orbitopathy
17444,32911689,igf1r
17445,32911689,igf1r antibodies
17446,32911689,tshr
17447,32911689,tshr antibodies
17448,32911689,hyaluronan
17449,32911689,receptor crosstalk cois targeting tshr and igf-1r.
17450,32376473,*circular rna
17451,32376473,*rna sequencing
17452,32376473,*thyroid-associated ophthalmopathy cois
17453,33327837,"*hyperthyroidism, graves' disease"
17454,33327837,*liver abnormalities
17455,33327837,*liver dysfunction
17457,32854689,coexistent primary and secondary hyperthyroidism
17458,32854689,graves’ disease
17459,32854689,tsh-secreting pituitary adenoma
17460,32854689,tshoma
17461,32854689,thyrotropinoma cois disorders editorial board.
17462,32573180,*graves’ disease
17463,32573180,*autoimmunity
17464,32573180,*peptides
17465,32573180,*thyroid
17467,32199749,*trab
17468,32199749,*antithyroid drugs
17469,32199749,*hyperthyroidism
17470,32199749,*methimazole
17471,32199749,*propylthiouracil cois of interests.
17473,32977740,*graves' orbitopathy
17474,32977740,*hif-1α
17475,32977740,*caveolin-1
17476,32977740,*deiodinase 3
17477,32977740,*enos
17478,32977740,*oxidative stress
17479,34494503,*pd-1
17480,34494503,*pd-l1
17481,34494503,*pd-l2
17482,34494503,*regulatory t cell
17483,34494503,*severity
17484,34494503,*single nucleotide polymorphism
17485,33541945,hyperthyroidism
17486,33541945,thyrotoxicosis
17487,33541945,valvar diseases cois
17488,33153489,*adipogenesis
17489,33153489,*gene modification
17490,33153489,*graves’ ophthalmopathy
17491,33153489,*phosphatase of regenerating liver-1
17492,33153489,*placenta-derived mesenchymal stem cells cois
17493,32605565,case report
17494,32605565,graves’ disease
17495,32605565,hypercalcemia
17496,32605565,osteoporosis
17497,32605565,thymic enlargement cois
17498,32342657,*graves’ disease
17499,32342657,*association analysis
17500,32342657,*sex-specific
17501,32342657,*single nucleotide polymorphism cois
17504,31910101,*graves' disease
17505,31910101,*muscle strength
17506,31910101,*quality of life
17507,31910101,*thyrotoxicosis
17508,31910101,*vitamin d
17509,34867801,*cd40
17510,34867801,*graves’ disease
17511,34867801,*association analysis
17512,34867801,*expression quantitative trait locus
17513,34867801,*single nucleotide polymorphisms cois commercial or financial relationships that could be construed as a potential conflict of interest.
17517,34074094,*graves disease
17518,34074094,*hashimoto disease
17519,34074094,*immune checkpoint inhibitor
17520,34074094,"*polymorphism, single nucleotide"
17521,34074094,*programmed cell death 1 ligand cois was reported.
17524,32088015,endoscopic modified lothrop procedure
17525,32088015,endoscopic sinus surgery
17526,32088015,frontal sinusitis
17527,32088015,graves’ orbitopathy
17528,32088015,orbital decompression cois related with this paper.
17530,32483756,"thyroid stimulating hormone receptor, antagonist, thienopyrimidine, thyroid gland"
17531,31926048,anti-programmed death 1 therapy
17532,31926048,graves’ disease
17533,31926048,"type 1 diabetes cois k.k. and eli lilly japan k.k. hiroshi kagamu is a scientific advisor of immunit research inc; has received honoraria from astrazeneca k.k., bristol‐myers squibb co. and ono pharmaceutical co.; and research funding from boehringer ingelheim pharmaceuticals inc. the other authors declare no conflict of interest."
17534,33935970,*graves’ ophthalmopathy
17535,33935970,*corticosteroids
17536,33935970,*cytokines
17537,33935970,*rituximab
17538,33935970,*teprotumumab
17539,33935970,*tocilizumab cois commercial or financial relationships that could be construed as a potential conflict of interest.
17542,33719776,*thyroid-associated ophthalmopathy
17543,33719776,*blood flow velocity
17544,33719776,*fractal analysis
17545,33719776,*functional slit-lamp biomicroscopy
17546,33675209,addison’s disease
17547,33675209,graves’ disease
17548,33675209,adrenal insufficiency
17549,33675209,autoimmune polyglandular syndrome type 2
17550,33675209,"thyrotoxicosis cois design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication."
17551,32820337,*case-control
17552,32820337,*grave's disease (gd)
17553,32820337,*hyperthyroidism
17554,32820337,*intestinal microbiota
17555,32820337,*prospective
17556,32820337,*thyroid-stimulating antibodies (tsab) cois manuscript.
17558,31237221,graves’ ophthalmopathy
17559,31237221,thyroid disorders
17560,31237221,age-related macular degeneration
17561,31237221,amiodarone
17562,31237221,diabetic retinopathy
17563,31237221,ocular metastasis.
17564,34831419,*graves’ orbitopathy
17565,34831419,*igf-1
17566,34831419,*rock inhibitor
17567,34831419,*orbital fibroblast
17568,34831419,*prostanoid ep2 agonist
17569,34831419,*three-dimension (3d) cell culture cois
17570,33473054,acute respiratory distress syndrome (ards)
17571,33473054,coronavirus disease 2019 (covid-19)
17572,33473054,severe acute respiratory syndrome (sars)
17573,33473054,severe acute respiratory syndrome coronavirus-2 (sars-cov-2)
17574,33473054,thyroid
17575,31978406,anti-thyroid drugs
17576,31978406,graves’ disease
17577,31978406,hyperthyroidism
17578,31978406,lysophosphatidylserine
17579,31978406,phosphatidylserine-specific phospholipase a1
17580,31978406,thyroid hormones
17581,34899596,*igf1r
17582,34899596,*tsab
17583,34899596,*tshr
17584,34899596,*adipogenesis
17585,34899596,*hyaluronan
17586,34899596,*thyroid eye disease cois commercial or financial relationships that could be construed as a potential conflict of interest.
17587,33776929,*dosimetry—radiation
17588,33776929,*hyperthyroidism (graves’ disease)
17589,33776929,*hyperthyroidism—diagnosis
17590,33776929,*hypothyroidism
17591,33776929,*radioiodine
17592,33776929,*radioiodine (131i) treatment cois distribute the software generated in this article. the remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
17594,32957802,graves’ orbitopathy
17595,32957802,ethmoid sinus volume
17596,32957802,proptosis reduction
17597,32957802,thyroid eye disease
17598,33583620,*endocrinology
17599,33583620,*h1n1 infection
17600,33583620,*influenza
17601,33583620,*thyroid storm cois
17602,32187946,"decompression, surgical"
17603,32187946,diplopia
17604,32187946,esotropia
17605,32187946,graves ophthalmopathy
17606,32187946,ophthalmologic surgical procedures
17607,32471411,early hypothyroidism
17608,32471411,graves’ disease
17609,32471411,radioactive iodine
17610,32471411,therapy cois publication of this paper.
17612,34742035,*alemtuzumab
17613,34742035,*autoimmunity
17614,34742035,*crohn's disease
17615,34742035,*graves' disease
17616,34742035,*igg
17617,34742035,*igg4
17618,34742035,*multiple sclerosis
17619,34061946,*addison’s disease
17620,34061946,*additional autoimmune disease
17621,34061946,*autoimmune polyglandular syndrome
17622,34061946,*autoimmune thyroid disease
17623,34061946,*type 1 diabetes mellitus
17624,33998766,case-control study
17625,33998766,dipeptidyl peptidase-4
17626,33998766,"graves' disease cois lectures and received research funding from some organizations as described below. there was no financial support for this study. akinobu nakamura received research funding from mitsubishi tanabe pharma co. and ono pharmaceutical co. ltd. hideaki miyoshi received honoraria for lectures from astellas pharma inc., dainippon pharma co., eli lilly, mitsubishi tanabe pharma co., msd, novartis pharma, novo nordisk pharma, kowa pharmaceutical co., ltd., nippon boehringer ingelheim co., ono pharmaceutical co. ltd. and sanofi, and received research funding from astellas pharma inc., daiichi sankyo, dainippon pharma co., eli lilly, mitsubishi tanabe pharma co., novo nordisk pharma, kowa pharmaceutical co., abbott japan co., nippon boehringer ingelheim co., ono pharmaceutical co. ltd. and taisho toyama pharmaceutical co., ltd. tatsuya atsumi received honoraria for lectures from mitsubishi tanabe pharma co., chugai pharmaceutical co. ltd., astellas pharma inc., takeda pharmaceutical co. ltd., pfizer inc., abbvie inc., eisai co. ltd., daiichi sankyo co. ltd., bristol‐myers squibb co., ucb japan co. ltd., eli lilly japan k.k., and received research funding from astellas pharma inc., takeda pharmaceutical co. ltd., mitsubishi tanabe pharma co., chugai pharmaceutical co. ltd., daiichi sankyo co. ltd., otsuka pharmaceutical co. ltd., pfizer inc. and alexion inc. the other authors declare no conflict of interest."
17628,33138008,*graves’ disease
17629,33138008,*human leukocyte antigen (hla)
17630,33138008,*recurrence
17631,33138008,*subacute thyroiditis cois
17632,32062033,autoimmunity
17633,32062033,graves' disease
17634,32062033,hashimoto's autoimmune thyroiditis
17635,32062033,single nucleotide polymorphism (snp)
17636,32062033,toll-like receptors (tlrs)
17637,32062033,type 1 diabetes mellitus (t1dm)
17639,32880061,bavans
17640,32880061,detachable steel wire-rimmed retractor
17641,32880061,kn retractor
17642,32880061,vans
17643,32880061,video-assisted neck surgery
17645,33211376,graves' disease
17646,33211376,cohort
17647,33211376,systemic lupus erythematosus
17651,32359703,graves disease
17652,32359703,leukemia lymphocytic chronic b-cell
17653,32359703,neoplasms/secondary
17654,32359703,prostatic neoplasms
17655,32359703,pruritus
17656,32466854,*hypocalcemia
17657,32466854,*thyroidectomy
17658,32466854,*vitamin d deficiency
17660,31980336,*autoimmunity
17661,31980336,*graves' disease
17662,31980336,*t-cells
17663,31980336,*tsh receptor
17664,31980336,*thyroid cois patent application pct/us2016/067775 for using small molecules to block hla-dr3. dr. tomer also submitted 2 additional provisional patent disclosures that are not related to the content of this manuscript. dr. tomer was previously (1/2015–6/2017) the pi on a basic research project jointly funded by the juvenile diabetes research foundation and pfizer. the current manuscript is not related to that research project. the other authors have nothing to declare.
17665,33758937,*graves’ disease
17666,33758937,*programmed cell death 1
17667,33758937,*regulatory t cells
17668,33758937,*thyroid hormone
17669,32666771,thyroid ophthalmopathy
17670,34470463,*autoimmune thyroid disease
17671,34470463,*intractability
17672,34470463,*polymorphism
17673,34470463,*severity
17674,34470463,*vitamin a
17675,33234057,*16s rrna sequencing
17676,33234057,*graves' disease
17677,33234057,*alpha diversity
17678,33234057,*gut microbiota
17679,33234057,*metabolism cois
17680,34975767,*graves’ disease
17681,34975767,*bacterial translocation
17682,34975767,*intestinal barrier
17683,34975767,*intestinal fatty acid-binding protein
17684,34975767,*leaky gut
17685,34975767,*lipopolysaccharide
17686,34975767,*quality of life cois commercial or financial relationships that could be construed as a potential conflict of interest.
17687,33587909,*3-dimension (3d) tissue culture
17688,33587909,*ep2 agonist
17689,33587909,*grave's disease
17690,33587909,*grave's orbitopathy
17691,33587909,*human orbital fibroblast
17692,33587909,*pgf2α agonist
17693,33587909,*rock inhibitor
17694,33587909,*rho-associated coiled-coil containing protein kinase (rock)
17695,33437990,*antinuclear antibodies
17696,33437990,*indirect immunofluorescence
17697,33437990,*systemic autoimmune disease
17698,32061922,*graves' ophthalmopathy fibroblasts
17699,32061922,*insulin-like growth factor 1 receptor
17700,32061922,*receptor crosstalk
17701,32061922,*tsh receptor stimulating antibodies
17702,32061922,*thyroid-stimulating hormone receptor cois of interest.
17703,31969085,*adipogenesis
17704,31969085,*chondrogenesis
17705,31969085,*muscle-derived stem cells
17706,31969085,*myogenesis
17707,31969085,*osteogenesis
17708,33476778,*dysthyroid optic neuropathy
17709,33476778,*grave disease
17710,33476778,*grave orbitopathy
17711,33476778,*orbit decompression
17713,32707005,*thyroid eye disease
17714,32707005,*insulin-like growth factor i receptor
17715,32707005,*monoclonal antibody
17716,32707005,*teprotumumab
17717,32707005,*thyrotropin receptor
17720,33298481,gynaecological cancer
17721,33298481,stroke
17722,33298481,thyrotoxicosis cois
17723,33645503,*covid-19
17724,33645503,*epidemics
17725,33645503,*influenza
17726,33645503,*predict
17727,33645503,*virus
17728,33196862,antithyroid medication
17729,33196862,antithyroid-induced arthritis syndrome
17730,33196862,arthritis
17731,33196862,fever
17732,33196862,thiamazole
17733,33498689,graves’ ophthalmopathy
17734,33498689,eear fluids
17735,33498689,ehyroid-associated ophthalmopathy
17736,33498689,exosomes
17737,33498689,extracellular vesicle
17738,33498689,eytokines cois
17739,33877318,*akt1
17740,33877318,*egfr/pi3k/akt signaling
17741,33877318,*lncrna lpal2
17742,33877318,*mir-1287-5p
17743,33877318,*orbital fibroblast activation
17744,33877318,*thyroid eye disease
17746,32425952,*autoantibodies
17747,32425952,*autoimmune
17748,32425952,*nephropathy
17749,32425952,*phospholipase a2 receptor
17750,32425952,*thyroid disease
17752,33745401,"*“thyroid eye disease, thermal imaging, ocular surface temperature, caruncular  temperature”"
17755,34752648,graves’ disease
17756,34752648,hyperthyroidism
17757,34752648,thyroid-stimulating hormone receptor antibody cois
17759,33121876,*graves' disease
17760,33121876,*interferon
17761,33121876,*interleukin
17762,33121876,*thyroid-stimulating hormone receptor antibody
17763,33121876,*tumor necrosis factor
17764,34680057,*graves’ ophthalmopathy
17765,34680057,*c-jun n-terminal kinase
17766,34680057,*orbital fibroblast
17767,34680057,*p38
17768,34680057,*pirfenidone
17769,34680057,*transforming growth factor-β1 cois
17770,33868176,*graves’ orbitopathy
17771,33868176,*t cell immunity
17772,33868176,*effector t cell
17773,33868176,*fibrocyte
17774,33868176,*orbital fibroblast
17775,33868176,"*thyroid-associated ophthalmology cois (81930024, 81761168037, 81770974, 81800695, 82071003, 82000879, 81570883, 81600766, 31701046, 31600971, and 31500714), the national key r&d program of china (2018yfc1106100, 2018yfc1106101), the shanghai sailing program (18yf1412300), the research grant of the shanghai science and technology committee (20dz2270800, 17dz2260100, 19410761100, and 19dz2331400), the clinical research plan of shdc (shdc2020cr3051b), the project of medical robots (imr-nph202002) from the clinical joint research center of the institute of medical robots, shanghai jiaotong university-shanghai ninth people’s hospital, the collaborative research project of translational medicine collaborative innovation center, shanghai jiaotong university school of medicine (tm201718), the shanghai municipal education commission—gaofeng clinical medicine grant support (20152228), the shanghai jiaotong university translational medicine crossed research grant (zh2018zda12, zh2018qna07), the sample database project of shanghai ninth people’s hospital (ybkb201901), and the joint innovation team for young physicians of shanghai ninth people’s hospital (qc202002).the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
17776,33419752,emergency medicine
17777,33419752,respiratory medicine cois
17778,34887833,*graves’ disease
17779,34887833,*hla variants
17780,34887833,*ptpn22 gene
17781,34887833,*genetic predictors
17782,34887833,*treatment cois commercial or financial relationships that could be construed as a potential conflict of interest.
17783,32519199,association
17784,32519199,graves’ disease
17785,32519199,mica
17786,32519199,thionamide-induced agranulocytosis
17787,32253999,*antithyroid drug
17788,32253999,*hyperthyroidism
17789,32253999,*long-term treatment
17790,34916298,*graves’ disease
17791,34916298,*organoids
17792,34916298,*thyroid
17794,33781112,*graves’ ophthalmopathy
17795,33781112,*tepezza
17796,33781112,*hearing loss
17797,33781112,*teprotumumab
17798,33781112,*thyroid eye disease
17799,34887857,*: autoimmune disease
17800,34887857,*autoimmunity
17801,34887857,*gastric cancer
17802,34887857,*risk
17803,34887857,*standardized incidence rate cois commercial or financial relationships that could be construed as a potential conflict of interest.
17804,34355625,trab
17805,34355625,thyroid function
17806,34355625,hysterosalpingography (hsg)
17807,34355625,infertility
17808,34355625,thyrotoxicosis
17809,32874051,orbital decompression
17810,32874051,pneumocephalus
17811,32874051,thyroid eye disease cois
17812,32797475,graves’ disease
17813,32797475,antioxidant parameters
17814,32797475,hyperthyroidism
17815,32797475,lipid peroxidation
17816,32797475,thyroid orbitopathy
17818,34949642,*graves’ disease
17819,34949642,*autoimmune
17820,34949642,*fibrocyte
17821,34949642,"*thyroid cois therapeutic targeting of igf-i receptor in autoimmune diseases (to t.j.s. and held by the university of california, los angeles, and the lundquist institute). he is a consultant for horizon therapeutics."
17822,32419081,*cd40
17823,32419081,*ctla4
17824,32419081,*graves’ disease
17825,32419081,*pparg
17826,32419081,*ptpn22
17827,32419081,*polymorphism
17828,32372394,children and adolescents
17829,32372394,low-dose radioactive iodine (131i)
17830,32372394,outpatients treatment
17831,32372394,radiation exposure
17832,33653401,children
17833,33653401,glucocorticoid pulse therapy
17834,33653401,graves’ disease
17835,33653401,thyroid antibodies
17836,33653401,thyroid function cois
17841,32246145,*graves’ disease
17842,32246145,*hashimoto’s thyroiditis
17843,32246145,*genetic risk
17844,32246145,*heterogeneity
17845,32246145,*large chinese cohort
17846,34381538,acromegaly
17847,34381538,case report
17848,34381538,empty sella
17849,34381538,grave´s disease
17850,34381538,hyperthyroidism cois
17852,33322192,*graves’ orbitopathy
17853,33322192,*exophthalmos
17854,33322192,*intraocular pressure
17855,33322192,*topical medications cois
17857,32328068,*graves' disease
17858,32328068,*hashimoto's thyroiditis
17859,32328068,*follicular helper t cells
17860,32328068,*lymphoid tissue–inducer-like cells
17861,32328068,*regulatory t cells
17862,32328068,*thyroid autoimmune disease
17863,33597925,*erk
17864,33597925,*graves’ ophthalmopathy
17865,33597925,*ras homolog family member a (rhoa)
17866,33597925,*rho‑associated protein kinase (rock)
17867,33597925,*y-27632
17868,33597925,*myofibroblast
17869,33597925,*p38
17870,33597925,*simvastatin cois commercial or financial relationships that could be construed as a potential conflict of interest.
17874,34271828,*ait
17875,34271828,*trab
17876,34271828,*amiodarone
17877,34271828,*autoimmunity
17878,34271828,*thyrotoxicosis
17879,32545596,grave´s disease
17880,32545596,hashimoto’s thyroiditis
17881,32545596,non-celiac wheat sensitivity
17882,32545596,celiac disease
17883,32545596,gut microbiota
17884,32545596,iodine
17885,32545596,iron
17886,32545596,probiotics
17887,32545596,thyroid
17888,32545596,thyroid cancer cois
17889,32338082,*b-cell activating factor
17890,32338082,*cytokines
17891,32338082,*graves’ disease
17892,32338082,*hashimoto’s thyroiditis
17893,32338082,*autoimmune thyroid disease
17894,33912135,*graves’ disease
17895,33912135,*rna sequencing
17896,33912135,*t cell receptor sequencing
17897,33912135,*persistent graves’ disease
17898,33912135,*refractory graves’ disease
17899,33912135,*regulatory t cell cois commercial or financial relationships that could be construed as a potential conflict of interest.
17900,32116430,goiter
17901,32116430,thyroid
17902,32116430,thyroidectomy
17903,32121432,somatostatin analog
17904,32121432,cancer
17905,32121432,carcinoid
17906,32121432,lanreotide
17907,32121432,neuroendocrine tumor
17908,32121432,octreotide
17909,32121432,pasireotide
17910,32121432,"pituitary adenoma cois novartis, and pfizer as speaker fees, served on an advisory board, and received lecture fees and sponsorship for travel and accommodation in international scientific meetings from ipsen, novartis, and pfizer. none of them had role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results."
17911,32572659,hypothyroidism
17912,32572659,goitre
17913,32572659,hyperthyroidism
17914,32572659,physiology
17915,32572659,thyroid carcinoma
17916,33040848,ct
17917,33040848,cancer
17918,33040848,goiter
17919,33040848,mr imaging
17920,33040848,surgical implications
17921,33040848,thyroid
17922,33040848,thyroid nodules cois
17923,32342248,hypoparathyroidism
17924,32342248,recurrent nerve injury
17925,32342248,thyroid carcinoma
17926,32342248,thyroid surgery
17927,32342248,thyroidectomy
17928,32234570,*central neck lymph node dissection
17929,32234570,*hypocalcemia
17930,32234570,*hypoparathyroidism
17931,32234570,*thyroidectomy
17932,31941844,adipogenesis
17933,31941844,caffeine
17934,31941844,graves’ orbitopathy
17935,31941844,oxidative stress
17936,31941844,thyroid eye disease
17937,33167878,bowel perforation
17938,33167878,gastrointestinal mucormycosis
17939,33167878,mucormycosis
17940,33167878,rhizopus microsporus
17941,33167878,streptococcus pyogenes
17942,33167878,toxic shock syndrome cois
17943,34653776,*graves' disease
17944,34653776,*sars-cov-2
17945,34653776,*type 1 diabetes mellitus
17946,34653776,*vaccine
17947,32896170,*graves’ disease
17948,32896170,*zinc transporter
17949,32896170,*children
17950,32896170,*non-toxic nodular goiter
17951,32896170,*thyroid tissue
17952,34956094,*contrast-enhanced ultrasound (ceus)
17953,34956094,*partially cystic papillary thyroid carcinomas (pcptcs)
17954,34956094,*partially cystic thyroid nodules
17955,34956094,*thyroid carcinomas
17956,34956094,*thyroid ultrasonography cois commercial or financial relationships that could be construed as a potential conflict of interest.
17957,33208049,*graves' disease
17958,33208049,*hla-dr3 mice
17959,33208049,*t cells
17960,33208049,*tetramer assay
17961,32734637,*asian
17962,32734637,*cosmesis
17963,32734637,*minimally invasive video-assisted thyroidectomy
17964,32734637,*neck scar
17965,32734637,*thyroidectomy
17966,35130216,"thyroidectomy, harmonic scalpel, classical ligation, suture hemorrhage, recurrent  laryngeal nerve injury."
17969,33939906,thyroid nodule
17970,33939906,ablation techniques
17971,33939906,ethanol
17972,33939906,nodular goiter
17973,32950466,covid-19
17974,32950466,free t3
17975,32950466,free t4
17976,32950466,hypothyroidism
17977,32950466,hypothyroïdie
17978,32950466,orbitopathie
17979,32950466,orbitopathy
17980,32950466,sars-cov-2
17981,32950466,t3l
17982,32950466,t4l
17983,32950466,tsh
17984,32950466,thyrotoxicose
17985,32950466,thyrotoxicosis
17986,33754530,anaplastic thyroid carcinoma
17987,33754530,leucocytosis; goitre
17989,33665799,turkey
17990,33665799,elderly people
17991,33665799,goitre
17992,33665799,hyperthyroidism
17993,33665799,hypothyroidism
17994,33665799,iodized salt
17995,34721289,*clnm
17996,34721289,*lasso
17997,34721289,*llnm
17998,34721289,*ptc
17999,34721289,*cn0 cois commercial or financial relationships that could be construed as a potential conflict of interest.
18000,32303903,*hereditary non-autoimmune hyperthyroidism
18001,32303903,*inverse agonist and antagonists
18002,32303903,*somatic and germline mutation
18003,32303903,*tsh receptor
18004,32303903,*toxic adenoma
18005,32303903,*toxic multinodular goitre cois
18007,33202999,*case-control studies
18008,33202999,*cohort studies
18009,33202999,*hearing loss
18010,33202999,*hyperthyroidism
18011,33202999,*sudden cois
18012,33339489,frank hartley
18013,33339489,clubfoot
18014,33339489,exstrophy of the bladder
18015,33339489,facial neuralgia
18016,33339489,goiter
18017,33964951,ck19
18018,33964951,follicular
18019,33964951,hbme1
18020,33964951,niftp
18021,33964951,papillary cois
18022,33402480,braf mutation
18023,33402480,microrna
18024,33402480,papillary thyroid cancer cois
18025,33466826,cohort
18026,33466826,diet
18027,33466826,iodine
18028,33466826,pregnancy
18029,33466826,"thyroid cois develop the myfood24 online dietary assessment system for use in research, teaching and for health. the remaining authors have nothing to declare. the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript or in the decision to publish the results."
18030,33459001,*hashimoto disease
18031,33459001,*adolescent
18032,33459001,*child
18033,33459001,*goiter
18034,33459001,*hypothyroidism cois
18035,33213335,*hyperthyroidism
18036,33213335,*raiu test
18037,33213335,*graves' disease
18038,33213335,*multinodular
18039,33213335,*pathology
18040,33213335,*thyroid scan
18041,33213335,*toxic
18042,32518973,benign neoplasm
18043,32518973,goiter
18044,32518973,thyroid cancer
18045,32733376,*children
18046,32733376,*hypertrichosis
18047,32733376,*pituitary hypertrophy
18048,32733376,*severe autoimmune hypothyroidism
18049,32733376,*symptoms
18050,32267105,* metastasis
18051,32267105,* multinodular goiter
18052,32267105,*thyroid carcinoma
18053,33412925,*goiter
18054,33412925,*statins
18055,33412925,*thyroid cancer
18056,33412925,*thyroiditis
18057,33412925,*thyrotoxicosis
18060,33812374,macroadenoma
18061,33812374,pituitary
18062,33812374,pregnancy
18063,33812374,thyrotoxicosis cois
18064,32697397,doppler ultrasound
18065,32697397,graves disease
18066,32697397,graves orbitopathy
18067,32697397,central retinal artery
18068,32697397,ophthalmic artery
18069,32697397,toxic goiter
18070,33980057,*decision aid tool
18071,33980057,*levothyroxine dosage
18072,33980057,*patient tailored
18073,33980057,*pharmacokinetic modeling
18074,33980057,*thyroidectomy cois
18075,32149464,* thyroid surgery
18076,32149464,*ent
18077,32149464,*hyperthyroidism
18078,32149464,*thyroid
18079,32149464,*thyroid cancer
18081,31868128,*alu element
18082,31868128,*tg
18083,31868128,*congenital hypothyroidism
18084,31868128,*goiter
18085,31868128,*novel mutation
18086,31868128,*thyroglobulin cois
18087,32939627,ectopic thyroid tissue
18088,32939627,follicular adenoma
18089,32939627,goiter
18090,32939627,lung
18091,32939627,thoracoscopic surgery
18093,32909177,ancient rome
18094,32909177,fine arts
18095,32909177,goiter
18096,32909177,hans christian gram
18097,32909177,history
18098,32909177,hyperthyroidism
18100,32372240,egypt
18101,32372240,endemic goiter
18102,32372240,hashimoto’s thyroiditis
18103,32372240,papillary thyroid carcinoma
18104,32372240,thyroid cancer
18105,33619709,mri
18106,33619709,genetic diseases
18107,33619709,goitre
18108,33619709,haemochromatosis
18109,33619709,iron
18110,33619709,iron overload
18111,33619709,liver biopsy
18112,33619709,thyroid
18113,32377868,goiter
18114,32377868,graves’ disease
18115,32377868,hashimoto’s thyroiditis
18116,32377868,iodine-induced hyperthyroidism
18117,32377868,thyroid autonomy
18118,34378152,*congenital hypothyroidism
18119,34378152,*dyshormonogenesis
18120,34378152,*goiter
18121,34378152,*thyroid cancer
18122,33135832,*māori health
18123,33135832,*head and neck
18124,33135832,*thyroid surgery
18125,33319230,*hypothyroidism
18126,33319230,*chronic diseases
18127,33319230,*comorbidity
18128,33319230,*network analysis
18129,34637944,early diagnosis
18130,34637944,hamartoma syndrome
18131,34637944,hereditary
18132,34637944,multiple
18133,34637944,neoplastic syndromes
18134,34637944,pten phosphohydrolase
18135,34637944,phenotype
18137,33905626,thyroid cancer
18138,33905626,mrna expression
18139,33905626,polymorphism
18140,33905626,transforming growth factor-β
18141,33779362,thyroid
18142,33779362,hypocalcaemia
18143,33779362,meta-analysis
18144,33779362,prevalence
18145,33779362,risk factor cois conflicts of interest.
18147,33910357,complications − recurrent nerve
18148,33910357,hypoparathyroidism − lethality
18149,33910357,thyroid surgery
18150,34479126,diffuse thyroid diseases
18151,34479126,grave’s diseases
18152,34479126,hashimoto’s thyroiditis
18153,34479126,shear wave elastography
18154,34479126,ultrasonography
18155,33008929,*amiodarone-induced thyroid dysfunction
18156,33008929,*autoimmunity
18157,33008929,*destructive thyroiditis
18158,33008929,*hyperthyroidism
18159,33008929,*toxic multinodular goiter
18160,33008929,*toxic thyroid adenoma
18161,32458745,*goiter
18162,32458745,*iodine
18163,32458745,*iodine deficiency
18164,32458745,*salt
18165,32458745,*universal salt iodization cois
18166,34841823,*cohort studies
18167,34841823,*goiter
18168,34841823,*hyperthyroidism
18169,34841823,*hypothyroidism
18170,33072219,relapse risk
18171,33072219,benign focal pathology
18172,33072219,nodular goiter
18173,33072219,thyroid gland
18174,33028642,*ewing's sarcoma
18175,33028642,*multinodular goiter
18176,33028642,*neoplasm of the genitourinary tract
18177,34425332,gene expression
18178,34425332,klln
18179,34425332,multinodular goiter
18180,34425332,pten
18181,34425332,papillary thyroid carcinoma
18182,33914231,*goiter
18183,33914231,*iodine
18184,33914231,*iodized salt
18185,33914231,*thyroid
18186,33914231,*thyroid autoimmunity cois
18187,33749812,bethesda classification
18188,33749812,thyroid cancer
18189,33749812,thyroid nodule
18190,32838791,*breast cancer
18191,32838791,*genetic pleiotropy
18192,32838791,*hyperthyroidism
18193,32838791,*mammographic density cois
18194,32930933,congenital hypothyroidism
18195,32930933,duox2
18196,32930933,newborn screening
18197,32930933,tg
18198,32930933,tpo
18199,32930933,tshr
18200,32765423,*congenital hypothyroidism
18201,32765423,*dyshormonogenesis
18202,32765423,*genes
18203,32765423,*goiter
18204,32765423,*iodine
18205,32765423,*screening
18206,32765423,*thyroid hypoplasia
18207,34382851,cervical stitch sinus
18208,34382851,deep neck infection
18209,34382851,diabetes
18210,34382851,suture granuloma
18211,34382851,thyroidectomy
18212,34382851,wound
18213,34382851,wound healing
18215,31960358,mitochondria
18216,31960358,oxidative stress
18217,31960358,ros
18218,31960358,selenium
18219,31960358,thyroid
18221,34121740,autoimmune disease
18222,34121740,hashimoto's thyroiditis
18223,34121740,hypocalcemia
18224,34121740,thyroid peroxidase antibody
18225,34121740,thyroidectomy cois
18226,32505587,resistance to thyroid hormone
18227,32505587,thrb gene
18228,32505587,thyroid hormone receptor beta cois
18229,34426423,endoscopy
18230,34426423,surgery
18231,34426423,thyroid disease
18232,34426423,thyroiditis cois
18233,34051706,*goiter
18234,34051706,*nodule
18235,34051706,*thyroid
18236,32582023,*hashimoto's thyroiditis
18237,32582023,*hashitoxicosis
18238,32582023,*autoimmune thyroiditis (ait)
18239,32582023,*goiter
18240,32582023,*thyroid autoantibodies
18241,33901280,"*8-oxo-7,8-dihydro-2’-deoxyguanosine"
18242,33901280,"*8-oxo-7,8-dihydroguanosine"
18243,33901280,*graves disease
18244,33901280,*hyperthyroidism
18245,33901280,*oxidative stress
18246,33901280,*toxic nodular goiter
18247,34093427,*langerhans cell histiocytosis
18248,34093427,*chemotherapy
18249,34093427,*spontaneous thyroid hemorrhage
18250,34093427,*thyroid
18251,34093427,*thyroidectomy cois commercial or financial relationships that could be construed as a potential conflict of interest.
18254,33796075,*gh
18255,33796075,*igf-i
18256,33796075,*acromegaly
18257,33796075,*comorbidity
18258,33796075,*complication
18259,33796075,*pituitary adenoma cois commercial or financial relationships that could be construed as a potential conflict of interest.
18260,32792004,denosumab rebound
18261,32792004,fracture
18262,32792004,hypercalcemia
18263,32792004,hyperparathyroidism
18264,32792004,osteoporosis cois
18265,34219897,hyperthyroidsm
18266,34219897,thyroid neoplasms
18267,34219897,thyrostatic drugs cois interest. this article does not include any studies with human participants or animals performed by any of the authors.
18268,34937506,thyroid disorders
18269,34937506,male infertility factor
18270,34937506,pathospermia
18271,34248839,*congenital hypothyroidism
18272,34248839,*familial origin
18273,34248839,*high throughput molecular screening
18274,34248839,*oligogenicity
18275,34248839,*thyroid dyshormonogenesis cois commercial or financial relationships that could be construed as a potential conflict of interest.
18277,33052461,edge
18278,33052461,localization
18279,33052461,oxidative stress
18280,33052461,thyroid
18281,33052461,tumor
18282,34431326,covid-19
18283,34431326,sars-cov-2
18284,34431326,goiter
18285,34431326,surgery
18286,34431326,thyroid cancer
18287,34431326,thyroidectomy
18288,32178945,aberrant left subclavian artery
18289,32178945,non-recurrent inferior laryngeal nerve
18290,32178945,right-sided aortic arch
18291,32178945,thyroid surgery cois disclosed on this work.
18292,34196952,cost-effectiveness analysis
18293,34196952,intraoperative nerve monitoring
18294,34196952,recurrent laryngeal nerve palsy
18295,34196952,total thyroidectomy
18296,34196952,visual nerve identification
18297,32606189,thyroid
18298,32606189,malignancy
18299,32606189,microcalcifications
18300,32606189,nodule
18301,32606189,shape cois
18304,34889796,disfigurement
18305,34889796,horner syndrome
18306,34889796,steroids
18307,34889796,thyroidectomy cois
18310,33004747,follicular thyroid adenoma
18311,33004747,follicular thyroid carcinoma
18312,33004747,ultrasound signal cois
18313,32253953,*interventional ultrasonography
18314,32253953,*ablation techniques
18315,32253953,*high-intensity focused ultrasound ablation
18316,32253953,*nodular goiter
18317,32253953,*ultrasound imaging
18318,33459000,*graves disease
18319,33459000,*adolescent
18320,33459000,*antithyroid agents
18321,33459000,*child
18322,33459000,*hyperthyroidism cois
18323,33250466,alkaline phosphatase
18324,33250466,body pain
18325,33250466,muscle weakness
18326,33250466,normocalcemic hyperparathyroidism cois
18329,33194956,*kashmir
18330,33194956,*hypothyroidism
18331,33194956,*thyroid dysfunction
18332,33194956,*tribal population
18333,33194956,*urinary iodine
18334,32897650,*dicer1
18335,32897650,*cytology
18336,32897650,*fine-needle aspiration
18337,32897650,*follicular neoplasm
18338,32897650,*papillary thyroid carcinoma
18339,32897650,*poorly differentiated thyroid carcinoma
18340,32897650,*thyroid
18341,32430544,benign goiter
18342,32430544,case number threshold
18343,32430544,routine data
18344,32430544,vocal cord palsy
18345,32430544,volume outcome
18346,32458504,mitochondria
18347,32458504,mitochondria-eating protein
18348,32458504,mitophagy
18349,32458504,oncocytic cell tumor
18350,32458504,thyroid cois
18351,33541277,deficiency
18352,33541277,goiter
18353,33541277,magnitude
18354,33541277,micronutrient
18355,33541277,prevalence
18356,33541277,urine iodine cois
18358,32621001,*endocrine dysfunction
18359,32621001,*hemorrhagic stroke
18360,32621001,*ischemic stroke
18361,32621001,*pituitary
18362,31952842,*cervical embryonal rhabdomyosarcoma
18363,31952842,*dicer1-related multinodular goiter
18364,31952842,*ovarian sex-cord stromal tumors
18365,31952842,*pleuropulmonary blastoma
18366,31952842,"*sertoli-leydig cell tumors of the ovary cois private company with a mission to develop liquid biopsy diagnostics for rare cancers which includes dicer1-related cancers described in this work. none of the diagnostics under development are discussed in this work. dr. stewart provides contract telegenetics services to genome medical, inc."
18367,34670545,hyperthyroidism
18368,34670545,icm
18369,34670545,iodinated contrast media
18370,34670545,iodine-induced
18371,34670545,tachycardia cois
18372,32189188,*distant metastases
18373,32189188,*ft-ump
18374,32189188,*mi-ftc
18375,32189188,*radioiodine therapy
18376,32189188,*wdt-ump
18377,32081771,*biomarker
18378,32081771,*follicular thyroid adenoma
18379,32081771,*follicular thyroid carcinoma
18380,32081771,*roc curve analysis
18381,32081771,*real-time pcr
18382,32081771,*microrna cois
18385,33119125,dielectric properties
18386,33119125,open-ended coaxial line
18387,33119125,thyroid nodules
18388,32974689,ablation techniques
18389,32974689,high-intensity focused ultrasound ablation
18390,32974689,interventional ultrasonography
18391,32974689,nodular goiter
18392,32974689,ultrasonic imaging
18396,33932399,*change
18397,33932399,*expression
18398,33932399,*s hla-g
18399,33932399,*thyroid cancer
18400,33932399,*mir-199b-5p
18401,32088313,*congenital hypothyroidism
18402,32088313,*genotype-phenotype analysis
18403,32088313,*next-generation sequencing
18404,32088313,*thyroid peroxidase cois
18405,31867598,*tg
18406,31867598,*tpo
18407,31867598,*congenital hypothyroidism
18408,31867598,*goiter
18409,34191415,thyroid cancer
18410,34191415,endoscopic
18411,34191415,goiter
18412,34191415,surgery
18413,34191415,thyroidectomy
18415,32757959,* dioscorea bulbifera l
18416,32757959,*8-epidiosbulbin e acetate
18417,32757959,*diosbulbin b
18418,32757959,*hepatotoxicity
18419,32757959,*metabolic activation
18421,34706470,*anxiety
18422,34706470,*depression
18423,34706470,*obesity
18424,34706470,*personality
18425,34706470,*temperament
18426,34008223,dicer1
18427,34008223,follicular thyroid carcinoma
18428,34008223,histology
18429,34008223,macrofollicular variant
18430,34008223,mutation
18433,33331320,adenoma
18434,33331320,diagnosis
18435,33331320,hürthle cell tumor
18436,33331320,thyroid gland
18438,34050759,*adolescents
18439,34050759,*goiter
18440,34050759,*hyperthyroidism
18441,34050759,*hypothyroidism
18442,34050759,*thyroid
18443,34050759,*type 2 diabetes
18444,33210503,adenoma
18445,33210503,cyst
18446,33210503,follicular cancer
18447,33210503,thyroid gland
18448,33210503,ultrasound examination
18449,33329389,*diagnosis
18450,33329389,*hyperthyroidism
18451,33329389,*pathogenesis
18452,33329389,*pituitary adenoma
18453,33329389,*thyroid-stimulating hormone-secreting pituitary adenoma
18454,33329389,*treatment cois commercial or financial relationships that could be construed as a potential conflict of interest.
18455,34695620,pericardial effusion
18456,34695620,pleural effusion
18457,34695620,pleural hemangioma
18458,34695620,recurrent
18462,33180037,tshr mutation
18463,33180037,hyperthyroidism
18464,33180037,neonatal
18465,33180037,nonautoimmune
18466,32484412,diode
18467,32484412,laser
18468,32484412,metastatic
18469,32484412,thyroid
18470,32484412,trachea
18473,33722923,18f-fdg
18474,33722923,pet/ct
18475,33722923,breast metastasis
18476,33722923,follicular thyroid carcinoma
18477,33722923,iodine scan
18478,33393527,follicular carcinoma
18479,33393527,malignant
18480,33393527,neoplasm
18481,33393527,ovary
18482,33393527,struma ovarii
18483,33393527,teratoma cois
18484,33405016,*dysphagia
18485,33405016,*dysphonia
18486,33405016,*reflux disease
18487,33405016,*swallowing
18488,33405016,*thyroid
18489,33405016,*thyroid weight
18490,33405016,*thyroidectomy
18491,33405016,*voice cois
18492,33690170,*braf
18493,33690170,*mmp2
18494,33690170,*cancer
18495,33690170,*invasion
18496,33690170,*mutation
18497,33690170,*oncogene
18498,33690170,*thyroid cancer
18499,33970434,global health
18500,33970434,goiter
18501,33970434,telemedicine
18502,33970434,thyroid cancer
18503,33970434,thyroid ultrasound
18504,33970434,"ultrasound cois technology have financial stake in medical innovation and technology which works on developing technology to bring medical imaging to rural areas. all other authors have no financial disclosures. the manuscript and its contents were produced by the university of rochester and medical imaging ministries of the americas authors without financial conflict. the medical innovation and technology authors previewed the document, and any changes were subject to approval from the university of rochester and medical imaging ministry of the americas authors."
18505,32228164,*dicer1
18506,32228164,*child
18507,32228164,*follicular thyroid carcinomas
18508,32228164,*multinodular goiter
18510,33557336,alternative diet
18511,33557336,diet
18512,33557336,iodine
18513,33557336,iodine deficiency
18514,33557336,vegetarian diet cois
18515,34069656,mediterranean diet
18516,34069656,sars-cov-2 infection
18517,34069656,dietary habits
18518,34069656,healthcare professionals cois
18519,32631402,graves’ disease
18520,32631402,hyperthyroidism
18521,32631402,scintigraphy
18522,32631402,thyroid uptake
18523,32631402,thyrotoxicosis cois
18525,34418036,"synchronous thyroid malignancies, papillary thyroid carcinoma, lymphoma"
18526,32166365,*child
18527,32166365,*congenital hypothyroidism
18528,32166365,*gland
18529,32166365,*intrathyroid thymus
18530,32166365,*nodules
18531,32166365,*thyroid
18532,32166365,*thyroiditis
18533,32166365,*ultrasonography
18534,33676861,*endoscopic surgery
18535,33676861,*minimally invasive surgery
18536,33676861,*toetva
18537,33676861,*thyroidectomy
18538,34219881,fine-needle biopsy
18539,34219881,galectin-3
18540,34219881,reverse transcriptase polymerase chain reaction
18541,34219881,thyroid neoplasms
18542,34219881,thyroid nodule
18543,33319473,*oligometastasis
18544,33319473,*small cell lung cancer
18545,33319473,*thyroid metastasis
18547,32731688,follicular thyroid adenoma
18548,32731688,follicular thyroid cancer
18549,32731688,recurrent laryngeal nerve palsy
18550,32731688,elective lymph node dissection
18551,32731688,follicular variant of papillary thyroid cancer
18552,32645970,covid-19 infection
18553,32645970,dietary habits
18554,32645970,lockdown
18555,32645970,obesity cois
18556,32703500,braf mutation
18557,32703500,fine-needle aspiration
18558,32703500,papillary thyroid carcinoma
18559,32703500,thyroid nodule
18564,34230069,hyperthyroidism
18565,34230069,molecular imaging
18566,34230069,thyroid functional autonomy
18567,34230069,thyroid nodules
18568,33507638,men 2
18569,33507638,thyroid gland surgery
18570,33507638,thyroid nodule
18571,33507638,thyroidectomy
18574,31566142,intestinal microbiota
18575,31566142,autoimmune thyroid diseases
18576,31566142,gut dysbiosis
18577,31566142,hyperthyroidism
18578,31566142,hypothyroidism
18579,31566142,thyroid hormones.
18580,33077306,epithelial mesenchymal transition
18581,33077306,papillary thyroid carcinoma
18582,33077306,six1
18583,33077306,tgf-β/smad2/3 cois
18584,33028431,*iodine deficiency
18585,33028431,*iodine supplementation
18586,33028431,*lipiodol capsules
18587,33028431,*thyroid disease
18588,33028431,*women
18589,34855191,rathke
18590,34855191,cleft cysts
18591,34855191,headache
18592,34855191,hyperprolactinaemia
18593,34855191,hypopituitarism
18594,34855191,pituitary incidentaloma
18595,32436480,*adults
18596,32436480,*iodine fortification
18597,32436480,*serum iodine
18598,32436480,*thyroid autoimmunity
18599,32436480,*urinary iodine
18601,33007517,ccna1 gene
18602,33007517,cyclin a1
18603,33007517,diagnostic
18604,33007517,molecular marker
18605,33007517,papillary thyroid cancer
18606,33007517,protein expression
18607,33656790,afirma genomic sequencing classifier
18608,33656790,atypia of undetermined significance
18609,33656790,de quervain's thyroiditis
18610,33656790,molecular tests
18611,33176840,autosomal genetic disease
18612,33176840,gene mutation
18613,33176840,thyroid hormone
18614,33176840,thyroid hormone receptor β
18615,33176840,thyroid hormone resistance cois
18616,34803909,*biomarker
18617,34803909,*complement c4-a
18618,34803909,*papillary thyroid carcinoma
18619,34803909,*plasminogen
18620,34803909,*prediction cois commercial or financial relationships that could be construed as a potential conflict of interest.
18621,33750374,complication
18622,33750374,gasless trans-axillary endoscopic thyroidectomy
18623,33750374,hypoglossal nerve palsy cois
18624,33445950,thyroid surgery − transoral endoscopy – toetva − case report of the first toetva  patient at university hospital brno
18625,33213237,intratracheal ectopic thyroid
18626,33213237,adenomatous hyperplasia
18627,33213237,diagnosis
18628,33213237,ectopic
18629,33213237,thyroid
18630,33213237,treatment cois conflict of interest.
18632,33868182,*autoimmune thyroid disease
18633,33868182,*epigenetic effect
18634,33868182,*resistance to thyroid hormone
18635,33868182,*thyroid dysgenesis
18636,33868182,*thyroid hormone receptor
18637,33868182,*variant of unknown significance cois commercial or financial relationships that could be construed as a potential conflict of interest.
18639,32037778,*fine needle aspiration cytology
18640,32037778,*focus number
18641,32037778,*malignancy
18642,32037778,*predictivity
18643,32037778,*thyroid nodules
18645,32286703,*dapk
18646,32286703,*dna methylation
18647,32286703,*pten
18648,32286703,*diagnosis
18649,32286703,*thyroid nodules
18650,31808043,*fasting glucose
18651,31808043,*observational studies
18652,31808043,*randomized controlled trials
18653,31808043,*time restricted feeding
18654,31808043,*weight loss
18655,32816208,dropouts
18656,32816208,obesity
18657,32816208,treatment failure
18658,32816208,weight management cois
18659,33346472,covid-19
18660,33346472,russia
18661,33346472,epidemic
18662,33346472,iodine deficiency
18663,33346472,iodized salt
18665,33112496,dicer1
18666,33112496,autopsy
18667,33112496,prostate
18668,33112496,rhabdomyosarcoma
18669,32760349,*lymph node metastasis
18670,32760349,*papillary thyroid cancer
18671,32760349,*thyroglobulin antibodies
18672,32760349,*thyroid nodule
18673,32760349,*thyroidectomy
18676,33310924,*iodine supply
18677,33310924,*iodized salt
18678,33310924,*jódellátottság
18679,33310924,*jódozott só
18680,33310924,*pregnant women
18681,33310924,*várandós anyák
18682,33310924,*“silent” prophylaxis
18683,33310924,*„silent” profilaxis
18684,33773966,congenital hypothyroidism
18685,33773966,gland in situ
18686,33773966,monoallelic mutations
18687,33773966,thyroid dysgenesis
18688,33773966,thyroid transcription factors
18689,33740798,anxiety
18690,33740798,depression
18691,33740798,primary hyperparathyroidism
18692,33333891,rthβ
18693,33333891,thrb
18694,33333891,hypercholesterolemia
18695,33333891,hypothyroidism
18696,33333891,resistance to thyroid hormones
18697,33333891,thyroid
18698,33333891,thyroid hormone receptor cois
18699,32687189,* saliva iodine
18700,32687189,*iodine status
18701,32687189,*thyroid function
18702,32676935,covid-19; sars-cov-2
18703,32676935,subacute thyroiditis
18704,32676935,viral thyroiditis cois
18705,33921293,gluten sensitivity
18706,33921293,gut microbiota
18707,33921293,gut mycobiota
18708,33921293,mental status cois
18709,34803920,*cardiac arrhythmias
18710,34803920,*hypothyroidism
18711,34803920,*levothyroxine
18712,34803920,*osteoporosis
18713,34803920,*replacement therapy
18714,34803920,*thyroid cois commercial or financial relationships that could be construed as a potential conflict of interest.
18715,33631011,*duox system genes
18716,33631011,*clinical phenotype
18717,33631011,*congenital hypothyroidism
18718,33631011,*targeted region sequencing
18719,33631011,*thyroid gland
18720,32500518,*covid-19
18721,32500518,*endocrine emergencies
18722,32500518,*endocrine surgery
18723,32500518,*thyroid cancer cois
18725,34400129,economic impact
18726,34400129,hypocalcemia
18727,34400129,hypocalcémie
18728,34400129,hypoparathyroidism
18729,34400129,hypoparathyroïdie
18730,34400129,impact économique
18731,34400129,quality of life
18732,34400129,qualité de vie
18733,34400129,thyroidectomy
18734,34400129,thyroïdectomie
18735,32811342,*elderly
18736,32811342,*hyperthyroidism
18737,32811342,*methimazole
18738,32811342,*radioiodine
18739,33582938,china
18740,33582938,morbidity
18741,33582938,thyroid nodules
18742,33582938,urinary iodine concentration cois
18744,33147928,dose effect
18745,33147928,iodine
18746,33147928,thyroid nodule
18747,33147928,u-shaped curve
18748,33147928,urine
18749,31983029,*lateral lymph node metastasis
18750,31983029,*papillary thyroid carcinoma
18751,31983029,*predictive model
18752,31983029,*risk stratification
18753,31983029,*treatment strategy
18754,31789139,ccl5
18755,31789139,cav-1
18756,31789139,chemokine
18757,31789139,hashimoto’s thyroiditis
18758,31789139,pparγ
18759,31789139,pioglitazone.
18761,34594299,*autoimmune thyroid antibodies
18762,34594299,*fine needle aspirate (fna)
18763,34594299,*microcalcification
18764,34594299,*thyroid cancer
18765,34594299,*tumor size cois commercial or financial relationships that could be construed as a potential conflict of interest.
18766,33460435,*dicer1 mutation
18767,33460435,*thyroid cancer genes
18768,33460435,*thyroid nodules
18769,33106852,*hypothyroidism
18770,33106852,*levothyroxine
18771,33106852,*meta-analysis
18772,33106852,*systematic review
18773,33106852,*thyroidectomy
18774,33106852,*weight gain
18775,32988358,thyroid carcinoma
18776,32988358,aggressive
18777,32988358,breast carcinoma
18778,32988358,diagnostic algorithm
18779,32988358,radiopharmaceuticals
18780,32988358,synchronous
18781,34376229,cardiac metastasis
18782,34376229,case report
18783,34376229,follicular thyroid carcinoma
18784,34376229,hurthle cell carcinoma
18785,34376229,multisite metastases
18786,34376229,pancreatic metastasis
18787,34376229,unusual metastases cois
18788,33111192,*toetva
18789,33111192,*tort
18790,33111192,*transoral endoscopic thyroidectomy
18791,33111192,*transoral robotic thyroidectomy
18793,34010443,desiccated thyroid extracts
18794,34010443,hypothyroidism
18795,34010443,iodine
18796,34010443,levothyroxine
18797,34010443,liothyronine
18798,34010443,selenium
18799,34010443,survey
18800,34010443,thyroid hormones
18801,33772338,thyroid
18802,33772338,malignancy
18803,33772338,nodule
18804,33772338,ultrasonography
18805,33406977,*salt iodization
18806,33406977,*thyroid autoantibodies
18807,33406977,*thyroid dysfunction
18808,31928176,*tibetan
18809,31928176,*iodine nutrition
18810,31928176,*oxygen-deficient plateau
18811,31928176,*thyroid disorders
18813,33645517,ptc
18814,33645517,tpoab
18815,33645517,tgab
18816,33645517,extrathyroidal extension
18817,33645517,lymph node metastasis
18818,32696176,*gli3 gene
18819,32696176,*glis3 gene
18820,32696176,*thyroid dysgenesis
18821,32696176,*thyroid hemiagenesis
18822,32696176,*whole-exome sequencing cois
18823,34126658,autoantibody
18824,34126658,autoimmune thyroiditis
18825,34126658,pediatrics
18826,34126658,thyroid cancer
18827,34126658,thyroid nodule
18828,33643218,*radiofrequency ablation
18829,33643218,*technique
18830,33643218,*thermal ablation
18831,33643218,*thyroid nodules
18832,33643218,*ultrasound cois commercial or financial relationships that could be construed as a potential conflict of interest.
18834,32276716,*graves’ disease
18835,32276716,*outpatient surgery
18836,32276716,*pediatric surgery
18837,32276716,*thyroid cancer
18838,32276716,*thyroid nodule
18839,32276716,*thyroidectomy cois conflicts of interest to disclose.
18840,34539567,*biallelic variant
18841,34539567,*characteristic
18842,34539567,*hypothyroidism
18843,34539567,*oligogenic variant
18844,34539567,*whole-exome sequencing cois commercial or financial relationships that could be construed as a potential conflict of interest.
18845,34284528,cns tumor
18846,34284528,plurihormonal pituitary adenoma
18847,34284528,sella turcica
18848,33827539,hyperparathyroidism
18849,33827539,intrathyroidal parathyroid
18850,33827539,parathyroid cancer
18851,33827539,surgical approach
18852,33827539,thyroid cancer cois
18853,33683595,*chek2
18854,33683595,*dna repair
18855,33683595,*familial non-medullary thyroid carcinoma (fnmtc)
18856,33683595,*founder pathogenic variant
18857,33683595,*thyroid
18859,33104041,*hyperthyroidism
18860,33104041,*parkinson’s disease
18861,33104041,*hypothyroidism
18862,33104041,*neurodegenerative disorder
18863,33104041,*pathophysiology
18864,33104041,*thyroid disease
18865,33104041,*thyroid dysfunction
18868,33254347,"diagnosis, surgical procedures, operative"
18869,33254347,root of neck neoplasms cois relevant financial relationships with commercial interests to disclose.
18870,34644122,*chloride channel
18871,34644122,*chloride exchanger
18872,34644122,*drug discovery
18873,34644122,*epithelium
18874,34644122,"*solute carrier proteins cois applications for chloride transport modulators, which are owned by their respective universities."
18875,33920190,*ages
18876,33920190,*mage
18877,33920190,*rage
18878,33920190,*glycation
18879,33920190,*oxidative stress
18880,33920190,*thyroid gland pathology cois
18882,33751486,autoimmune thyroid disease
18883,33751486,children and adolescents
18884,33751486,dna methylation
18885,33751486,hashimoto thyroiditis
18886,33751486,melting curve analysis
18887,33751486,ptpn22
18888,33035689,*cell free mtdna
18889,33035689,*nd4/nd1
18890,33035689,*thyroid cancer
18891,33035689,*mtdna copy number
18892,33035689,*mtdna integrity
18893,32430758,*ovarian sertoli-leydig cell tumors
18894,32430758,*slcts
18895,34171097,*cancer
18896,34171097,*carcinoma
18897,34171097,*follicular
18898,34171097,*mutation
18899,34171097,*thyroid
18900,34171097,*whole-genome
18901,32910988,*cysteine cathepsins
18902,32910988,*non-canonical trafficking
18903,32910988,*nuclear forms
18904,32910988,*proliferation-promoting
18905,32910988,*thyroid cancer cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
18906,33004735,ablation techniques
18907,33004735,consensus
18908,33004735,guideline
18909,33004735,nodular goiter
18910,33004735,thyroid neoplasms cois
18912,34080176,*hysterosalpingography
18913,34080176,*iodine excess
18914,34080176,*lactation
18915,34080176,*oil-soluble iodinated contrast
18916,34080176,*pregnancy
18917,33096991,*autoimmune thyroid disease
18918,33096991,*cardiac tamponade
18919,33096991,*hypothyroidism
18920,33096991,*pericardial effusion
18921,33096991,*turner syndrome cois
18922,32675393,papillary thyroid carcinoma
18923,32675393,genetic variation
18924,32675393,lncrna
18925,32675393,thyroid function
18926,32072403,fscn1
18927,32072403,immunohistochemistry
18928,32072403,methylation
18929,32072403,promoter
18930,32072403,thyroid cancer
18932,33124651,*tsh
18933,33124651,*congenital hypothyroidism
18934,33124651,*cutoff
18935,33124651,*newborn screening
18937,32188421,maternal and neonatal complications
18938,32188421,pregnancy
18939,32188421,urinary iodine concentration cois
18940,32851577,*cd71
18941,32851577,*primary immune deficiency
18942,32851577,*tfr1
18943,32851577,*a mutation in tfrc
18944,32851577,*combined immunodeficiency cois
18945,32899424,mir-146b
18946,32899424,mir-181b
18947,32899424,mir-21
18948,32899424,mir-221
18949,32899424,mir-222
18950,32899424,papillary thyroid carcinoma
18951,32899424,plasma cois
18952,32842364,detection rate
18953,32842364,fluorescence intensity
18954,32842364,influencing factor
18955,32842364,parathyroid glands
18956,32714280,*cushing's disease
18957,32714280,*dicer1
18958,32714280,*corticotropinoma
18959,32714280,*disease-modifying gene
18960,32714280,*pituitary neuroendocrine tumor
18961,34740022,*acromegaly
18962,34740022,*igf-1
18963,34740022,*risk factors
18964,34740022,*thyroid nodules
18966,31964247,*cost-effectiveness
18967,31964247,*decision-analytic modeling
18968,31964247,*effectiveness
18969,31964247,*iodine deficiency-related diseases
18970,31964247,*systematic review
18971,33036505,axillary approach
18972,33036505,"surgical procedures, minimally invasive"
18973,33036505,thyroid neoplasms
18974,33036505,thyroidectomy
18976,32075540,*china
18977,32075540,*iodine
18978,32075540,*prevalence
18979,32075540,*thyroid disorders
18980,32075540,*universal salt iodization
20476,23646218,benign thyroid hypertrophy
20477,23646218,giant goiter
20478,23646218,goiter
20479,23646218,multinodular goiter
20480,23646218,thyroidectomy
20489,23136541,nodular goiter
20490,23136541,peri-operative treatment
20491,23136541,surgical intervention. cois
20492,23998691,hyperthyroidism
20493,23998691,hypothyroidism
20494,23998691,menopause
20495,23998691,nodular goiter
20496,23998691,thyroid hormone function
20510,22362641,congenital hypothyroidism
20511,22362641,dyshormonogenetic goiter
20512,22362641,euthyroid
20513,22362641,follicular lesion
20514,22362641,follicular neoplasm
20517,24847400,large goiter
20518,24847400,morbidity
20519,24847400,thyroidectomy
20530,23688788,complications
20531,23688788,goiter
20532,23688788,levothyroxine
20533,23688788,lobectomy
20534,23688788,mng
20535,23688788,multinodular
20536,23688788,recurrence
20537,23688788,resection
20538,23688788,thyroid
20539,23688788,thyroidectomy
20548,24117750,minimally invasive surgery
20549,24117750,retrosternal goiter
20550,24117750,robot-assisted surgery
20551,24227901,lingual thyroid goiter
20552,24227901,thyroid ectopias
20553,24227901,transoral robotic surgery
20578,24239133,bocio endotorácico
20579,24239133,esternotomía
20580,24239133,intrathoracic goiter
20581,24239133,mediastino posterior
20582,24239133,posterior mediastinum
20583,24239133,sternotomy
20584,24239133,thoracotomy
20585,24239133,thyroidectomy
20586,24239133,tiroidectomía
20587,24239133,toracotomía
20610,25047208,extracervical scarless neck thyroidectomy (esnt)
20611,25047208,minimal neck incision thyroidectomy (mnit)
20612,25047208,minimally invasive video-assisted thyroidectomy (mivat)
20613,25047208,nodular goitre
20614,25047208,thyroid cancer
20622,24239215,chirurgie oculo-motrice
20623,24239215,chirurgie palpébrale
20624,24239215,corticosteroids
20625,24239215,corticothérapie
20626,24239215,dysthyroid orbitopathy
20627,24239215,décompression orbitaire
20628,24239215,eyelid surgery
20629,24239215,graves’ disease
20630,24239215,graves’ orbitopathy
20631,24239215,maladie de basedow
20632,24239215,multidisciplinaire
20633,24239215,multidisciplinary
20634,24239215,oculomotor surgery
20635,24239215,orbital decompression surgery
20636,24239215,orbitopathie basedowienne
20637,24239215,orbitopathie dysthyroïdienne
20638,24239215,radiation therapy
20639,24239215,radiothérapie
20666,24043977,airway stenting
20667,24043977,radiofrequency ablation
20668,24043977,thyroid goiter
20728,23993801,airway obstruction
20729,23993801,caesarean section
20730,23993801,fibreoptic intubation
20731,23993801,thyroidectomy
20752,24211307,carcinome papillaire de la thyroïde
20753,24211307,goitre multi-nodulaire
20754,24211307,hyperthyroidie
20755,24211307,hyperthyroidism
20756,24211307,multinodular goiter
20757,24211307,panuveitis
20758,24211307,panuvéite
20759,24211307,papillary thyroid carcinoma
20760,24211307,vascularite veineuse
20761,24211307,venous vasculitis
20767,23337610,graves’ disease
20768,23337610,hyperthyroidism
20769,23337610,suicide
20778,23838540,deafness
20779,23838540,enlarged vestibular aqueduct
20780,23838540,pendred syndrome
20781,23838540,pendrin
20782,23838540,slc26a4
20788,24211158,anxiety disorders
20789,24211158,autoimmune thyroiditis
20790,24211158,depression
20791,24211158,goiter
20792,24211158,hashimoto's thyroiditis
20796,23685895,nob1
20797,23685895,papillary thyroid carcinoma
20798,23685895,clinical significance
20799,23685895,immunohistochemistry
20800,23685895,quantitative rt–pcr
20832,23650151,delhi
20833,23650151,iodine deficiency disorders
20834,23650151,iodized salt
20835,23650151,urinary iodine excretion
20839,24327568,fine-needle cytology
20840,24327568,mantel zone lymphoma
20841,24327568,micrornas
20842,24327568,primary thyroid lymphoma
20843,24327568,thyroid cancer
20847,24043280,goiter
20848,24043280,neonatal graves’ disease
20849,24043280,respiratory failure
20850,24043280,thyroid
20853,23690528,airway management
20854,23690528,anesthesia
20855,23690528,general
20856,23690528,thyroidectomy
20859,23428758,agreement
20860,23428758,bocio
20861,23428758,concordancia
20862,23428758,goitre
20863,23428758,interobservador
20864,23428758,interobserver
20867,23645248,oestrogen
20868,23645248,progenitor cells
20869,23645248,thyroid nodules
20870,23645248,thyroid stem cells
20872,24082285,radioiodine
20873,24082285,hyperthyroidism
20887,24144816,benign multinodular goiter
20888,24144816,complications
20889,24144816,incidental thyroid cancer
20890,24144816,jóindulatú multinodularis golyva
20891,24144816,szövődmények
20892,24144816,tapasztalatok
20893,24144816,total thyreoidectomia
20894,24144816,total thyroidectomy
20895,23303305,endocrinology
20896,23303305,intensive care
20897,23303305,neonatology
20924,24249820,laryngeal nerve palsy
20925,24249820,methimazole
20926,24249820,pediatric graves’ disease
20927,24249820,reversible
20928,24249820,vocal cord paralysis
20968,24222113,braf mutations
20969,24222113,"hras, kras and nras mutations"
20970,24222113,kras codon 59 deletion
20971,24222113,follicular-patterned thyroid lesions
20980,22987562,carotid sheath dissection
20981,22987562,intraoperative neuromonitoring
20982,22987562,recurrent laryngeal nerve
20983,22987562,thyroid surgery
20984,22987562,vagal nerve stimulation
21019,24376294,endemic goitre
21020,24376294,parathyroid surgery
21021,24376294,video-assisted parathyroidectomy
21022,24376294,video-assisted thyroidectomy
21037,23473435,bisturí armónico
21038,23473435,bocio multinodular
21039,23473435,budget impact
21040,23473435,harmonic scalpel
21041,23473435,impacto económico
21042,23473435,multinodular goitre
21043,23473435,thyroidectomy
21044,23473435,tiroidectomía
21080,22351646,fine-needle aspiration
21081,22351646,malignant melanoma
21082,22351646,thyroid cyst wall atypia
21101,25103076,graves disease
21102,25103076,thyroidectomy
21103,25103076,volume
21121,24629864,graves' disease
21122,24629864,childhood
21123,24629864,hyperthyroidism
21128,23918194,nerve monitoring
21129,23918194,parathyroid surgery
21130,23918194,recurrent laryngeal nerve
21131,23918194,thyroid surgery
21141,24411211,acute pericarditis
21142,24411211,graves' disease
21143,24411211,thyroid crisis
21145,24034725,adaptive thresholding
21146,24034725,contrast enhancement
21147,24034725,image segmentation
21148,24034725,morphology
21149,24034725,planar scintigraphy
21150,24034725,radioiodine therapy
21151,24034725,thyroid volume estimation
21152,24034725,ultrasonography
21191,22511831,decompression
21192,22511831,optic neuropathy
21193,22511831,radiation
21194,22511831,steroid
21195,22511831,thyroid eye diseases cois
21205,24070662,anti–thyroid peroxidase antibodies
21206,24070662,autoimmune thyroiditis
21207,24070662,hashimoto's thyroiditis
21208,24070662,quality of life
21209,24070662,thyroidectomy
21217,24199816,basedow graves’ disease
21218,24199816,cas
21219,24199816,proptosis
21220,24199816,thyroid
21227,24704350,graves ophthalmopathy
21228,24704350,diplopia
21229,24704350,exophthalmos
21230,24704350,keratitis
21231,24704350,natural orifice transluminal endoscopic surgery
21237,22991383,laser ablation
21238,22991383,multinodular goiter
21239,22991383,thyroid nodules
21241,24291390,at
21242,24291390,angiogenesis
21243,24291390,anti-tpo
21244,24291390,anti-tg
21245,24291390,autoantibody
21246,24291390,ci
21247,24291390,edn1
21248,24291390,ednra
21249,24291390,endothelin 1
21250,24291390,endothelin family
21251,24291390,endothelin receptor type a
21252,24291390,gd
21253,24291390,graves' disease
21254,24291390,hwe
21255,24291390,hardy–weinberg equilibrium
21256,24291390,icam1
21257,24291390,intercellular adhesion molecule 1
21258,24291390,mmi
21259,24291390,or
21260,24291390,odds ratio
21261,24291390,ophthalmopathy
21262,24291390,ptu
21263,24291390,polymorphism
21264,24291390,snps
21265,24291390,tnfα
21266,24291390,trab
21267,24291390,tsh
21268,24291390,tsh receptor antibody
21269,24291390,tumor necrosis factor α
21270,24291390,utr
21271,24291390,untranslated region
21272,24291390,vegf
21273,24291390,anti-thyroglobulin
21274,24291390,anti-thyroid
21275,24291390,anti-thyroid peroxidase
21276,24291390,confidence interval
21277,24291390,methimazole
21278,24291390,propylthiouracil
21279,24291390,single nucleotide polymorphisms
21280,24291390,thyroid-stimulating hormone
21281,24291390,vascular endothelial growth factor
21284,23518423,brain infarction
21285,23518423,encephaloduroarteriosynangiosis (edas)
21286,23518423,graves’ disease
21287,23518423,hyperthyroidism
21288,23518423,moyamoya disease
21324,23868574,goiter
21325,23868574,iodized salt
21326,23868574,thyroid
21327,23868574,urinary iodine excretion
21355,24311524,orbit
21361,23482353,medicare
21362,23482353,age-associated disease
21363,23482353,comorbidity
21364,23482353,disease onset
21365,23482353,older people
21366,23482353,time trends
21368,24154901,autoimmune thyroiditis
21369,24154901,inferior thyroid artery
21370,24154901,thyroid doppler sonography
21371,23329888,asian populations.
21372,23329888,graves' disease
21373,23329888,hla-b*46
21374,23329888,meta-analysis cois
21388,23477757,embarazo
21389,23477757,enfermedad de graves
21390,23477757,gestational transient thyrotoxicosis
21391,23477757,graves’ disease
21392,23477757,hiperemesis gravídica
21393,23477757,hipertiroidismo
21394,23477757,hyperemesis gravidarum
21395,23477757,hyperthyroidism
21396,23477757,pregnancy
21397,23477757,tirotoxicosis gestacional transitoria
21407,22952313,graves
21408,22952313,graves disease
21409,22952313,hyperthyroidism
21410,22952313,myasthenia gravis
21411,22952313,ophthalmoplegia
21412,22952313,ptosis
21413,22952313,thyroid
21457,23535627,asian continental ancestry group
21458,23535627,graves ophthalmopathy
21459,23535627,psychiatric status rating scales
21479,23709442,graves’ orbitopathy
21480,23709442,tsh-receptor autoantibody
21481,23709442,disease activity
21482,23709442,severity cois
21485,23835254,anestesia
21486,23835254,anesthesia
21487,23835254,cirugía de descompresión orbitaria
21488,23835254,embarazo
21489,23835254,graves-basedow
21490,23835254,oftalmopatía
21491,23835254,ophthalmopathy
21492,23835254,orbital decompression surgery
21493,23835254,orbitopathy
21494,23835254,orbitopatía
21495,23835254,pregnancy
21503,22416184,autoimmunity
21504,22416184,cag-a
21505,22416184,graves’ disease
21506,22416184,hashimoto’s thyroiditis
21507,22416184,helicobacter pylori
21508,22416184,hyperthyroidism
21509,22416184,hypothyroidism
21526,24119625,graves' disease
21527,24119625,moyamoya syndrome
21528,24119625,antithyroid therapy
21546,23796613,(131)i
21547,23796613,children
21548,23796613,edad pediátrica
21549,23796613,enfermedad de graves
21550,23796613,graves disease
21551,23796613,i(131)
21552,23796613,radioiodine therapy
21553,23796613,radioyodo
21554,23538281,cáncer de tiroides
21555,23538281,enfermedad de graves
21556,23538281,graves’ disease
21557,23538281,pequeñas-moléculas
21558,23538281,receptor de la tsh
21559,23538281,small molecules
21560,23538281,tsh-receptor
21561,23538281,thyroid
21562,23538281,thyroid cancer
21563,23538281,thyrotropin (tsh)
21564,23538281,tiroides
21565,23538281,tirotropina (tsh)
21574,24646903,enfermedad de la superficie ocular
21575,24646903,graves’ ophthalmopathy
21576,24646903,lentes de contacto mini esclerales
21577,24646903,mini-scleral contact lenses
21578,24646903,ocular surface disease
21579,24646903,oftalmopatía de graves
21591,23962080,autoimmune thyroid disease
21592,23962080,intractability
21593,23962080,polymorphism
21594,23962080,severity
21595,23962080,thyrotropin receptor
21636,24231095,graves' ophthalmopathy
21637,24231095,bulbar conjunctiva
21638,24231095,dry eye
21639,24231095,impression cytology
21640,24231095,in vivo confocal microscopy
21641,24135759,adipogenesis
21642,24135759,orbital fibroblasts
21643,24135759,proliferation
21644,24135759,thyroid eye disease
21646,22985335,graves’ disease
21647,22985335,hypoparathyroidism
21648,22985335,thyroid cancer
21649,22985335,thyroidectomy
21650,22985335,thyrotoxicosis
21657,23806737,ca-125
21658,23806737,ct
21659,23806737,hyperthyroidism
21660,23806737,meigs syndrome
21661,23806737,pleural effusion
21662,23806737,tfts
21663,23806737,tg-ab
21664,23806737,tpo-ab
21665,23806737,tsh
21666,23806737,tsh receptor
21667,23806737,tshr
21668,23806737,tshr-ab
21669,23806737,thyroid cancer
21670,23806737,us
21671,23806737,cancer antigen-125
21672,23806737,computed tomography
21673,23806737,thyroglobulin autoantibodies
21674,23806737,thyroid function tests
21675,23806737,thyroid peroxidase autoantibodies
21676,23806737,thyrotropin
21677,23806737,thyrotropin receptors
21678,23806737,thyrotropin receptors autoantibodies
21679,23806737,ultrasound
21707,23060717,acquired lower eyelid epiblepharon
21708,23060717,graves ophthalmopathy
21709,23060717,lower eyelid epiblepharon repair
21710,23060717,lower eyelid retraction cois
21714,23728841,dicer1
21715,23728841,family history
21716,23728841,multinodular goiter
21717,23728841,ovarian sertoli-leydig cell tumors
21718,23728841,tumor surveillance
21736,24029729,graves' disease
21737,24029729,rhesus monkeys
21738,24029729,thyrotropin receptor a-subunit
21744,24629859,fetal diseases
21745,24629859,goiter
21746,24629859,graves disease
21747,24629859,humans
21748,24629859,hyperthyroidism
21749,24629859,hypothyroidism
21750,24629859,maternal–fetal exchange
21751,24629859,pregnancy
21752,24629859,thyroid diseases: drug therapy
21753,24629859,thyroxine: administration and dosage
21761,24307850,agranulocytosis
21762,24307850,graves disease
21763,24307850,guillain-barre syndrome cois
21778,23757290,disease intractability
21779,23757290,disease severity
21780,23757290,hashimoto’s disease
21781,23757290,il-10
21782,23757290,single nucleotide polymorphism
21801,24177168,autoimmune thyroid diseases
21802,24177168,erythropoietin
21803,24177168,intractability
21804,24177168,severity
21805,24177168,single nucleotide polymorphism
21806,23954851,antioxidants
21807,23954851,biomarkers of oxidative stress
21808,23954851,chondroitin sulfate
21809,23954851,graves' disease
21835,23849367,asian patients
21836,23849367,hypokalemia
21837,23849367,paralysis
21838,23849367,thyrotoxicosis
21839,23849367,weakness
21853,24227294,gwas
21854,24227294,causal variants
21855,24227294,colocalisation
21856,24227294,genetic association
21858,22907781,graves' disease
21859,22907781,minimal-incision thyroidectomy
21860,22907781,minimally invasive surgery
21861,22907781,postoperative complications
21862,22907781,thyroid
21887,24289805,gpr174
21888,24289805,graves' disease
21889,24289805,poland
21890,24289805,x chromosome
21891,24289805,association
21892,24289805,autoimmune disease
21893,24289805,rs3827440
21894,24289805,single nucleotide polymorphism
21895,23756266,drug-induced cholestasis
21896,23756266,plasmapheresis
21897,23756266,thyrotoxicosis
21911,23954255,autoimmune thyroid disease
21912,23954255,ci
21913,23954255,caga
21914,23954255,edta
21915,23954255,ethylene diamine tetraacetic acid
21916,23954255,ft3
21917,23954255,ft4
21918,23954255,gd
21919,23954255,graves disease
21920,23954255,h. pylori
21921,23954255,hla
21922,23954255,helicobacter pylori
21923,23954255,human leukocyte antigen
21924,23954255,igg
21925,23954255,immunoglobulin g
21926,23954255,or
21927,23954255,pcr
21928,23954255,spss
21929,23954255,statistical product and service solutions
21930,23954255,tpoab
21931,23954255,trab
21932,23954255,tsh
21933,23954255,tgab
21934,23954255,confidence intervals
21935,23954255,cytotoxin-associated gene a
21936,23954255,dntp
21937,23954255,deoxy-ribonucleoside triphosphate
21938,23954255,free thyroxine
21939,23954255,free triiodothyronine
21941,23954255,odds ratio
21942,23954255,polymerase chain reaction
21943,23954255,thyroglobulin antibody
21944,23954255,thyroid peroxidase antibody
21945,23954255,thyroid stimulating hormone
21946,23954255,thyrotrophin receptor antibody
21954,24124099,diplopia
21955,24124099,endoscopic orbital floor decompression
21956,24124099,inferomedial orbital strut
21957,24124099,orbital decompression
21975,23839980,endoscopic orbital decompression
21976,23839980,graves' orbitopathy
21977,23839980,complications
21978,23839980,exophthalmos
21979,23839980,sinonasal
21987,22972028,*pingmu decoction
21988,22972028,*apoptosis
21989,22972028,*adipocytes
21990,22972028,*graves' ophthalmophathy
22003,24311923,epidemiology
22004,24311923,graves ophthalmopathy
22005,24311923,korea
22006,24311923,prevalence
22007,24311923,risk factors cois
22032,24411304,hashimoto's thyroiditis
22033,24411304,metastatic burden
22034,24411304,metastatic disease
22035,24411304,multi-nodular goiter
22036,24411304,thyroglobulin
22037,24411304,thyroid cancer
22038,24411304,thyroidectomy
22039,24411304,thyroiditis
22042,23827012,anticorps anti-cytoplasme des polynucléaires neutrophiles
22043,23827012,antineutrophil cytoplasmic antibodies
22044,23827012,benzylthio-uracile
22045,23827012,benzylthiouracil
22046,23827012,graves’ disease
22047,23827012,maladie de basedow
22048,23827012,vascularite
22049,23827012,vasculitis
22051,23667180,complex traits
22052,23667180,endocrinology
22053,23667180,genetics
22054,23667180,genome-wide
22055,23667180,thyroid disease
22061,25443353,hashimoto's thyroiditis
22062,25443353,autoimmune thyroiditis
22063,25443353,encephalopathy
22064,25443353,hallucinations
22065,25443353,steroids
22074,22787382,bullous systemic lupus erythematosus
22075,22787382,drug-induced lupus erythematosus
22076,22787382,graves disease
22077,22787382,methimazole
22092,23919315,graves' disease
22093,23919315,cardiomegaly
22094,23919315,forensic autopsy
22095,23919315,forensic science
22096,23919315,hyperthyroidism
22097,23919315,sudden unexpected death
22100,24456861,atrophic renal parenchyma-like tumor
22101,24456861,comparative genomic hybridization
22102,24456861,humara
22103,24456861,kidney
22104,24456861,thyroid-like renal tumor
22133,24011567,graves’ disease
22134,24011567,incidental malignancy
22135,24011567,surgical therapy
22157,23681867,endocrine diseases
22158,23681867,pharmacotherapy
22164,23901889,b lymphocytes
22165,23901889,graves' disease
22166,23901889,t lymphocytes
22181,23973401,cryptococcal meningitis
22182,23973401,lupus
22183,23973401,opportunist infection
22184,23578170,anti-gal
22185,23578170,increased immunogenicity
22186,23578170,tumour vaccine
22187,23578170,wound healing
22188,23578170,α-gal epitopes
22194,24095912,autoimmun thyreoiditis
22195,24095912,autoimmune thyroiditis
22196,24095912,diabetes mellitus
22197,24095912,fertility
22198,24095912,meddőség
22199,24095912,selenium
22200,24095912,szelén
22210,24334133,autoimmunity
22211,24334133,autoimmunitás
22212,24334133,infertility
22213,24334133,meddőség
22214,24334133,pajzsmirigy
22215,24334133,post partum periódus
22216,24334133,postpartum period
22217,24334133,pregnancy
22218,24334133,terhesség
22219,24334133,thyroid
22230,23845451,(131)i-iodide
22231,23845451,cáncer folicular de tiroides
22232,23845451,enfermedad metastásica
22233,23845451,follicular thyroid cancer
22234,23845451,metastatic disease
22235,23845451,radioiodine therapy
22236,23845451,spect
22237,23845451,terapia con yodo radioactivo
22238,23845451,yodo radioactivo (131)i cois this work there are no financial or ethical conflicts of interest.
22241,23664858,cox
22242,23664858,cox-2
22243,23664858,il
22244,23664858,il-1β
22245,23664858,nf
22246,23664858,nf-κb
22247,23664858,pg
22248,23664858,pge(2)
22249,23664858,tao
22250,23664858,cyclooxygenase
22251,23664858,interleukin
22252,23664858,nuclear factor
22253,23664858,orbital fibroblast
22254,23664858,pirfenidone
22255,23664858,prostaglandin
22256,23664858,thyroid-associated ophthalmopathy
22258,23958483,octreotide
22259,23958483,somatostatin analogs
22260,23958483,tsh-secreting pituitary tumor
22261,23958483,thyrotropinoma
22267,23958398,antibodies
22268,23958398,apoptosis
22269,23958398,proliferation
22270,23958398,ros-signaling
22271,23958398,tsh receptor
22272,23958398,thyrocyte
22316,24335091,thyroid carcinoma
22317,24335091,cancer
22318,24335091,endocrine surgery
22319,24335091,follicular carcinoma
22320,24335091,neoplastic thrombus
22332,24250332,jaundice
22333,24250332,thionamides
22334,24250332,thyrotoxicosis
22343,24291398,cox-2
22344,24291398,cellular antioxidant defense mechanisms
22345,24291398,cerebral cavernous malformations
22346,24291398,free radicals
22347,24291398,krit1
22348,24291398,reactive oxygen species
22349,24291398,c-jun
22354,22386642,ait
22355,22386642,amiodarone
22356,22386642,bmi
22357,22386642,body mass index
22358,22386642,chd
22359,22386642,congenital heart defects
22360,22386642,cyanosis
22361,22386642,drug toxicity
22362,22386642,hyperthyroidism
22363,22386642,lvef
22364,22386642,t3
22365,22386642,t4
22366,22386642,tsh
22367,22386642,amiodarone-induced thyrotoxicosis
22369,22386642,congenital heart disease
22370,22386642,left ventricular ejection fraction
22371,22386642,thyroid stimulating hormone
22372,22386642,thyroxine
22373,22386642,triiodothyronine
22378,23553532,thyroid disorders
22379,23553532,epidemiology
22380,23553532,otolaryngology
22381,23553532,specialty
22382,23553532,thyroid nodule
22383,23553532,thyroidectomy
22402,24273003,cd-44
22403,24273003,hbme-1
22404,24273003,fine needle aspiration cytology
22405,24273003,galectin-3
22406,24273003,papillary thyroid carcinoma
22416,23838336,angiosarcoma
22417,23838336,haematoma
22418,23838336,haemothorax
22419,23838336,pleural metastasis
22423,23569858,granuloma
22424,23569858,thyroid
22425,23569858,tuberculosis cois
22434,24189283,at
22435,24189283,autoimmune thyroiditis
22436,24189283,ccl
22437,24189283,cd
22438,24189283,cia
22439,24189283,cs
22440,24189283,csf
22441,24189283,cxcl
22442,24189283,cxcl10
22443,24189283,cxcr3
22444,24189283,circulating cxcl10 levels
22445,24189283,cryoglobulinemia
22446,24189283,gad
22447,24189283,gd
22448,24189283,go
22449,24189283,graves
22450,24189283,graves' disease
22451,24189283,graves' ophthalmopathy
22452,24189283,graves’ disease
22453,24189283,graves’ ophthalmopathy
22454,24189283,gtx
22455,24189283,hepatitis c virus infection associated mixed cryoglobulinemia
22456,24189283,ifn
22457,24189283,ifn-γ-induced protein 10
22458,24189283,il
22459,24189283,ip-10
22460,24189283,jia
22461,24189283,juvenile idiopathic arthritis
22462,24189283,mc
22463,24189283,mc+hcv
22464,24189283,mcp-1
22465,24189283,mdc/ccl22
22466,24189283,mig
22467,24189283,mmi
22468,24189283,mp
22469,24189283,nf-kb
22470,24189283,nk
22471,24189283,npsle
22472,24189283,ppar-γ
22473,24189283,ptc
22474,24189283,papillary thyroid cancer
22475,24189283,peroxisome proliferator-activated receptor-γ
22476,24189283,psa
22477,24189283,psoriatic arthritis
22478,24189283,ra
22479,24189283,rankl
22480,24189283,rantes
22481,24189283,ret/ptc
22482,24189283,rheumatoid arthritis
22483,24189283,sf
22484,24189283,sle
22485,24189283,ss
22486,24189283,ssc
22487,24189283,st
22488,24189283,sjögren syndrome
22489,24189283,systemic lupus erythematosus
22490,24189283,systemic sclerosis
22491,24189283,t helper
22492,24189283,t1d
22493,24189283,tarc/ccl17
22494,24189283,tfc
22495,24189283,tnf
22496,24189283,tng
22497,24189283,tr
22498,24189283,th
22499,24189283,thyroid follicular cells
22500,24189283,thyroiditis
22501,24189283,toxic nodular goiter
22502,24189283,type 1 diabetes
22504,24189283,cerebrospinal fluid
22505,24189283,chemokine (c–c motif) ligand
22506,24189283,chemokine (c–x–c motif) ligand
22507,24189283,chemokine (c–x–c motif) receptor 3
22509,24189283,cluster of differentiation
22510,24189283,collagen-induced arthritis
22511,24189283,corticosteroid
22512,24189283,glutamic acid decarboxylase
22514,24189283,hyperthyroid gd
22515,24189283,interferon
22516,24189283,interleukin
22518,24189283,macrophage-derived chemokine/ccl22
22519,24189283,methimazole
22520,24189283,methylprednisolone
22521,24189283,mixed cryoglobulinemia
22522,24189283,monocyte chemotactic protein-1
22523,24189283,monokine induced by ifn-γ
22524,24189283,natural killer
22525,24189283,neuropsychiatric sle
22526,24189283,normal t cell expressed and secreted
22527,24189283,nuclear factor-kappa b
22531,24189283,rearranged in transformation/ptc
22532,24189283,receptor activator of nuclear factor kappa-b ligand
22534,24189283,scxcl10
22535,24189283,synovial fluid
22536,24189283,synovial tissue
22539,24189283,teleradiotherapy
22540,24189283,thymus and activation regulated chemokine/ccl17
22543,24189283,tumor necrosis factor
22562,23808516,bronchoscopy
22563,23808516,cardiothoracic surgery
22564,23808516,critical care medicine
22565,23808516,intervention techniques
22566,23808516,ventilation
22571,24484950,ectopic thyroid
22572,24484950,laryngeal location
22573,24484950,surgical treatment
22574,24484950,leczenie chirurgiczne
22575,24484950,lokalizacja krtaniowa
22576,24484950,tarczyca ektopowa
22601,23572163,differentiated thyroid carcinoma
22602,23572163,follow-up
22603,23572163,neck ultrasound
22604,23572163,radioiodine remnant ablation
22605,23572163,recurrence
22606,23572163,thyroglobulin
22611,24292913,case-based learning
22612,24292913,self-directed learning
22613,24292913,soft skills
22624,23240978,cowden syndrome
22625,23240978,pten
22626,23240978,ganglioneuromas
22627,23240978,hamartomatous polyps
22628,23240978,mosaicism
22637,23780707,clinicopathological characteristics
22638,23780707,incidental
22639,23780707,nonincidental
22640,23780707,papillary thyroid microcarcinoma
22641,23780707,surgical treatment
22647,24077472,case-control studies
22648,24077472,congenital hypothyroidism
22649,24077472,iran
22650,24077472,logistic regression
22651,24077472,propensity score
22652,23881987,lymphoma
22653,23881987,primary thyroid lymphoma
22654,23881987,thyroid
22655,23881987,thyroid malignancy
22656,23881987,thyroid surgery cois article.
22666,22431287,cowden disease
22667,22431287,cowden syndrome
22668,22431287,pathology
22669,22431287,surgical management
22670,22431287,thyroid
22672,24629858,dehal1 gene
22673,24629858,iyd
22674,24629858,congenital hypothyroidism
22675,24629858,iodide recycling
22676,24629858,mass spectrometry
22677,24629858,mental retardation
22678,24629858,neonatal screening
22684,23693108,"carcinoma, papillary, follicular"
22685,23693108,thyroid neoplasms
22689,24067547,t3
22690,24067547,amiodarone-induced thyrotoxicosis
22691,24067547,heart
22692,24067547,hyperthyroidism
22693,24067547,hypothyroidism
22694,24067547,thyroid hormone
22695,24067547,thyrotoxicosis
22696,24067547,triiodothyronine
22708,23933148,congenital hypothyroidism
22709,23933148,deletion
22710,23933148,inversion
22711,23933148,mutation
22712,23933148,thyroglobulin gene
22745,24301304,circulating biomarkers
22746,24301304,microrna
22747,24301304,papillary thyroid cancer
22748,24301304,recurrence
22749,24301304,tissue biomarkers
23109,21274344,pendred syndrome
23110,21274344,congenital hypothyroidism
23111,21274344,pseudo−pendred syndrome
23112,21274344,thyroid peroxidase defect
23142,21274318,thyrotropin receptor
23143,21274318,germline mutation
23144,21274318,nonautoimmune hyperthyroidism
23364,21274321,congenital hypothyroidism
23365,21274321,thyroxine
23434,21052505,clinical course
23435,21052505,optic nerve diseases
23436,21052505,risk factors
23437,21052505,thyroid-associated orbitopathy cois
23542,21274336,hyperthyroidism
23543,21274336,isolated
23544,21274336,neonatal
23545,21274336,sialadenitis
23546,21274336,submandibular
23579,21716594,biological assay
23580,21716594,graves disease
23581,21716594,"immunoglobulins, thyroid-stimulating"
23582,21716594,"receptors, thyrotropin"
23583,21716594,thyrotropin-binding inhibitory immunoglobulin cois
23626,20379454,depression
23627,20379454,graves ophthalmopathy
23628,20379454,quality of life cois
23647,20195406,graves disease
23648,20195406,thyroid neoplasms
23649,20195406,ultrasonography cois
23770,20157407,congenital fibrosis syndrome of the extraocular muscles
23771,20157407,congenital retraction
23772,20157407,epiblepharon
23773,20157407,lower eyelid retraction
23774,20157407,thyroid-associated ophthalmopathy
23823,22148004,destructive thyroiditis
23824,22148004,graves disease
23825,22148004,interferons
23873,20835551,immunohistochemistry
23874,20835551,ndrg1
23875,20835551,thyroid carcinoma
23876,20835551,thyroid gland
23877,20835551,tissue microarray
23948,20808683,mutation
23949,20808683,thyroid hormone receptor
23950,20808683,thyroid hormone receptors beta
23951,20808683,thyroid hormone resistance syndrom
23952,20808683,thyroid neoplasms
24162,25058777,sternotomy
24163,25058777,substernal goiter
24164,25058777,surgery
24165,25058777,treatment
24166,25047203,us elastosonography
24167,25047203,indeterminate nodules
24168,25047203,thyroid
24169,25047203,thyroid nodules
24170,25047203,thyroid ultrasound
24173,24622964,adenomatous multinodular goiter
24174,24622964,airway obstruction
24175,24622964,mediastinum
24176,24622964,neck mass
24177,24622964,pediatric
24179,25297557,plummer's disease
24180,25297557,cat
24181,25297557,hyperthyroidism
24182,25297557,thyroid
24183,25297557,thyrotoxicosis
24185,25976851,sternotomy
24186,25976851,substernal goiter
24187,25976851,thyroidectomy
24188,25363013,amniocentesis
24189,25363013,intrauterine therapy
24190,25363013,l-thyroxine
24191,25363013,labor dystocia
24192,25363013,polyhydramnios
24193,26327954,histology
24194,26327954,pre-sternale
24195,26327954,surgery
24196,26327954,thyroid enlargement
24197,25555013,riedel thyroiditis
24198,25555013,amiodarone-induced thyroiditis
24199,25555013,subacute thyroiditis
24207,25752670,complications
24208,25752670,electrocautery
24209,25752670,substernal goiter
24210,25752670,thyroidectomy
24211,25752670,ultrasonic devise
24217,26955411,granuloma
24218,26955411,multinodular goiter
24219,26955411,tuberculosis
24222,25157987,cervical approach
24223,25157987,complications
24224,25157987,elderly
24225,25157987,mediastinal goiter
24226,25157987,thyroidectomy
24230,24931349,goiter
24231,24931349,recurrent laryngeal nerve
24232,24931349,thyroid
24233,24931349,thyroid hormone
24234,24931349,thyroidectomy
24241,26161201,immunohistochemical examination
24242,26161201,goiter
24243,26161201,systemic amyloidosis
24253,26443487,deafness
24254,26443487,genetics
24255,26443487,genome
24256,26443487,hearing loss
24257,26443487,sequencing
24267,25499094,developing countries
24268,25499094,endemic goiter
24269,25499094,iodine deficiency
24270,25499094,thyroidectomy
24272,25242682,anaplastic thyroid carcinoma
24273,25242682,goiter
24274,25242682,survival
24278,24880605,cervico-mediastinal goiter
24279,24880605,recurrent laryngeal nerve palsy
24280,24880605,substernal goiter
24281,24880605,thyroid surgery
24282,24880605,total thyroidectomy
24288,26389933,epidemiology
24289,26389933,metabolic syndrome
24290,26389933,prevalence
24291,26389933,risk factor
24296,24519672,iodine deficiency
24297,24519672,children
24298,24519672,goiter prevalence
24300,25594634,multinodular goiter
24301,25594634,recurrence classification description: endocrinology
24302,25594634,thyroidectomy
24305,25981745,multinodular goiter
24306,25981745,proliferation
24307,25981745,proteomics
24308,25981745,ttf1
24316,25614405,doppler sonography
24317,25614405,calcification
24318,25614405,diffuse large b-cell lymphoma
24319,25614405,head and neck ultrasound
24320,25614405,nodular goiter
24321,25614405,sonography
24322,25614405,thyroid lymphoma
24325,26293122,basedow
24326,26293122,graves
24327,26293122,autoimmunity
24328,26293122,chemokines
24329,26293122,thyroid
24330,25629792,endemic
24331,25629792,goiter
24332,25629792,iodine
24333,25629792,pregnancy
24334,25629792,thyroid
24335,25667715,atrioventricular
24336,25667715,hyperthyroidism
24337,25667715,multinodular goiter
24339,25047199,epidemiology
24340,25047199,goitre
24341,25047199,iodine deficiency
24342,25047199,nodular goitre
24343,25047199,nodules
24344,25047199,review
24346,25613936,endemic goiter
24347,25613936,enquête épidémiologique
24348,25613936,epidemiological survey
24349,25613936,goitre endémique
24350,25613936,hormones thyroïdiennes
24351,25613936,iode urinaire
24352,25613936,iodine deficiency disorders
24353,25613936,thyroid hormones
24354,25613936,troubles dus à la carence en iode
24355,25613936,urinary iodine
24361,25592327,graves’ disease
24362,25592327,hyperthyroidism
24363,25592327,hypocalcemia
24364,25592327,recurrent laryngeal nerve palsy
24365,25592327,thyroidectomy
24366,25592327,toxic multinodular goiter
24367,25047207,goitre
24368,25047207,iodine deficiency
24369,25047207,iodine prophylaxis
24372,24651704,graves' disease
24373,24651704,autoimmune
24374,24651704,inflammation
24378,25047210,nodular goitre
24379,25047210,radioiodine
24380,25047210,recombinant human thyrotropin
24381,25047210,thyroid diseases
24382,25047201,alcohol
24383,25047201,environmental risk factors
24384,25047201,goitre aetiology
24385,25047201,insulin resistance
24386,25047201,oral contraceptives
24387,25047201,parity
24388,25047201,smoking
24389,25047201,twins
24393,25047205,cytology
24394,25047205,fine needle aspiration
24395,25047205,molecular diagnostics
24396,25047205,thyroid cancer
24397,24595624,airway management
24398,24595624,airway obstruction
24399,24595624,endotracheal intubation
24400,24595624,goiter
24401,24595624,intubation
24402,24595624,nodular
24404,24462913,autoinmunidad tiroidea
24405,24462913,bipolar disorder
24406,24462913,bocio
24407,24462913,goitre
24408,24462913,hipertiroidismo
24409,24462913,hipotiroidismo
24410,24462913,hyperthyroidism
24411,24462913,hypothyroidism
24412,24462913,lithium
24413,24462913,litio
24414,24462913,thyroid
24415,24462913,thyroid autoimmunity
24416,24462913,tiroides
24417,24462913,trastorno bipolar
24420,25047206,non-toxic goitre
24421,25047206,patient-reported outcome measure
24422,25047206,quality of life
24423,26337337,cardiac surgical procedures
24424,26337337,coronary artery bypass
24425,26337337,retrosternal goitre
24426,26337337,thyroidectomy
24428,25047202,nodular goitre
24429,25047202,nuclear medicine
24430,25047202,positron emission tomography
24431,25047202,scintigraphy
24432,25047204,fna
24433,25047204,cytology
24434,25047204,diagnostic pitfalls
24435,25047204,morphology
24436,25047204,nodular goitre
24441,25633667,compound heterozygous mutations
24442,25633667,congenital hypothyroidism
24443,25633667,cryptic splice site
24444,25633667,mutation
24445,25633667,thyroglobulin gene
24451,24628230,horner's syndrome
24452,24628230,carotid dissection
24453,24628230,multinodular goiter
24454,24628230,trigeminal autonomic cephalgia
24455,24589354,adenomatous goiter
24456,24589354,human thyroid
24457,24589354,leakiness
24458,24589354,nog mouse
24459,24589354,thymic lymphoma
24460,24589354,transplantation
24465,24706172,goitre
24466,24706172,risk factors
24467,24706172,sternotomy
24468,24706172,thyroid gland
24469,24706172,thyroidectomy
24470,24703798,graves' disease
24471,24703798,pericarditis
24472,24703798,thyrotoxicosis
24474,25896315,thyroid cancer
24475,25896315,thyroidectomy
24476,25896315,toxic nodular goiter
24480,26261619,intra-thyroid thyroglossal duct cyst (ittdc)
24481,26261619,nodule
24482,26261619,thyroid gland
24483,26261619,ultrasound (us)
24484,25047200,goitre
24485,25047200,oesophagus
24486,25047200,radioiodine
24487,25047200,swallowing
24488,25047200,thyroidectomy
24489,25047200,trachea
24490,25047200,upper airway obstruction
24491,27057257,inferior laryngeal nerve
24492,27057257,non-recurrent
24493,27057257,total thyroidectomy
24494,24759378,retrosternal goiter
24495,24759378,complications to surgery
24496,24759378,intrathoracic goiter
24497,24759378,nodular goiter
24498,24759378,recurrent laryngeal nerve injury
24499,24759378,substernal goiter
24500,24759378,surgical treatment
24519,26069028,allergy
24520,26069028,endocrinology
24521,26069028,nutrition
24527,26163018,acromegaly
24528,26163018,goiter
24529,26163018,thyroid autoimmunity
24530,26163018,thyroid nodules
24536,26039459,branchial cyst
24537,26039459,cervical sinus
24538,26039459,iodine deficiency
24539,26039459,thyroid goiter
24546,26826478,hypoparathyroidism
24547,26826478,outcome
24548,26826478,recurrent laryngeal nerve palsy
24549,26826478,surgery
24550,26826478,thyroid
24551,26826478,à venir
24555,24774362,acute pericarditis
24556,24774362,brown adipose tissue
24557,24774362,spodick's sign
24561,25167783,graves disease
24562,25167783,qol
24563,25167783,surgery
24564,25167783,thypro
24565,25167783,toxic goiter
24570,25667686,etiology
24571,25667686,ectopic intrathoracic goiter
24572,25667686,mediastinal cyst
24582,24530085,algorithmes
24583,24530085,algorithms
24584,24530085,anesthésie générale
24585,24530085,difficult intubation
24586,24530085,general anesthesia
24587,24530085,impossible mask ventilation
24588,24530085,intubation difficile
24589,24530085,thyroidectomy
24590,24530085,thyroïdectomie
24591,24530085,tracheostomy
24592,24530085,trachéotomie
24593,24530085,ventilation au masque impossible
24594,26504073,hashimoto's thyroiditis
24595,26504073,thyroid cancer
24596,26504073,intraglandular dissemination
24597,26504073,multinodular thyroid
24598,26504073,nodular goitre
24599,26504073,papillary carcinoma
24602,25113865,old people
24603,25113865,parathyroidectomy
24604,25113865,primary hyperparathyroidism
24605,25113865,thyroid nodules
24608,25389240,imp3
24609,25389240,immunohistochemistry
24610,25389240,nucleophosmin
24611,25389240,papillary carcinoma
24612,25389240,thyroid
24613,26824209,clinicopathologic characteristics
24614,26824209,familial
24615,26824209,papillary carcinoma
24616,26824209,thyroid carcinoma
24620,26194563,goiter
24621,26194563,medical diagnosis
24622,26194563,painting
24623,26194563,parmigianino
24629,25102228,adrenomedullin 2
24630,25102228,goiter
24631,25102228,immunohistochemistry
24632,25102228,intermedin
24633,25102228,iodine-deficiency
24637,26834286,cardiomyopathy
24638,26834286,extracorporeal membrane oxygenation
24639,26834286,heart failure
24640,26834286,hyperthyroidism
24641,26834286,"thyrotoxicosis cois financial, or other relationship with any healthcare-related business or other entity whose products or services are discussed in this paper."
24644,26405494,plunging goitre
24645,26405494,cervical region
24646,26405494,western algeria
24650,26514949,antithyroid drug
24651,26514949,graves’ disease
24652,26514949,maladie de basedow
24653,26514949,relapse
24654,26514949,récidive
24655,26514949,traitement médical antithyroïdien
24663,25661375,autophagy
24664,25661375,autophagy-related protein light chain 3 (lc3)-ii
24665,25661375,papillary thyroid cancer
24669,25847147,goiter
24670,25847147,hypoparathyroidism
24671,25847147,parathyroid
24672,25847147,substernal
24673,25847147,thyroidectomy
24682,26322488,aggregate risk
24683,26322488,cumulative risk
24684,26322488,goitrogens
24685,26322488,perchlorate
24686,26322488,probabilistic risk assessment
24687,26322488,regulatory rationality
24694,25824071,graves’ orbitopathy
24695,25824071,guidance
24696,25824071,referral pathways
24697,25824071,thyroid eye disease
24704,24456910,benign tumor
24705,24456910,chirurgie cervicale
24706,24456910,glande submandibulaire
24707,24456910,neck surgery
24708,24456910,submandibular gland
24709,24456910,thyroid
24710,24456910,thyroïde
24711,24456910,tumeur bénigne
24713,24974154,central neck dissection
24714,24974154,lymph node metastasis
24715,24974154,papillary thyroid carcinoma
24716,24974154,thymosin beta 10
24722,26662651,myocardial scintigraphy
24723,26662651,sestamibi
24724,26662651,thyroid autoimmune disease
24725,26662651,thyroid cancer
24726,26662651,thyroid nodules
24731,26610563,khyber pakhtunkhwa
24732,26610563,pakistan
24733,26610563,community engagement
24734,26610563,goitre
24735,26610563,iodine deficiency
24736,26610563,iodised salt
24737,26610563,urinary iodine concentration
24741,26414819,drainage
24742,26414819,hemostasis
24743,26414819,thyroidectomy
24744,26414819,valsalva maneuver
24747,26074258,complications
24748,26074258,inferior
24749,26074258,intraoperative neurophysiological monitoring
24750,26074258,laryngeal nerve
24751,26074258,recurrent laryngeal nerve palsy
24752,26074258,thyroid gland
24755,24713328,dissociative amnesia
24756,24713328,dissociative disorder
24757,24713328,graves' disease
24758,24713328,hyperthyroidism
24764,25043767,airway
24765,25043767,goiter
24766,25043767,hemorrhage
24767,25043767,tpa
24768,25043767,thyroid
24769,26254997,benign goiter
24770,26254997,hashimoto thyroiditis
24771,26254997,quality of life
24772,26254997,thyroidectomy
24775,25722226,antithyroid drugs
24776,25722226,glucocorticoids
24777,25722226,graves’ disease
24778,25722226,graves’ orbitopathy
24779,25722226,radioiodine
24780,25722226,thionamides
24781,25722226,thyroidectomy
24783,25726089,graves’ disease
24784,25726089,postoperative complications
24785,25726089,total thyroidectomy
24786,25366513,drinking-water
24787,25366513,goitre
24788,25366513,iodine excess
24789,25366513,iodised salt
24790,25366513,prevalence
24792,25745526,thyroid
24793,25745526,papillary carcinoma
24794,25745526,tuberculosis
24795,24726024,bocio
24796,24726024,cervicotomy
24797,24726024,cervicotomía
24798,24726024,esternotomía
24799,24726024,goitre
24800,24726024,mediastinal
24801,24726024,mediastino
24802,24726024,sternotomy
24807,25342401,airway management
24808,25342401,endotracheal intubation
24809,25342401,goitre
24810,25342401,retrosternal
24811,25342401,thyroidectomy
24813,25194170,catatonia
24814,25194170,graves' disease
24815,25194170,hyperthyroidism
24816,25194170,postpartum psychosis
24817,25194170,psychosis
24824,24795511,iodine deficiency disorder
24825,24795511,iodized salt
24826,24795511,thyroid functions
24827,24795511,urinary iodine concentration
24834,25914194,diagnostic accuracy
24835,25914194,fine-needle aspiration biopsy
24836,25914194,histopathology
24837,25914194,thyroid nodule
24838,25914194,ultrasonography
24843,25197416,ectopic thyroid tissue
24844,25197416,bilateral thyroid goiter
24845,25197416,the recurrent laryngeal nerve
24846,25197416,thyroiditis
24847,25197416,ultrasound
24857,25563504,drinking water
24858,25563504,iodine-deficiency disorders
24859,25563504,table salt
24860,25563504,urinary iodine content
24861,25066642,cáncer de tiroides
24862,25066642,enfermedad nodular tiroidea
24863,25066642,hormona paratiroidea
24864,25066642,nodular thyroid disease
24865,25066642,tsh
24866,25066642,thyroid cancer
24868,24670538,papillary thyroid carcinoma
24869,24670538,cyclo-oxygenase-2
24870,24670538,matrix metalloproteinase-9
24871,24670538,vascular endothelial growth factor
24883,26185318,adenolipoma
24884,26185318,cowden syndrome
24885,26185318,ganglioneuroma
24886,26185318,gastrointestinal polyps
24887,26185318,hamartoma
24888,26185318,pten
24889,26185318,pten-hamartoma tumor syndrome
24890,26185318,papillary carcinoma
24891,26185318,storiform collagenoma
24892,26185318,thyroid
24893,26457492,brafv600e mutation
24894,26457492,kras mutation
24895,26457492,rassf1a methylation
24896,26457492,fine-needle aspiration biopsy
24897,26457492,nodular goiter
24915,24525284,anesthésie péridurale cervicale
24916,24525284,cervical epidural anesthesia
24917,24525284,perioperative risk
24918,24525284,risque périopératoire
24919,24525284,thyroidectomy
24920,24525284,thyroïdectomie
24921,26117483,compression of tracheobronchial tree
24922,26117483,intrathoracic goitre
24923,26117483,pulmonary tuberculosis
24924,24962366,adenoid cystic pattern
24925,24962366,fine-needle aspiration
24926,24962366,hyaline globule
24927,24962366,spindle-cell thymoma
24928,24962366,type a thymoma
24934,25326671,intraoperative neuromonitoring
24935,25326671,palsied recurrent laryngeal nerve
24936,25326671,secondary thyroidectomy
24940,24876155,emergency department
24941,24876155,respiratory
24960,26834925,delayed diagnosis
24961,26834925,historical tumors
24962,26834925,socioeconomic level
24980,25421156,autoimmunity
24981,25421156,environment
24982,25421156,genetics
24983,25421156,graves’ disease
24984,25421156,hyperthyroidism
24991,25596664,age
24992,25596664,glucocorticoids
24993,25596664,graves’ disease
24994,25596664,graves’ orbitopathy
24995,25596664,natural history
24996,25596664,radiotherapy
24999,25637365,corticoides
25000,25637365,corticosteroids
25001,25637365,graves ophthalmopathy
25002,25637365,irradiación
25003,25637365,irradiation
25004,25637365,oftalmopatía de graves
25005,25637365,orbitopatía tiroidea
25006,25637365,radioterapia
25007,25637365,radiotherapy
25008,25637365,thyroid orbitopathy
25012,25313112,restrictive strabismus
25013,25313112,strabismus surgery
25020,24835350,corneal biomechanical properties
25021,24835350,corneal hysteresis
25022,24835350,thyroid eye disease
25023,24835350,visa classification
25034,26730171,dysfunction
25035,26730171,esophagopathy
25036,26730171,graves’ disease
25037,26730171,heartburn
25038,26730171,odynophagia
25040,25744236,calcification
25041,25744236,contrast-enhanced ultrasound
25042,25744236,roc curve
25043,25744236,thyroid nodules
25047,24661105,antibodies
25048,24661105,graves' disease
25049,24661105,hla drb1 haplotype
25050,24661105,phenotype
25051,24661105,severity
25058,26105719,antithyroid drugs
25059,26105719,basedow’s disease
25060,26105719,graves’ disease
25061,26105719,birth defects
25062,26105719,epidemiology
25063,26105719,incidence
25064,26105719,pregnancy
25065,26105719,spontaneous abortion
25066,26105719,stillbirth
25067,26105719,thy rotoxicosis
25068,26105719,thyroid disease
25074,24841498,dysthroid optic neuropathy
25075,24841498,orbital radiotherapy
25076,24841498,thyroid eye disease
25082,25953846,epidemiology
25083,25953846,orbit
25087,24510380,fish
25088,24510380,fna
25089,24510380,pax8/pparg
25090,24510380,ret/ptc
25091,24510380,thyroid cancer
25092,24891174,clinical practice guidelines
25093,24891174,clinical practice survey
25094,24891174,hyperthyroidism
25095,24891174,management
25098,25736544,25-hydroxyvitamin d
25099,25736544,graves’ disease
25100,25736544,hyperthyroidism
25101,25736544,prognosis
25102,25736544,radioiodine therapy
25103,25378983,graves disease
25104,25378983,renal infarction cois
25106,24830583,association
25107,24830583,graves’ disease
25108,24830583,polymorphisms
25109,24830583,toll like receptor
25116,25305147,estrogen
25117,25305147,fsh
25118,25305147,lh
25119,25305147,progesterone
25120,25305147,thyroid neoplasms
25126,24833206,euthyroidism
25127,24833206,graves disease
25128,24833206,methimazole
25129,24833206,remission
25133,25430040,graves' disease
25134,25430040,toll-like receptor
25135,25430040,association
25136,25430040,polymorphisms
25140,25746910,diabetes
25141,25746910,graves'
25142,25746910,ophthalmopath severity
25149,25239229,founder mutation
25150,25239229,haplotype analysis
25151,25239229,iran
25152,25239229,linkage analysis
25153,25239229,pendred syndrome
25154,25239229,slc26a4 gene
25159,26007334,graves’ disease
25160,26007334,vitamin d
25161,26007334,meta-analysis
25162,26007334,meta-regression
25163,26007334,sensitivity analysis
25180,25766333,graves’ disease
25181,25766333,magnetic resonance hydrography
25182,25766333,magnetic resonance imaging
25183,25766333,ureteral myxedema
25187,24409943,graves’ disease
25188,24409943,graves’ ophthalmopathy
25189,24409943,radioiodine
25190,24409943,thyroid eye disease
25192,25286078,graves' disease
25193,25286078,hashimoto's thyroiditis
25194,25286078,interleukin-4
25195,25286078,meta-analysis
25196,25286078,polymorphism
25200,24823620,brown adipose tissue (bat)
25201,24823620,glucose metabolism
25202,24823620,hyperthyroidism
25203,24823620,muscle
25204,24823620,positron-emission tomography and computed tomography (pet-ct)
25209,24505195,decompression
25210,24505195,exophthalmos
25211,24505195,graves ophthalmopathy
25212,24505195,orbit cois
25215,25253825,graves disease
25216,25253825,intrathyroid vascularity
25217,25253825,painless thyroiditis
25218,25253825,power doppler sonography
25219,25253825,superficial structures
25229,24994866,inflammatory cytokine
25230,24994866,lacrimal gland
25231,24994866,ocular surface
25232,24994866,tears
25233,24994866,thyroid-associated ophthalmopathy
25236,24970896,131i
25237,24970896,camera based uptake
25238,24970896,thyroid uptake probe
25242,25670394,autoimmune disease
25243,25670394,graves’ disease
25244,25670394,interleukin-23
25245,25670394,single nucleotide polymorphism
25254,25361748,orbit
25264,24502333,dysthyroid optic neuropathy
25265,24502333,graves orbitopathy
25266,24502333,intraocular pressure
25267,24502333,orbital decompression
25268,24502333,superior ophthalmic vein
25269,25244551,diplopia
25270,25244551,graves’ disease
25271,25244551,orbital decompression
25272,25244551,repeat
25273,25244551,thyroid ophthalmopathy
25274,25188661,hiv
25275,25188661,antiretroviral therapy
25276,25188661,hyperthyroidism
25277,25188661,hypothyroidism
25278,25188661,thyroid
25285,25444029,adolescent
25286,25444029,graves disease
25287,25444029,infarction
25288,25444029,magnetic resonance imaging
25289,25444029,middle cerebral artery
25290,25444029,muscular diseases
25293,25596774,basedow
25294,25596774,graves’ disease
25295,25596774,hashimoto
25296,25596774,ischémie sclérale
25297,25596774,ophtalmopathie
25298,25596774,ophthalmopathy
25299,25596774,plication
25300,25596774,plissement
25301,25596774,recession
25302,25596774,recul
25303,25596774,scleral ischemia
25304,25596774,surgical technique
25305,25596774,technique chirurgicale
25320,26505217,gaze-evoked amaurosis
25321,26505217,optic neuropathy
25322,26505217,thyroid eye disease
25333,24697361,autoimmune thyroid diseases
25334,24697361,ctla-4
25335,24697361,meta-analysis
25336,24697361,single nucleoside polymorphisms
25337,24697361,susceptibility
25341,24646814,clec16a
25342,24646814,graves’ disease (gd)
25343,24646814,hashimoto’s thyroiditis (ht)
25344,24646814,autoimmune thyroid diseases (aitds)
25345,24646814,complex genetics
25346,24646814,complex immunity
25347,24646814,infection
25348,24646814,innate immunity
25349,24646814,resistance
25350,24646814,single-nucleotide polymorphisms (snps)
25351,24646814,tolerance
25356,25543543,autoimmunity
25357,25543543,graves’ disease
25358,25543543,polymorphisms
25359,25543543,thyroid-stimulating hormone receptor
25365,26499253,creatinine
25366,26499253,estimated glomerular filtration rate
25367,26499253,standardized cystatin c
25368,26499253,thyroid hormone
25370,25558015,cancer de la thyroïde
25371,25558015,graves’ disease
25372,25558015,maladie de basedow
25373,25558015,nodule non-palpable
25374,25558015,non-palpable nodule
25375,25558015,thyroid cancer
25376,25558015,ultrasonography
25377,25558015,échographie
25383,24560831,cellulitis
25384,24560831,ecthyma gangrenosum
25385,24560831,graves’ disease
25386,24560831,pseudomonas aeruginosa
25402,25294349,"illness and disease, chronic"
25403,25294349,"illness and disease, experiences"
25404,25294349,interpretative phenomenological analysis (ipa)
25405,25294349,qualitative analysis
25406,25294349,quality of life
25407,25294349,rehabilitation
25408,25294349,"research, qualitative"
25414,25775381,epo
25415,25775381,erythrocytosis
25416,25775381,hif-1α
25417,25775381,hyperthyroidism
25419,25058606,cytokines
25420,25058606,graves disease
25421,25058606,thyroid
25422,25692426,fine needle aspiration biopsy
25423,25692426,hashimoto's thyroiditis
25424,25692426,papillary thyroid carcinoma
25428,26240504,biological assay
25429,26240504,chronic inactive graves' orbitopathy
25430,26240504,mc4-tsi
25431,26240504,thyroid-stimulating immunoglobulin
25432,26240504,thyrotropin-binding inhibitory immunoglobulin cois was reported.
25436,25342622,cd44
25437,25342622,cox-2
25438,25342622,hyaluronic acid
25439,25342622,orbital fibroblast
25440,25342622,thyroid-associated ophthalmopathy
25441,25028161,association
25442,25028161,graves’ disease
25443,25028161,toll like receptor
25444,25028161,case-control study
25445,25028161,single nucleotide polymorphisms
25446,24627146,il-1β
25447,24627146,hyaluronic acid
25448,24627146,hyaluronic acid synthase
25449,24627146,mitogen-activated protein kinase
25450,24627146,orbital fibroblast
25451,24627146,pirfenidone
25452,24627146,thyroid-associated ophthalmopathy
25456,25892161,thyroid eye disease
25457,25892161,decompression
25458,25892161,diplopia
25459,25892161,orbit
25460,25892161,proptosis
25469,25576458,graves’ orbitopathy
25470,25576458,ich guideline
25471,25576458,intravenous steroids
25472,25576458,medical dictionary for regulatory activities (meddra)
25473,25576458,safety
25474,24486115,autoinmunidad tiroidea materna
25475,24486115,children born from mothers with autoimmune thyroid disease
25476,24486115,enfermedad de graves en el embarazo
25477,24486115,hijo de mujer con enfermedad tiroidea autoinmunitaria
25478,24486115,hipotiroidismo
25479,24486115,hypothyroidism
25480,24486115,pregnancy in graves disease
25481,24486115,thyroid autoimmunity in pregnancy
25484,26321629,magnetic resonance imaging
25485,26321629,methylprednisolone pulse therapy
25486,26321629,proptosis
25487,26321629,thyroid-associated ophthalmopathy
25488,26321629,volume
25489,24742542,graves' disease
25490,24742542,polymorphism
25491,24742542,transforming growth factor β1
25496,25770161,epidemiology
25497,25770161,eye
25498,25770161,ophthalmology
25503,25223473,a1555g
25504,25223473,hearing loss
25505,25223473,heteroplasmy
25506,25223473,mt-rnr1
25507,25223473,pendred syndrome
25508,25223473,slc26a4
25510,25759125,autoantibody
25511,25759125,graves'
25512,25759125,disease
25513,25759125,latent virus
25514,25759125,pathogenesis
25515,25759125,plasma cell differentiation
25519,24714170,carcinoma
25520,24714170,goiter
25521,24714170,thyroidectomy
25524,25937486,"anti-neutrophil cytoplasmic antibodies,"
25525,25937486,"drug-induced,"
25526,25937486,"graves’ disease,"
25527,25937486,"propylthiouracil,"
25528,25937486,small vessel vasculitis
25532,24989709,diplopia
25533,24989709,image-guided surgery
25534,24989709,proptosis
25535,24989709,strabismus
25536,24989709,thyroid eye disease
25537,24989709,visual acuity
25538,24989709,visual field
25544,25290043,deafness
25545,25290043,iran
25546,25290043,slc26a4
25547,25290043,enlarged vestibular aqueduct
25548,25290043,genetic linkage
25549,25290043,goiter
25550,25290043,mutation screening
25560,25768836,graves’ disease
25561,25768836,autoantibodies
25562,25768836,glycoprotein-hormone receptor
25563,25768836,small molecule ligands
25564,25768836,thyroid cancer
25565,25768836,thyroid-stimulating hormone receptor cois received no payment in preparation of this manuscript.
25572,25257150,<sup>131</sup>i
25573,25257150,dose/response analysis
25574,25257150,graves’ disease
25575,25257150,hyperthyroidism
25576,25257150,radioiodine
25581,26028555,graves' disease
25582,26028555,hypothyroidism
25583,26028555,postpartum thyroid disease
25584,26028555,pregnancy
25585,26028555,thyrotoxicosis
25586,25836060,depression
25587,25836060,graves’ orbitopathy
25588,25836060,diplopia
25589,25836060,elevation
25590,25836060,vertical strabismus
25597,24938857,graves’ disease
25598,24938857,intraoperative blood loss
25599,24938857,thyroidectomy
25602,25207976,ipilimumab
25603,25207976,myositis
25604,25207976,thyroid eye disease
25605,25207976,thyroid orbitopathy
25606,25121573,asia-pacific
25607,25121573,graves’ orbitopathy
25608,25121573,survey
25614,24697978,contour
25615,24697978,eyelid surgery
25616,24697978,keratopathy
25617,24697978,lagophthalmos
25618,24697978,symmetry
25621,25208306,reactivation
25622,25208306,thyroid-associated orbitopathy
25623,25208306,traum
25628,25134846,b-cell epitopes
25629,25134846,graves’ disease
25630,25134846,igg subclasses
25631,25134846,intramolecular epitope spreading
25632,25134846,thyroglobulin autoantibodies
25633,25120780,autoimmune thyroid diseases (aitds)
25634,25120780,graves’ disease (gd)
25635,25120780,hashimoto’s thyroiditis (ht)
25636,25120780,t helper 22 (th22) cell
25637,25120780,interleukin 22 (il-22)
25638,24903731,autoimmune co-morbidity
25639,24903731,autoimmune gastritis
25640,24903731,autoimmune thyroid diseases
25641,24903731,coeliac disease
25642,24903731,thyroid-associated orbitopathy
25646,25046415,autoimmune thyroid disease
25647,25046415,intractability
25648,25046415,polymorphism
25649,25046415,severity
25650,25046415,vitamin d
25660,25741204,children
25661,25741204,congenital hypothyroidism
25662,25741204,diffuse thyroid disease
25663,25741204,nodule
25664,25741204,thyroid disease
25665,25741204,ultrasonography
25666,25109914,graves-kór
25667,25109914,graves’ disease
25668,25109914,graves’ orbitopathy
25669,25109914,biological therapy
25670,25109914,biológiai terápia
25671,25109914,endokrin orbitopathia
25672,25109914,selenium
25673,25109914,szelén
25674,24938636,alemtuzumab
25675,24938636,autoimmunity
25676,24938636,sickle cell disease
25677,24938636,stem cell transplant
25678,24938636,thyroid dysfunction
25679,24838983,autoimmunity
25680,24838983,echocardiography
25681,24838983,hyperthyroidism
25682,24838983,pulmonary hypertension
25686,24674955,stroke
25687,24674955,cerebrovascular disease
25688,24674955,hematologic disease
25689,24674955,hyperthyroidism
25690,24674955,steroids
25691,24674955,thrombotic angiopathy
25694,25039242,biological treatment
25695,25039242,graves’disease
25696,25039242,endocrine orbitopathy
25697,25039242,hyperthyroidism
25698,25039242,thyroid
25703,24862674,focus
25704,24862674,harmonic
25705,24862674,knot tie technique
25706,24862674,sutureless
25707,24862674,thyroidectomy
25708,24862674,ultracision
25709,25839128,cd28
25710,25839128,cd4(+)cd28(−) t cells
25711,25839128,graves’ disease
25712,25839128,t-lymphocyte subsets
25715,25207388,electromagnetic image guidance
25716,25207388,graves’ ophthalmopathy
25717,25207388,orbital decompression
25722,25373929,graves’ disease
25723,25373929,hyperthyroidism
25724,25373929,laser doppler fluxmetry
25725,25373929,postocclusive reactive hyperaemia
25726,25373929,skin microcirculation
25728,24726178,antithyroid medication
25729,24726178,graves’ disease
25730,24726178,neonatal thyroid dysfunction
25731,24726178,outcome
25734,25122677,histone modifications
25735,25122677,interferon
25736,25122677,thyroiditis cois
25744,24784317,autoimmune thyroid diseases
25745,24784317,t regulatory cells
25746,24784317,forkhead box p3
25747,24784317,gene polymorphism
25748,25283079,midkine (mk)
25749,25283079,multi-nodular goiter (mng)
25750,25283079,nuclear factor-kappa b (nf-κb)
25751,25283079,papillary thyroid cancer (ptc)
25752,25283079,receiver operating characteristic (roc) curves
25753,25283079,synchronous metastasis
25754,26163757,gene expression profiling
25755,26163757,granulomatosis with polyangiitis
25756,26163757,microarray analysis
25757,26163757,molecular pathology
25758,26163757,orbit pathology
25759,26163757,orbital pseudotumor
25760,24793198,ct analysis
25761,24793198,deep lateral wall
25762,24793198,exophthalmos reduction
25763,24793198,orbital decompression
25764,24793198,orbital fat
25767,25615025,cytotoxic t-lymphocyte antigen-4
25768,25615025,polymorphism
25769,25615025,thyroid-associated ophthalmopathy
25770,24617953,graves' ophthalmopathy
25771,24617953,drug therapy
25772,24617953,glucocorticoid
25773,24617953,meta-analysis
25775,25648436,antibiotics
25776,25648436,mediastinitis
25777,25648436,negative pressure therapy
25778,25648436,streptococcus
25779,25648436,thyroidectomy
25783,24801540,autoimmunity
25784,24801540,children
25785,24801540,cytokines
25786,24801540,serum
25787,24801540,thyroid
25794,26523178,basedow disease
25795,26523178,papillary carcinoma
25796,26523178,thyroid
25802,26593863,autoimmune thyroid disease (aitd)
25803,26593863,graves’ disease (gd)
25804,26593863,hashimoto's thyroiditis (ht)
25805,26593863,maladie de basedow (gd)
25806,26593863,maladies thyroïdiennes auto-immunes (mait)
25807,26593863,polymorphisme de nucléotide unique (snp)
25808,26593863,récepteur à la vitamine d (vdr)
25809,26593863,single nucleotide polymorphism (snp)
25810,26593863,thyroïdite de hashimoto (ht)
25811,26593863,vitamin d receptor (vdr)
25813,25876459,graves' orbitopathy
25814,25876459,quality of life
25815,25876459,strabismus surgery
25816,25876459,success criteria
25824,25455307,graves' disease
25825,25455307,sensory ataxia
25826,25455307,sensory evoked potentials
25827,25455307,thyrotoxicosis
25828,25132194,contact lens sensor
25829,25132194,glaucoma
25830,25132194,intraocular pressure
25831,25132194,thyroid eye disease
25843,26034078,immunology
25844,26034078,orbit
25845,25847746,anti tsh-receptor antibody
25846,25847746,immunoassay
25847,25847746,pre
25848,25550791,graves’ hyperthyroidism
25849,25550791,nuocytes
25850,25550791,cytokines
25851,25550791,transcription factors
25852,26373794,graves' disease (gd)
25853,26373794,hashimoto's thyroiditis (ht)
25854,26373794,il1f7
25855,26373794,il37
25856,26373794,autoimmune thyroid diseases (aitds)
25857,26373794,single nucleotide polymorphisms (snps)
25868,26180468,diplopia
25869,26180468,graves’ disease
25870,26180468,restrictive strabismus
25871,26180468,strabismus surgery
25872,26180468,thyroid orbitopathy cois
25874,25900177,graves’ disease
25875,25900177,hashimoto’s thyroiditis
25876,25900177,oxidative status
25877,25900177,prolidase
25879,25859801,dsa = digital subtraction angiography
25880,25859801,gd = graves disease
25881,25859801,graves disease
25882,25859801,mmd = moyamoya disease
25883,25859801,mra = mr angiography
25884,25859801,t3 = triiodothyronine
25885,25859801,t4 = thyroxine
25886,25859801,tia = transient ischemic attack
25887,25859801,tsh = thyroid stimulating hormone
25888,25859801,disease progression
25889,25859801,ft3 = free triiodothyronine
25890,25859801,ft4 = free thyroxine
25891,25859801,moyamoya disease
25892,25859801,stroke
25893,25859801,vascular disorders
25895,25736545,dysthyroid optic neuropathy
25896,25736545,thyroid eye disease
25897,25736545,thyroid stimulating immunoglobulins
25906,25988433,exophthalmos
25907,25988433,graves’ orbitopathy
25908,25988433,globe luxation
25909,25988433,malar hypoplasia
25910,25988433,orbital decompression
25911,24434244,graves' ophthalmopathy
25912,24434244,quality of life
25913,24434244,questionnaire
25916,25176403,indirect calorimetry
25917,25176403,metabolic syndrome
25918,25176403,resting energy expenditure
25919,25176403,tetraiodothyronine
25920,25176403,thyroid stimulating hormone
25921,25176403,triiodothyronine
25923,26256985,tsh receptor autoantibody
25924,26256985,total thyroidectomy
25925,26256985,thyroid benign mass
25926,26256985,thyroid cancer
25927,26256985,thyroid-associated orbitopathy cois
25929,25159204,graves' orbitopathy
25930,25159204,adipogenesis
25931,25159204,heme oxygenase-1
25932,25159204,inflammation
25933,25159204,orbital fibroblasts
25934,25159204,oxidative stress
25935,25159204,tanshinone iia
25938,24990808,autoimmune thyroid disease
25939,24990808,intractability
25940,24990808,mir-125a
25941,24990808,polymorphism
25942,24990808,severity
25948,24798189,autoimmune thyroid disease
25949,24798189,graves'
25950,24798189,hashimoto's thyroiditis
25951,24798189,disease
25952,24798189,single nucleotide polymorphism
25953,24798189,tumor necrosis factor α-induced protein 3
25956,26141364,endonasal approach
25957,26141364,endoscopic assisted
25958,26141364,optic nerve
25959,26141364,orbit
25960,26141364,paranasal sinuses
25961,26141364,skull base
25965,25708657,foxp3
25966,25708657,graves' disease
25967,25708657,regulatory t cell
25968,25708657,single nucleotide polymorphism
25974,24460515,dry eye syndrome
25975,24460515,graves’ disease
25976,24460515,graves’ orbitopathy
25980,26041458,graves’ disease
25981,26041458,tsh receptor antibody
25982,26041458,antithyroid drugs
25983,26041458,hyperthyroidism
25984,26041458,pregnancy
25986,25320726,drug induced liver injury (dili)
25987,25320726,endocrinology
25988,25320726,hepatotoxicity
25989,25320726,idiosyncratic hepatic injury
25990,25320726,risk factors cois
25994,26116233,graves' disease (gd)
25995,26116233,histone acetylation
25996,26116233,histone modifications
25997,26116233,peripheral blood mononuclear cells (pbmcs)
26007,26344731,eyelid retraction
26008,26344731,optic neuropathy
26009,26344731,orbit
26010,26344731,restrictive myopathy
26011,26344731,thyroid eye disease
26013,25310344,adult strabismus
26014,25310344,diplopia
26015,25310344,operation dosage
26016,25310344,orbit
26017,25310344,thyriod eye disease
26021,25120331,drug-related side effects and adverse reactions
26022,25120331,graves disease
26023,25120331,methimazole
26024,25120331,pancreatitis cois
26027,26564931,cyclotropia
26028,26564931,double maddox rod test
26029,26564931,strabismus surgery
26030,26564931,thyroid eye disease
26033,24510024,extraocular muscles
26034,24510024,magnetic resonance imaging
26035,24510024,orbit
26036,24510024,thyroid-associated orbitopathy
26037,24510024,ultrasound
26038,26113403,autoimmune disease
26039,26113403,graves’ disease
26040,26113403,interleukin 7
26041,26113403,soluble interleukin 7 receptor
26047,25936345,cd40
26048,25936345,ctla-4
26049,25936345,genetic polymorphism
26050,25936345,graves' disease
26051,24712973,linear morphoea
26052,24712973,localised scleroderma
26054,24777217,graves’ disease
26055,24777217,adverse drug reactions
26056,24777217,disease management
26057,24777217,methimazole
26058,24777217,pediatric
26061,25617714,dna methylation
26062,25617714,dnmts
26063,25617714,graves' disease
26064,25617714,icam1
26065,25617714,mbds
26066,25617714,medip-chip
26077,25256279,anca
26078,25256279,hyperthyroidism
26079,25256279,propylthiouracil
26080,25256279,vasculitis
26083,25172242,ccl2
26084,25172242,cxcl10
26085,25172242,chemokines
26086,25172242,extra-ocular muscles
26087,25172242,graves' ophthalmopathy
26090,25444703,goitre ovarien
26091,25444703,meigs syndrome
26092,25444703,ovarian goiter
26093,25444703,ovarian tumor
26094,25444703,struma ovarii
26095,25444703,syndrome de meigs
26096,25444703,teratome
26097,25444703,thyroid
26098,25444703,thyroïde
26099,25444703,tumeur ovarienne
26100,25444703,tératome
26101,25457466,compressive optic neuropathy
26102,25457466,graves' orbitopathy
26103,25457466,spontaneous decompression
26114,25059686,decompression
26115,25059686,orbital surgery
26116,25059686,piezosurgery
26117,25059686,proptosis
26118,25059686,thyroid associated orbitopathy
26120,24576228,graves’ disease
26121,24576228,hyperthyroidism
26122,24576228,hypothyroidism
26123,24576228,prenatal care
26124,24576228,thyroidectomy
26125,26415610,alkaline phosphatase
26126,26415610,graves disease
26127,26415610,hypocalcemia
26128,26415610,thyroidectomy
26132,25814196,aetiopathogenesis of warthin's tumour
26133,25814196,autoimmune diseases
26134,25814196,lymphatic-rich stroma
26135,25814196,warthin's tumour
26137,24478186,cd20
26138,24478186,cd4
26139,24478186,cd8
26140,24478186,foxp3
26141,24478186,graves’ disease
26142,24478186,hashimoto's thyroiditis
26143,24478186,regulatory t cells
26148,25455505,bone metastases
26149,25455505,cirugía
26150,25455505,dosimetry
26151,25455505,dosimetría
26152,25455505,metástasis ósea
26153,25455505,surgery
26154,25455505,thyroid
26155,25455505,tiroides
26156,25455505,rtsh
26157,26425054,graves disease
26158,26425054,plasmapheresis
26159,26425054,thyrotoxicosis cois
26171,25412700,graves' disease
26172,25412700,hashimoto's thyroiditis
26173,25412700,th17 cells
26174,25412700,interleukins
26175,25412700,regulatory t cells
26179,26600899,struma ovarii
26180,26600899,histopathology
26181,26600899,ovarian goiter
26182,26600899,ovarian teratoma
26183,26600899,thyroid
26185,24956560,cytokine
26186,24956560,graves disease
26187,24956560,graves ophthalmopathy
26188,24956560,parp-1
26189,24956560,polymorphism
26191,25576242,adipokines
26192,25576242,graves׳ disease
26193,25576242,hashimoto׳s thyroiditis
26194,25576242,leptin
26195,25576242,pamp׳s
26196,25989711,autoimmune thyroid disease
26197,25989711,graves' disease
26198,25989711,hashimoto's thyroiditis
26199,25989711,interferon regulatory factor 8
26202,25647271,autoimmune thyroid disease (aitd)
26203,25647271,graves’ disease (gd)
26204,25647271,hashimoto’s thyroiditis (ht)
26205,25647271,interleukin-21 (il-21)
26206,25647271,interleukin-21 receptor (il-21r)
26207,25281394,gd
26208,25281394,kir3dl1
26209,25281394,nk
26210,25281394,nkg2a
26211,25281394,nkg2d
26212,25281394,nkp30
26214,25434508,chester-erdheim disease
26215,25434508,diabetes insipidus
26216,25434508,diabetes insípida
26217,25434508,enfermedad de chester-erdheim
26218,25434508,hipopituitarismo
26219,25434508,histiocitosis de células de langerhans
26220,25434508,hypopituitarism
26221,25434508,langerhans cell histiocytosis
26229,25586901,marinelli
26230,25586901,thyroid nodules
26231,25586901,combined therapy
26232,25586901,dosimetry
26233,25586901,microwave ablation
26234,25586901,radioiodine therapy
26236,24958412,benign and malignant thyroid nodules
26237,24958412,contrast-enhanced sonography
26238,24958412,maximum intensity
26239,24958412,microvessel density
26240,24958412,superficial structures
26246,25161183,cancer
26247,25161183,elastography
26248,25161183,thyroid nodules
26251,26406404,papillary thyroid carcinoma
26252,26406404,mutation
26253,26406404,thyroperoxidase
26255,25960045,follicular thyroid neoplasia
26256,25960045,differential diagnostics
26257,25960045,goitre
26258,25960045,immunohistochemistry
26259,25960045,stem cell marker
26270,26048691,alström syndrome
26271,26048691,follicular variant of papillary thyroid carcinoma
26272,26048691,thyroid cancer
26273,26048691,thyroid goitre
26275,25328134,cancer
26276,25328134,contrast agents
26277,25328134,follicular adenoma
26278,25328134,goiter
26279,25328134,quantitative parameter
26280,25328134,thyroid
26281,25328134,time-intensity curve
26282,25328134,ultrasonography
26283,26191283,cytokeratin 17
26284,26191283,immunohistochemistry
26285,26191283,lymph node metastasis
26286,26191283,papillary thyroid carcinoma
26289,25400776,papillary thyroid carcinoma (ptc)
26290,25400776,percentage of brafv600e alleles
26291,25400776,preoperative risk stratification
26292,25400776,pyrosequencing
26293,25940693,autonomously functioning thyroid nodule
26294,25940693,meta-analysis
26295,25940693,nodular goitre
26296,25940693,scintigraphy
26297,25940693,thyroid
26298,25940693,thyroid-stimulating hormone
26303,25707564,graves disease
26304,25707564,hypocalcemia
26305,25707564,multinodular goiter
26306,25707564,papillary carcinoma of thyroid
26307,25707564,parathyroid
26308,25707564,parathyroid adenoma
26309,25707564,recurrent laryngeal nerve
26310,25707564,thyroid
26311,25054230,aa amyloidosis
26312,25054230,chronic renal disease
26313,25054230,cystic fibrosis
26314,25054230,goiter
26315,25054230,intestinal disorders
26316,25054230,proteinuria
26319,25868389,ffpe
26320,25868389,nanostring analysis
26321,25868389,biomarkers
26322,25868389,circadian clock
26323,25868389,papillary thyroid carcinoma cois
26324,26578494,cribriform variant
26325,26578494,papillary carcinoma
26326,26578494,sonography
26327,26578494,thyroid
26328,26578494,ultrasound
26330,26437373,antiepileptic drugs
26331,26437373,goiter
26332,26437373,metabolic risk
26333,26437373,subclinical hypothyroidism
26334,26437373,thyroid hormones
26337,25120855,africa
26338,25120855,surgical camp
26339,25120855,uganda
26354,27057249,harmonic focus curved shears
26355,27057249,hemostasis
26356,27057249,thyroid
26357,27057249,thyroidectomy
26370,24993783,child
26371,24993783,differentiated thyroid cancer
26372,24993783,goitre
26373,24993783,hypoparathyroidism
26374,24993783,lobectomy with isthmusectomy
26375,24993783,medullary thyroid cancer
26376,24993783,recurrent laryngeal nerve paralysis
26377,24993783,thyroidectomy
26378,24434360,autoimmunity
26379,24434360,hashimoto
26380,24434360,thyroiditis
26385,25524940,papillary thyroid carcinoma
26386,25524940,rt-pcr
26387,25524940,mir-146a
26388,25524940,mir-146b
26390,25017947,cost-benefit
26391,25017947,goiter
26392,25017947,thyroid cancer
26393,25017947,thyroidectomy
26397,24866072,incidental carcinoma
26398,24866072,microcarcinoma
26399,24866072,thyroid
26400,24862663,hypocalcemia
26401,24862663,parathyroid hormone
26402,24862663,thyroidectomy
26406,25601586,thyroid cancer
26407,25601586,complications of thyroid surgery
26408,25601586,intraoperative neuromonitoring
26409,25601586,patient outcomes
26410,25601586,recurrent laryngeal nerve injury
26425,25217004,percutaneous tracheostomy
26426,25217004,tracheostomy
26428,25889269,goiter
26429,25889269,nitrate
26430,25889269,nitrite
26431,25889269,thyroid cancer
26432,25889269,thyroid function
26436,26327979,hashimoto′s thyroitidis
26437,26327979,acute
26438,26327979,sickle cell anemia
26440,26905714,association
26441,26905714,hashimoto's thyroiditis
26442,26905714,histopathology
26443,26905714,medullary carcinoma of thyroid.
26448,25946974,nicotinamide phosphoribosyltransferase
26449,25946974,nodular goiter
26450,25946974,reverse transcriptase polymerase chain reaction
26451,25946974,thyroid cancer
26452,25946974,thyroid gland
26453,25946974,visfatin
26456,24550235,calcitonin
26457,24550235,fine-needle aspiration cytology
26458,24550235,medullary thyroid carcinoma
26462,24388198,cadmium toxicity
26463,24388198,preneoplastic lesions
26464,24388198,thyroid gland
26466,25556330,hyperthyroidism
26467,25556330,potassium chloride repletion
26468,25556330,thyrotoxic hypokalemic periodic paralysis
26469,25556330,ventricular arrhythmia
26470,25934417,hypoparathyroidism
26471,25934417,intra-operative parathyroid hormone
26472,25934417,parathyroid hormone decline
26473,25934417,total thyroidectomy
26475,25156133,graves’ disease
26476,25156133,hyperthyroidism
26477,25156133,hyperthyroïdie
26478,25156133,iode 131
26479,25156133,maladie de basedow
26480,25156133,radioiodine dose
26481,25156133,thyroid
26482,25156133,thyroïde
26492,25824846,drug overdose
26493,25824846,hyperthyroxinemia
26494,25824846,levothyroxine overdose
26495,25824846,thyroid crisis
26496,25824846,thyrotoxicosis
26497,25598424,differential diagnosis
26498,25598424,hydatid cyst
26499,25598424,thyroid
26500,25598424,unusual location
26501,25476178,ct
26502,25476178,hyperthyroidism
26503,25476178,incidental thyroid nodule
26504,25476178,mr imaging
26505,25476178,radioactive iodine scan
26506,25476178,thyroid cancer
26507,25476178,ultrasonography
26513,26210625,children
26514,26210625,hyperthyroidism
26515,26210625,hypothyroidism
26516,26210625,incidental
26517,26210625,nodule
26518,26210625,overt
26519,26210625,thyroid
26520,26210625,ultrasonography
26528,25873114,antiandrogens  prolactin
26544,24760746,graves' disease
26545,24760746,hashimoto's thyroiditis
26546,24760746,autoimmune thyroiditis
26547,24760746,erythrovirus b19
26548,24760746,parvovirus b19
26553,26347012,angiogenesis
26554,26347012,atherosclerosis
26555,26347012,cholesterol
26556,26347012,pleiotropic effect
26557,26347012,statins
26560,25480825,cancer
26561,25480825,nodules
26562,25480825,oncology
26563,25480825,pediatrics
26564,25480825,therapeutics
26565,25480825,thyroid cois article.
26569,24578322,double salt fortification
26570,24578322,human health
26571,24578322,micronutrient assessment
26572,24578322,mineral deficiency
26581,24768495,fine needle aspiration
26582,24768495,thyroid
26583,24768495,thyroid bed
26584,26374222,adenomatous hyperplasia
26585,26374222,brenner tumor
26586,26374222,mucinous cystadenoma
26587,26374222,papillary thyroid carcinoma
26588,26374222,serous cystadenoma
26589,26374222,struma ovarii
26590,26374222,strumal carcinoid
26591,25755717,cd147
26592,25755717,rna interference
26593,25755717,thyroid cancer-experimental
26594,25755717,genetics
26595,25755717,glycolysis
26596,25755717,pathology-thyroid
26597,24493789,barriers
26598,24493789,discharge
26599,24493789,outpatient
26600,24493789,thyroidectomy
26601,26823860,braf
26602,26823860,papillary thyroid cancer
26603,26823860,ras
26604,26823860,ret
26609,26406959,thyroid cancer
26610,26406959,diagnosis
26611,26406959,fine needle aspiration biopsy (fnab)
26612,26406959,transforming growth factor-β 1
26615,26475096,ectopic lymphoid tissue
26616,26475096,hashimoto's thyroiditis
26617,26475096,human parvovirus b19
26618,26475096,pathogenesis
26619,26475096,positive regulatory domain zinc finger protein 1
26621,24750986,difficult thyroidectomy
26622,24750986,difficulty scale
26623,24750986,graves disease
26624,24750986,hashimotos thyroiditis
26625,24750986,risk adjustment
26626,24750986,thyroid
26631,26408676,thyroid sarcoma
26632,26408676,clinical sign
26633,26408676,review
26634,26408676,thyroid imaging
26636,25487217,131i therapy
26637,25487217,benign thyroid disease
26638,25487217,dosimetry
26644,26417067,ccm
26645,26417067,ros
26646,26417067,autophagy
26647,26417067,endothelial‐to‐mesenchymal transition (endmt)
26648,26417067,mtor
26652,25639351,saccharomyces cerevisiae
26653,25639351,antioxidants
26654,25639351,avenanthramides
26655,25639351,biofactors
26656,25639351,cerebral cavernous malformation
26657,25639351,metabolic engineering
26658,25639351,phenolic compounds
26659,25639351,plant secondary metabolites
26660,26302664,*iodine intake
26661,26302664,*iodized salt
26662,26302664,*nutrición yódica
26663,26302664,*sal yodada
26664,26302664,*urinary iodine concentrations
26665,26302664,*yoduria
26667,25829390,ambulatory surgical procedures
26668,25829390,outpatient
26669,25829390,perioperative complications
26670,25829390,revisits
26671,25829390,surgery
26672,25829390,thyroid surgery
26673,25829390,thyroidectomy
26674,25041837,galectin-3
26675,25041837,hbme-1
26676,25041837,immunohistochemistry
26677,25041837,thyroid nodules
26681,25593151,dietary intake
26682,25593151,dietary supplements
26683,25593151,folate
26684,25593151,folic acid
26685,25593151,"vitamin b-9 cois the scientific advisory boards of conagra, inc., mccormick spice, the mushroom council, the california walnut commission, and bay state milling; and is a consultant to nestle, inc. kl wiemer and kb miller are employees of general mills, inc. o dary, ma philbert, v tarasuk, and cl taylor, no conflicts of interest. cl keen serves on advisory boards of advocare, herbalife, mars, inc., mccormick spice, and theralogix. jc king serves on the scientific advisory board for conagra; has received research funding from the almond board of california, the california walnut commission, thrasher foundation, harvest plus, the nestle foundation, usda, and nih; and has provided consultation to the alliance for potato research and education and ilsi north america. pc gaine and ab jarvis were employees of ilsi north america when the manuscript was prepared. rl bailey is a government liaison to the ilsi north america committee on fortification."
26687,25968604,founder effect
26688,25968604,mutation
26689,25968604,structural modeling
26690,25968604,tpo
26691,25968604,thyroid dyshormonogenesis
26693,25193578,adjuvant therapy
26694,25193578,differentiated thyroid carcinoma
26695,25193578,radioiodine ablation
26696,25193578,total thyroidectomy
26697,25193578,urinary iodine
26698,25175810,new sporadic neoplastic syndrome
26699,25175810,papillary and medullary carcinomas
26700,25175810,urothelial
26701,25917998,levothyroxine
26702,25917998,preoperative localization
26703,25917998,primary hyperparathyroidism
26704,25917998,sestamibi scintigraphy
26705,25917998,ultrasound
26711,25837167,braf
26712,25837167,dna
26713,25837167,biomarker
26714,25837167,papillary thyroid carcinoma
26715,25837167,plasma cois
26717,24582076,cleft lip and palate
26718,24582076,ex utero intrapartum treatment (exit)
26719,24582076,fetal diagnosis
26720,24582076,micrognathia
26721,24582076,prenatal consultation
26723,26119458,acoustic radiation force impulse
26724,26119458,elastography
26725,26119458,thyroid nodule
26726,26119458,ultrasound
26729,25111330,chinese population
26730,25111330,fine-needle aspiration biopsy
26731,25111330,genetic alterations
26732,25111330,thyroid nodules
26737,25836323,dicer1
26738,25836323,embryonal rhabdomyosarcoma
26739,25836323,ovary
26740,25836323,pediatric tumors
26741,25836323,mirna
26743,26342107,papillary thyroid carcinoma
26744,26342107,undifferentiated thyroid carcinoma
26745,26342107,vegf
26746,26342107,mir-205
26747,26342107,microrna
26751,26041374,h271d
26752,26041374,resistance to thyroid hormones
26753,26041374,thyroid hormone receptor beta gene (thrβ)
26755,25155806,dairy product
26756,25155806,iodized salt
26757,25155806,urinary iodine
26758,25486933,cerebrovascular disorders
26759,25486933,endothelium
26760,25486933,genetics
26761,25486933,hemorrhage
26762,25486933,stroke
